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Abstract
Novel Bisnaphthalimidopropyl Polyamine Derivatives: Their Mode of Action
in a Breast Cancer Cell System
Gemma A Barron, for the degree of Doctor of Philosophy
The synthesis and characterisation of novel bisnaphthalimidopropyl polyamine
(BNIPP) derivatives, has gained pace over the last couple of years, as they have
enhanced aqueous solubility, without loss of biological activity, in contrast to parent
bisnaphthalimide derivatives. Recent work has shown that bisnaphthalimidopropyl
spermidine (BNIPSpd) bis-intercalates to DNA, induces oxidative DNA damage, depletes
polyamine levels and causes cell death, by apoptosis, in human colon cancer CaCO-2
and HT-29 cells. The aim of this thesis was to synthesise new BNIPP derivatives to
highlight the important structural features required for biological activity, particularly,
bisnaphthalimidopropyl functionality, and investigate their subsequent modes of action in
breast cancer MDA-MB-231 and breast epithelial MCF-10A cells. Initially, work focused
on determining the DNA binding affinities and biological activity of BNIPP derivatives. All
BNIPP derivatives, except bisphthalimidopropyl diaminodecane (BPHPDadec) and
mononaphthalimidopropylamine (NPA) (Δ Tm values of 15.8 and 10.2 °C, respectively, C50
values of > 10 µM, IC50 values of > 40 µM), exhibited strong DNA binding affinities and
cytotoxic properties in both cell lines. Results indicate that BNIPP derivatives interact with
DNA by bis-intercalation suggesting, therefore, that BNIPP derivatives target DNA. For
the first time, an investigation into the mechanism of cellular entry, via the polyamine
transport (PAT) system, was studied. However, none of the BNIPP derivatives utilised the
MGBG-specific PAT system, suggesting that BNIPP derivatives utilise other modes of
cellular entry. Two BNIPP derivatives, BNIPSpd and BNIPDaCHM, were further
investigated, and results show that these derivatives significantly induced a dose
dependent increase in DNA strand breaks from ≥ 0.1 μM, after 4 hours. BNIPSpd and
BNIPDaCHM (at non toxic concentrations) also inhibited the repair of oxidative (H2O2) and
methylative (MMS)-induced DNA strand breaks. Based on phosphatidylserine exposure
and membrane integrity analyses, early apoptotic cell death was determined as a mode of
cell death utilised by both BNIPSpd and BNIPDaCHM (5 µM), after only 0.5 hours
treatment in MDA-MB-231 cells. Interestingly, BNIPDaCHM was identified, using HDAC
assay kits, as a potent and selective SIRT2 enzyme inhibitor, thus, identifying, a novel
structural backbone for the selective inhibition of HDAC enzymes.
Keywords: Bisnaphthalimidopropyl, Bis-intercalation, DNA damage, Apoptosis, HDAC
inhibition, Breast cancer
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1Chapter 1
Introduction
21.1. Cancer
For over a century, differences between cancerous (neoplastic) and normal cells
have been recognised (Balducci 2007), and, the disease continues to dominate as a
present day risk to human life.
A neoplasm or tumour is a build up or ‘lump’ of abnormal cells, where cells have
escaped the normal controls of the cell cycle, resulting in irregular cell proliferation and
differentiation. A tumour is benign when neoplastic cells grow slowly in a non aggressive
self contained manner without spreading to the surrounding tissues (Stavros et al. 1995,
Cancer Research UK 2004). A tumour is malignant when neoplastic cells grow in an
uncontrolled abnormal manner, invade adjacent tissues and metastasise to distant sites,
with the formation of new tumours (Gupta and Massagué 2006, Chiang and Massagué
2008). Cancer can be used to describe both benign and malignant tumours, but only
malignant tumours are truly cancerous, and often fatal (Blows 2005). The common
hallmarks of malignant cell growth have been recently expanded by Luo et al. (2009) to
include the stress phenotypes. Therefore, including the stress phenotypes, the hallmarks
of malignant cell growth are: self-sufficiency in growth signals, insensitivity to anti-growth
signals, evasion of programmed cell death (apoptosis), limitless replicative potential,
sustained angiogenesis (Hanahan and Weinburg 2000), together with metabolic stress,
proteotoxic stress, mitotic stress, oxidative stress, deoxyribonucleic acid (DNA) damage
stress and finally evasion of immune surveillance (Hanahan and Weinburg 2000, Luo et
al. 2009, Zhivotovsky and Orrenius 2010).
Over 200 different types of cancers have been identified, with 54 % of all newly
diagnosed cases worldwide being accounted for by breast, lung, colorectal (large bowel)
and prostate cancers (Cancer Research UK 2009a). In 2006, approximately 293,000
people were diagnosed with cancer in the UK (Cancer Research UK 2009a); with the
latest statistics indicating that one in three people will be diagnosed with some form of
cancer during their lifetime in the UK (Cancer Research UK 2009b).
1.1.1. Breast Anatomy
A woman’s breast is composed of adipose tissue, connective tissue and gland
(lobes) tissue. In a lactating woman, milk is produced by these lobes, and delivered to the
nipple by small tubes, known as milk ducts (NHS Choices UK 2008) (refer to Figure 1.1).
The natural development of breast tissue occurs in response to hormones, in particular,
during puberty, pregnancy and breast feeding (World Cancer Research Fund-UK, 2010).
3Figure 1.1.: Internal structure of a women’s breast (adapted from Cancerbackup, May 2009,
available from http://www.cancerbackup.org.uk/Cancertype/Breast/DCISLCIS)
1.1.2. Epidemiology of Breast Cancer
Breast cancer is the most common cancer in the UK (even though it is extremely
rare in men), with around 46,000 new cases of breast cancer diagnosed in women and
300 new cases in men, in 2006 (Cancer Research UK 2009c). Latest statistics indicate
that breast cancer incidence rates have risen by over 50% in the last 25 years (Cancer
Research UK 2009c), with rates higher in more developed countries (e.g., North America
and Europe) than in less developed countries (e.g., Africa and Asia) (Cancer Research
UK 2009d). Although the survival rates of breast cancer have improved over the last 20
years because of earlier detection and improved treatment; breast cancer remains the
third most common cause of death (8 %) after lung (22 %) and colorectal (10 %) cancers
in the UK (Cancer Research UK 2009c, Cancer Research UK 2009d).
1.1.3. Aetiology of Breast Cancer
Although the aetiology of breast cancer remains largely unknown (Debruin and
Josephy 2002); breast cancer can be associated with three distinct groups of risk factors:
reproductive and hormonal factors, environmental (including lifestyle) factors, and
hereditary factors.
The age of an individual is highly influential in the aetiology of breast cancer, and
has been suggested to be the strongest risk factor; as the risk of breast cancer increases
with age, with 8 out of 10 breast cancer cases developing in postmenopausal women,
over the age of 50 (Cancerbackup 2008). Therefore, several reproductive factors related
to age have been identified that influence the risk of breast cancer. These include (i) age
at menarche (i.e., younger age at menarche (before age of 12), higher risk of breast
cancer), (ii) age at first birth (i.e., younger age at first birth, lower risk of breast cancer), (iii)
breastfeeding (i.e., breastfeeding for longer, lower risk of breast cancer), and (iv) age at
menopause (i.e., older age at menopause (over age of 55), higher risk of breast cancer).
4Besides reproductive factors, hormonal factors have also been linked to the risk of breast
cancer, including (i) endogenous hormones (i.e., higher levels of oestrogen or
testosterone, higher risk of breast cancer) or exogenous hormones (i.e., use of oral
contraceptives or hormone replacement therapy, higher risk of breast cancer) (Key et al.
2001).
Studies into geographic variations related to the incidence of breast cancer have
shown that cases of breast cancer are higher in developed countries, suggesting that
environmental and lifestyle choices are highly influential in the aetiology of breast cancer.
The risk of breast cancer is linked to (i) a high Body Mass Index (BMI1; ie, being
overweight or obese, particularly after menopause), (ii) drinking alcohol (i.e., drinking
more than two units of alcohol per day over several years’ increases risk by 7 – 12%)
(Cancerbackup 2008, Cancer Research UK 2009d), (iii) a lack of physical activity (i.e.,
moderate physical activity reduces the risk of breast cancer) (Key et al. 2001), or (iv)
exposure to ionising radiation or environmental oestrogens (e.g.,
dichlorodiphenyltrichloroethane (DTT) or polychlorinated biphenyls (PCBs) (Keys et al.
2001).
Environmental and lifestyle factors rather than inherited genetic factors are
primarily responsible for most cases of breast cancer. However, a small number of breast
cancer cases (5 – 10%) are hereditary. For these genetically predisposed cases,
occurrence is due to an inherited germline mutation within, for example, the BRCA1
(BReast CAncer 1), BRCA2 (BReast CAncer 2) or TP53 (Tumour Protein p53) genes
(Blows 2006, Nelson et al. 2005, Balducci 2007). Mutations in BRCA1 and BRCA2 genes
result in a high incidence of breast (56 – 84% risk), and in some cases, ovarian (15 – 45%
risk) cancers (Key et al. 2001, Honrado et al. 2006). These genes are involved in
transcriptional regulation, induction of apoptosis, control of cell cycle and DNA repair
mechanisms (Yang and Lippman 1999, DeBruin and Josephy 2002, Honrado et al. 2006).
Whilst, mutations in TP53, a tumour suppressor gene, are the most common in human
cancers (found in 50% of human cancers) (Bertheau et al. 2008); it is also responsible for
the regulation of apoptosis, cell cycle and DNA repair mechanisms (DeBruin and Josephy
2002).
1.1.4. Types of Breast Cancer
There are various different types of breast cancer, classified as either non-invasive
or invasive. Approximately 80 % of all breast cancer cases, diagnosed in women, develop
within the cells which line the milk ducts, known as non-invasive Ductal cancer (NHS
Choices UK 2008). Other forms of breast cancer can occur within the cells which line the
milk producing lobes (Lobular cancer), below the skin of the breast where the tumour has
1 BMI is calculated by dividing the weight by height squared. A BMI less than 18.5 is underweight;
18.5 – 24.9 is an ideal weight; 25 – 29.9 is overweight and 30 and over is obese.
5blocked the lymph nodes (Inflammatory Breast Cancer, IBC) or around the nipple (Paget’s
disease of the breast) (NHS Choices 2008, National Cancer Institute 2006, Cancer
Research UK 2009e). Breast cancer can also spread or metastasise to other organs
within the body, in particular, the lungs, liver, bones and brain (Lacroix 2006, Chiang and
Massagué 2008, Hu, Kang and Wang 2009).
Hormones, in particular, oestrogens are important in the development and
maintenance of female characteristics, including breast development. Oestrogens bind
the estrogen receptors (ER; a protein molecule and member of the transcription factor
family), resulting in cell proliferation (Yamaguchi and Hayashi 2009). Consequently, the
levels of ER expression can denote the particular type of breast cancer. For example,
cells which have ERs, thus oestrogen dependent, are ER-positive breast cancer cells
(ER+), whilst cells which do not have ERs, thus oestrogen independent, are ER-negative
breast cancer cells (ER-) (Koutsilieris et al. 1999, Lacroix and Leclercq 2004). ER+ breast
cancer cells exhibit a better prognosis and are more responsive to treatment, whereas
ER- breast cancer cells are highly invasive and do not respond well to current treatments
(Koutsilieris et al. 1999, Rochefort et al. 2003, Lacroix and Leclercq 2004).
1.1.5. Treatment of Breast Cancer
Treatment of breast cancer is generally dependent upon an individual’s
circumstances (i.e., ER expression levels: ER+ or ER-), but commonly involves removal of
the tumour by surgical excision. Chemotherapy, radiotherapy and, in some cases,
hormone or biological therapy (i.e., treatment working with either hormones or the immune
system, respectively) can be used, either before surgery (non-adjuvent therapy) or after
surgery (adjuvent therapy). These treatments aim to increase patient survival and prevent
the occurrence of metastatic tumour formation (Garibolidi et al. 2007, NHS Choices UK
2008).
Adjuvent chemotherapy is the most common approach for the treatment of primary
and advanced breast cancers: ER+ breast cancers can be treated with anti-oestrogen
(endocrine) therapies, and ER- breast cancers can be treated by chemotherapy.
Endocrine therapies block the effect of oestrogen, thus, decreasing the rate of breast
cancer cell proliferation (Yamaguchi and Hayashi 2009). Examples of endocrine
therapies include tamoxifen (for premenopausal women) or aromatase inhibitors (for
postmenopausal women) (Figure 1.2). Chemotherapy instead kills cells with the use of
cytotoxic agents, for example, anthracyclines or taxanes, which can be used individually
or in combination therapy (Friedrichs, Hölzel and Jänicke 2002) (Figure 1.2).
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Figure 1.2.: Structure of A. Tamoxifen, B. Anastrazole, C. Daunorubicin (Daunomycin), D.
Doxorubicin (Adriamycin), E. Docetaxal (Taxotere®) and F. Paclitaxal (Taxol®)
Over the last 20 years, adjuvent chemotherapy has been the key mode of breast
cancer treatment, but response and survival rates remain modest over time (Robson and
Verma 2009). The search for novel chemotherapeutics with less toxicity, better sensitivity
and greater response rates, and with increased patient survival, therefore, remains critical
for the future enhanced treatment of breast cancer (Arcamore 1992, Widakowich et al.
2007).
71.2. Cancer Therapeutics and Apoptosis
The treatment of cancer is highly reliant upon cytotoxic chemotherapeutic agents,
as discussed in Section 1.1.5. Investigations into the mode of action of chemotherapeutic
agents have established that many affect cancer cell death by initiation of apoptosis (or
programmed cell death) (Kerr et al. 1994, Hannun 1997, Hu and Kavanaugh 2003,
D’Agostini et al. 2005) (Table 1.1). However, a consequence of this is that the
effectiveness of anti cancer agents is limited, since they do not discriminate between
cancerous and non cancerous cells (MacFarlane 2009). Identification of novel targets
related to apoptotic pathways and, the development of specific anti cancer agents which
selectively induce apoptosis in cancer cells alone remains, therefore, of paramount
importance (Kaufmann 1989, Hannun 1997, Lowe and Lin 2000).
Table 1.1.: Apoptosis-inducing chemotherapeutic agents used for the treatment of cancer
Chemotherapeutic Agents associated
with Apoptosis
Cancer Types associated with
Apoptosis
Bleomycin
Camptothecin
Chlorambucil
Cis-platinum
Cyclophosphamide
Dexamethasone
Doxorubicin
Etoposide
5-Flourouracil
Melphalan
Methotrexate
Paclitaxel
Vincristine
Bladder carcinoma
Breast carcinoma
Colon carcinoma
Leukaemia
Lung Carcinoma
Lymphoma
Ovarian carcinoma
Testicular carcinoma
Note: adapted from Hannun (1997)
1.2.1. Cell Death: Apoptosis and Necrosis
Cell death can occur by multiple mechanisms; however, apoptosis and, to some
extent, necrosis remain central to the area of cancer research. Cell death is defined by
distinct morphological characteristics that are specific to each mode of cell death.
Apoptosis (or programmed cell death) is an important feature in normal cell
development, as it regulates cellular homeostasis by balancing between cell proliferation
and cell death (Schwartzman and Cidlowski 1993, Kerr et al. 1994, Scovass 2006). Also
defined as cellular suicide or physiological cell death; apoptosis occurs when a single cell
or small cell population voluntarily inactivate and completely dissemble their own
structural components after exposure to external stimuli (Schwartzman and Cidlowski
1993, Holdenrieder and Stieber 2004). The morphological characteristics of apoptosis
(Figure 1.3) involve cell shrinkage, cytoplasmic and cell membrane blebbing, chromatin
8condensation, DNA fragmentation and the formation of apoptotic bodies, which are rapidly
removed by phagocytosis (Kerr et al. 1994, Jin and El-Deiry 2005, Scovassi 2006, Burz et
al. 2009). Removal by phagocytosis eliminates the risk of an inflammatory response in
surrounding tissues. Apoptosis is a highly controlled energy dependent process, which is
extremely important in the removal of damaged or dysfunctional cells in multi-cellular
organisms. If these damaged cells are not efficiently removed, the formation of several
pathological conditions, such as, cancer, autoimmune and degenerative diseases, or
developmental defects could occur (Jin and El-Deiry 2005, Burz et al. 2009).
Necrosis, in contrast, occurs in cell populations or whole tissues, and results in
cellular swelling, organelle dissolution and chromatin lysis, where ultimately the plasma
membrane ruptures and the cellular contents leaks out (Figure 1.3). This leads to an
inflammatory response in the adjacent extracellular space and surrounding tissues
(Schwartzman and Cidlowski 1993, Jin and El-Deiry 2005). Also defined as accidental or
pathological cell death, necrosis occurs in response to a variety of harmful conditions,
including hyperthermia, hypoxia, direct cell trauma or exposure to toxic substances
(Schwartzman and Cidlowski 1993, Chamond et al. 1999, Holdenrieder and Stieber
2004).
Figure 1.3.: The morphological differences between apoptosis and necrosis (Adapted from
Direction maladies infectieuses et transmissibles, Aug 2009, available from
http://www.pasteur.be/_en/indexf273.html?page=cellular_microbiology)
1.2.1.1. Cell Death Pathways
Apoptosis can be activated by two distinct, yet linked, signaling pathways: the
death receptor (extrinsic) pathway and mitochondrial (intrinsic) pathway (MacFarlane
2009) (Figure 1.4). Both pathways stimulate initiator and effector caspases (cysteine-
dependent aspartate-specific proteases), present in cells as pro-caspases, thus, leading
9to caspase activation via the ‘caspase cascade’ (Holdenrieder and Stieber 2004,
MacFarlane 2009).
In the extrinsic pathway, activation of the cell surface death receptors CD95 ligand
(CD95-L) and tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)
(members of the TNF receptor superfamily of proteins) results in the formation of a ‘death-
inducing signaling complex’ (DISC), which activates the initiator pro-caspase-8 and -10,
whilst in the intrinsic pathway, mitochondrial stress (e.g., DNA damage) disturbs the
mitochondria, and results in the release of cytochrome c2 (Holdenrieder and Stieber 2004,
MacFarlane 2009). When released into the cytosol, cytochrome c binds to the apoptotic
protease-activating factor-1 (Apaf-1), resulting in the formation of an apoptosome
complex, which activates the initiator pro-caspase-9 (Igney and Krammer 2002,
MacFarlane 2009). Activation and cleavage of pro-caspase-8, -9 or -10 leads to activation
of effector caspases-3, -6 and -7, which in turn cleave and activate apoptotic cell death
(Igney and Krammer 2002).
Release of
Cytochrome c
TRAIL CD95
Figure 1.4.: Simplified representation of the key steps in apoptotic signaling pathways. CD95
ligand (CD95-L), tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and
apoptotic protease-activating factor-1 (Apaf-1)
2 Cytochrome c is released from the inner membrane space of the mitochondria, and is regulated
by members of the Bcl-2 family (anti-apoptotic members; Bcl-2, Bcl-xL and pro-apoptotic members;
Bax, Bak).
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1.3. Cancer Therapeutics and Epigenetics
Epigenetics, defined as “heritable changes in gene expression that occur without
changes in the DNA sequence” (Schemies et al. 2009), can explain the diversity of
phenotypes within a population (Esteller 2008). Classical epigenetic modifications, such
as, DNA methylation or histone acetylation, play an essential role in normal cell
physiology, where modifications can regulate, for example, the development and
progression of cancer (Carey and La Thangue 2006, Esteller 2008). Interestingly, histone
acetylation, and more so, histone deacetylation have been identified as therapeutic
targets (Ropero and Esteller 2007, Paris et al. 2008).
The recent development of drugs, which target epigenetic modifications, has
created a new class of chemotherapeutic agents: histone deacetylase (HDAC) inhibitors
(Carey and La Thangue 2006). Inhibition of HDACs (i.e., histone hyperacetylation via
HDAC inhibitors) can cause cell growth arrest, induce cell differentiation, changes in gene
expression, cell cycle arrest, and finally, apoptosis (Minucci and Pelicci 2006, Glaser
2007, Bieliauskas and Pflum 2008). However, only one HDAC inhibitor has been
approved so far by the U.S. Food and Drug Administration (FDA), suberoyl hydroxamic
acid (SAHA; Vorinostat; Figure 1.5), approved for the treatment of cutaneous T-cell
lymphoma (CTCL) (Mann et al. 2007, Richon et al. 2009). Therefore, the discovery of
drugs related to HDAC inhibition, and the development of combination strategies (i.e.,
epigenetic therapy with chemotherapy), remains of high importance, and could make it
possible to reduce toxicity, increase sensitivity, and remove resistance to current
therapies, which are the main reasons for unsuccessful cancer treatment (Kristensen et
al. 2009).
H
N
N
HO
O
OH
Figure 1.5.: Structure of SAHA
1.3.1. Histone Modifications
Eukaryotic DNA is packaged in core nucleosomes, which are composed of an
octamer of proteins called histones (2 copies each of H2A, H2B, H3 and H4) (Kristensen
et al. 2009). As histones are positively charged; an interaction with the negatively
charged phosphate groups allows DNA to wind tightly around the nucleosomes. This
interaction between histones and DNA, forms chromatin, which exist in two conformations
(i.e., open or closed). Conformational changes in living cells are highly reliant upon the
post-translational histone modifications: histone acetylation and histone deacetylation
(Figure 1.6). Histone acetylation involves the addition of an acetyl group to the lysine
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chains on histones, and is catalysed by histone acetyltransferases (HATs), whilst removal
of acetyl groups can be achieved by histone deacetylation, via histone deacetylases
(HDACs). Acetylation neutralises the positive charge of histones, thus, loosening their
interaction with DNA, and opening the chromatin structure (Kristensen et al. 2009).
Acetylation is associated with transcriptional activation (Legube and Trouche 2003), and is
involved in DNA proliferation, DNA repair and chromosomal organisation (Esteller 2008,
Kristensen et al. 2009).
Ac
Ac
Ac Ac
Ac
CH3
O
Acetyl group
Ac
Acetylation
(HAT)
Deacetylation
(HDAC)
Histone
DNA
DNA
Ac Acetyl groups
Lysine tails
Figure 1.6.: Epigenetic changes: histone acetylation and histone deacetylation
HDAC inhibition causes transcriptional deactivation, where the chromatin structure
closes, therefore, altering the overall structure of chromatin (Saunders and Verdin 2006).
As polyamines (Section 1.4) are important in altering the structure and conformation of
Deoxyribonucleic Acid (DNA), Ribonucleic Acid (RNA) and proteins (Childs et al. 2003);
they may also aide or hinder HDAC inhibition (Hobbs et al. 2002, Saunders and Verdin
2006). Saunders and Verdin (2006) found that polyamine depletion in human colon
cancer HCT116 cells blocked apoptotic cell death induced by HDAC inhibitors (the cyclic
tetrapeptide trapoxin A and short-chain fatty acid sodium butyrate). Thus, polyamines
appear to modulate the cellular response of HDAC inhibitors.
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1.4. Cancer Therapeutics and Polyamines
Polyamines play an essential role in normal cell proliferation and differentiation,
and their levels are regulated in accordance with the rate of cell growth. Inhibition of cell
proliferation and growth has, therefore, been associated with a decrease in polyamine
levels (Pegg 1988, Pegg and McCann 1982, Russell 1983, Davidson et al. 1999). In
addition, polyamines have been suggested to play a vital role in the development of
cancer, as it was observed by Wallace et al. (2000) and Wallace and Caslake (2001) that
breast and colon cancer cells have higher concentrations of polyamines, compared with
the equivalent normal cells. Polyamines were, thus, thought to be a biochemical marker
for cancer (Criss 2003). However, increased levels of polyamines are not only restricted
to individuals with cancer: elevated levels can also be found in individuals with Cystic
Fibrosis, Psoriasis, Duchenne Muscular Dystrophy, or even during pregnancy (Russell et
al. 1978, Wallace and Caslake 2001, Wallace and Fraser 2003, Larqué et al. 2007). As a
result, polyamines have a limited role as specific biochemical cancer markers.
Nevertheless, intracellular polyamine levels have been used as tools to determine the
efficiency of several novel polyamine derivatives as anti cancer agents (Porter and
Bergeron 1988, Wallace and Fraser 2003).
Over the last twenty years, particular attention was paid to the inhibition of the
polyamine biosynthetic and catabolic pathways (Bergeron et al. 1988, Casero and Woster
2009). Specific inhibitors have been identified for every enzyme in the polyamine
biosynthetic pathway i.e., ornithine decarboxylase (ODC), S-adenosyl methionine
decarboxylase (SAMDC), spermidine/spermine N1-acetyltransferase (SSAT) and
polyamine oxidase (PAO) (Casero and Woster 2001), however, their efficacy is limited
and none of these inhibitors has ever reached the pharmaceutical market.
Recent efforts have focused on the identification of novel derivatives that produce
cellular effects independent of, or in addition to, the inhibition of polyamine biosynthetic
enzymes; polyamine linker chains also continue to be used to improve the cellular uptake
of potential anti cancer agents (Casero and Woster 2009).
1.4.1. Polyamines
The naturally occurring polyamines, Spermidine (Spd) (C7H19N3) and Spermine
(Spm) (C10H26N4) and, the diamine, Putrescine (Put) (C4H12N2) (Figure 1.7) are present
within all eukaryotic cells (Tabor and Tabor 1985). They are small, water soluble, nitrogen
bearing long aliphatic polycation chains, which have multiple functions, particularly, within
the normal growth and proliferation of mammalian cells (Thomas and Thomas 2001).
Putrescine, spermidine and spermine also have specific roles in embryonic development
(i.e., increased polyamine synthesis in the foetus increases cell growth or accumulation of
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polyamines aides tooth development), cell cycle (i.e., depletion of polyamines by inhibition
of the polyamine biosynthetic pathway alters rate of cell cycle) and cancer (i.e.,
accumulation of putrescine and spermidine in cells favours malignant transformation)
(Gritli-Linde et al. 1995, Pegg 1988, Seiler et al. 1998, Larqué et al. 2007). Polyamines
have also been found to have a stimulating effect on DNA, RNA and protein synthesis
(Childs et al. 2003) and, can protect DNA, proteins and lipids from oxidative damage, as
they are scavengers of reactive-oxygen species (ROS) (Khuhawar and Qureshi 2001, Ah
Byun et al. 2009).
H2N
NH2
H2N
H
N NH2
Putrescine
1,4-Diaminobutane
Spermidine
N-(3-aminopropyl)butane-1,4-diamine
H2N NH
H
N NH2
Spermine
N,N'-bis(3-aminopropyl)butane-1,4-
diamine
Figure 1.7.: Structures of polyamines putrescine, spermidine and spermine
1.4.1.1. Polyamine Biosynthesis and Catabolism
Polyamines are endogenously synthesised and catabolised by two highly
regulated pathways: the biosynthetic pathway and the catabolic pathway (Figure 1.8).
Both pathways synthesise polyamines from each other (i.e., biosynthesis occurs in order
of putrescine, spermidine and spermine, whilst catabolism occurs in the reverse order), by
seven independent enzyme reactions (Seiler et al. 1996, Criss 2003, Wallace 2007).
In the biosynthetic pathway, polyamines are firstly synthesised via decarboxylation
of L-ornithine, by the enzyme ODC, which produces putrescine ([1] Figure 1.8).
Secondly, decarboxylation of S-adenosylmethionine (SAM) produces decarboxylated S-
adenosylmethionine, catalysed by SAMDC ([2] Figure 1.6). Thirdly, spermidine is derived
from putrescine by the addition of a propylamine group from SAM, by the action of the
enzyme spermidine synthase ([3] Figure 1.8). Finally, spermine is derived from
spermidine, by the enzyme spermine synthase and the addition of a second propylamine
group from SAM ([4] Figure 1.8) (Wallace et al. 2003, Larqué et al. 2007).
In the catabolic pathway, polyamine interconversion is controlled by two coupled
reactions: acetylation, controlled by the enzyme SSAT ([5] Figure 1.8), and cleavage, via
the action of the enzyme POA ([6] Figure 1.8) (Larqué et al. 2007). Additionally, a new
enzyme, spermine oxidase has recently been identified, which oxidises spermine to
produce spermidine with exclusion of the N-acetylation step ([7] Figure 1.8) (Wallace
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2007, Hector et al. 2008). Polyamines are also exogenously sourced from the diet by
active gut uptake (from cheese, fruit and vegetables), and by adsorption of intestinal and
pancreatic secretions (Larqué et al. 2007).
CO2 CO2
H2N NH
H
N NH2
H2N
NH2
H
N NH2H2N
SSAT
PAO
SSAT
PAO
S-adenosylmethionine
Decarboxylated S-adenosylmethionine
L-Ornithine
Putrescine
Spermidine
Spermine
N1-acetylspermidine
N1-acetylspermine
5-methyl thioadenosine
5-methyl thioadenosine
SPERMIDINE SYNTHASE
SPERMINE SYNTHASE
SAMDC ODC
L-Methionine
MAT
L-Arginine
ARGINASE
[1][2]
[3]
[4]
[5]
[5]
[6]
[6]
[7]
SPERMINE
OXIDASE
Figure 1.8.: The pathway of polyamine biosynthesis and catabolism. Methionine
adenosyltransferase (MAT), ornithine decarboxylase (ODC), S-adenosyl methionine decarboxylase
(SAMDC), polyamine oxidase (PAO) and spermidine/spermine N1-acetyl transferase (SSAT) ([n]
indicates each independent enzyme reaction, [n] = [1 - 7])
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1.5. Cancer Therapeutics and Polyamine Derivatives
Research within the field of polyamine derivatives was originally focussed upon the
synthesis and development of polyamine analogues and derivatives which inhibit specific
enzymes of the polyamine biosynthetic (ODC and/or SAMDC) and catabolic (SSAT and/or
PAO) pathways, as mentioned previously (Bergeron et al. 1988, Casero and Woster
2009) (Section 1.4; Figure 1.8). The shift away from the study of polyamine biosynthetic
or catabolic enzymes was due to their limitations as anti cancer agents. Current research
now focuses on the development of analogues that contain polyamine linker chains, in
order to improve transport into cells, via the polyamine transporter (PAT) (Seiler et al.
1996) or to serve as carriers (Casero and Woster 2009).
1.5.1. Symmetrical Bis(alkyl)Polyamine Derivatives as Anti
Cancer Agents
The first polyamine derivatives synthesised as anti cancer agents were the
symmetrical N-alkylated spermidine derivatives, comprising of a series of N4 spermidine
substituted derivatives (N4-methyl-spermidine, N4-ethyl-spermidine, N4-acetyl-spermidine,
N4-hexyl-spermidine, N4-hexanoyl-spermidine, N4-benzyl-spermidine and N4-benzoyl-
spermidine) (Porter et al. 1982), and N1, N8 spermidine derivatives [N1, N8-bis(ethyl)-
spermidine, N1, N8-bis(acetyl)-spermidine, N1, N8-bis(propyl)-spermidine and N1, N8-
bis(propionyl)-spermidine] (Porter et al. 1985). These derivatives were synthesised using
methodologies described by Bergeron (1986) and were structurally similar to the natural
polyamines (i.e., with terminal primary amines and various alkyl linker lengths) (Casero
and Woster 2009). Out of the 11 N-alkylated spermidine derivatives, only N4-hexyl-
spermidine (HSpd), N1, N8-bis (ethyl)-spermidine (BESpd) and, N1, N8- bis (propyl)-
spermidine (BPSpd) (Porter et al. 1985) (Figure 1.9) showed antiproliferative activity
against L1210 leukaemia cells (50% inhibition after 48 hours at 30, 40 and 50 µM,
respectively). BESpd was most effective at depleting putrescine and spermidine levels
and reducing spermine by approximately 50% after 96 hours (Porter et al. 1985). BESpd
also decreased the activity of ODC (98% decrease) and SAMDC (62% decrease) (Porter
et al. 1985). BESpd was thought to be acting as a biosynthetic enzyme regulator;
however, it could not control the normal functions of polyamines (i.e., cell growth) (Porter
et al. 1985).
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Figure 1.9.: Structures of bis (alkyl) spermidine derivatives: a: HSpd, b: BESpd and c: BPSpd
Following the positive results obtained from Porter et al. (1985), additional
symmetrical N-alkylated polyamines were synthesised to determine their structure activity
relationships, comprising of the series of N1, N12 dialkylated spermine derivatives
(Bergeron et al. 1988). The N1, N12 bis (methyl)-spermine (BMSpm), (N1, N12 bis (ethyl)-
spermine (BESpm) and N1, N12 bis-propyl spermine (BPSpm), were the most active
derivatives, in comparison with N1, N1, N12, N12 terminally tetra alkylated spermine
(TESpm), N4, N9 internally alkylated spermine (IDESpm) or 1, 20-bis (N-ethylamino) -
4,8,13,17-tetraazaeicosane (YANK) (Figure 1.10). The activity order was found to be
spermine derivatives (ethyl > propyl > methyl) > YANK > spermidine derivatives (Bergeron
et al. 1988). BESpm was the most cytotoxic analogue with IC503 values of 10 and 0.1 μM
after 48 and 96 hours, respectively (Bergeron et al. 1988). BESpm also demonstrated a
similar cytotoxicity against Daudi human Burkett’s lymphoma cells and promyelocytic
leukaemia HL-60 cells (IC50 values less than 1 µM after 96 and 144 hours in both cell
lines) (Bergeron et al. 1988). Further investigations by Porter et al. (1987) demonstrated
that BESpm had the potential to be both an antiproliferative agent (IC50 values after 48
hours of 1 µM in L1210 murine leukaemia cells), and also a probe for investigating the
regulation of the polyamine pathway (at 10 µM BESpm decreased ODC (99%) and
SAMDC (84%) activities (Porter et al. 1987).
3 IC50 (Inhibitory Concentration) is defined as the derivative concentration that causes 50% growth
inhibition of the cell population compared to that of control cells.
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Figure 1.10.: Structures of bis (alkyl) spermine derivatives: a: BMSpm, b: BESpm, c: BPSpm, d:
TESpm, e: IDESSpm and f: YANK
Pegg et al. (1989) further investigated the work of Bergeron, Porter et al. (1985,
1987 and 1988) regarding the symmetrical bis (alkyl) polyamine derivatives: BESpm, N1,
N11 Bis (ethyl) norspermine (BENSpm) and N1, N14 Bis (ethyl) homospermine (BEHSpm)
(Figure 1.11) on cellular polyamine metabolism in human colon HT-29 cancer cells. All
derivatives reduced intracellular polyamine levels (> 90% reduction by all derivatives), with
the greatest reduction in spermine levels (BENSpm, 94%; BESpm, 86%, and BEHSpm,
60%). These derivatives also brought about a greater reduction of polyamine levels than
a mixture of α-Difluoromethyl ornithine (DFMO, an inhibitor of ODC) and 5’-deoxy-5’-[N-
methyl-N-[2-(aminooxy) ethyl]) amino adenosine (MAOEA, an inhibitor of SAMDC) (Pegg
et al. 1989). ODC and SAMDC activity was decreased (Pegg et al. 1989, Bergeron et al.
1988), whilst SSAT activity was increased, thus promoting the degradation of polyamines
(Pegg et al. 1989, Creaven et al. 1997). However, the bis (alkyl) spermine derivatives,
like the bis (alkyl) spermidine derivatives, were unable to act as replacements for
polyamines and control the normal cell regulatory functions of polyamines.
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Figure 1.11.: Structures of bis (alkyl) spermine derivatives: a: BESpm, b: BENSpm and c:
BEHSpm
18
The most effective bis (alkyl) polyamine derivatives are BESpm and BENSpm
(Figure 1.11). BENSpm has undergone Phase I and II clinical trials (Creaven et al. 1997,
Streiff and Bender 2001, Hahm et al. 2002, Wolff et al. 2003). Although, it was found to
be safe with minimal toxicity, it did not show any significant clinical effects in the treatment
of breast and colon cancer (Streiff and Bender 2001, Hahm et al. 2002, Wolff et al. 2003,
Casero and Woster 2009). However, convincing preclinical data by Hector et al. (2008)
could allow the facilitation of a clinical trial, which would involve the combination of
BENSpm with two standard chemotherapeutic agents, oxaliplatin and 5-fluorouracil (5-FU)
to be used in the treatment of colorectal cancer.
1.5.2. Symmetrical Bis(alkyl)Polyamine Derivatives with
Modified Linker Chains as Anti Cancer Agents
A second generation of the symmetrical bis (alkyl) spermine derivatives (Figure
1.10 - 11) were synthesised with specific alterations to the flexible polyamine backbone of
BESpm. The derivatives consisted of conformational restrictions which were introduced
by replacement of the central butane linker region with a cis- and trans-cyclopropyl, a cis-
and trans-cyclobutyl ring, a cis- and trans- double bond, a triple bond or a 1, 2-
disubstituted aromatic ring (Figure 1.12).
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Figure 1.12.: Structures of conformationally restricted derivatives of BESpm: i, cis- and trans-
cyclopropyl, ii, a –cyclobutyl ring, iii, a cis- and trans- double bond, iv, a triple bond or v, a 1, 2-
disubstituted aromatic ring
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The cis- and trans-cyclopropyl (i), cis- and trans-cyclobutyl ring (ii) and cis- and
trans-double bond (iii) derivatives (Figure 1.12) showed low micromolar toxicity, with ID504
values of 0.01 – 2 µM after 6 days, against human lung A549, colon HT-29, prostate
DU145 and brain U251MG cancer cells, with less toxicity in prostate PC-3 and breast
MCF-7 (ID50 values of 0.24 - > 31.25 µM, after 6 days) cancer cells (Reddy et al. 1998).
No significant difference in toxicity was observed between the cis- or trans- conformations
of these derivatives (i, ii and iii), or the depletion of intracellular polyamine levels in
DU145 prostate cancer cells (Reddy et al. 1998). Reddy et al. (1998) synthesised two
further conformationally restricted derivatives of BESpm, iv and v (Figure 1.12),
containing a triple bond or a 1, 2-disubstituted aromatic ring, respectively. These
derivatives did not exhibit toxicity against any of the cancer cell lines investigated, except
in DU145 cancer cells, where ID50 values of 1.33 µM and 12.60 µM, were observed after 6
days, respectively. These derivatives did not deplete intracellular polyamine levels in
DU145 cells, however, it should be noted that iv and v were taken up by DU145 cancer
cells just as effectively as the other derivatives investigated (Reddy et al. 1998).
The cis-double bond derivative, cis-iii (CGC-11047) (Figure 1.13) is currently in
Phase I clinical trials for cancer treatment (Holst et al. 2006), and has been found to inhibit
the growth of small cell lung cancer H82 and H69, and non small cell lung cancer A549
and H157 cell lines (Hacker et al. 2008). Within the non small lung cancer cells, CGC-
11047 decreased ODC activity, significantly increased polyamine catabolism and depleted
polyamine pools. The same effects were observed to a lesser degree in the small lung
cancer cells (Hacker et al. 2008, Casero and Woster 2009). CGC-11047 is therefore a
promising new conformationally restricted polyamine analogue, although further preclinical
and clinical trials need to be undertaken.
N
H
N
H
N
H
N
H
Figure 1.13.: Structure of conformationally restricted BESpm analogue cis-iii (CGC-11047)
4 ID50 (Infectious Dose) is defined as the drug dose required to reduce the final cell number to 50%
of the control (Twentyman and Luscomber 1987).
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1.6. Cancer Therapeutics and DNA Intercalating Agents
DNA is an important biochemical target in the design of anti cancer therapeutic
compounds. Intercalating anti cancer compounds target DNA by interfering with the
processes of DNA replication and transcription (Lerman 1961, Palchaudhari and
Hergenrother 2007, Anderson et al. 2009), and classically contain planar or
heteroaromatic chromophores. DNA intercalating agents work by reversibly binding to
DNA, by insertion and stacking between the base pairs of the DNA double helix (Martinez
and Chacon-Garcia 2005, Kamel et al. 2007), thus resulting in the DNA partially
unwinding and lengthening. As a result, DNA replication and transcription is inhibited
(Thomas 2000, Palchaudhuri and Hergenrother 2007). Many intercalating anti cancer
agents also target topoisomerase II (TOPO II) activity. TOPO II is an essential enzyme
that has a critical role in the processes of DNA untangling and unknotting. The inhibition
of TOPO II can elevate the number of DNA double strand breaks, therefore, leading to
irreparable, permanent strand breaks, which may trigger apoptosis (Burden and Osheroff
1998, Hande 1998, Fortune and Osheroff 2000, Brana et al. 2001). Doxorubicin is an
example of an intercalating TOPO II poison (Figure 1.2)
Alongside, DNA intercalation compounds can also target DNA by electrostatic
interactions (non specific binding along the exterior of the DNA helix), or groove binding
interactions (specific binding with the edges of the base pairs in either the major or minor
grooves within the DNA double helix) (Brana et al. 2001, Martinez and Chacon-Garcia
2005) (refer to Chapter 3).
Several chemotherapeutic agents classically use DNA intercalation, for example
anthracyclines (e.g., doxorubicin and daunorubicin; Figure 1.2), and acridine (e.g.,
proflavin) derivatives (Demeunynck 2004, Ferguson and Denny 2007, Ashley and Poulton
2009). However, the DNA intercalating compounds of interest to this study are
naphthalimides and bisnaphthalimides. These derivatives intercalate by the planar
aromatic rings inserting between the base pairs of the DNA double helix, which distorts
the DNA backbone, and leads to their cytotoxicity against a panel of human cancer cell
lines (Brana et al. 1980, Brana et al. 2001, Brana and Ramos 2001, Kong Thoo Lin et al.
2003, Martinez and Chacon-Garcia 2005).
1.6.1. Naphthalimides
Mononaphthalimide compounds were designed and synthesised, in the 1970s.
They are comprised of the structural components of several anti tumour agents (the β-
nitronaphthalene of the aristolochic acid, the glutarimide rings of cycloheximide, CG-603,
and the basic side chain of tilorone) (Figure 1.14) into a single molecule. Napthalimides
were easily synthesised by condensation of 3-nitro-1,8-naphthalic anhydride with the
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corresponding amine, as described by Brana and Ramos (2001). Subsequently, a larger
group of naphthalimides were synthesised by Brana et al. (2001) and Brana and Ramos
(2001) which consisted of napthalimides with varying side chains, and ring substitutions.
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Figure 1.14.: Structure of anti tumour agents contributing to the design of naphthalimides
(important structural components are boxed in red)
A basic terminal group in the side chain is essential for cytotoxic activity, since
substitution of the nitrogen atom with a carbon, sulphur and oxygen atom resulted in
inactive compounds (Brana et al. 2001, Brana and Ramos 2001). A decrease in basicity
of the substitutes on the naphthalimido ring (i.e., at position 5) also reduced their activity
(Brana and Ramos 2001). The key structural requirements for optimal activity of
naphthalimides are shown in Figure 1.15.
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(CH2)n Y
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R
R = CH3, (CH2)4
Y = N
n = 2,3
X = NO2, NH2, OCH3
5
Figure 1.15.: Structure of the key structural requirements for monosubstituted naphthalimides
A quantitative structure activity relationship (QSAR) study was undertaken for
compounds substituted at position 5 (Figure 1.15), and the most active derivatives
screened and evaluated by the National Cancer Institute (NCI), in the USA (Brana and
Ramos 2001). The most active derivatives were named mitonafide (NSC 300288) and
amonafide (NSC 308847) (Figure 1.16), which were active in leukaemia (P388 and
L1210), and human cervical (HeLa and KB) cancer cells, respectively (Brana and Ramos
2001). Mitonafide and amonafide both bind to double stranded DNA by intercalation of
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the chromophore group and inhibit TOPO II action (Waring et al. 1979, Hsiang et al. 1989,
Brana et al. 1993, 2001, Chau et al. 2008). However, TOPO II inhibition was not
observed in naphthalimides, which lack the basic side chain (Brana and Ramos 2001).
NO2
N OO
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CH3H3C
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Figure 1.16.: Structures of a: Mitonafide and b: Amonafide
Mitonafide and amonafide have been extensively studied, and were selected for
Phase I and II clinical trials (Saez et al. 1989, Brana et al. 1993, Asbury et al. 1997, Brana
et al. 2001, 2004). During Phase I clinical trials, mitonafide resulted in inappropriate
central nervous system (CNS) toxicity in five patients treated with daily short (1 hour)
administration schedules, (doses above 118 mg/m2 x 5 days), resulting in an irreversible
loss of memory in all five patients, and in one case, leading to dementia (Llombart et al.
1992, Brana et al. 1997, Brana and Ramos 2001). This was considered to be due to a
dose-limiting toxicity, which was related to the short administration schedule (Llombart et
al. 1992). Further Phase I clinical trials which administered mitonafide as a continuous
120 hour infusion, did not result in CNS toxicity (Rosell et al. 1992, Casado et al. 1996).
However, slower administration resulted in a lack of efficacy of mitonafide in the treatment
of solid tumours, subsequently leading to the removal of mitonafide from further clinical
trials. Amonafide has also been removed from clinical trials (Ott et al. 2008), as it is
metabolised into an active metabolite N-acetyl amonafide, which is responsible for severe
myelosupression (Alami et al. 2007).
Other naphthalimides that are structurally similar to amonafide have been
synthesised to increase the potency of the mononaphthalimide series. One approach
involved the modification of the chromophore to include an anthracene moiety rather than
the simpler naphthalene (Brana et al. 1997, Brana and Ramos 2001). These compounds
were tested against human melanoma UAC375, ovarian OVCAR3 cancer and leukaemia
L1210 cells for their cytotoxicity (Brana and Ramos 2001). Azonafide (Figure 1.17) was
the most cytotoxic compound, with a higher cytotoxicity than Amonafide in all cell lines
(IC50 values ranged between 0.007 – 0.071 µM for azonafide, and 0.625 – 2.180 µM for
amonafide) (Sami et al. 1993, Brana et al. 1997, 2001, Brana and Ramos 2001).
Additional approaches included further substitutions to the chromophore, thus, resulting in
new types of phenanthrene and azaphenanthrene analogues of Azonafide (Brana et al.
2001).
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Figure 1.17.: Structure of Azonafide
1.6.2. Bisnaphthalimides
In the 1980s, Brana et al. (1993, 2001) designed and synthesised a new series of
symmetrical bis-intercalating compounds: the bisnaphthalimides. These compounds
comprised of key structural components of parent naphthalimides, and were synthesised
using a similar method (i.e., nucleophilic reaction of 1, 8-naphthalic anhydride with the
corresponding alkyltetraamine), as described by Brana et al. (1993, 1995, 2003). In
contrast to naphthalimides, the structure of bisnaphthalimides lead to improvements in the
DNA binding capacity, and, thus, the overall therapeutic profile of these compounds as
anti cancer agents (Brana and Ramos 2001). Bisnaphthalimides are composed of two
chromophore units (naphthalimido rings) linked together by linker chains containing at
least one or two amine groups (Figure 1.18), since in the mononaphthalimide series, the
amino group was proven to be essential for cytotoxic activity (Brana et al. 1993, 2001).
Thus, a series of compounds with different substitutions in the chromophore, as well as
differences in the length of the linker chain were designed and synthesised (Brana et al.
1993, Bailly et al. 2003).
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Figure 1.18.: Basic bisnaphthalimide structure (Z indicates the position of the linker chain)
Structural changes were found to improve the biological activity of these
compounds by increasing their cytotoxic activity in human colon HT-29 cancer cells, when
compared to the parent compounds (Brana et al. 1993, 2001). Cytotoxicity increased with
certain chromophore substitutions, in the order NO2 > H > NH2 > CH3CONH in compounds
with the same linker chain (IC50 values of 0.72, 2.70, 39.00 and >100 µM, respectively)
(Brana and Ramos 2001) (Figure 1.19). Also, the length and nature of the linker chain
was responsible for altered cytotoxicity (Brana et al. 1993, Brana and Ramos 2001).
However, the bisnaphthalimide compounds failed to provide an accurate structure activity
relationship, thus, suggesting different mechanisms of intercalation, even if TOPO II
activity had been significantly inhibited (Brana et al. 1993, Brana and Ramos 2001).
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Although, bisnaphthalimides had an increased cytotoxicity, compared with
naphthalimides; many were poorly soluble in aqueous solutions, which renders their
testing difficult (Brana et al. 1995).
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X
Figure 1.19.: Chromophore substituted bisnaphthalimide structure (X indicates the position of the
chromophore substitution; NO2, H, NH2 and CH3CONH)
In 1992, Du Pont Merck Pharmaceuticals synthesised a new series of non-
symmetric bisnaphthalimide compounds (Brana et al. 1995). These compounds
comprised of an acenaphthalimide chromophore to increase aqueous solubility, and a
conveniently substituted naphthalimide ring to produce anti tumour activity (Brana et al.
1995, Brana and Ramos 2001) (Figure 1.20). These compounds, however, were less
cytotoxic and did not drastically improve the aqueous solubility compared with the
symmetrical bisnaphthalimides (Brana et al. 1995).
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Figure 1.20.: Basic acenaphthalimide bisnaphthalimide structure
Interestingly, a study conducted by Bailly et al. (1996) found that
bisnaphthalimides could intercalate bifunctionally into the double helix via the major
groove. These derivatives were formed by linking two non-substituted naphthalimide
groups with a polyamine linker, and the derivatives bearing these structural features were
LU79553, (Elinafide), LU 77655 and LU84743 (Bailly et al. 1996) (Figure 1.21). The most
cytotoxic bisnaphthalimide, Elinafide, (Figure 1.21), had three methylene groups in its
linker chain, but lacked any substitutions to the chromophore (Bousquet et al. 1995, Brana
and Ramos 2001, Ralton et al. 2007). Elinafide was selected for Phase I and II clinical
trials in Europe and the USA (Bousquet et al. 1995, Bailly et al. 1996, Brana et al. 1993,
2001, 2003, Villalona-Calero et al. 2001). However, its future development as an anti
cancer agent has been delayed as Denny (2004) found that its dose-limiting toxicity (DLT)
was of a cumulative nature.
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Figure 1.21.: Structure of a: LU 79553 (Elinafide), b: LU77655 and c: LU 84743
Bisnaphthalimides have shown promise as DNA targeted anti cancer agents,
which intercalate with DNA and inhibit TOPO II action. To achieve this, the key features
required are (i) nitro substitutions in the chromophore rings (Brana et al. 1993), (ii) two
internal nitrogen atoms (Bailly et al. 1996), or (iii) an alkyl linker chain of at least 3
methylene groups (Bailly et al. 1996, Brana et al. 1997). However, as these compounds
are poorly soluble in aqueous solutions (Bailly et al. 2003), further studies are required to
improve this major obstacle (Brana et al. 2004).
1.6.3. Novel Bisnaphthalimidopropyl Polyamine Derivatives
Bisnaphthalimidopropyl polyamine (BNIPP) derivatives were initially designed and
synthesised, in 2000, by Kong Thoo Lin and Pavlov (2000), who incorporated natural
polyamines into the structure of bisnaphthalimides (e.g., elinafide, Figure 1.21). Kong
Thoo Lin and Pavlov (2000) theorised that the addition of more heteroatoms into the linker
chain would result in an increased aqueous solubility of bisnaphthalimides, hence,
improve their solubility, activity and, thus, their potential as anti cancer agents (Kong Thoo
Lin and Pavlov 2000). BNIPP derivatives were synthesised comprising of two
naphthalimido rings linked by the natural polyamines: putrescine, spermidine, spermine
and an oxa-polyamine (oxa-putrescine), using a three step reaction which incorporated
the synthetic strategies for bis (alkyl) polyamines (Bergeron 1986) (Section 1.5.1), and
bisnaphthalimide derivatives (Brana et al. 1993, Brana et al. 1995, Brana et al. 2003)
(Section 1.6.2), and introducing an N-alkylation reaction (Kong Thoo Lin and Pavlov
2000). The newly synthesised bisnaphthalimidopropyl putrescine (BNIPPut), spermidine
(BNIPSpd), spermine (BNIPSpm) contain 2, 3, or 4 nitrogen atoms in their linker chain,
respectively, whilst oxa-putrescine (BNIPOPut) has 2 nitrogen and 2 oxygen atoms in its
linker chain (Kong Thoo Lin and Pavlov 2000, Pavlov et al. 2001) (Figure 1.22).
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Figure 1.22.: Structures of bisnaphthalimidopropyl polyamine derivatives: BNIPPut, BNIPOPut,
BNIPSpd, BNIPSpm and BNIPOSpm
Cytotoxicity of the BNIPP derivatives was initially conducted at the National
Cancer Institute (NCI) in the USA, who determined an in vitro screen in a variety of human
cancer cell lines, including leukaemia, lung, colon, prostrate and breast cancer cells (Kong
Thoo Lin and Pavlov 2000). After 48 hours treatment, BNIPOPut (oxa-putrescine) was
the least cytotoxic derivative with a mean GI505 value of 68.55 μM, whereas BNIPPut,
BNIPSpd and BNIPSpm exhibited 0.58, 1.42 and 4.31 μM mean GI50 values, respectively
(Kong Thoo Lin and Pavlov 2000). Cytotoxicity was in the order of BNIPPut, followed by
BNIPSpd, BNIPSpm and then BNIPOPut (Kong Thoo Lin and Pavlov 2000). However, in
previous bis (alkyl) polyamine derivative screens, spermine derivatives tended to be more
cytotoxic than spermidine derivatives (Section 1.5.1), in contrast with the results obtained
for BNIPP derivatives. Results also showed that the cytotoxicity and aqueous solubility of
BNIPP derivatives was dependent upon the length of the polyamine linker chain (i.e.,
shorter polyamine; greater cytotoxicity), and the number of heteroatoms in the compound
(i.e., more heteroatoms; greater aqueous solubility, whilst the introduction of oxygen
atoms dramatically decreased cytotoxicity) (Kong Thoo Lin and Pavlov 2000, Pavlov et al.
2001). BNIPPut and BNIPOPut were not, however, used in further studies, because they
were insoluble in both water and 10% DMSO (although soluble in 10% DMSO after
heating) (Kong Thoo Lin and Pavlov 2000).
5 GI50 (Growth Inhibition) is defined as the concentration required for 50 % inhibition of cell growth,
compared to that of untreated cells (Kong Thoo Lin and Pavlov 2000).
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Interestingly, BNIPPut, BNIPSpd and BNIPSpm were found to be highly selective
against breast cancer cells. As BNIPPut, BNIPSpd and BNIPSpm were 202-, 443- and
24-fold more active against breast cancer HS 578T cells than NCI/ADR-RES cells,
respectively (Kong Thoo Lin and Pavlov 2000).
Pavlov et al. (2001) expanded the work of Kong Thoo Lin and Pavlov (2000) by
investigating the cytotoxic properties of BNIPSpd, BNIPSpm and BNIPoxa-spermine
(BNIPOSpm) (Figure 1.22) in human breast cancer MCF-7 cells. The DNA binding
properties and nuclear localisation of these derivatives were also investigated by Pavlov
et al. (2001). All BNIPP derivatives were capable of significantly inhibiting the growth of
MCF-7 cells, with IC50 values for BNIPSpd, BNIPSpm and BNIPOSpm of 1.38, 2.91 and
8.45 μM, respectively (Pavlov et al. 2001). BNIPOSpm, although the least cytotoxic, had
the highest DNA binding affinity, followed by BNIPSpd and BNIPSpm (Δ Tm6 of 22.0, 20.6
and 18.3 °C compared to Calf Thymus DNA without BNIPP derivative, respectively)
(Pavlov et al. 2001). The fluorescent properties of the BNIPP derivatives were exploited,
and all derivatives were located in the cell nuclei of the MCF-7 cells, after 8-hours
treatment (Pavlov et al. 2001). These results support those of Kong Thoo Lin and Pavlov
(2000); as cytotoxicity remains dependent upon the length of the polyamine linker (i.e.,
shorter polyamine (BNIPSpd); greater cytotoxicity), and the number of heteroatoms (i.e.,
more heteroatoms (BNIPOSpm); lower cytotoxicity) (Pavlov et al. 2001, Pavlov et al.
2002). Finally, BNIPP derivatives were found to bind to DNA by intercalation and groove
binding (Pavlov et al. 2001); a similar mode of action to that of the parent
bisnaphthalimides (Brana and Ramos 2001).
A study undertaken by Kong Thoo Lin et al. (2003) discovered, for the first time
that BNIPSpd and BNIPSpm induced apoptotic cell death in human leukaemia HL-60
cells. HL-60 cells treated for 24 hours with BNIPSpd and BNIPSpm showed
characteristics of undergoing apoptotic cell death, in particular, HL-60 cells treated with
BNIPSpd (Kong Thoo Lin et al. 2003). Again, this study can be compared with the
previous studies of Kong Thoo Lin and Pavlov (2000) and Pavlov et al. (2001), as
cytotoxicity, and also DNA binding affinity of BNIPP derivatives is dependent upon the
nature of the polyamine linker chain (Kong Thoo Lin et al. 2003).
6
Δ Tm is defined as the melting temperature difference between drug treated Calf Thymus DNA
and Calf Thymus DNA without drug.
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Figure 1.23.: Structures of bisaminooxypropylnaphthalimido polyamine derivatives: BNIPOPut,
BNIPOSpd and BNIPOSpm
A further extension of the original work by Kong Thoo Lin and Pavlov (2000),
involved the synthesis of three new bisaminooxypropylnaphthalimido polyamine
derivatives, BNIPOPut, BNIPOSpd and BNIPOSpm (Figure 1.23), where oxygen atoms
were introduced into the α-position of the naphthalimido ring (Dance et al. 2005). Dance
et al. (2005) rationalised that synthesising these new BNIPP derivatives would show an
enhancement of aqueous solubility, without affecting cytotoxicity. The results obtained for
the new BNIPP derivatives were compared with BNIPSpd and BNIPSpm (Dance et al.
2005) and showed that solubility of these new BNIPP derivatives was increased, and all
derivatives had good solubility properties in 20% DMSO. However, the presence of
oxygen atoms in the α-position caused a decrease in cytotoxicity in MCF-7 cells. After 24
hours, BNIPOPut and BNIPOSpm were the least cytotoxic derivatives with IC50 values of
> 50 µM, whereas BNIPSpd, BNIPSpm and BNIPOSpd exhibited IC50 values of 1.5, 13.3
and 32.1 µM, respectively (Dance et al. 2005). This order of cytotoxicity was the same
after 48 hours (i.e., BNIPSpd > BNIPSpm > BNIPOSpd > BNIPOSpm > BNIPOPut).
Therefore, cytotoxicity was again highly reliant on the nature of the polyamine linker chain
between the two napthalimido rings (Kong Thoo Lin and Pavlov 2000, Pavlov et al. 2001,
Kong Thoo Lin et al. 2003, Dance et al. 2005). In addition, this study also revealed that
bisnaphthalimidopropyl functionality was essential for optimum cytotoxicity, as an oxygen
atom in the α-position, reduced cytotoxicity (Dance et al. 2005). All BNIPP derivatives,
irrespective of the polyamine linker chain, were able to interact with DNA in the order
BNIPSpd > BNIPSpm > BNIPOSpd > BNIPOSpm > BNIPOPut (Dance et al. 2005),
suggesting, therefore, a relationship between DNA binding affinity and cytotoxicity. The
most active BNIPP derivatives, BNIPSpd and BNIPSpm, alongside BNIPOSpm were
selected for DNA damage studies. After 4 hours, BNIPSpd and BNIPSpm caused
significant DNA damage (at 0.1 µM); however, BNIPOSpm did not achieve a similar level
of DNA damage to that of BNIPSpm after 12 hours treatment in MCF-7 cells (Dance et al.
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2005). These results highlight the importance of DNA as a biological target for BNIPP
derivatives.
Further syntheses of bisnaphthalimidopropyl di- [diamino-octane (BNIPDaoct),
diamino-nonane (BNIPDanon) and diamino-decane (BNIPDadec)], and triamines
[dipropyl-triamine (BNIPDpta) and diethyltriamine (BNIPDeta)] (Figure 1.24), based on the
parent derivative, BNIPSpd, were synthesised to modify the central linker chain by
introducing different alkyl lengths with 2 or 3 nitrogen atoms (Oliveira et al. 2007). Oliveira
et al. (2007) were, thus, modulating the number of positive charges present within each
BNIPP derivative, and its effect on cytotoxicity in human colon cancer CaCO-2 cells. After
24 hours, all BNIPP derivatives, except BNIPDeta (IC50 value of 21.7 µM) exerted IC50
values in the range of 0.47 – 6.20 µM, with the order of cytotoxicity the same after 48
hours (Oliveira et al. 2007). The results also demonstrate that removing a nitrogen atom
from the linker chain did not affect cytotoxic properties. Interestingly, Oliveira et al. (2007)
showed that by increasing the length of the linker chain; aqueous solubility increased.
Previously, when an alkyl linker was a butyl linker, the BNIPP derivative (BNIPPut) was
not soluble in water or 10% DMSO (Kong Thoo Lin and Pavlov 2000). Therefore,
aqueous solubility is also highly reliant on the nature of the polyamine linker chain.
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Figure 1.24.: Structures of bisnaphthalimidopropyl polyamine derivatives: BNIPDaoct, BNIPDanon,
BNIPDadec, BNIPDpta and BNIPDeta
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The most recent study conducted by Ralton et al. (2009) focused on BNIPSpd
treatment in human colon cancer CaCO-2 and HT-29 cells. After 48 hours, BNIPSpd was
more cytotoxic in CaCO-2 cells (IC50 0.15 µM) compared to HT-29 cells (IC50 1.64 µM)
(Ralton et al. 2009). In both cell lines, BNIPSpd induced significant DNA damage after 4
hours, caused cell death by apoptosis, and depleted intracellular spermidine and
spermine levels after 24 hours (Ralton et al. 2009), suggesting that BNIPP derivatives
primarily induce apoptosis in colon cancer cells (Ralton et al. 2009).
Bisnaphthalimidopropyl polyamine (BNIPP) derivatives have been shown to enhance
solubility and activity, which provides a good basis for their further development as
potential anti cancer agents (Ralton et al. 2007).
Interestingly a recent publication by Filosa et al. (2009) described the synthesis of
a series of bisnaphthalimide derivatives containing heterocyclic and other cyclic moieties
inserted into the linker chain, for example, piperazine, cis-dimethylpiperazine, diazabicyclo
[3.2.1] octane or cyclopropane groups. This group have modified the N-alkylation reaction
originally developed by Kong Thoo Lin and Pavlov (2000). After 72 hours, N1, N1-bis [2-
(5-nitro-1, 3-dioxo-2,3-dihydro-1H-benz[de]-iso-quinolin-2-yl)]propane-2-ethanediamine
(Figure 1.25) was identified as the most active derivative with an IC50 value of 0.50 µM, in
HT-29 cells (Filosa et al. 2009). This derivative was also found to effectively intercalate
with DNA, and significantly induce apoptosis (40% at 0.1 µM) in HT-29 cells (Filosa et al.
2009).
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Figure 1.25.: Structure of N1, N1-bis [2-(5-nitro-1, 3-dioxo-2,3-dihydro-1H-benz[de]-iso-quinolin-2-
yl)]propane-2-ethanediamine
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1.7. Aims of Project
The aim of this project was to synthesise new BNIPP derivatives and determine
their cytotoxicity and mode of action within a breast cancer cell system. This study was
undertaken to complement and further previous studies on breast cancer MCF-7 cells,
human leukaemia HL-60 cells and, colon cancer CaCO-2 and HT-29 cells (Kong Thoo Lin
and Pavlov 2000, Pavlov et al. 2001, Dance et al. 2005, Ralton 2006, Oliveira et al. 2007,
Ralton et al. 2009).
Four novel BNIPP derivatives were synthesised based on synthetic methods
previously described by Kong Thoo Lin and Pavlov (2000), Dance et al. (2005) and
Oliveira et al. (2007). These derivatives were synthesised to highlight and confirm the
importance of the common features found within BNIPP derivatives, and demonstrate, in
particular, that the bisnaphthalimido moiety was essential for biological activity.
As BNIPP derivatives have been previously shown to bind to DNA by bis-
intercalation (Pavlov et al. 2001, Dance et al. 2005), a selection of BNIPP derivatives were
investigated for their DNA binding affinities by examination of DNA binding capacity and
competitive displacement, and by molecular modelling.
Human MDA-MB-231 breast adenocarcinoma cells and human MCF-10A breast
epithelial cells were used, in order to establish a structure-activity relationship and to
determine the biological activity of BNIPP derivatives on cell morphology, and cellular
uptake and distribution. BNIPP derivative affinity for the MGBG-specific polyamine
transport system and their ability to reduce intracellular polyamine levels were also
investigated. Breast cancer MDA-MB-231 cells were chosen in this study to expand and
compare work which had been undertaken in breast cancer MCF-7 cells (Pavlov et al.
2002, Dance et al. 2005). MCF-7 cells are oestrogen receptor dependent (oestrogen
positive; ER+), and exhibit a favourable response to chemotherapy, whereas MDA-MB-
231 cells are oestrogen receptor independent (oestrogen negative; ER-), highly invasive
and do not respond well to current chemotherapy treatments (Koutsilieris et al. 1999,
Lacroix and Leclercq 2004). For that reason, the MDA-MB-231 cells can provide a
reliable model by which to study the effects of BNIPP treatment on breast cancer cells that
are highly resistant to chemotherapy.
Furthermore, the effect of BNIPP derivative treatment on MDA-MB-231 cells, in
relation to DNA damage and natural DNA repair mechanisms were investigated. BNIPP
derivatives have also been shown to induce apoptotic cell death in HL-60, HT-29 and
CaCO-2 cells (Kong Thoo Lin et al. 2003, Ralton 2006). Further investigations into the
mode of cell death were undertaken in this study by examination of early apoptotic cell
death and cell cycle distribution. In addition, the effects of BNIPP derivatives on p53 and
p21Waf1/Cip1 gene expression were investigated. Finally, the effect of BNIPP derivatives on
histone deacetylase (HDAC) inhibition was studied after encouraging observations by
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colleagues in Portugal (Tavares et al. 2010). Tavares et al. (2010) identified for the first
time that BNIPP derivatives were inhibitors of the human SIRT1 enzyme (e.g., IC50 value
of 116.5 and 97.4 µM for BNIPDaoct and BNIPDanon, respectively). Recently, HDAC
inhibitors (HDACi) have shown promise as anti cancer agents and have, thus, aided the
interest of screening BNIPP derivatives as potential HDAC inhibitors (Taylor et al. 2008,
Cang et al. 2009, Casero and Woster 2009, Epping and Bernards 2009).
1.7.1. Layout of Thesis
The results chapters (Chapters 2 – 7) have been arranged, so that each individual
chapter has its own specific introduction, material and methods, results, discussion and
conclusion sections so to provide an in depth analysis of each area.
Chemical synthesis and characterisation of BNIPP derivatives are fully explained
in Chapter 2. DNA binding and molecular modelling studies of BNIPP derivatives are
described in Chapter 3. Cell morphology, cytotoxicity, cellular uptake and distribution,
polyamine transport and effect on polyamine intracellular levels by BNIPP derivatives are
explained in Chapter 4, whilst the extent of DNA damage and the effect on repair
mechanisms are explained in Chapter 5. Chapter 6 focuses on the effect of BNIPP
derivatives on apoptotic cell death, cell cycle distribution, p53 and p21Waf1/Cip1 mRNA
levels, whereas Chapter 7 describes HDAC inhibition by BNIPP derivatives.
The final chapter (Chapter 8) combines all the findings from this study into an
integrated final summary, which includes concluding and future work sections.
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Chapter 2
Synthesis of Novel Bisnaphthalimidopropyl
Polyamine Derivatives
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2.1. Synthesis of Novel Bisnaphthalimidopropyl
Polyamine Derivatives
A number of bis(alkyl)polyamine analogues have previously been published
indicating their potential anti cancer properties. These compounds have the ability to
inhibit cell growth in a variety of cancer cell lines, for example, in leukaemia (L1210),
Burkett’s lymphoma (Daudi), colon (HT-29), prostrate (DU145), ovarian (OVCAR3) and
breast (MCF-7) cancer cells (Porter et al. 1985, Bergeron et al. 1988, Pegg et al. 1989,
Reddy et al. 1998, Brana and Ramos 2001, Pavlov et al. 2001). Polyamine analogues
have been shown to deplete intracellular polyamine levels, and in some cases, have
decreased the activity of certain important enzymes within the polyamine biosynthetic
pathway (Porter et al. 1985, Pegg et al. 1989). Furthermore, several analogues including
cis-iii (CGC-11047) are currently undergoing Phase I and II clinical trials (Casero and
Woster 2009) (Figure 1.13).
Naphthalimido and bisnaphthalimido derivatives have also revealed potential anti
cancer properties. These derivatives bind to DNA by intercalation, where the planar
aromatic rings insert between the base pairs of the DNA double helix, thus resulting in
cytotoxicity within several cancer cell lines including melanoma (UAC375) and colon (HT-
29) cancer cells (Brana et al. 2001, Brana and Ramos 2001). The naphthalimide
Amonafide and the bisnaphthalimide Elinafide were selected for Phase I and II clinical
trials (Brana et al. 2003). Following on from these derivatives, Bisnaphthalimidopropyl
polyamine (BNIPP) derivatives, linked to the natural polyamines with diamino and triamino
alkyl linker chains were synthesised by Kong Thoo Lin and Pavlov (2000). These BNIPP
derivatives were synthesised to overcome the biological obstacles faced by
bisnaphthalimides with regards to their aqueous insolubility and delivery (Ralton et al.
2007). BNIPP derivatives were found to demonstrate enhanced aqueous solubility, and
exhibited in vitro anti cancer activity (Kong Thoo Lin and Pavlov 2000, Pavlov et al. 2001,
Dance et al. 2005).
The aim of the experimental work presented in this chapter was to synthesise and
characterise several new members of the BNIPP derivative series: two
bisnaphthalimidopropyl diamino derivatives; a bisphthalimidopropyl diamino derivative and
a mononaphthalimidopropyl derivative (Figure 2.1).
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Figure 2.1.: Structures of Bisnaphthalimidopropyl diaminooxaoctane (BNIPDaoxoct),
Bisnaphthalimidopropyl diaminodicyclohexylmethane (BNIPDaCHM), Bisphthalimidopropyl
diaminodecane (BPHPDadec) and mononaphthalimidopropylamine (NPA)
The general synthetic methods used to synthesise the bis(alkyl)polyamine
analogues, naphthalimides, bisnaphthalimides, and BNIPP derivatives relevant to this
project are described below (Sections 2.1.1 – 2.1.5).
2.1.1. General Synthetic Method for Symmetrical
Bis(alkyl)Polyamine Analogues
The most extensively studied symmetrical bis(alkyl)polyamine analogue, Bis-
ethylspermine (BESpm) was synthesised by Bergeron and colleagues in 1988. BESpm
and subsequent bis (ethyl) analogues have been synthesised in a three step reaction [1-
3] (Figure 2.2). The starting material used was the commercially available spermine
tetrahydrochloride, which was protected and activated by p-toluenesulfonyl chloride (Ts-
Cl) in dry dichloromethane, at room temperature, for 48 hours [1]. The resulting
sulfonamide was treated with sodium hydride in dimethylformamide (DMF), in the
presence of excess ethyl iodide which yielded N1, N12 Bis-ethyl – N1, N4, N9, N12
tetratosylspermine [2]. Deprotection of the sulfonyl protecting groups was carried out by
treatment with sodium in liquid ammonia at -78 °C for 4 hours, to give N1, N12 Bis-
ethylspermine. N1, N12 Bis-ethylspermine was purified as a hydrochloride salt [3]
(Bergeron et al. 1988). The synthesis of BESpm and its analogues is simple and only
dependent upon the availability of the starting material, the parent polyamine backbone.
This method is amenable to larger scale synthesis.
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Figure 2.2.: General synthetic method for the synthesis of N1, N12 bis-ethylspermine (BESpm).
Reagents and conditions: [1] Ts-Cl, CH2Cl2, 10% NaOH (aq), RT, 48 h [2] NaH, DMF, Ethyl iodide,
0 °C, 1 hr, reflux at 70 – 80 °C, 12 h [3] THF, Na spheres in liquid NH3, -78 °C, 4 h.
2.1.2. General Synthetic Method for Confomationally
Restricted Bis(alkyl)Polyamine Analogues
The conformationally restricted bis(alkyl)polyamine analogues of BESpm were
synthesised by Reddy and colleagues (1998) by a general synthetic strategy again
consisting of a three step reaction [1-3] (Figure 2.3). The common starting material was a
cis-trans-1,2-bis (mesitylenesulfonyloxy)methyl compound, prepared from either the
commercially available cis-trans-1,2-bis(dihydroxymethyl)cyclopropane, cis-trans-1,2-
bis(dihydroxymethyl)cyclobutane, cis-trans-2-butenediol, butyne-1,4-diol or benzene-1,2-
dimethanol molecules by esterification [1]. Protection and activation of the N1-
ethylpropane-1, 3-diamine was carried out with mesitylenesulfonyl chloride (Mts) in
sodium hydroxide and dioxane at room temperature for 18 hours. For the synthesis of the
fully protected conformationally restricted analogues, N-alkylation with N-Ethyl-N-(3-
(mesitylenesulfonylamino)propyl)mesitylenesulfonamide, in the presence of sodium
hydride and anhydrous DMF, yielded the fully protected analogues [2]. Deprotection to
release the amino groups was carried out by established procedures using phenol and
hydrogen bromide in glacial acetic acid at room temperature for 48 hours, to give
3,7,13,17-tetraaza-9,10-[(E)-1,2-cyclopropyl] octadecane, 3,7,13,17-tetraaza-9,10-[(Z)-
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1,2-cyclopropyl]octadecane, 3,7,13,17-Tetraaza-9,10-[(E)-1,2-cyclobutyl]octadecane,
3,7,13,17-Tetraaza-9,10-[(Z)-1,2-cyclobutyl]octadecane, (E)-3,7,12,16-Tetraazaoctadec-9-
ene, (Z)-3,7,12,16-Tetraazaoctadec-9-ene, 3,7,12,16-Tetraazaoctadec-9-yne and 9,10-
Benzo-3,7,12,16-tetraazaoctadecane, as their corresponding tetrahydrochloride salts [3]
(Bergeron et al. 1994, Roemmele and Rapoport 1988, Reddy et al. 1998).
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Figure 2.3.: Example of the general synthetic method for the synthesis of conformationally
restricted BESpm analogues. Example shown for the synthesis of 3,7,13,17-Tetraaza-9,10-[(E)-
1,2-cyclopropyl] octadecane. Reagents and Conditions: [1] Pyridine, Mts, 25 °C, 3 h [2] N-Ethyl-N-
(3-(mesitylenesulfonylamino)propyl) mesitylenesulfonamide, NaH, DMF, 70 °C, 4 h [3] HBr/glacial
CH3CO2H in Phenol, RT, 48 h.
2.1.3. General Synthetic Method for Naphthalimide
Derivatives
As indicated in Section 1.6, the intercalating compounds relevant to this research
project are the naphthalimides and bisnaphthalimides which were first synthesised by
Brana and colleagues (2001) (Figure 2.4).
NO2
O OO
N
NH2
OO
N CH3H3C
CH3H3C
NO2
N OO
N
O
NH2
OO
[3]
[1]
[2]
Figure 2.4.: General synthetic method in the synthesis of mitonafide [1] and amonafide [2-3].
Reagents and conditions: [1] NH2(CH2)2N(CH3)2, C2H5OH, reflux, 2 h [2] H2/Pd [3]
NH2(CH2)2N(CH3)2, C2H5OH, reflux, 2 h
The synthesis of Mitonafide and Amonafide, the most active compounds in the
naphthalimide series were synthesised by one step and two step reactions, respectively
(Brana et al. 1993, 2001). The starting material, 3-nitro-1,8-naphthalic anhydride was
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used in the synthesis of both mitonafide and amonafide. 3-nitro-1, 8-naphthalic anhydride
and N, N-dimethylethylenediamine were refluxed in ethanol for 2 hours to produce
mitonafide [1]. 3-nitro-1, 8-naphthalic anhydride was first hydrogenated over 10 %
palladium on carbon (Pd/C) to give 3-amino-1, 8-naphthalic anhydride [2] followed by the
addition of N, N-dimethylethylenediamine, which were refluxed in ethanol for 2 hours to
produce amonafide [3] (Brana et al. 2001).
The two step synthesis of amonafide is simple but is highly dependent upon the
availability of 3-amino-1, 8-naphthalic anhydride. 3-amino-1, 8-naphthalic anhydride is not
readily available in vast quantities, thus making its pharmaceutical preparation
exceedingly difficult. Several scaled up variations to the methods described have been
approved, therefore, allowing the production of amonafide in acceptable pharmaceutical
quantities (Ajami and Barlow 2004, Brown 2005).
2.1.4. General Synthetic Method for Bisnaphthalimide
Derivatives
Due to the success of the naphthalimide derivatives, Brana and colleagues (1993,
2001) designed and synthesised bisnaphthalimide derivatives. The derivatives were
based on the most active naphthalimides: mitonafide and amonafide.
The general synthesis for the preparation of bisnaphthalimide derivatives was
similar to that of naphthalimide derivatives. A nucleophilic reaction of 1, 8-naphthalic
anhydride with the corresponding alkyltetraamine in a 2:1 ratio was refluxed in ethanol,
until reaction completion (Brana et al. 1993, Brana et al. 1995, Brana et al. 2003) (Figure
2.5).
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Figure 2.5.: General synthetic method in the synthesis of bisnaphthalimides [1] reflux, C2H5OH (X
and Y indicates the position of the chromophore substitution; NO2, H, NH2 and CH3CONH. Z
indicates the position of the linker chain).
2.1.5. General Synthetic Method for Bisnaphthalimidopropyl
Polyamine (BNIPP) Derivatives
BNIPP derivatives were synthesised by Kong Thoo Lin and Pavlov in 2000, with
the subsequent synthesis of additional BNIPP derivatives in 2005 (Dance et al. 2005).
The general synthetic strategy used to synthesise the BNIPP derivatives involves a three
step reaction [1-3], by combining the synthetic strategies for bis (alkyl) polyamine and
bisnaphthalimide analogues (Figure 2.6).
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Figure 2.6.: General synthetic method in the synthesis of bisnaphthalimidopropyl polyamine
derivatives. [1] Ts-Cl, pyridine, 4 °C, 4h [2] DMF, Mts, Cs2CO3, 85 °C, 12 h [3] HBr/glacial
CH3CO2H in CH2Cl2 , RT, 24 h. (Z indicates the position of the linker chain).
The common intermediate was toluenesulfonyloxypropylnaphthalimide, which was
prepared from N-(3-hydroxypropyl) naphthalimide upon reaction with Ts-Cl, at 4 °C for 12
hours [1] (Figure 2.6). Protection and activation of the natural polyamines, diamines and
triamines was carried out with mesitylenesulfonyl chloride (Mts) in pyridine at room
temperature for 4 hours. Fully protected BNIPP derivatives were obtained by N-alkylation
of mesitylatediamines with toluenesulfonyloxypropylnaphthalimide, in the presence of
caesium carbonate in anhydrous DMF. This reaction successfully yielded fully protected
BNIPP derivatives. Deprotection of the Mts groups with hydrobromic acid/glacial acetic
acid in CH2Cl2, at room temperature, for 24 hours, afforded BNIPP derivatives as their
corresponding dihydrobromide salts [2-3] (Figure 2.6) (Kong Thoo Lin and Pavlov 2000,
Dance et al. 2005).
2.1.6. Instrumental Techniques for Identification and
Characterisation of Derivatives
The instrumental techniques employed to characterise the products at each
reaction stage were Thin Layer Chromatography (TLC), Nuclear Magnetic Resonance
(NMR) and Mass Spectrometry (MS). TLC is a straightforward and low-cost separation
technique, which is widely used in the rapid identification of several components within a
solution (Braithwaite and Smith 1994). TLC was used to determine reaction completion
and compound purity at each stage. For TLC determination, a silica gel aluminium plate
(adsorbent stationary phase) was spotted with a small drop of the mixture, using a micro
pipette. Once dry, the silica gel plate was placed and stood vertically in a solvent (mobile
phase) within a TLC development tank. As the solvent travels up the plate by capillary
action, the components in the solution travel at different rates, thus separating the mixture
into discrete spots. The spots are visualised under UV-light (Figure 2.7).
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Figure 2.7.: A TLC development tank (Left) and thin-layer chromatogram (Right). (KEY: - R.
Reactant Mixture, M. Mix of Reactant and Product and P. Product Mixture)
Nuclear Magnetic Resonance (NMR) is an important and powerful analytical tool,
which was used to determine and characterise the complete structure of each
intermediate and the final products. NMR samples were prepared by dissolving the
sample in a deuterated solvent, for example, Chloroform-D (CDCl3) or Dimethyl Sulfoxide-
D6 (DMSO-d6). This solution was transferred to an NMR tube, capped and introduced
into the NMR instrument. The sample was lowered into the NMR probe, rotated, locked,
shimmed, then acquired and processed by Bruker Topspin 1.3 software, to give an NMR
spectrum.
In essence, NMR spectroscopy relies upon the magnetic properties (nuclear spin)
of specific atomic nuclei, in particular, proton (1H or hydrogen) and carbon-13 (13C) nuclei.
1H NMR allows the detection of protons, whereas 13C NMR detects carbon nuclei, both in
relation to their immediate environments. Another 13C NMR experiment, Distortionless
Enhancement of Polarisation Transfer (DEPT-135), can be used to verify similar
information to that of 13C NMR. For DEPT-135 NMR, the -CH3 and CH signals appear
above the baseline but the -CH2- signals appear inverted (below the baseline).
Quaternary carbons are not visible using this 13C NMR technique. Therefore, DEPT-135
can be used to confirm the number of hydrogens attached to carbons within a compound
(Figure 2.8). 1H and 13C NMR are observed at different frequencies, 400.1 and 100.6,
respectively. Therefore, the complete chemical structure of a compound can be
successfully determined by 1H, 13C and DEPT-135 NMR (Loudon 2002b).
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Figure 2.8.: An example of the 13C and DEPT-135 spectra of Ibuprofen (Highlighted signals
indicate quaternary carbons which are not visible in DEPT-135 and -CH2- groups which appear
inverted)
Alongside NMR spectroscopy, Mass Spectrometry (MS), was employed to
determine the purity and molecular mass of final BNIPP derivatives and their fragments.
As a result, MS was used to verify the structure of each new member of the BNIPP
derivative series. The basic principle of MS is to generate and separate charged
molecules according to their mass-to-charge ratio (m/z): the mass of an ion, using an
electric and/or magnetic field. Molecules are firstly introduced into the MS, through an
inlet and, converted to a charged or ionised form by an ion source. Several ionisation
methods exist, but the preferred method used in the analysis of BNIPP, BPHP and NPA
derivatives was Electrospray Ionisation (ESI). ESI was used for both low and high
resolution MS. The basis of ESI is to atomise a sample solution into highly charged
droplets, thus producing negatively charged ions which are accelerated into a mass
analyser, amplified and detected, upon which a mass spectrum is produced (Siuzdak
1996, Loudon 2002a).
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2.2. Materials
2.2.1. Materials
All reagents were purchased from Fisher Scientific, UK unless otherwise stated,
and were used without purification.
3-amino-1-propanol Sigma-Aldrich, UK
N-(3-Bromopropyl) phthalimide Lancaster Synthesis, UK
Caesium carbonate Lancaster Synthesis, UK
Chloroform-D Cambridge Isotope Laboratories Inc, USA
1, 10 Diaminodecane Aldrich, UK
4, 4 Diaminodicyclohexylmethane Aldrich,UK
1, 8 Diamino-3, 6-dioxaoctane Acros Organics, Belgium
1, 8 Diazabicyclo [5.4.0] undec-7-ene (DBU) Lancaster Synthesis, UK
Dimethyl Sulfoxide Aldrich, UK
Dimethyl Sulfoxide-D6 Cambridge Isotope Laboratories Inc, USA
Hydrazine hydrate Lancaster Synthesis, UK
Hydrobromic acid/glacial acetic acid Acros Organics, Belgium
Mesitylenesulphonylchloride (Mts) Sigma-Aldrich, UK
1, 8-naphthalic anhydride Aldrich, UK
Potassium phthalimide Lancaster Synthesis, UK
Silica 60 F254 gel Merck, Germany
Toluenesulphonyl chloride Lancaster Synthesis, UK
2.2.2. Instrumentation
Thin Layer Chromatography (TLC) was performed on silica gel 60 F254 Aluminium
plates (2 cm x 5 cm) (Merck, Germany) in a chloroform:methanol (99:1 or 97:3) mobile
phase, and spots visualised using UV-light (254 nm).
Nuclear Magnetic Resonance (NMR) spectroscopy was recorded on a Bruker 400
Ultrashield spectrometer operating at 400.1 MHz for proton (1H) and, 100.6 MHz for
carbon-13 (13C) and DEPT-135 NMR. Wilmad 5 mm Economy NMR Tubes (N51 glass,
WG-1228-8) were purchased from Goss Scientific Ltd, UK. The NMR solvents,
Chloroform-D (CDCl3) and Dimethyl Sulfoxide-D6 (DMSO-d6) were used for analysis of
reaction intermediates and final products as their corresponding dihydrobromide or
hydrochloride salts, respectively.
The mass spectral analysis was undertaken at the Engineering and Physical
Sciences Research Council’s (EPSRC) National Mass Spectrometry Service Centre at
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Swansea University, Swansea, UK. ESI spectra were obtained on a ZQ4000 (low
resolution) or a MAT95XP instrument (accurate mass).
Dichloromethane was distilled over phosphorus pentoxide (P2O5).
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2.3. Methods
The strategy adopted to synthesise the bisnapthalimidopropylalkyl diamine
analogues, Bisnaphthalimidopropyl diaminooxaoctane (BNIPDaoxoct) and
Bisnaphthalimidopropy diaminodicyclohexylmethane (BNIPDaCHM) (Figure 2.1), was
based on the synthetic methods previously described (Section 2.1.5) (Scheme A) (Kong
Thoo Lin and Pavlov 2000, Dance et al. 2005).
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Scheme A.: Strategy for the synthesis of bisnaphthalimidopropylalkyl-diamine derivatives.
Reagents and Conditions: (i) ts-Cl, Pyridine, 0-5 °C, 12 hr. (ii) 2, Mts, Cs2CO3, DMF, 50 °C, 96 hr
for 3 and 4. (iii) HBr/glacial CH3CO2H, CH2Cl2, RT, 24 hr. (iv) ts-Cl, C8H4KNO2, DMF, 50 °C, 12 hr.
(v) 6, C2H5OH, hydrazine hydrate, 85 °C, 12 hr; Ethanol/conc. HCl
Scheme B.: Strategy for the synthesis of bisphalimidopropyl diaminodecane. Reagents and
Conditions: (vi) 7, N-(3-(Bromopropyl)phthalimide, Cs2CO3, DMF, 85 °C, 12 hr.
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2.3.1. Synthesis of Toluenesulfonyloxypropylnaphthalimide
(2)
1, 8-Naphthalic anhydride (6.46 g, 0.03258 mol) was dissolved in
dimethylformamide (DMF) (70 mL), followed by the addition of 3-amino-1-propanol (2.45
g, 0.03258 mol) and 1, 8 diazabicyclo [5.4.0] undec-7-ene (DBU) (7.45 mL). The solution
was stirred for 4 hours, at 85 °C. The resulting solution was poured into icy water (200
mL) to form a precipitate. The latter was filtered off and washed with water. The product,
N-(3-hydroxypropyl)naphthalimide, 1 (82.9 %) (Scheme A) was pure enough to be taken
to the next step without further purification. 1H NMR (CDCl3): δ 8.6 – 7.7 (aromatic
protons), 4.3 (CH2-OH), 3.6 (N-CH2), 3.1 (broad, OH), 2.0 (CH2). 13C NMR (CDCl3): δ
165.0 (C=O), 134.0 – 122.0 (aromatic carbons), 59.0, 37.0, 31.0 (3 x CH2) (Figure A.1.,
Appendix 1).
1 (5.10 g, 0.02 mol) was dissolved in anhydrous pyridine (80 mL). The solution
was stirred for 15 minutes, at 0 °C. Toluenesulphonyl chloride (Ts-Cl) (5.72 g, 0.03 mol)
was added slowly, over 30 minutes and was left overnight, at 4 °C. The solution was
poured into icy water (200 mL) to form a precipitate. The latter was filtered off and
washed thoroughly with water. Pure toluenesulfonyloxypropylnaphthalimide, 2 (75 %)
was obtained by recrystallised from ethanol (Scheme A). 1H NMR (CDCl3): δ 8.6 – 7.7
(aromatic protons), 7.3 (O-Ts aromatic protons), 4.2 (CH2-O, CH2-N), 2.3 (CH3), 2.1 (CH2)
(Figure 2.10). 13C NMR (CDCl3): δ 165.0 (C=O), 138.0 – 125.0 (aromatic carbons), 146.0
- 129.0 (O-Ts aromatic carbons), 70.0, 39.0, 29.0 (3 x CH2), 23 (CH3) (Figure A.2.,
Appendix 1).
2.3.2. General Method for the Synthesis of N, N-
Dimesitylalkyl diamines (3-5)
The corresponding diamines (0.01145 mol) (1.69 g 1, 8 Diamino-3, 6-dioxaoctane;
2.41 g 4, 4 Diaminodicyclohexylmethane, 1.97 g 1, 10 Diaminodecane) were individually
dissolved in anhydrous pyridine (70 mL) followed by the addition of
mesitylenesulphonylchloride (Mts) (2.1 M excess) (5.26 g, 0.0240 mol; 5.50 g, 0.0250 mol;
5.26 g, 0.0204 mol respectively). The resulting solution was stirred for 4 hours, at room
temperature. Removal of the pyridine followed by the addition of icy water (200 mL),
resulted in the formation of a precipitate. The latter was filtered off, washed thoroughly
with water and dried under vacuo. All the dimesitylalkyldiamines (3-5) (61 – 75 %)
synthesised showed only one spot on TLC and they were used in the next step without
further purification (Scheme A and B).
2.3.2.1. N1, N8-Dimesityl-3, 6-dioxaoctane (3) (66 %), 1H NMR (CDCl3): δ 6.9
(aromatic protons), 5.5 (-CH2-O), 3.4 (-CH2-O), 3.0 (-CH2-N), 2.5 (CH3.Mts), 2.2 (CH3.Mts).
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13C NMR (CDCl3): δ 140 – 127 (aromatic carbons), 70.7 (4 x CH2-O), 40.7 (2 x CH2-NH),
21.5 (CH3.Mts), 13.6 (CH3.Mts) (Figure A.3., Appendix 2).
2.3.2.2. N4, N4-Dimesityldicyclohexylmethane (4) (61 %), 1H NMR (CDCl3): δ
8.6 (NH), 7.7 – 6.9 (aromatic protons), 4.7 (-CH-N), 2.6 (CH3.Mts), 2.3 (CH3.Mts), 1.8 – 0.8
(-CH2- and cyclohexane protons). 13C NMR (CDCl3): δ 140.0 – 127.0 (aromatic carbons),
43.0 (2 x CH-N.cyclohexane), 39.0 (CH2), 30.1 – 27.0 (cyclohexane carbons), 21.5
(CH3.Mts), 13.6 (CH3.Mts) (Figure 2.12).
2.3.2.3. N1, N10-Dimesityldecane (5) (75 %), 1H NMR (CDCl3): δ 6.9 (aromatic
protons), 4.6 (NH), 2.9 (-CH2-N), 2.7 (-CH2-), 2.3 (-CH2-), 1.4 (CH3.Mts), 1.2 (CH3.Mts).
13C NMR (CDCl3): δ 140.0 – 127.0 (aromatic carbons), 40.7 (2 x CH2-NH), 30.0 – 26.0 (8 x
CH2), 21.5 (CH3.Mts), 13.6 (CH3.Mts) (Figure A.3., Appendix 2).
2.3.3. General N-alkylation Reaction
Dimesitylalkyldiamines (3-4) (0.50 g) (0.00098 mol, 3; 0.00087 mol, 4) were
dissolved in DMF (7 mL) followed by the addition of 2 (2.1 M excess) (0.84 g, 0.00205
mol; 0.75 g, 0.00183 mol, respectively) and caesium carbonate (6 M excess) (1.90 g,
0.00585 mol; 1.69 g, 0.00521 mol, respectively). The solution was left stirring for 96 hours
at 50 °C. Reaction completion was monitored by TLC. The solution was poured into icy
water (200 mL) to form a precipitate. Hydrochloric Acid (HCl) (20 mL, 2 M) was added to
neutralise the solution. The precipitate was collected by filtration and washed thoroughly
with water.
2.3.4. General Deprotection Reaction
The fully protected bisnaphthalimidopropylalkyl diamino derivatives were dissolved
in anhydrous dichloromethane followed by the addition of hydrobromic acid (33 wt %)
solution in glacial acetic acid. Each solution was left stirring for 24 hours at room
temperature. The precipitate formed was filtered off and washed with dichloromethane
(20 mL), and ether (5 mL) (BNIPDaCHM) (75 %) (Scheme A). For BNIPDaoxoct (69 %),
dichloromethane and hydrobromic acid/glacial acetic acid were removed under vacuo and
the residue washed with dichloromethane (5 mL). The crude product was recrystallised
with absolute ethanol (Scheme A).
2.3.4.1. BNIPDaoxoct, 1H NMR (DMSO-d6): δ 8.5 (NH), 8.2 – 7.8 (aromatic
protons), 3.5 (O-CH2), 3.4 (O-CH2), 3.2 (N-CH2), 2.7 – 1.7 (-CH2-). 13C NMR (DMSO-d6):
δ 161.0 (C=O), 138.0 – 125.0 (aromatic carbons), 72.0 (O-CH2), 70.0 (O-CH2), 50.0 – 30.0
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(-CH2-) (Figure A.4., Appendix 3). HRMS (ESI): calculated for C36H40N4O6Br2, 702.6134
[M-2H-Br]+, found: 702.2589 [M-2H-Br]+.
2.3.4.2. BNIPDaCHM, 1H NMR (DMSO-d6): δ 8.5 (NH), 8.0 – 7.5 (aromatic
protons), 3.2 (N-CH2), 2.6 – 1.2 (-CH2- and cyclohexane protons). 13C NMR (DMSO-d6): δ
161.0 (C=O), 136.0 – 122.0 (aromatic carbons), 51.0 – 27.0 (-CH2- and cyclohexane
carbons) (Figure 2.14). HRMS (ESI): calculated for C43H50N4O4Br2, 685.3753 [M-H-2Br]+,
found: 685.3748 [M-H-2Br]+ (Figure A.5., Appendix 4).
2.3.5. Synthesis of Bisphthalimidopropyldiaminodecane
(BPHPDadec)
N1, N10-Dimesityldecane, 5 (0.5 g, 0.00093 mol) was dissolved in DMF (7 mL)
followed by the addition of N-(3-Bromopropyl)phthalimide (2.1 M excess) (0.52 g, 0.01956
mol) and caesium carbonate (6 M excess) (1.81 g, 0.00558 mol) (Scheme B). The
solution was left stirring overnight, at 85 °C. Reaction completion was monitored by TLC.
The solution was poured into icy water (200 mL) to form a precipitate followed by the
addition of HCl (20 mL, 2 M). The precipitate was collected by filtration, washed
thoroughly with water and dried under vacuo.
The fully protected derivative (0.2 g, 0.00219 mol) was dissolved in anhydrous
dichloromethane (5 mL) followed by the addition of hydrobromic acid/glacial acetic acid
(0.8 mL). The solution was left stirring for 24 hours at room temperature. The precipitate
formed was filtered off and washed with dichloromethane (20 mL), ether (5 mL) and dried
under vacuo to give BPHPDadec (96 %), as its dihydrobromide salt (Scheme B).
2.3.5.1. BPHPDadec, 1H NMR (DMSO-d6): δ 8.3 (NH), 7.8 (aromatic protons), 3.6
(N-CH2), 3.2 (NH-CH2), 2.5 – 1.2 (-CH2-). 13C NMR (DMSO-d6): δ 135.0 (C=O), 142.0 –
122.0 (aromatic carbons), 46.0 (NH-CH2), 39.0 (N-CH2), 32.0 – 27.0 (-CH2-) (Figure 2.16).
HRMS (ESI): calculated for C32H44N4O4Br2, 547.3279 [M-2HBr+H]+, found: 547.3281 [M-
2HBr+H]+ (Figure A.6., Appendix 4).
2.3.6. Synthesis of Naphthalimidopropylamine (NPA)
2.3.6.1. Step 1
2 (0.5 g, 0.00122 mol) was dissolved in DMF (7 mL) followed by the addition of
Potassium phthalimide (1.95 M excess) (0.44 g, 0.00237 mol). The solution was left
stirring for 12 hours, at 50 °C. Reaction completion was monitored by TLC. The solution
was poured into icy water (200 mL) to form a precipitate, 6. The precipitate was collected
by filtration, washed thoroughly with water and recrystallised with absolute ethanol. 6, (65
%) (Scheme A). 1H NMR (CDCl3): δ 8.2 – 7.5 (aromatic protons), 4.3 (CH2-N), 3.8 (N-
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CH2, naphthalimido), 2.1 (-CH2). 13C (CDCl3): δ 161.0 (C=O), 140.0 – 123.0 (aromatic
carbons), 39.0 (CH2-N), 38.0 (N-CH2), 27.0 (-CH2-).
2.3.6.2. Step 2
6 (0.5g, 0.00130 mol) was dissolved in Ethanol (25 mL) followed by the addition of
Hydrazine hydrate (10 M excess) (650 µL, 0.01300 mol). The solution was left stirring for
12 hours, at 85 °C. Reaction completion was monitored by TLC. The ethanol was
evaporated off and followed by the addition of dichloromethane (10 mL) giving rise to a
precipitate. The latter was filtered off and the filtrate was evaporated to dryness to give
thick oil, as naphthalimidopropylamine (NPA) in quantitative yield. The latter was
immediately converted to its corresponding hydrochloride salt by dissolving the amine in
ethanol (2 mL), followed by the addition of concentrated HCl (3 mL) followed by ether (10
mL). The white precipitate formed was filtered off, recrystallised (95% ethanol) and dried
under vacuo to give NPA (26%) as the hydrochloride salt (Scheme A).
2.3.6.2.a. NPA, 1H NMR (DMSO-d6): δ 8.5 – 7.9 (aromatic protons), 4.1 (N-CH2), 3.3
(-NH2), 2.8 (CH2-NH2), 2.0 (-CH2-). 13C NMR (DMSO-d6): δ 164.0 (C=O), 134.0 – 122 .0
(aromatic carbons), 38.0 (CH2-NH2), 37.0 (N-CH2), 26.0 (-CH2-) (Figure 2.18). HRMS
(ESI): calculated for C15H14N2O2 255.1131 [M+H]+, found: 255.1128 [M+H]+.
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2.4. Results and Discussion
The synthesis of a selection of new BNIPP derivatives, two
bisnaphthalimidopropylalkyl diamines (BNIPDaoxoct and BNIPDaCHM),
bisphthalimidopropyl diaminodecane (BPHPDadec) and mononaphthalimidopropylamine
(NPA), has been described above (Section 2.3 and, Schemes A and B). The rationale for
synthesising these analogues was to (i) demonstrate that bisnaphthalimido moiety is
essential for biological activity, for example, in BPHPDadec, the naphthalimido rings were
replaced with phthalimide rings, and in the case of NPA only one naphthalimido ring is
present, and (ii) study the effect upon biological activity when the alkyl linker chains are
modified with the introduction of oxygen atoms or cyclohexane rings, for example,
BNIPDaoxoct and BNIPDaCHM. Earlier work has demonstrated that the length of the
alkyl linker chain was extremely important for enhanced solubility, and effective biological
activity against colon cancer (CaCO-2) cells (Oliveira et al. 2007).
2.4.1. Synthesis of Bisnaphthalimidopropyl diamine
Derivatives (BNIPDaoxoct and BNIPDaCHM)
The synthetic strategy adopted to synthesise the bisnapthalimidopropyl diamino
analogues, BNIPDaoxoct and BNIPDaCHM, was based on methods previously developed
and is outlined in Scheme A (Kong Thoo Lin and Pavlov 2000, Dance et al. 2005, Oliveira
et al. 2007). The common starting material was toluenesulfonyloxypropylnaphthalimide, 2,
which was prepared from N-(3-hydroxypropyl) naphthalimide, 1. Protection and activation
of the diamines was carried out with mesitylenesulfonyl chloride (Mts) in pyridine at room
temperature to give compounds 3 to 4 in high yield (66 and 61 % respectively). For the
synthesis of the fully protected BNIPP derivatives, N-alkylation with
toluenesulfonyloxypropylnaphthalimide, 2, in the presence of caesium carbonate in
anhydrous DMF yielded fully protected BNIPP derivatives. Deprotection with hydrobromic
acid/glacial acetic acid in CH2Cl2 gave BNIPDaoxoct and BNIPDaCHM, as their
corresponding dihydrobromide salts in high yields of 69 and 75 %, respectively (Scheme
A, Reactions i-iii).
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2.4.1.1. Synthesis of Toluenesulfonyloxypropylnaphthalimide. 2.
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Figure 2.9.: Synthesis of N-(3-hydropropyl) naphthalimide, 1, and
toluenesulfonyloxypropylnaphthalimide, 2 (Scheme A, Reaction i).
Initially N-(3-hydroxypropyl) naphthalimide, 1 (82.9 %), was obtained from the
reaction between 1, 8-Naphthalic anhydride in DMF with 3-amino-1-propanol and DBU.
Toluenesulfonyloxypropylnaphthalimide, 2 (75 %), was obtained from the reaction with 1
in pyridine with Toluenesulphonyl chloride (Scheme A, Reaction i) (Figure 2.9). The
products, 1 and 2 were characterised by TLC and NMR analyses (Figures A.1 and A.2.,
Appendix 1). By using NMR spectroscopy, the important structural features of 2 were
confirmed by their chemical shift, expressed in parts per million (ppm). In 1H spectra the
chemical shifts for alkyl groups are generally present between 0.8 – 5.0 ppm. Therefore,
Figure 2.10 shows the methylene (-CH2-) and methyl (-CH3) group (from the tosyl group)
at 2.1 and 2.3 ppm, respectively. The methylene groups, C-CH2- and CH2-O were found
at 4.2 ppm, with the aromatic protons from the naphthalene and benzene groups were
observed between 7.7 – 8.6 ppm. The 1H spectrum for 2 is shown in Figure 2.10.
Figure 2.10.: 1H NMR spectra of toluenesulfonyloxypropylnaphthalimide, 2.
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2.4.1.2. General Method for the Synthesis of N, N- Dimesitylalkyl diamines. 3-5.
HN
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H2N x
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RT., 4 h NH
S OO
x = 3
4
5
Figure 2.11.: Synthesis of dimesitylalkyldiamines; N1, N8 – dimesityl-3,6-dioxaoctane (3), N4, N4 –
dimesityldicyclohexylmethane (4), N1, N10-dimesityldecane (5).
Dimesitylalkyldiamines were obtained from the corresponding diamines in pyridine
with Mesitylenesulphonylchloride. N1, N8 – Dimesityl-3,6-dioxaoctane 3, N4, N4 –
Dimesityldicyclohexylmethane 4 and N1, N10-Dimesityldecane 5, in yields of 66, 61 and 75
%, respectively (Figure 2.11). 3, 4 and 5 were characterised by TLC and NMR analyses
(Figure A.3., Appendix 2). Figure 2.12 shows the methylene (-CH2-) groups from the
cyclohexane rings between 0.8 – 1.8 ppm. Methyl (-CH3 groups from Mts) were found
between 2.3 – 4.7 ppm and the aromatic protons from the benzene group of Mts were
observed between 6.9 - 7.7 ppm. The amino (-NH-) group was present at 8.6 ppm. Since
the two cyclohexane rings in 4 and BNIPDaCHM can adopt three interchangeable
conformational arrangements, (i) boat, (ii) twisted boat and (iii) chair. As a result, complex
multiplets resonance signals between 0.8 – 3.4 ppm and 20 – 56 ppm, in the 1H and 13C
NMR spectra of 4 and BNIPDaCHM, respectively (Figures 2.12). The 1H spectrum of 4 is
shown in Figure 2.12.
Figure 2.12.: 1H NMR spectra of N4, N4–dimesityldicyclohexylmethane, 4.
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2.4.1.3. General N-alkylation Reaction
Fully protected BNIPP derivatives were obtained by N-alkylation of the
dimesitylalkyldiamines, 3-4 which were reacted with 2 in a 2:1 ratio in DMF, in the
presence of caesium carbonate (Scheme A, Reaction ii). Completion of the reaction was
monitored by TLC. After drying, the fully protected BNIPP derivative products were
produced in high yields (83 – 96 %).
2.4.1.4. General Deprotection Reaction
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Figure 2.13.: Synthesis of protected and deprotected bisnaphthalimidopropyl diaminooxaoctane
(BNIPDaoxoct) and bisnaphthalimidopropyl diaminodicyclohexylmethane (BNIPDaCHM)
Derivatives (Scheme A, Reaction ii and iii).
The deprotected BNIPP analogues; BNIPDaoxoct and BNIPDaCHM were
obtained from the reaction between fully protected BNIPP derivatives in anhydrous CH2Cl2
with hydrobromic acid/glacial acetic acid (Figure 2.13) (Scheme A, iii). BNIPDaoxoct and
BNIPDaCHM, as their corresponding dihydrobromide salts were obtained in high yields of
69 and 75 %, respectively. BNIPDaoxoct and BNIPDaCHM were characterised by NMR
and MS analyses (Figure A.5., Appendix 4). Generally, for BNIPDaoxoct and
BNIPDaCHM, the 1H NMR showed methylene (-CH2-) groups between 1.2 – 3.5 ppm and
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aromatic protons from the naphthalene group between 7.5 -8.2 ppm. The amino (-NH)
groups were present at 8.5 ppm. The 13C NMR for BNIPDaoxoct and BNIPDaCHM
showed aliphatic hydrocarbons (-CH2-) between 27 – 72 ppm with aromatic carbons from
the naphthalene group between 122 – 138 ppm. The amide (N-C=O) groups were
observed at 161 ppm. The DEPT-135 spectra (Figure 2.14 and Figure A.4., Appendix 3)
showed that the -CH2- groups present in the propyl and cyclohexane groups were
inverted, between 27 – 70 ppm, and the quaternary carbons, e.g., from the amide had
disappeared. An example of the 13C and DEPT-135 NMR spectra of BNIPDaCHM are
shown in Figure 2.14.
Figure 2.14.: 13C and DEPT-135 NMR spectra of BNIPDaCHM
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2.4.2. Synthesis of Bisphthalimidopropyldiaminodecane
(BPHPDadec)
MtsHN
NHMts + N
O
O
Br
DMF/Cs2CO3
85 °C., 12 h
HBr/glacial CH3CO2H in CH2Cl2
RT., 24 h
N
O
O
BPHPDadec
N
H
H
N
.2HBr
N
O
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Figure 2.15.: Synthesis of bisphthalimidopropyl diaminodecane (BPHPDadec) (Scheme B, vi and
iii)
BPHPDadec was synthesised by treating dimesitylenediaminodecane, 5, with N-
(3-Bromopropyl) phthalimide in DMF in the presence of caesium carbonate (Figure A.3.,
Appendix 2). Subsequent deprotection with hydrobromic acid/glacial yielded BPHPDadec
as its dihydrobromide salt, at 96 % (Scheme B, Reaction vi and iii) (Figure 2.15).
BPHPDadec was characterised by TLC, NMR and MS analyses (Figure A.6., Appendix 4).
For BPHPDadec (Figure 2.16), the 1H NMR showed methylene (-CH2-) groups between
1.2 – 3.6 ppm, in particular, the CH2-N was observed at 3.6 ppm. The aromatic protons
from the naphthalene group and the amine (NH) groups were present at 7.8 ppm and 8.3
ppm, respectively. The 13C NMR for BPHPDadec showed aliphatic hydrocarbons (-CH2-)
between 27 – 46, with aromatic carbons between 122 – 135 ppm and the amide (N-C=O)
group at 168 ppm. The DEPT-135 spectra verified the -CH2- groups, which were inverted,
between 27 – 46 ppm, and the quaternary carbons, which had disappeared. The 1H, 13C
and DEPT-135 spectra of BPHPDadec are shown in Figure 2.16.
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Figure 2.16.: 1H, 13C and DEPT-135 NMR spectra of BPHPDadec
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2.4.3. Synthesis of Naphthalimidopropylamine (NPA)
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Figure 2.17.: Synthesis of naphthalimidopropylamine (NPA)
To synthesise naphthalimidopropylamine (NPA), nucleophilic substitution of the
toluenesulfonyl (tosyl) group from 2 was achieved with potassium phthalimide. Treatment
with hydrazine hydrate gave the corresponding amine, 6 (65 %), which was converted to
its hydrochloric salt, NPA (26 %) (Scheme A, Reactions iv and v) (Figure 2.17). 6 was
characterised by TLC and NMR. The final product, NPA was characterised by TLC, NMR
and MS analyses. For NPA (Figure 2.18), the 1H NMR showed methylene (-CH2-) groups
between 2.0 – 4.1 ppm, in particular, the CH2-N was observed at 4.1 ppm. The aromatic
protons from the naphthalene group were observed between 7.9 – 8.5 ppm, with the
amine (-NH2-) group present at 3.3 ppm. The 13C NMR, for NPA showed aliphatic
hydrocarbons (-CH2-) between 26 - 38 and aromatic carbons from the naphthalene group,
between 125 - 165 ppm. The amide group (N-C=O) group was observed at 164 ppm.
The DEPT-135 spectra confirmed the -CH2- groups, which were again inverted (26 – 38
ppm). The quaternary carbons had also disappeared. The 1H, 13C and DEPT-135 spectra
of NPA are shown in Figure 2.18.
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Figure 2.18.: 1H, 13C and DEPT-135 NMR spectra of NPA
BNIPDaoxaoct, BNIPDaCHM, BPHPDadec and NPA were all synthesised by
modification of the N-alkylation reaction previously used to synthesise the parent BNIPP
derivatives (Kong Thoo Lin and Pavlov 2000, Oliveira et al. 2007). All of the new BNIPP
derivatives exhibited good solubility, at a 10 mM concentration (50 % DMSO/water) and
were stored as stock solutions at 0-5 °C. The N-alkylation reaction has been further
developed by other groups, for example, Filosa and colleagues (2009), who have recently
reported the synthesis and biological activity of a series of bisnaphthalimides containing
heterocyclic and other cyclic moieties. These alterations include insertion of piperazine,
cis-dimethylpiperazine, diazabicyclo [3.2.1] octane and cyclopropane groups into the
aminoalkyl linker chain. Filosa et al. (2009) adapted and modified the three step reaction
described, to suit their specific requirements. It is important to note, that during the
tosylation reaction, the best condition in which to synthesise these novel BNIPP
derivatives, at a maximum yield, was to use four times excess Ts-Cl (Filosa et al. 2009).
This was in contrast to the two times excess Ts-Cl used in the successful synthesis of
BNIPP derivatives (Kong Thoo Lin and Pavlov 2000, Dance et al. 2005, Oliveira et al.
2007).
Therefore, the syntheses of many future potential bisnaphthalimido and
bisphthalimido derivatives can be achieved by amendment of the highly convenient three
step procedure shown in Scheme A and B.
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2.5. Conclusions
Two protected bisnaphthalimidopropyl diamino analogues (BNIPDaoxoct and
BNIPDaCHM) together with bisphthalimidopropyl diaminodecane (BPHPDadec) and
mononaphthalimidopropylamine (NPA) were successfully synthesised and all BNIPP
derivatives exhibited good solubility properties in 50 % DMSO.
The synthetic route chosen to produce the protected BNIPP and BPHP derivatives
was an N-alkylation reaction. This reaction has been used in the successful synthesis of
previous BNIPP derivatives, and was found to be simple and reproducible, and did not
produce by-products. Complete deprotection gave the BNIPP and BPHP derivatives, as
their dihydrobromide salts (69, 75 and 96 % yield, respectively). Via a similar synthetic
process NPA was produced. Essentially NPA, a mononaphthalimide derivative, was
synthesised by a simple two step reaction, producing NPA as a hydrochloric salt (26 %
yield). The successful synthetic strategies adopted for BNIPDaoxoct, BNIPDaCHM,
BPHPDadec and NPA has led to the subsequent evaluation of (i) their DNA binding
affinities (Chapter 3), (ii) biological properties in human breast cancer MDA-MB-231 and
human epithelial MCF-10A cells (Chapters 4 – 6), and (iii) their potential to inhibit histone
deacetylase (HDAC) activity (Chapter 7).
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Chapter 3
DNA Binding Properties of BNIPP Derivatives
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3.1. DNA Binding Properties of BNIPP Derivatives
For over forty years, nucleic acids have been extensively studied as potential
targets in anticancer drug design. The interaction of an anticancer drug with
Deoxyribonucleic Acid (DNA) initially results in changes to the conformation of the DNA
double helix, which subsequently leads to an interruption of the processes involved in
DNA replication, transcription and repair, leading ultimately to cell death (Brana et al.
2001, Seaton et al. 2003, Martinez and Chacon-Garcia 2005, Huang et al. 2009).
Anticancer drugs can interact with DNA by binding to and/or modifying the DNA structure
via several mechanisms of action. These mechanisms include (i) DNA intercalation
between the base pairs, (ii) DNA groove binding via non-covalent interactions with the
major or minor grooves of the DNA, or (iii) DNA alkylation with interstrand or intrastrand
cross linking.
The aim of the experimental work presented in this chapter was to investigate the
DNA binding properties of the BNIPP derivatives.
3.1.1. DNA Intercalation
DNA intercalating anticancer drugs usually contain planar or heteroaromatic
chromophores with an attached side chain, and reversibly bind to DNA by insertion and
stacking between the base pairs of the DNA double helix (Martinez and Chacon-Garcia
2005, Kamal et al. 2007, Strekowski and Wilson 2007). DNA intercalators are held in
place between the base pairs by Van der Waal’s interactions, thus creating a stable
complex (Anderson et al. 2009). As a result, the DNA becomes partially unwound and
lengthens, which leads to the inhibition of DNA replication and transcription (Palchaudhari
and Hergenrother 2007, Anderson et al. 2009). Classic examples of DNA intercalating
compounds include acridines (e.g., proflavine) and anthracyclines (e.g., daunorubicin and
doxorubicin) (Demeunynck 2004, Martίnez and Chacόn-Garcίa 2005, Ferguson and 
Denny 2007, Ashley and Poulton 2009) (Figure 3.1). Proflavin is currently used as a
topical antiseptic (Chakraborty and Casu 2009), whilst daunorubicin and doxorubicin,
although relatively non-selective, are currently in clinical use as anticancer agents in the
treatment of acute leukaemias, breast, ovarian and bladder cancers (Cancer Research
UK, 2009a, Cancer Research UK, 2009b)
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Figure 3.1.: Structures of the DNA intercalating compounds: a: Proflavin, b: Daunorubicin and c:
Doxorubicin
In addition to the classic examples of DNA intercalating compounds (Figure 3.1),
several structurally uncommon DNA intercalating compounds have been reported in
recent years (Palchaudhur and Hergenrother 2007). These compounds do not contain
the characteristic features (i.e. fixed planar or heteroaromatic chromophores) usually
present in the classic DNA intercalating compounds, but instead have two or three
unfused rings (Snyder 2007). Examples include chlorpheniramine, an antihistamine, and
prodigiosin, a prospective anticancer agent (Montaner et al. 2005, Palchaudhur and
Hergenrother 2007, Snyder 2007) (Figure 3.2).
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Figure 3.2.: Structures of the structurally uncommon DNA intercalating compounds: a:
Chlorpheniramine and b: Prodigiosin
Several DNA intercalating anticancer compounds have also been shown to
prevent the action of the enzyme Topoisomerase (TOPO). There are two key TOPO
enzymes, I and II, which are responsible for single-stranded (ss) and double stranded (ds)
breaks in DNA, respectively (Palchaudhuri and Hergenrother 2007). The TOPO I enzyme
is monomeric, with responsibility of ss DNA cleavage (Forterre et al. 2007), whilst the
essential ubiquitous TOPO II enzyme found within eukaryotic organisms, catalyses DNA
unwinding, and controls the processes required to untangle and unknot ds DNA.
Moreover, TOPO II has a fundamental role in DNA replication and transcription, and also
aids chromosomal organisation prior to mitosis (Burden and Osheroff 1998, Demeunynck
2004, Denny 2004, Palchaudhuri and Hergenrother 2007, Patrick 2009).
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The inhibition of TOPO II enzyme activity can be divided into two classes. The
members of the first class are termed TOPO II inhibitors (catalytic inhibitors), whereas the
members of the second class are TOPO II poisons. TOPO II inhibitors work by binding
the enzyme onto DNA and blocking the overall catalytic activity of the TOPO II enzyme,
resulting in cell death (Larsen et al. 2003, Montaner et al. 2005, Nitiss 2009). TOPO II
poisons are aptly named because they do not kill cancer cells by inhibiting the function of
the TOPO II enzyme itself, but rather poison DNA by stabilising the levels of TOPO II-DNA
complexes irreversibly. Complex stabilisation disables the TOPO II enzyme, thus leading
to the formation of ‘double strand breaks’ (Burden and Osheroff 1998, Demeunynck 2004,
Montaner et al. 2005, Montecucco and Biamonti 2007, Palchaudhuri and Hergenrother
2007, Nitiss 2009). These ds DNA breaks consequently induce cellular DNA damage,
which can again lead to cell death (Nitiss 2009).
Examples of relevant DNA intercalating and DNA non-intercalating compounds
that exert their cytotoxic activity as TOPO II poisons are anthracyclines (e.g., daunorubicin
and doxorubicin), anthraquinones (e.g., mitoxantrone), and etoposide, respectively
(Burden and Osheroff 1998, Kamal et al. 2007, Montecucco and Biamonti 2007) (Figures
3.1 and 3.3). These compounds are currently in clinical use as anticancer agents in the
treatment of small-cell lung, bladder, stomach and breast cancers (Hande 1998, Minotti et
al. 2004).
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Figure 3.3.: Structures of the DNA intercalating and non-intercalating compounds with TOPO II
action: a: Mitoxantrone and b: Etoposide
The well known cytotoxic DNA intercalating compounds relevant to this project are
the naphthalimides (e.g. amonafide) and bisnaphthalimides (e.g. elinafide) as previously
stated in Section 1.6 (Figures 1.16 and 1.21) (Brana et al. 2001, Brana and Ramos 2001,
Martinez and Chacon-Garcia 2005, Yang et al. 2005, Filosa et al. 2009, González-Bulnes
and Gallego 2009). These compounds are structurally similar to the BNIPP derivatives,
with the presence of one or two naphthalimido rings respectively, and a flexible aminoalkyl
linker chain which contains at least one amine group: an important structural assembly,
which has proved to be essential for the attainment of strong DNA binding affinity and
cytotoxic activity (Brana et al. 1993, 2001). The possible mechanism of action of
naphthalimide and bisnaphthalimide derivatives has been shown to be achieved by
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intercalation or bis-intercalation of the chromophore unit between the base pairs of the
DNA double helix, respectively (Hsiang et al. 1989, Brana et al. 1993, 2001, Chau et al.
2008). Previously investigated BNIPP derivatives also demonstrate DNA binding through
bis-intercalation (Pavlov et al. 2001, Dance et al. 2005). An assessment into the
mechanism of action of the newly synthesised (Figure 2.1), and existing BNIPP
derivatives (Figure 3.4) will be discussed later in this chapter.
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Figure 3.4.: Structures of bisnaphthalimidopropyl polyamine derivatives (BNIPPs):
Bisnaphthalimidopropyl Spermidine (BNIPSpd), Bisnaphthalimidopropyl Putrescine (BNIPPut),
Bisnaphthalimidopropyl Diaminohexane (BNIPDahex), Bisnaphthalimidopropyl Diaminooctane
(BNIPDaoct), Bisnaphthalimidopropyl Diaminodecane (BNIPDadec) and Bisnaphthalimidopropyl
Diaminododecane (BNIPDadodec).
3.1.2. DNA Groove Binding
Groove binding compounds are generally crescent-shaped (i.e. rounded or curved)
molecules which can interact with either the DNA major or, more often, the DNA minor
grooves. DNA groove binders are stabilised by non-covalent (electrostatic) interactions
(Lauria et al. 2007, Palchaudhuri and Hergenrother 2007). At present, the mechanism of
action for the majority of groove binding drugs is relatively unknown. Evidence suggests
that these compounds do not dramatically change the structure of DNA, in contrast to
DNA intercalating compounds, but rather act in a sequence specific manner by widening
the grooves of the DNA, thus directly blocking and/or inhibiting protein-DNA recognition
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(Chen et al. 1993, Suh and Chaires 1995, Lauria et al. 2007, Strekowski and Wilson 2007,
Cai et al. 2009). The most commonly studied groove binders include mitomycin C,
distamycin A and the bisbenzimidazole, Hoechst 33258 (Seaton et al. 2003, Strekowski
and Wilson 2007, Cai et al. 2009) (Figure 3.5). Notably, the anthracyclines (daunorubicin
and doxorubicin, Figure 3.1) bind to DNA by both intercalation and groove binding as they
possess an aromatic (intercalative) feature and a side (groove binding) chain
(Palchaudhuri and Hergenrother 2007).
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Figure 3.5.: Structures of the DNA groove binding compounds: a: Mitomycin C, b: Distamycin A
and c: Bisbenzimide Hoechst 33258
The natural polyamines spermine and spermidine and, to a lesser extent, their
precursor putrescine (Figure 1.7) are known to interact and stabilise DNA and RNA
duplexes via electrostatic interactions with DNA (Pavlov et al. 2001, Peña et al. 2007,
Winkler et al. 2009). Polyamines have also been shown to stabilise double stranded over
single stranded structures (Feuerstein et al. 1990). Polyamine structures are well adapted
to fit into the DNA grooves where they bind strongly with both the major and to a lesser
extent the minor grooves (Le Pecq et al. 1975, Hou et al. 2001, Strekowski and Wilson
2007).
3.1.3. DNA Alkylation
DNA alkylating compounds are electrophilic compounds which react with electron-
rich regions on DNA, and are classified as either mono-, bi- or tri-functional. This
functionality is reliant upon whether a compound has one, two or three electron-deficient
reactive groups (Sanderson and Shield 1996, Patrick 2009). Alkylating agents disrupt
DNA by the attachment of alkyl groups to nucleotide bases in particular, the N-7 of
guanine. This region is particularly susceptible for alkylation, as it is the most nucleophilic
site in the DNA (Sanderson and Shield 1996). Alkylating agents can form cross linkages
between DNA and proteins [1], or DNA strands, either interstrand [2] or intrastrand [3]
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(Figure 3.6), and are capable of inducing permanent nucleotide mutations (Sanderson and
Shield 1996, McHugh et al. 2001, Anderson et al. 2009, Patrick 2009). Alkylating agents
have poor molecular specificity because they can act upon both DNA and proteins. As a
result, they can disrupt DNA replication and transcription, and/or alter protein structure
and function (Sanderson and Shields 1996, Patrick 2009). Compounds that produce
interstrand and intrastrand cross links have been shown to be important effective
chemotherapeutic compounds, which are commonly used in the treatment of leukaemias,
lymphomas, and solid tumours (i.e. breast, lung and bladder cancers) (McHugh et al.
2001, Anderson et al. 2009, Cancer Research UK 2009c and 2009d, Patrick 2009).
These compounds can be used as both single agents, or as part of a combined
chemotherapy regimen (McHugh et al. 2001). The mechanism of action of several
alkylating agents with regards to interstrand or intrastrand cross links will be discussed
further in Sections 3.1.3.1 and 3.1.3.2.
Figure 3.6.: The possible modes of DNA interaction achieved by cross linking compounds
(adapted from McHugh et al. 2001). [1] DNA-Protein cross link, [2] Interstrand cross link and [3]
Intrastrand cross link.
3.1.3.1. Alkylating Agents with Interstrand Cross Linkage
Interstrand cross linking compounds can form cross links between the two
complementary strands of DNA which results in the DNA structure becoming distorted.
Distortions of the DNA structure, if unrepaired, can cause the inhibition of DNA replication
and transcription (McHugh et al. 2001). Examples of interstrand cross linking alkylating
compounds include the nitrogen mustards (chloromethine and the prodrug,
cyclophosphamide) and chloroethylnitrosoureas (carmustine and lomustine) (Figure 3.7).
CH3
N
Cl Cl
a
Cl
N N
H
Cl
N O
O
c
Cl
N
N
N
H
O
O
d
P
O NH
N Cl
Cl
O
b
Figure 3.7.: Structures of DNA alkylating compounds with interstrand cross linkage: a:
Chlormethine, b: Cyclophosphamide, c: Carmustine and d: Lomustine.
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It is important to note that the prodrug mitomycin C; an aforementioned groove
binder (Figure 3.5) can be converted into monofunctional or bifunctional alkylating agents
by bio reductive activation, mediated by flavoenzymes in living cells (Bizanek et al. 1992,
Rao 1992, Cummings et al. 1995). Mitomycin C can form interstrand cross links between
guanine groups (Patrick 2009).
3.1.3.2. Alkylating Agents with Intrastrand Cross Linkage
In contrast, intrastrand cross linking compounds can form cross links on the same
strand of DNA, which generally occur on the N-7 or O-6 positions of adjacent guanine
molecules (McHugh et al. 2001, Patrick 2009). Intrastrand cross linkers are usually
platinum (Pt) based agents which are held in place by the formation of covalent Pt-DNA
links (Patrick 2009, Pizarro and Sadler 2009). Intrastrand cross links, as with interstrand
cross links, can result in distortion and unwinding of DNA, thus inhibiting replication and
transcription once more (Malinge et al. 1999, McHugh et al. 2001). Several critical RNA-
dependent activities, such as splicing and translation, can also be inhibited by intrastrand
cross links (Hostetter et al. 2009). Pt based compounds are also linked to the induction of
apoptosis (Hostetter et al. 2009, Pizarro and Sadler 2009). The Pt agents cis-diammonia
dichloroplatinum (II), known as cisplatin, and carboplatin are the most common examples
of intrastrand cross linking compounds (Figure 3.8).
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Figure 3.8.: Structures of DNA alkylating compounds with intrastrand cross linkage: a: Cisplatin
and b: Carboplatin
3.1.4. Assessment of DNA Binding Interactions
Several in vitro experiments have been used to determine the physical interactions
of a compound with DNA. These methods include studies into thermal (melting)
denaturation, competitive displacement of DNA bound ethidium bromide (EtBr), changes
in viscosity, circular dichroism (CD), isothermal titration calorimetry (ITC), NMR
spectroscopy (31P NMR spectra), X-ray diffraction, and computer-assisted molecular
modelling. All of these methods have been successfully used in the determination of DNA
binding interactions (Suh and Chaires 1995, Coury et al. 1996, Doyle 1997, Martinez and
Chacon-Garcia 2005, Palchaudhuri and Hergenrother 2007, Strekowski and Wilson 2007,
Ott et al. 2008).
The instrumental techniques of thermal (melting) denaturation (Figure 3.9),
competitive displacement of DNA bound EtBr (Figure 3.10) and molecular modelling were
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used in this study to investigate DNA binding as a possible mode of action used by BNIPP
derivatives.
DNA thermal denaturation is a simple and convenient technique, which is widely
used in the identification of derivatives with DNA intercalative properties. In thermal
denaturation studies, ds DNA is heated and thermally denatured into ss DNA in the
presence and absence of derivatives (Martinez and Chacon-Garcia 2005, Palchaudhuri
and Hergenrother 2007) (Figure 3.9). If a derivative stabilises DNA; thermal denaturation
is increased (i.e., increase Tm), thus indicating DNA intercalation. The increase in Tm
provides an efficient means by which to estimate the extent of DNA intercalation, albeit in
a non selective manner. For that reason, the more selective technique of competitive
displacement of DNA bound EtBr was employed to verify the mode of action of DNA
intercalation (Martinez and Chacon-Garcia 2005, Ott et al. 2008).
UV Light
ds DNA absorbs
UV light at 260 nm
Heating
ss DNA absorbs
more UV light than ds DNA (at 260 nm)
Absorbance (nm)
Temperature (°C)
Figure 3.9.: Method of thermal denaturation.
EtBr is a classical DNA intercalator (Figure 3.10A) which results in the substantial
enhancement of emitted fluorescence when bound to DNA (McConnaughie and Jenkins
1995, Geall and Blagbrough 2000, Pavlov et al. 2001). Intercalating agents exert a higher
DNA binding affinity than EtBr will displace DNA-bound EtBr, resulting in fluorescence
quenching (Dance et al. 2005) (Figure 3.10B). The extent of fluorescence quenching is
proportional to the amount of EtBr displaced by a derivative. As a result, the ability of a
derivative to competitively displace EtBr bound to DNA can, alongside thermal
denaturation, verify the mechanism of binding of selected derivatives (Ott et al. 2008).
Tm
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Figure 3.10.: Structure of EtBr (A) and method of competitive displacement of DNA bound EtBr (B)
A
B
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3.2. Materials
3.2.1. Materials
All reagents were purchased from Fisher Scientific, UK unless otherwise stated,
and were used without purification.
Calf Thymus DNA Sigma-Aldrich, UK
Dimethyl sulfoxide Aldrich, UK
Doxorubicin hydrochloride Sigma-Aldrich, UK
Ethidium Bromide Sigma-Aldrich, UK
Hoechst 33258 Sigma-Aldrich, UK
Mitoxantrone dihydrochloride Sigma-Aldrich, UK
Saline Sodium Citrate Fisons Scientific Apparatus, UK
3.2.2. Instrumentation
Optimal thermal denaturation studies were performed in stoppered quartz cuvettes
(1 cm path length) using a Shimadzu UV-1650 PC UV-Vis spectrophotometer fitted with a
temperature controller (Shimadzu, Japan), and water supply.
Fluorescent-binding studies were carried out in disposable cuvettes (1 cm path
length) using a LS55 Luminescence spectrophotometer (Perkin Elmer, USA), at room
temperature (excitation 481 nm; emission 596 nm).
Molecular modelling simulations were performed on a Silicon Graphics Octane
R12000 or a Hewlett Packard 1902 workstation. The molecular structures were
generated using the Insight-II Version 2005 graphics interface, and Discover 98.0
simulation software (Accelrys, UK).
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3.3. Methods
3.3.1. Bisnaphthalimidopropyl (BNIPP) Derivatives
BNIPP derivatives were synthesised as previously described in Section 2.3. Stock
solutions of each BNIPP derivative (10 mM for BNIPSpd, BNIPPut, BNIPDahex,
BNIPDaoct, BNIPDadec, BNIPDadodec, BNIPDaCHM and BPHPDadec; 90 mM for
BNIPDaoxoct and NPA) in 50 % dimethylsulfoxide (DMSO)/water were prepared and
stored at 0 – 5 °C until required. Stock solutions of the positive controls: doxorubicin,
mitoxantrone and Hoechst 33258 (10 mM), and the natural polyamines: putrescine,
spermidine and spermine (10 mM) in 50 % DMSO/water were also prepared, and stored
at 0 – 5 °C. Prior to use, all stock solutions were further diluted to the desired final
concentration in 0.01 M Saline Sodium Citrate (SSC) buffer.
3.3.2. Thermal Denaturation Studies
A DNA working solution (100 mM) was prepared by dissolving Calf Thymus DNA
(2.5 mg) in 0.01 M Saline Sodium Citrate (SSC) buffer (100 mL). BNIPP derivatives,
positive controls and polyamine working solutions (100 µM) were prepared from their
respective stock solutions (10 mM in 50 % DMSO/water), and further diluted to give the
final concentration of 10 µM in 0.01 M SSC buffer. DNA-test solutions were prepared by
adding 500 µL Calf Thymus DNA (100 mM), 400 µL 0.01 M SSC buffer and 100 µL test
solution (100 µM) together. The DNA-test solution was mixed and incubated for 12 hours,
at room temperature. After 12 hours incubation, the DNA-test solutions were analysed at
260 nm, where the temperature was increased at a rate of 1 °C/minute between 40 – 100
°C, using the UV-Vis spectrophotometer as described in Section 3.2.2. The thermal
melting point (Tm (°C)) was computer generated by establishment of the first derivative
curve of absorbance against temperature.
3.3.3. Fluorescence-Binding Studies
Calf Thymus DNA solution (100 mM) was prepared as described in Section 3.3.2.
EtBr solution (200 µM) was prepared by dissolving 7.886 mg EtBr in distilled water (100
mL). The BNIPP derivative working solutions were prepared as previously described
(Section 3.3.2), and were further diluted in 0.01 M SSC to give the final concentrations of
1, 2, 4, 6, 8 and 10 µM. DNA-BNIPP derivative test solutions were prepared by adding
varying volumes of the BNIPP derivative solutions in 0.01 M SSC Buffer to Calf Thymus
DNA (200 µL) and EtBr (20 µL) in 1 mL Eppendorf tubes. DNA-BNIPP derivative
solutions were thoroughly mixed, incubated for 15 minutes at room temperature, and
analysed using a luminescence spectrophotometer as described in Section 3.2.2. The C50
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values are defined as the derivative concentration (µM) required to generate a 50 %
decrease in the fluorescence of DNA bound EtBr.
3.3.4. Molecular Modelling
All molecular structures were generated and energy minimised using the Insight II
molecular modelling system as described in Section 3.2.2. The cff91 force-field was used
for atom potentials and for all energy calculations, minimisations and molecular dynamics
simulations. The DNA duplex (PDB ID 108D) used was obtained from the Protein Data
Bank, formerly the Brookhaven Protein Database (available from www.pdb.org) (Figure
3.11).
Figure 3.11.: The ball and stick model of the DNA duplex (DUPLEXICI99), looking from a side
view. The red arrows indicate the two intercalation sites of the DNA duplex. Carbon atoms are
coloured green, nitrogen atoms are blue, oxygen atoms in red and hydrogen atoms in white.
Phosphorus counterions are coloured purple.
The intercalation sites of the DNA oligonucleotide d(5’-CGCTAGCG-3’)2 were
generated by removal of the bis-intercalating dye 1,1’-(4,4,8,8-tetramethyl-4,8-
diazaundecamethylene) bis[4-(3-methyl-2,3-dihydrobenzo-1,3-thiazolyl-2-
methylidene)quinolinium] tetraiodide (TOTO) (Spielmann et al. 1995) (Cairns, Personal
Communication). The DNA model with TOTO removed was subsequently used herein to
determine the DNA binding affinities of a selection of BNIPP derivatives: BNIPSpd,
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BNIPDaoct, BNIPDaoxoct, BNIPDaCHM, BPHPDadec and NPA. Ball and stick images of
all the derivatives investigated are shown in Figure 3.12.
Figure 3.12.: Structures of BNIPP derivatives (a-f) as shown by ball and stick images. The images
are a BNIPSpd, b BNIPDaoct, c BNIPDaoxoct, d BNIPDaCHM, e BPHPDadec and f NPA. Carbon
atoms are coloured green, nitrogen atoms are blue, oxygen atoms in red and hydrogen atoms in
white. Phosphorus counterions are coloured purple.
Manual docking of these BNIPP derivatives was achieved by insertion of the
chromophores midway into the two available intercalating sites of the DNA duplex using
the program described in Section 3.2.2. All bond and torsion angles were allowed to
rotate freely. Two alternative docking conformations were constructed for BNIPSpd, with
three docking conformations for BNIPDaoxoct, BPHPDadec and NPA, and four docking
conformations for BNIPDaoct and BNIPDaCHM. The DNA-BNIPP derivative complexes
were initially submitted for molecular dynamics simulations in the unfixed state. Due to
the resultant instability of the unfixed DNA-BNIPP derivative complexes in this
environment, especially during dynamic simulations, selected DNA-BNIPP derivative
complexes (2 complexes per BNIPP derivative) were resubmitted for molecular dynamic
simulations with the bases surrounding the intercalation sites fixed. Each unfixed complex
was minimised using a conjugate gradient algorithm (the Polak-Ribiere variant) until an
energy convergence criterion of 1 kcal mol-1 A-1 was reached (steepest descent
convergence of 100, and a maximum of 10,000 steps). Fixed complexes were however
minimised using the conjugate gradient algorithm until an energy convergence criterion of
0.1 kcal mol-1 A-1 was reached, with a steepest descent convergence of 100, and a
maximum of 50,000 steps. Molecular dynamics (MD) simulations were carried out for
100,000 frequency steps (fs), at 300 K (10 dynamics simulations), with a cut-off distance
of 9.5 A. The final average conformations were then minimised as described above.
Binding enthalpies for each BNIPP derivative were determined by calculation of
the potential energy of each DNA-BNIPP derivative complex (ECOMPLEX) and subtracting
the sum of the energies of the non intercalated DNA (EDNA) and BNIPP derivatives (EBNIPP)
from this value. The enthalpy of binding interactions (EBIND) were calculated using the
equation: EBIND = ECOMPLEX – [EBNIPP + EDNA], where ECOMPLEX, EBNIPP and EDNA are the
a b
c
d
e f
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computed potential energies for the minimised average DNA-BNIPP derivative complex,
free BNIPP derivative and free DNA conformations, respectively (Cairns et al. 2002), and
the more negative the binding energy (EBIND); the stronger the DNA binding interaction.
3.3.5. Data Analysis
Unless otherwise stated, each data set contained a minimum of three independent
experiments, in which each experiment comprised of at least three internal replicates,
expressed as mean ± Standard Deviation (SD).
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3.4. Results
3.4.1. Effect of BNIPP Derivatives on DNA Binding Affinity by
Thermal Denaturation
The extent of DNA binding affinity demonstrated by each BNIPP derivative (10 µM)
was determined by thermal denaturation (Tm) studies.
The thermal denaturation profile presented in Figure 3.13 displays the thermal
denaturation curves obtained in the presence and absence of 10 µM BNIPDaCHM. The
curves are a representation of all the thermal denaturation curves obtained for the other
BNIPP derivatives, positive controls (data not shown) and polyamines (data not shown).
Figure 3.13.: The effect of temperature (°C) on UV absorbance for Calf Thymus DNA incubated in
the absence and presence of 10 µM BNIPDaCHM. The curves shown in the graph are
representative of the thermal denaturation curves obtained for all BNIPP derivatives analysed (data
not shown).
Table 3.1 shows the Tm values of each BNIPP derivative, and doxorubicin,
mitoxantrone and Hoechst 33258 (10 µM). Tm values for all BNIPP derivatives ranged
between 81.2 – 91.9 °C showing melting temperature differences (Δ Tm) of 25.0 – 35.7 °C
compared to the melting point of Calf Thymus DNA alone (Tm value of 56.2 °C). The
increase in Tm from these BNIPP derivatives was in the same range as the extensively
studied intercalators, doxorubicin (Δ Tm 30.2 °C) and mitoxantrone (Δ Tm 34.8 °C),
suggesting an intercalative DNA binding interaction. The most active DNA binding
derivative was identified as BNIPDahex (Δ Tm 35.7 °C).
Temperature (°C)
Calf Thymus DNA
10 µM BNIPDaCHM
+ Calf Thymus DNA
UV Absorbance
(at 260 nm)
75
Table 3.1.: Effect of BNIPP derivative treatment on thermal denaturation
Derivativea Tm (°C)b
Calf Thymus DNA alone 56.2 ± 0.4
BNIPSpd 91.5 ± 0.6
BNIPPut 89.2 ± 2.5
BNIPDahex 91.9 ± 0.6
BNIPDaoct 88.7 ± 0.3
BNIPDadec 84.4 ± 0.2
BNIPDadodec 81.2 ± 0.7
BNIPDaoxoct 87.9 ± 0.6
BNIPDaCHM 87.4 ± 1.2
BPHPDadec 72.0 ± 2.4
NPA 66.3 ± 0.9
Doxorubicin 86.4 ± 1.2
Mitoxantrone 91.0 ± 1.5
Hoechst 33258 78.8 ± 0.9
a Calf Thymus DNA was incubated in the presence or absence of 10 µM BNIPP derivatives,
including BPHPDadec, NPA, doxorubicin, mitoxantrone and Hoechst 33258, at room temperature
for 12 hours.
b Tm is the temperature (°C) when 50% of the DNA is denatured. Data are the mean ± SD of three
independent experiments (n = 3).
It is interesting to note that among all of the BNIPP derivatives, the BNIPP
derivative with the longest linker chain (i.e., 12 carbons (C12); BNIPDadodec)
demonstrated the smallest increase in Tm value (Δ Tm 25.0). In addition, the BNIPP
derivative binding strength or the stability of the DNA duplex was marginally affected by
the addition of two oxygen atoms (BNIPDaoxoct) or two cyclohexane rings (BNIPDaCHM)
in the linker chain, with slightly lower Tm values (Δ Tm 31.7 °C and Δ Tm 31.2 °C,
respectively). In contrast, BPHPDadec and NPA induced a relatively small increase in Tm
when compared with the other BNIPP derivatives, with Δ Tm values of 15.8 °C and 10.1
°C, respectively. Therefore, these derivatives demonstrated a low intercalative affinity.
3.4.1.1. Effect of Polyamines on DNA Binding Affinity by Thermal
Denaturation
Further thermal denaturation studies into the DNA binding interactions of the
natural polyamines (putrescine, spermidine and spermine) were investigated and the
results are shown in Table 3.2.
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Table 3.2.: Effect of natural polyamine treatment on thermal denaturation
Polyaminea Tm (°C)b
Calf Thymus DNA alone 56.2 ± 0.4
Putrescine 73.6 ± 0.7
Spermidine 81.4 ± 0.5
Spermine 86.6 ± 1.2
a Calf Thymus DNA was incubated in the presence or absence of 10 µM polyamine salt, for 12
hours at room temperature.
b Tm is the temperature (°C) when 50% of the DNA is denatured. Data are the mean ± SD of three
independent experiments (n = 3).
All polyamines resulted in an increase in Tm values ranging between 73.6 – 86.6
°C. Δ Tm values were 17.4, 25.2 and 30.4 °C respectively when compared to the melting
point of Calf Thymus DNA alone (Tm value of 56.2 °C) (Table 3.2). The order of
polyamine thermal denaturation was thus spermine > spermidine > putrescine. This order
of binding strength can be explained by the increase in number of secondary amino
groups present in the structures of putrescine, spermidine and spermine, respectively.
Also, the Δ Tm for spermidine and spermine was greater than that of the extensively
studied groove binder, Hoechst 33258 (Δ Tm value of 22.6 °C) (Table 3.1).
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3.4.2. Effect of BNIPP Derivatives on DNA Binding Affinity by
Competitive Displacement of EtBr
The competitive displacement fluorescent assay of DNA bound EtBr was
performed to further validate the DNA binding affinity of each BNIPP derivative. The
fluorescence quenching of EtBr bound DNA by 1 – 10 µM BNIPDaCHM in 10 µM Calf
Thymus DNA and 2 µM EtBr is presented in Figure 3.14. The emission spectra are
representative of spectra obtained for each BNIPP derivative, except for BPHPDadec and
NPA which showed no quenching effects (data not shown).
Figure 3.14.: The effect of BNIPDaCHM concentration (1 – 10 µM) on fluorescence intensity for
fluorescence quenching of EtBr bound DNA.
Figure 3.15 shows an example of the % fluorescence intensity curve obtained at
the excitation/emission maxima (Ex/Em 481/596 nm) plotted against BNIPDaCHM
concentration (0 – 10 µM). The curve was representative of the % fluorescence intensity
curves obtained for each BNIPP derivative. In contrast, Figure 3.16 shows the %
fluorescence intensity curve obtained at the excitation/emission maxima (Ex/Em 481/594
nm) plotted against NPA concentration (0 – 10 µM) where EtBr displacement was not
achieved beyond the 50% decrease in fluorescence intensity (i.e., required to achieve a
C50 value for NPA or BPHPDadec).
BNIPDaCHM
(1 – 10 µM)
Calf Thymus DNA alone
1 µM BNIPDaCHM
2 µM BNIPDaCHM
4 µM BNIPDaCHM
6 µM BNIPDaCHM
8 µM BNIPDaCHM
10 µM BNIPDaCHM
+ Calf Thymus
DNA
Fluorescence
Intensity (a.u.)
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Figure 3.15.: The effect of BNIPDaCHM concentration on % fluorescence intensity. Emissions
were recorded at the Ex/Em maxima for the BNIPP derivatives (Ex/Em, BNIPDaCHM, 481/596nm).
Date are mean ± SD (n = 3).
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Figure 3.16.: The effect of NPA concentration on % fluorescence intensity. Emissions were
recorded at the Ex/Em maxima (Ex/Em, NPA, 481/596nm). Date are mean ± SD (n = 3).
All BNIPP derivatives, except BPHPDadec and NPA (C50 > 10 µM) competitively
displaced EtBr from DNA, with C50 values in the range of 1.4 – 3.8 µM (Table 3.3). The
order of BNIPP derivative binding strength to DNA was BNIPSpd > BNIPPut =
BNIPDahex > BNIPDaoct > BNIPDadec > BNIPDaoxoct > BNIPDadodec > BNIPDaCHM
> BPHPDadec = NPA.
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Table 3.3.: The effect of BNIPP derivatives on competitive displacement
Derivativea C50 (µM)b
Calf Thymus DNA alone ND
BNIPSpd 1.4 ± 0.1
BNIPPut 1.5 ± 0.3
BNIPDahex 1.5 ± 0.1
BNIPDaoct 1.7 ± 0.2
BNIPDadec 1.8 ± 0.1
BNIPDadodec 3.4 ± 0.3
BNIPDaoxoct 1.9 ± 0.4
BNIPDaCHM 3.8 ± 0.1
BPHPDadec > 10
NPA > 10
a 200 µL Calf Thymus DNA, 20 µL EtBr and varying volumes of the BNIPP derivatives were
prepared in 1 mL Eppendorf tubes. Solutions were mixed thoroughly and incubated for 15 minutes
at room temperature.
b C50 is the derivative concentration (µM) required to generate a 50 % decrease in the fluorescence
of bound EtBr. Data are the mean ± SD of three independent experiments (n = 3).
80
3.4.3. Molecular Modelling Study
Molecular modelling was carried out as previously described in Section 3.3.4.
Figure 3.17 reveals the mode of intercalation, either mono- or bis-intercalation that was
simulated by the BNIPP derivatives investigated. The naphthalimido or phthalimido
chromophores insert into the DNA duplex and intercalate with the base pairs. The
aminoalkyl linker of the bisnaphthalimidopropyl and bisphthalimidopropyl derivatives
appear to also bind to the grooves of the DNA duplex, thus also acting as possible groove
binders (Figure 3.17).
Figure 3.17.: Structures of the DNA Interactions between NPA, BPHPDadec and BNIPDaCHM (a,
b and c, respectively) and the DNA Duplex. The DNA is represented as a ball and stick model
(carbon atoms are coloured green, nitrogen atoms are blue, oxygen atoms in red, hydrogen atoms
in white, and phosphorus counterions are coloured purple). All derivatives are depicted as CPK
space-filled models, and are shaded red for NPA, blue for BPHPDadec and yellow for
BNIPDaCHM.
Figure 3.18 represents the effects of BNIPDaCHM (a) on the DNA duplex by
molecular modelling. Images (b - c) were obtained from the minimised average
conformational structure of BNIPDaCHM intercalated into the DNA duplex, when the
bases surrounding the intercalation site are either in an unfixed (b) or fixed (c) state. Each
image is representative of the minimised average conformations obtained for each
derivative when subjected to MD simulations. As shown in Figure 3.18 (a - c), the
structure of the DNA duplex was completely distorted and destroyed after MD simulations
in both an unfixed or fixed state. In most cases, the DNA duplex appeared to fold in on
itself completely during MD simulations.
a b cDNA Duplex
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Figure 3.18.: Structures of the DNA Interactions between BNIPDaCHM (a, b and c, respectively)
and the DNA Duplex. The DNA is represented as a ball and stick model (carbon atoms are
coloured green, nitrogen atoms are blue, oxygen atoms in red, hydrogen atoms in white, and
phosphorus counterions are coloured purple). BNIPDaCHM is depicted as a CPK space-filled
model, and are shaded yellow, a BNIPDaCHM present within the intercalation sites, b the final
average minimised structure of BNIPDaCHM in the DNA duplex with unfixed intercalation sites,
and c the final average minimised structure of BNIPDaCHM in the DNA duplex with fixed
intercalation sites. These images are representative of the results obtained for each derivative
investigated.
Molecular modelling studies were performed on these selected BNIPP derivatives
to rationalise the results obtained from the in vitro DNA binding studies as shown in
Sections 3.4.1 and 3.4.2. The computed energy results associated to each DNA/BNIPP
derivative complex with unfixed intercalation sites are presented in Table 3.4.
DNA Duplex a b c
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Table 3.4.: Computed potential energies (kcal mol-1) for the unfixed DNA-BNIPP derivative
complexes a, b
BNIPP Derivative DNA-BNIPP
Derivative
Complex
ECOMPLEX EBIND
BNIPSpd i
ii
606.49
627.37
-85.65
-64.76
BNIPDaoct i
ii
iii
iv
480.92
536.86
509.34
700.48
-198.19
-142.25
-169.77
21.371
BNIPDaoxoct i
ii
iii
643.92
703.32
729.14
224.31
283.71
309.53
BNIPDaCHM i
ii
iii
iv
680.50
692.18
705.93
683.522
18.85
30.52
44.27
21.87
BPHPDadec i
ii
iii
271.65
282.55
753.57
48.76
59.65
530.68
NPA i
ii
iii
294.28
313.21
339.24
-34.73
-15.80
10.22
a Where EDNA = 227.70 kcal mol-1 for the DUPLEXICI99 DNA duplex.
b Where EBNIPP is 464.44 kcal mol-1 for BNIPSpd, 451.41 kcal mol-1 for BNIPDaoct, 191.91 kcal mol-
1 for BNIPDaoxoct, 433.95 kcal mol-1 for BNIPDaCHM, -4.81 kcal mol-1 for BPHPDadec and 101.32
kcal mol-1 for NPA.
The DNA-BNIPP derivative complexes selected for further MD simulations with
fixed intercalation sites were complexes with the most negative EBIND energies. These
complexes were i and ii for BNIPSpd, i and iii for BNIPDaoct, i and ii for BNIPDaoxoct, i
and iv for BNIPDaCHM, i and ii for BPHPDadec, and i and ii for NPA as shown in Table
3.5.
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Table 3.5.: Computed potential energies (kcal mol-1) for the fixed DNA-BNIPP derivative
complexes a, b
BNIPP Derivative DNA-BNIPP
Derivative
Complex
ECOMPLEX EBIND
BNIPSpd i
ii
521.97
642.22
-170.17
-49.92
BNIPDaoct i
iii
500.53
508.72
-178.58
-170.39
BNIPDaoxoct i
ii
644.24
661.13
224.63
241.53
BNIPDaCHM i
iv
661.68
659.67
0.02
-1.98
BPHPDadec i
ii
462.31
255.57
189.42
-17.32
NPA i
ii
304.93
342.52
-24.09
13.50
a Where EDNA = 227.70 kcal mol-1 for the DUPLEXICI99 DNA duplex.
b Where EBNIPP is 464.44 kcal mol-1 for BNIPSpd, 451.41 kcal mol-1 for BNIPDaoct, 191.91 kcal mol-
1 for BNIPDaoxoct, 433.95 kcal mol-1 for BNIPDaCHM, -4.81 kcal mol-1 for BPHPDadec and 101.32
kcal mol-1 for NPA.
The results in Tables 3.4 and 3.5 show that there was little difference observed
between the EBIND obtained for the unfixed or fixed bases in the DNA-BNIPP derivatives
complexes suggesting that the instability and distortion of the helix (Figure 3.18) played a
very small part in the overall interaction. In this study, the more negative the binding
energy, the stronger the DNA binding interaction. Due to the presence of negative binding
energies, most of the derivatives were identified as active. The order for DNA binding
strength, as represented by EBIND (kcal mol-1) was BNIPDaoct > BNIPSpd > NPA >
BNIPDaCHM > BPHPDadec > BNIPDaoxoct. These results are in contrast to the rank
order obtained from the in vitro thermal denaturation and competitive displacement assays
(Tables 3.1 and 3.3).
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3.5. Discussion
3.5.1. Effect of BNIPP Derivatives on DNA Binding Affinity
In this study, DNA-binding affinities of BNIPP derivatives were achieved via
thermal denaturation and competitive EtBr displacement studies (Sections 3.4.1 and
3.4.2). These in vitro techniques provided the simplest means by which to study DNA
binding mechanisms (Johnson and Thomas 2002, Palchaudhuri and Hergenrother 2007),
and were used to evaluate and confirm that DNA was a target utilised by BNIPP
derivatives following on from studies by Pavlov et al. (2001) and Dance et al. (2005).
All BNIPP (10 µM) derivatives were able to stabilise the Calf Thymus DNA duplex
as demonstrated by increased Tm values (81.2 – 91.9 °C) when compared with Calf
Thymus DNA alone (Tm value of 56.2 °C) (Table 3.1). As stabilisation of the DNA duplex
has been shown to be a common feature of DNA intercalating anti cancer drugs (Martinez
and Chacon-Garcia 2005); it was confirmed that BNIPP derivatives interact with DNA
through bis-intercalation. These results are also in agreement with the findings of Pavlov
et al. (2001) and Dance et al. (2005).
BNIPDahex was identified to be the most active DNA binding derivative (Δ Tm 35.7
°C), and both BNIPDahex and BNIPSpd (Δ Tm 35.3 °C) had greater DNA binding affinities
than the extensively studied intercalator doxorubicin (Δ Tm 30.2 °C) (Table 3.1). Earlier
work had identified BNIPSpd to be the most active DNA binding member of the BNIPP
derivative series compared to BNIPOSpd and BNIPOSpm (Figures 1.22 and 1.23) (Pavlov
et al. 2001, Dance et al. 2005). Although, a different buffer (i.e., 0.01 M phosphate buffer)
was used in previous studies by Pavlov et al. (2001) and Dance et al. (2005), the DNA
binding trends observed in this study are very similar.
The more selective technique of EtBr displacement confirmed the mode of action
of BNIPP derivatives relative to DNA intercalation (Section 3.4.2) (Martinez and Chacon-
Garcia 2005, Ott et al. 2008). BNIPP derivatives induced effective displacement of DNA
bound EtBr in a dose dependent manner, thus, effectively competing with EtBr for DNA
intercalation sites and, as a result of their higher DNA binding affinities, effectively
displaced EtBr. The fluorescent emissions of the DNA bound EtBr were consequently
quenched, with C50 values in the range of 1.4 – 3.8 µM (Table 3.3). EtBr displacement
studies have been used in the literature to investigate many structurally different DNA
binding derivatives, for example, combilexines (Hotzel et al. 2002) or cation-substituted
anthrapyrazoles (Tan et al. 2007) (Figure 3.19). Hotzel et al. (2002) found weak DNA
binding (i.e., C50 > 140 µM) with combilexine derivatives, whereas Tan et al. (2007) found
that cation-substituted anthrapyrazole derivatives were effective DNA binders with C50
values ranging between 12 – 21 µM. Therefore, compared with these results, BNIPP
85
derivatives have higher DNA affinities than the most active cambilexine (a) or the most
active cation-substituted anthrapyrazoles (b-c) (Figure 3.19).
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Figure 3.19.: Structures of the most active cambilexine (a) and the most active cation-substituted
anthrapyrazoles (b-c)
DNA binding affinity of BNIPP derivatives can be greatly affected by structural
modifications to the central linker chain, including length, rigidity and the number of
positive charges. Previous work by Pavlov et al. (2001) stated that BNIPP derivatives with
spermidine and spermine linker chains showed an influence on the extent of DNA binding
affinity. Spermidine (+3 charge) and spermine (+4 charge) linkers exhibited a much
higher degree of DNA binding than their linear diaminoalkyl linker counterparts (+2
charge). Therefore, a relationship exists between the number of secondary amines
present in the linker chain (i.e., a higher electronegativity) (Feuerstein et al. 1990), and an
increase in Tm values (i.e., a higher DNA binding affinity), as demonstrated in this study
(Table 3.2). In addition, a detailed study carried out by Ouameur and Tajmir-Riahi (2004)
calculated the approximate distances between the outer primary amino groups of the all-
trans conformation (~ 6.23, 11.13 and 16.04 Ǻ, for putrescine, spermidine and spermine, 
respectively), and showed that the calculated N-N distances were closely related to the
length of the major (~ 16.4 Ǻ) and the minor (~ 6.02 Ǻ) grooves of the DNA duplex.  
Therefore, polyamines have the ideal net charge and size to generate strong DNA groove
binding interactions (Le Pecq et al. 1975, Hou et al. 2001, Strekowski and Wilson 2007),
and the results presented in Table 3.2 are in agreement with those findings.
For the BNIPP derivatives, thermal denaturation studies were also used to
investigate the effect of further modifications to the central linker chain (Table 3.1). These
modifications include an increase in alkyl chain length (i.e., chains with between 4 – 12
methylene groups), and the addition of either two oxygen atoms (i.e., increase charge) or
two cyclohexane rings (i.e., to some extent increase linker rigidity). BNIPP derivatives
with a chain length of between 4 – 8 methylene groups (BNIPPut, BNIPDahex and
BNIPDaoct respectively) exhibited high DNA binding affinities (Δ Tm values 32.5 – 35.7
°C) caused by strong electrostatic and hydrophobic interactions reasoned as groove
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binding interactions. The lower DNA binding affinities of BNIPDadec with 10 methylene
groups and BNIPDadodec with 12 methylene groups (Δ Tm values of 28.2 and 25.0 °C,
respectively) could be explained by an incomplete electrostatic interaction. The increased
flexibility in the alkyl linker chain can also contribute to the linker unwinding away from the
DNA, and that the two amino groups were not electronegative enough to ensure a stable
interaction with the phosphate groups on the DNA duplex. Furthermore, the absence of
highly electronegative atoms between the amino groups (e.g., nitrogen or oxygen atoms)
would not permit the formation of strong hydrogen bonds which may have stabilised a
longer alkyl chain. The derivatives BNIPDaoxoct and BNIPDaCHM exhibited a marginal
decrease in DNA binding affinity compared with the more effective BNIPP derivatives (Δ 
Tm values 31.7 and 31.2 °C, respectively), yet they were more effective than derivatives
with linear alkyl chain lengths of > 8 methylene groups. C50 values revealed BNIPDaoxoct
(C50 value of 1.9 µM) to be a more effective DNA binder than BNIPDaCHM (C50 value of
3.8 µM) (Table 3.3). The two oxygen atoms are highly electronegative, and can establish
strong hydrogen bonds with DNA grooves (major or minor) or with the phosphates of the
DNA backbone (Pavlov et al. 2001, Filosa et al. 2009). However, the differences in C50
values were not physiologically different to one another (i.e., a significant physiological
difference would be a difference of > 10 µM). These results do suggest that, linker chains,
as well as naphthalimido rings are critical in contributing to high DNA binding affinities.
The results in this study support the theory that BNIPP derivatives bind to DNA by
intercalation (i.e., the naphthalimido rings), and groove binding (i.e., the aminoalkyl linker
chain) (Kong Thoo Lin and Pavlov 2000, Pavlov et al. 2001).
It is impossible to definitively state whether the BNIPP derivatives bind by both
intercalation and groove binding using only thermal denaturation and displacement
assays. However, compelling evidence from the structural and in vitro data presented in
Tables 3.1 and 3.3 do strongly suggest that BNIPP derivatives may utilise both
mechanisms. In support of this theory, the symmetrical bisnaphthalimide Elinafide (Figure
1.21) which shares many structural features to that of BNIPP derivatives was found to bis-
intercalate into DNA (Bailly et al. 1996, Brana et al. 2001). In addition, using a
combination of DNase I footprinting, chemical probing, NMR and MD simulations,
Elinafide was shown to interact in a sequence specific manner with the hexanucleotide
d(ATGCAT)2. The linker chain (N,N’-bis(ethylene)-1,3-propylenediamine) was positioned
within the major groove of the DNA duplex, and its amino groups hydrogen bonded to the
guanine bases (Bailly et al. 1996, Gallego et al. 1999, Brana et al. 2001). Using molecular
modelling studies Filosa et al (2009) reported that several structurally related
bisnaphthalimide derivatives, with various aminoalkyl linker substitutions were also bis-
intercalators. The planar aromatic moieties were shown to intercalate between the base
pairs, and the linker chain was detailed to be the contributory factor in the stability of the
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complex, with the formation of Van der Waal’s interactions and hydrogen bonds with the
minor groove (Filosa et al. 2009).
Further studies which verify the groove binding potential, and sequence specificity
of BNIPP derivatives should be undertaken to compare with the binding interactions of
structurally related derivatives, such as Elinafide. Methods employed to determine these
interactions should include viscosity changes, electric linear dichroism, NMR and DNase I
footprinting (Palchaudhuri and Hergenrother 2007, Strekowski and Wilson 2007)
It is interesting to note that in comparison with the BNIPP derivatives, BPHPDadec
and NPA were not as effective in intercalating with Calf Thymus DNA (Tm values of 72.0
and 66.3 °C, thus Δ Tm values of 15.8 and 10.1 °C, respectively), and C50 values of > 10
µM (Tables 3.1 and 3.3). The reduced level of DNA intercalation can be related to the
structural differences between these derivatives and the BNIPP derivatives. Instead of
two naphthalimido rings, BPHPDadec consisted of two phthalimido rings, whilst NPA had
only one naphthalimido ring. Taken together, these results have shown that the presence
of bisnaphthalimidopropyl functionality and an optimum aminoalkyl linker chain length of 4
– 8 methylene groups are necessary to obtain strong DNA binding interactions.
3.5.2. Molecular Modelling
Molecular modelling studies were undertaken in an attempt to rationalise the in
vitro DNA binding results obtained for the BNIPP derivatives. Further investigations into
the mode of DNA binding were carried out for BNIPSpd, BNIPDaoct, BNIPDaoxoct,
BNIPDaCHM, BPHPDadec and NPA through MD simulations using the DNA duplex
model described in Section 3.3.4.
The DNA-BNIPP derivative complexes were initially attained by docking the BNIPP
derivative midway into the intercalation site on the DNA duplex. The BNIPP derivatives
(and BPHPDadec) were docked into both intercalation sites, whilst NPA was docked into
only one intercalation site (Figure 3.17). The DNA-BNIPP derivative complexes were
initially submitted for MD simulations with all atoms free to move (unfixed state) (Table
3.4). Due to the complete distortion of the DNA complex after MD simulations (Figure
3.18), the DNA-BNIPP derivative complexes were further refined whereby the heavy
atoms around the intercalation sites were fixed (Table 3.5). The results produced
demonstrated that there were no differences in the images obtained or the rank order of
DNA-BNIPP derivative binding energies (Figure 3.18; Tables 3.4 and 3.5). Although, it is
important to note that more negative EBIND results were observed when the intercalation
sites were fixed (Table 3.5).
The rank order obtained for derivatives after MD simulations were noticeably
different to that obtained in the Tm and EtBr displacement studies. There are several
reasons for this discrepancy. One of the reasons is the fact that the model used in this
study did not have the same base sequence as Calf Thymus DNA, thus resulting in
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different binding interactions between each system. In order to compare the results of the
BNIPP derivatives with that of Elinafide, the DNA hexamer d(ATGCAT)2 should have been
utilised (Gallego et al. 1999, Brana et al. 2004a). Another possible reason is that the
DNA-BNIPP derivative complexes were not allowed enough time to relax fully during MD
simulations resulting in only a small population of notable trajectories or ‘snap shots’ per
complex. To overcome this issue, the DNA-BNIPP derivative complexes should be
heated to 600 K, instead of 300 K, which would increase the number of trajectories and
dynamic simulations per DNA-BNIPP derivative complex. A third possibility was that
modelling was carried out in vacuo using a correction for implicit solvent (Distance
Dependent Dielectric of 4, and a Cutoff Distance of 9.5), yet a more realistic model would
have been to use an explicit solvent during the MD simulations. However, this would
result in more complex and lengthy MD simulations. In all situations, the bases would
again be in an unfixed and fixed state to correlate with the results obtained in this study.
Therefore, although the BNIPP derivatives were identified as active DNA binders
in the model utilised, it could be stated that the DNA model and MD simulations need to
be further refined in order to correlate the results obtained from the in vitro DNA binding
experiments (Sections 3.4.1 and 3.4.2).
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3.6. Conclusions
Thermal denaturation and EtBr displacement studies confirmed that the BNIPP
derivatives interact with DNA by the mechanism of bis-intercalation. All BNIPP
derivatives, except BPHPDadec and NPA (Δ Tm values of 15.8 and 10.2 °C, and C50
values of > 10 µM) exhibited strong DNA binding affinities. High DNA binding affinities
were observed in derivatives with an alkyl linker chain length with 4 – 8 methylene groups,
and the presence of nitrogen or oxygen atoms were shown to further enhance DNA
binding affinity. DNA binding affinity was reduced with longer alkyl linker chains
containing more than 10 methylene groups. The DNA binding results confirmed the
important structural features required to increase DNA binding affinity. These include (i)
bisnaphthalimidopropyl functionality; (ii) an alkyl linker chain of between 4 – 8 methylene
groups; and (iii) the presence of at least two amino groups.
MD simulations have also provided evidence that the BNIPP derivatives bind to
DNA in an intercalative manner, by exhibiting negative EBIND values for several of the
BNIPP derivatives. The MD simulations resulted in the complete distortion of the DNA
duplex for all derivatives analysed, although the model used needs to be further refined
before additional experiments are undertaken.
In conclusion, the results presented thus far strongly suggest that DNA could be
one of the main targets for BNIPP derivatives, and they bind DNA by bis-intercalation. In
an attempt to further elucidate the mode of action of selected BNIPP derivatives; their
toxicity, mode of cell uptake and their cellular distribution was assessed in breast cancer
MDA-MB-231 and breast epithelial MCF-10A cells (Chapter 4).
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Chapter 4
Cytotoxicity and Cellular Uptake Studies of BNIPP
Derivatives in MDA-MB-231 and MCF-10A Cells
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4.1. Cytotoxicity and Cellular Uptake Studies of BNIPP
Derivatives in MDA-MB-231 and MCF-10A Cells
The ability of compounds to induce death of cancer cells is one of the first
screenings to be carried out in order to elucidate the potential of proposed anti cancer
agents.
The aims of the experimental work presented in this chapter were to (i) screen all
the BNIPP derivatives for biological activity in breast cancer (MDA-MB-231) and breast
epithelial (MCF-10A) cells; (ii) study the cellular uptake and distribution of BNIPSpd,
BNIPDaoct, BNIPDaoxoct and BNIPDaCHM in MDA-MB-231 and MCF-10A cells; (iii)
investigate a possible mechanism of BNIPP derivative transport into cells, and (iv)
determine the effect of BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM on MDA-
MB-231 and MCF-10A intracellular polyamine levels.
4.1.1. Cytotoxicity
Cytotoxic chemotherapy is routinely used in the treatment of early and advanced
cancers, including breast cancer (Robson and Verma 2009). Cytotoxic anti cancer agents
exert their effect on cancer cells by interfering with the regulatory processes of cell
division and proliferation; causing DNA damage, which leads to cell death (Robson and
Verma 2009). Thus, the observation of cytotoxic effects provides an initial screen for
potential anti cancer agents.
4.1.1.1. Assessment of In Vitro Cytotoxicity
Numerous radioactive and non-radioactive cytotoxicity assays are available to
access in vitro cell survival and proliferation within mammalian cells. Radioactive assays,
including the use of radioisotopes, such as 51Cr, and radiolabelled biochemicals, such as
[3H]thymidine, are seldom used nowadays, due to (i) the requirement for highly regulated
working environments; (ii) exposure to dangerous radioactive reagents; and (iii) poor
radiolabelling of some tumour cells (Nakayama et al. 1997, Niu et al. 2001). To overcome
the problems encountered by radioactive assays, several non-radioactive assays have
been developed. Examples include: (i) the reduction of a tetrazolium salt dye, such as
MTT, XTT (sodium 2,3-bis(2-methoxy-nitro-5-sulfophenyl)-5-[(phenylamino)-carbonyl]-2H-
tetrazolium inner salt), or MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-
2-(4-sulfophenyl)-2H-tetrazolium inner salt) into their corresponding formazan crystals by
intracellular enzymes (Mosmann 1983, Denziot and Lang 1986, Vistica et al. 1991,
Goodwin et al. 1995, Nakayama et al. 1997); (ii) the release of intracellular lactate
dehydrogenase (LDH) into culture medium by the LDH leakage assay (Fotakis and
Timbrell 2006); (iii) the accumulation of neutral red (NR) dye within lysosomes in viable
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cells, via the neutral red assay (Valdivieso-Garcia et al. 1993, Fotakis and Timbrell 2006);
(iv) the reduction of Alamar BlueTM solution which contains resazurin (a fluorescent
oxidation-reduction indicator), and is reduced into resurfin by mitochondrial enzymes
(Nakayama et al. 1997, O’Brien et al. 2000, Holst and Oredsson 2005); (v) the
incorporation of bromodeoxyuridine (BrdU) into DNA in place of thymidine during DNA
replication (Ormerod 1997) or (vi) microscopic staining with Trypan Blue or fluorescent
DNA-specific dyes, such as Hoechst 33258 or ethidium bromide (Nakayama et al. 1997).
In this study, cytotoxicity was determined using the MTT assay. The MTT assay is
one of the most widely used cytotoxicity assays used to investigate a compound’s
biological activity, due to its simplicity, rapidity, sensitivity and semi-automation, without
the use of radioactivity (Mosmann 1983, Denziot and Lang 1986, Twentyman and
Luscombe 1987, Pozzolini et al. 2003). When added to viable proliferating cells, MTT a
yellow, water-soluble, tetrazolium salt dye, is taken up by the cells by endocytosis, and
reduced to purple, water-insoluble, formazan crystals, via mitochondrial nicotinamide
adenine dinucleotide phosphate (NADH) dependent dehydrogenases (Pozzolini et al.
2003, Holst and Oredsson 2005, Fotakis and Timbrel 2006) (Figure 4.1). The reduced
insoluble formazan crystals are transported to the cell surface by exocytosis dissolved in a
solvent and quantified spectroscopically (Twentyman and Luscombe 1987, Isobe et al.
2001). The resultant absorbance value is directly proportional to the number of viable
cells (Pozzolini et al. 2003, Holst and Oredsson 2005).
N N
N
N
S
N
CH3
CH3
+
Br -
N
N
N
S
N
CH3
CH3
NH
NADH NAD+
Viable Proliferating Cells
MTT (Tetrazolium Dye) Formazan Crystals
Figure 4.1.: The reduction reaction of yellow MTT tetrazolium salt to purple formazan crystals in
viable cells
4.1.2. Cellular Uptake
The uptake of exogenous and endogenous substances into cells can be achieved
by several different transport mechanisms. Due to the selectively permeable nature of the
plasma membrane; transport of molecules in and out of a cell is achieved in a highly
controlled manner. Transport mechanisms include passive diffusion and active transport
(Cooper and Hausman 2007). Passive diffusion, the simplest transportation mechanism,
allows small polar and non polar molecules (e.g., H2O, O2, CO2 molecules) to diffuse
across the membrane down their concentration gradient (Figure 4.2A). In contrast,
charged molecules (e.g., H+, Ca2+ or Na+ ions) or large polar molecules (e.g., glucose)
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cannot dissolve across the plasma membrane by passive diffusion and must utilise the
mechanism of active transport (Figure 4.2B and 4.2C). Active transport involves the
transportation of these latter molecules against their concentration gradient, with the use
of an energy source (i.e., from the hydrolysis of Adenosine triphosphate (ATP) (Cooper
and Hausman 2007). To further facilitate the uptake of these molecules, specific plasma
membrane proteins, which act as transporter systems are utilised. A diverse range of
transporter systems are known to exist, and each system transports a molecule across
the plasma membrane (Ganapathy et al. 2009, Patrick 2009). Examples of these
transporter systems include channel proteins or carrier proteins which are responsible for
the uptake of ions (e.g., the H+, Ca2+ or Na+ ions), amino acids (e.g., glutamine or leucine,
nucleic acids or polyamines (e.g., putrescine, spermidine or spermine) (Figure 4.2B and
C) (Seiler et al. 1996, Fuchs and Bode 2005, Cooper and Hausman 2007, Hu et al. 2008,
Ganapathy et al. 2009, Patrick 2009). As a consequence, specific transporter systems
have been identified as potential drug targets in the treatment of cancer. Interference with
the entry and availability of certain essential nutrients could inhibit the proliferation and
differentiation of cancer cells (Gardner et al. 2004, Ganapathy et al. 2009).
Figure 4.2.: The selective permeability of the plasma membrane. A represents passive diffusion,
B (an ion channel protein) and C (a carrier protein) both represent active transport (adapted from
Cooper and Hausman 2007, pp. 65)
4.1.2.1. Polyamine Transporter
One example of active transport and of particular interest for this study is the
polyamine transporter. Polyamines (Putrescine, Spermidine and Spermine) are present
within all prokaryotic and eukaryotic cells, and are essential for normal growth,
proliferation, and protein synthesis (Thomas and Thomas 2001, Ah Byun et al. 2009)
(Section 1.4). These charged nitrogen bearing polycation chains can be sourced
endogenously through the highly regulated biosynthetic pathway, or sourced exogenously
by active gut uptake from diet (from cheese, fruit or vegetables), and/or adsorption by
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CO2 H+ ions
Na+ ions
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A B C
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intestinal flora (Seiler et al. 1990, Milovic et al. 2001, Thomas and Thomas 2001, Larqué
et al. 2007). Exogenous polyamines are taken up by specific cells using a highly
regulated, energy-dependent polyamine transporter (PAT) system, as mentioned
previously in Section 4.1.2 (Seiler et al. 1996, Graminski et al. 2002, Mitchell et al. 2007).
It has been shown that rapidly dividing cells, for example colon, lung and breast cancer
cells, contain an activated PAT system, and higher levels of polyamines compared to that
of the corresponding non-cancerous cells (Seiler et al. 1996, Cullis et al. 1999, Wallace et
al. 2000, Gardner et al. 2004, Kaur et al. 2005, Tsen et al. 2008, Ah Byun et al. 2009).
Due to the structural tolerances of the PAT, various synthetic polyamine-like
derivatives and analogues, such as anthracen-9-ylmethyl-4,4-triamine trihydrochloride or
anthracen-9-ylmethyl-4,4-tetraamine tetrahydrochloride (Figure 4.3), can be imported into
cells, via the PAT system (Wang et al. 2003a, Gaboriau et al. 2004, Gardner et al. 2004).
For that reason, the BNIPP derivatives studied in this work may utilise the PAT system for
their cellular uptake in a similar way to that of other polyamine-like derivatives (Gardner et
al. 2004, Kaur et al. 2008a). In support of the BNIPP derivatives potential use of the
energy-dependent PAT system, it was found that incubation at 4 °C notably reduced the
uptake of BNIPP derivatives in breast cancer (MCF-7) cells, as determined by reduced
fluorescence (Seiler et al. 1996, Dance et al. 2005, Ralton 2006, Kimura et al. 2009).
Hence, the PAT represents a potential target for the enhanced uptake of anti cancer drugs
(Gardner et al. 2004, Tsen et al. 2008).
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Figure 4.3.: Structures of a: Anthracen-9-ylmethyl-4, 4-triamine, trihydrochloride and b: Anthracen-
9-ylmethyl-4, 4-tetraamine, tetrahydrochloride
Wang and colleagues (2003a, 2003b, 2003c) have identified a useful cellular
model, which can be used to determine the selective delivery and entry of non-native
polyamine-like derivatives, via the PAT (Mandel and Flintoff 1978, Heaton and Flintoff
1988). This model relies upon the comparative cytotoxicity of polyamine-like derivatives in
two Chinese Hamster Ovary (CHO) cell lines. The parental CHO cells have an active
PAT (PAT-active), and the CHO-MG cells; isolated after single-step selection for growth
resistance to Methylglyoxalbis (guanylhydrazone) (MGBG) (Figure 4.4), represent cells
with a mutant PAT, and are thus classified as PAT-inactive (Mandel and Flintoff 1978,
Heaton and Flintoff 1988). MGBG growth resistance in the CHO-MG cells was exploited
given that MGBG is a known substrate for the PAT system, and an inhibitor of polyamine
biosynthesis (e.g., SAMDC inhibition) and mitochondrial function (Mandel and Flintoff
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1978, Von Hoff 1994, Ekelund et al. 2001, Wang et al. 2003c, Casero and Marton 2007).
The CHO-MG cells can also provide a delivery system which is independent of the
MGBG-specific PAT (Wang et al. 2003a, Wang et al. 2003b, Wang et al. 2003c, Gardner
et al. 2004, Tsen et al. 2008).
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Figure 4.4.: Structure of Methylglyoxalbis (guanylhydrazone) (MGBG)
4.1.3. Intracellular Polyamine Levels
Intracellular polyamine levels have been shown to regulate the rate of cell growth
and proliferation (Khuhawar and Qureshi 2001, Thomas and Thomas 2001). Excessive
cell growth has been related to high levels of intracellular polyamines, and associated with
diseases of uncontrolled cell proliferation, such as cancer, including breast and colon
cancers (Pegg 1988, Seiler et al. 1996, Wallace et al. 2000, Gardner et al. 2004, Kaur et
al. 2005, Tsen et al. 2008, Ah Byun et al. 2009). In contrast, an inhibition of cell growth
has been linked to a decrease in intracellular polyamine levels (Russell 1983, Pegg 1988,
Davidson et al. 1999). For that reason, depletion of intracellular polyamine levels by
cytotoxic derivatives represents a potential target for the inhibition of cancerous cell
growth (Graminski et al. 2002).
4.1.3.1. Assessment of Intracellular Polyamine Levels
Several biological and chemical methods have been utilised for the detection of
intracellular levels of polyamines within plant or animal tissues and, body fluids (Seiler
1977). Biological methods, including enzymatic and immunological methods are seldom
used in polyamine detection because they (i) cannot discriminate between spermidine and
spermine, and (ii) cannot be automated (Seiler 1977). Chemical methods, including paper
chromatography, thin layer chromatography (TLC), paper electrophoresis and high
performance liquid chromatography (HPLC) can all be successfully utilised for polyamine
determination (Seiler 1977, Marcé et al. 1995, Khuhawar and Qureshi 2001). Gas
chromatography (GC) has also been used to analyse polyamines, though mainly within
foodstuffs (Rogers et al. 2003). However, GC is not routinely used for the analysis of
body fluids or cancer cells, due to difficulties regularly encountered during sample
derivatisation, purification, and separation (Larqué et al. 2007). In addition to the above
techniques, capillary zone electrophoresis (CZE) and flow injection analysis (FIA) coupled
with mass spectrometry (MS) have also gained some importance in the analysis of
polyamine levels within serum samples. Although these techniques showed increased
detection sensitivity, the overall practicalities of their use for routine polyamine analysis
96
require further investigation (Khuhawar and Qureshi 2001, Gaboriau et al. 2003, Gugliucci
2004).
HPLC, a simple, sensitive and rapid analytical technique, remains the technique of
choice for polyamine detection (Smith and Davies 1985, Marcé et al. 1995, Teti et al.
2002, Gugliucci 2004). Polyamines are positively charged molecules, which must
undergo either pre- or post-column derivatisation before they can be sensitively separated
and detected by UV absorbance or fluorescence (Marcé et al 1995). Pre-column
derivatisation with dansyl chloride (5-(dimethylamino) naphthalene-1-sulfonyl chloride)
(Figure 4.5) has been successfully utilised to separate and quantify the intracellular levels
of putrescine, spermidine and spermine. Dansyl chloride reacts with primary and
secondary amines, resulting in the formation of fluorescent di-, tri- and tetra- dansylated
polyamine derivatives from putrescine, spermidine and spermine, respectively (Khuhawar
and Qureshi 2001). These dansylated derivatives are highly fluorescent and can be
separated by reverse-phase HPLC (Kabra et al 1986).
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Figure 4.5.: Derivatisation reaction of polyamines (R) with dansyl chloride
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4.2. Materials
4.2.1. Materials
All reagents were purchased from Fisher Scientific, UK, unless otherwise stated,
and were used without purification.
Choleratoxin List Biological Laboratories. Inc, USA
Dansyl Chloride Fluka, UK
Difluoromethylornithine Sigma-Aldrich, UK
Dimethyl Sulfoxide Aldrich, UK
DMEM/F12 medium Lonza, Belgium
Doxorubicin Sigma-Aldrich, UK
Epidermal Growth Factor Invitrogen, UK
Etoposide Sigma-Aldrich, UK
Foetal Calf Serum Biosera, UK
Horse Serum Sigma-Aldrich, UK
Human Insulin Sigma-Aldrich, UK
Hydrocortisone Sigma-Aldrich, UK
Methylthiazolyldiphenyl-tetrazolium bromide Sigma-Aldrich, UK
Penicillin/Streptomycin Invitrogen, UK
Phosphate Buffered Saline Sigma-Aldrich, UK
RPMI-1640 medium Gibco, UK
Trypsin-EDTA Sigma-Aldrich, UK
4.2.2. Instrumentation
Aseptic cell culture techniques were undertaken within a HERASafe Class II
Safety Cabinet (Thermo Electron Corporation, Germany). All cell culture plastics were
sterile certified and tips were sterilised before use in a Boxer Autoclave (Boxer Lab
Equipment, UK). Cells were incubated at 37 °C, in a humidified 5% CO2 atmosphere
within a HERACell Incubator (Heraeus, Germany), and were counted using an improved
Neubauer Haemocytometer (Assitent, Germany).
Light and fluorescence microscopy experiments were visualised using a Leica
DMIL inverted light microscope (Leica Microsystems, UK) or a Leica DMIL inverted
fluorescence microscope (Leica Microsystems, UK) using a UV filter (excitation bandpass
(ultraviolet); 340 – 380 nm, emission longpass (blue); 425 nm). Microscopy images were
captured using a Leica DC 200 camera (Leica Microsystems, UK) and, viewed using
Infranview 3.91 software (Leica Microsystems, UK).
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For MTT Assay analysis, a 96 well plate reader (MRX II, Dynex Technologies,
USA) was utilised.
Pre-column derivatisation was undertaken using an activated Solid Phase
Extraction (SPE) column (Strata C18-E, 100 mg/mL, Phenomenex, UK), attached to a
VacMaster-10 (Sopachem, Belgium). HPLC was performed using an Adsorbosphere HS
C18 5U, 250 mm x 4.6 mm HPLC column (Adsorbosphere, UK) on a Spectra-Physics
SP8700 solvent delivery system with a SP8750 HPLC pump. A Shimadzu RF-535
Fluorescence HPLC monitor was used to detect dansyl fluorescence with excitation and
emission filters set at 340 nm and 514 nm, respectively. Results were visualised using a
Spectra Physics SP4270 integrator.
99
4.3. Methods
4.3.1. Cell Lines
4.3.1.1. MDA-MB-231 Cells
Human breast epithelial cancer MDA-MB-231 cells were purchased from the
European Collection of Cell Cultures (ECACC) (ECACC; 92020424). MDA-MB-231 cells
are metastatic cells, isolated from a pleural effusion of a breast cancer patient (Belkacemi
et al. 2006). These cells are estrogen receptor-negative, and with a mutant p53 tumour
suppressor protein (Koutsilieris et al. 1999, Belkacemi et al. 2006). MDA-MB-231 cells
were maintained in Roswell Park Memorial Institute 1640 medium (RPMI-1640)
(containing GlutaMAX™-1 with 25 mM HEPES) (Langdon. 2004) supplemented with 10 %
(v/v) Foetal Calf Serum (FCS) and, 1 % Penicillin (100 U/mL)/Streptomycin (100 µg/mL).
4.3.1.2. MCF-10A Cells
Human breast epithelial MCF-10A cells were purchased from the American Tissue
Culture Collection (ATCC) (ATCC; CRL-10317). MCF-10A cells are non-tumourigenic
cells, derived from the mammary tissue of a fibrocystic disease patient, and were used as
the normal cell control in breast cancer studies (Soule et al. 1990, Zientek-Targosz et al.
2008). These cells are also estrogen receptor-negative (Debnath et al. 2003). MCF-10A
cells were maintained in Dulbecco's Modified Eagle/Nutrient Mixture F-12 (DMEM/F12)
medium supplemented with 5 % (v/v) Horse Serum (HS), Human Insulin (10 µg/mL),
Hydrocortisone (0.5 µg/mL), Epidermal Growth Factor (EGF) (20 ng/mL), Choleratoxin
(100 ng/mL) and, Penicillin (100 U/mL) / Streptomycin (100 µg/mL). MCF-10A cells were
cultured from passage number 103 to 123, due to the increased instability and short
lifespan of epithelial cells.
4.3.1.3. CHO and CHO-MG Cells
Two Chinese Hamster Ovary (CHO) cell lines: the parental CHO cells with an
active polyamine transporter, and the polyamine-transport deficient mutant cell line, CHO-
MG, were kindly donated by Professor Wayne Flintoff, from the University of Western
Ontario, Canada (Mandel and Flintoff 1978). CHO and CHO-MG cells were maintained in
RPMI 1640 medium (containing L-Glutamine with no Phenol Red) supplemented with 10
% (v/v) FCS and, 0.5 % (v/v) Penicillin (100 U/mL) / Streptomycin (100 µg/mL).
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4.3.2. Maintenance of Cell Lines
Cells were incubated at 37 °C, in a humidified 5% CO2 atmosphere. MDA-MB-
231, MCF-10A, CHO and CHO-MG cells were grown in 75 cm2 tissue culture flasks and
sub cultured once 80% confluence was reached. Cells were washed twice with
Phosphate Buffered Saline (PBS) and detached with Trypsin-EDTA (1 x in PBS) solution.
All cells were counted using an improved Neubauer Haemocytometer.
For experimental analysis, exponentially growing MDA-MB-231 and MCF-10A
cells were plated at a density of 1 x 104 cells (96 well plate), 8 x 104 cells (24 well plate), 4
x 105 cells (6 well plate) or 1 x 106 cells (25 cm2 culture flask). CHO and CHO-MG cells
were plated at a density of 1 x 104 cells (96 well plate). Cells were cultured for 24 hours
before incubation with the BNIPP derivatives.
4.3.3. Preparation of BNIPP Derivatives
BNIPP derivatives were synthesised as previously described in Section 2.3, and
stored in stock (10 mM or 90 mM) solutions, at 0 – 5 °C until required (refer to Section
3.3.1). Stock solutions of the positive controls: etoposide and doxorubicin (10 mM) in 50
% DMSO were also prepared, and stored at 0 – 5 °C. Prior to use, all stock solutions
were diluted to the desired final concentrations with serum free medium (either RPMI
1640 or DMEM/F12).
4.3.4 . Light Microscopy
MDA-MB-231 and MCF-10A (8 x 104 cell/well) cells were incubated with BNIPSpd,
BNIPDaoct, BNIPDaoxoct or BNIPDaCHM (5 – 10 µM; 500 µL/well; 0.5 – 24 hours, at 37
°C) within 24 well plates and visualised using a Leica DMIL inverted light microscope, as
described in Section 4.2.2.
4.3.5. Fluorescence Microscopy
MDA-MB-231 and MCF-10A (8 x 104 cells/well) cells were incubated with
BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM (5 - 10 µM; 500 µL/well; 0.5 – 24
hours, at 37 °C) within 24 well plates. After the desired incubation time, the cell culture
medium containing the excess BNIPP derivatives was removed, and the cells washed
twice with PBS. 1 mL PBS was then added to each well. Cells were visualised using a
Leica DMIL inverted fluorescence microscope, as described in Section 4.2.2.
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4.3.6. Cytotoxicity
4.3.6.1. Colorimetric 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl
tetrazolium bromide (MTT) Assay
MDA-MB-231 and MCF-10A (1 x 104 cells/well) cells were seeded in 96 well
plates. After 24 hours, the BNIPP derivatives, etoposide or doxorubicin (100 µL/well; 24 –
72 hours) were added to each well to give a final concentration of 0.01, 0.1, 1, 5, 10, 15,
20 and 40 µM. The latter two compounds were used as positive controls (0.01 – 40 µM).
After the desired incubation time (24 – 72 hours), the cell culture medium was removed
and 100 µL of sterile-filtered (0.22 µM filter) MTT solution (1 mg/mL in serum free
medium) was added to each well (Rollino et al. 1995). The plates were incubated for 4
hours, at 37 °C. The MTT solution was carefully removed and DMSO (200 µL) was added
to each well. The addition of DMSO allows the dissolution of the metabolised MTT
product. The plates were shaken for 20 minutes, at room temperature and the
absorbance results quantified by measuring at 560 nm on a 96 well plate reader, as
described in Section 4.2.2.
The mean absorbance values for cells treated with different concentrations (0 – 40
µM) of BNIPP derivatives was expressed as % absorbance of cells treated with distilled
water (0.025% dH2O control cells). Control cells were equal to 100%, as no growth
inhibition was present. IC50 (Inhibitory Concentration) was defined as the derivative
concentration that causes 50% growth inhibition of the cell population compared to that of
control cells.
4.3.6.2. Polyamine Transporter Studies
CHO and CHO-MG (1 x 104 cells/well) cells were incubated with BNIPSpd,
BNIPDaoct, BNIPDaoxoct, BNIPDaCHM or MGBG (0-100 µM; for 48 hours) in 96-well
plates. The latter was used as a positive control. After 48 hours incubation, at 37 °C, cell
viability was determined using the MTT assay, as described in Section 4.3.6.1.
4.3.7. Polyamine Extraction
MDA-MB-231 and MCF-10A (1 x 106/25 cm2 flask) cells were incubated with
BNIPSpd, BNIPDaoct, BNIPDaoxoct, BNIPDaCHM (0-5 µM) or α-(Difluoromethyl)
ornithine (DFMO) (5 mM). The latter was used as a positive control as it is a selective
enzyme-activated inhibitor of Ornithine Decarboxylase (ODC); the first rate limiting
enzyme in the polyamine biosynthetic pathway.
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Figure 4.6.: Structure of DFMO
After 24 hours incubation, cells were harvested as described previously (Section
4.3.2) and centrifuged at 2500 rpm (Centaur 2, UK), for 5 minutes, at room temperature.
Cells were resuspended in PBS (10 mL) before counting, using an improved Neubauer
haemocytometer. Cells were centrifuged again at 2500 rpm (Centaur 2, UK) for 5 minutes
and, resuspended in 1 mL PBS. The cell suspension was transferred to a sterile
eppendorf and centrifuged at 8500 rpm (ALC Multispeed Refrigerated Centrifuge,
Thomson Scientific, UK), for 5 minutes, at 4 °C. The cell pellet was resuspended in 250
µL 10% Perchloric Acid and incubated on ice for 60 minutes, mixing once after 30
minutes. Cells were centrifuged at 12000 rpm (ALC Multispeed Refrigerated Centrifuge,
Thomson Scientific, UK), for 20 minutes, at 4 °C. The supernatant containing the
polyamine extract was transferred to a fresh sterile Eppendorf tube and stored at -20 °C
until required.
4.3.8. HPLC of Polyamines
4.3.8.1. Quantification of Polyamines as Dansyl Derivatives
The pre-column derivatisation method of dansyl derivatives was based on the
methods of Kabra et al (1986) and Marcé et al (1995).
4.3.8.2. Pre-column Derivatisation
In a sterile Eppendorf tube, 200 µL saturated sodium carbonate (7 g/100 mL
distilled water), 200 µL dansyl chloride (0.03 g/10 mL acetone, made fresh each day and
protected from light) and 50 µL polyamine extract or polyamine standard (in 0.1 M
Hydrochloric Acid) were added together. The solution was vortexed for 15 seconds and
incubated in the dark for 10 minutes, at 70 °C. The solution was allowed to cool to room
temperature before transferring to an activated SPE column (refer to Section 4.2.2).
During sample incubation, the SPE column was attached to a VacMaster-10 which was
activated with 2 column volumes of methanol (HPLC grade) followed by 2 column
volumes of deionised water. Once cooled, the polyamine solution was transferred to the
activated SPE column where the liquid was allowed to run through. The column was
washed with 2 column volumes of deionised water and the dansylated polyamines eluted
with 450 µL methanol.
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4.3.8.3. HPLC Analysis
A 20 µL aliquot of the elutant was injected onto the HPLC system, as described in
Section 4.2.2. The gradient used is shown in Table 4.1.
Table 4.1.: The HPLC mobile-phase gradient used in dansylated polyamine analysis a
Time (mins) Acetonitrile (%) H2O (%)
0 70 30
4 70 30
5 100 0
9 100 0
10 70 30
15 70 30
aAcetonitrile (HPLC grade) and water concentration in the mobile phase, expressed as a percent
(%) and time, expressed in minutes (mins). The flow rate was 1.5 mL/minute (based on Marce et
al 1995) (Attenuation 512; PT 2000).
Polyamines were separated and analysed in the order of Putrescine (Put),
Spermidine (Spd) and Spermine (Spm) with retention times of 6.1, 8.8 and 9.7 minutes
respectively. Figure 4.7 shows a typical chromatogram obtained from the HPLC
separation of polyamine standards, Figure 4.8 shows a typical chromatogram of untreated
MDA-MB-231 cell extract, whilst Figure 4.9 shows a typical chromatogram of BNIPSpd (5
µM; 24 hours) treated MDA-MB-231 cell extract.
Figure 4.7.: HPLC chromatogram of polyamines standards (Putrescine; Put, Spermidine; Spd and
Spermine; Spm). Polyamine standards (in 0.1 M Hydrochloric Acid) were derivatised using dansyl
chloride then separated and detected (Ex 340 nm; Em 514 nm) using reverse-phase HPLC
(Sections 4.37 and 4.38).
Put
Spd
Spm
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Figure 4.8.: HPLC chromatogram of untreated MDA-MB-231 cells (Putrescine; Put, Spermidine;
Spd and Spermine; Spm). Polyamine standards (in 0.1 M Hydrochloric Acid) were derivatised
using dansyl chloride then separated and detected (Ex 340 nm; Em 514 nm) using reverse-phase
HPLC (Sections 4.37 and 4.38).
Spd
Spm
Figure 4.9.: HPLC chromatogram of BNIPP derivative (BNIPSpd; 5 µM) treated MDA-MB-231
cells (Putrescine; Put, Spermidine; Spd and Spermine; Spm). Polyamine standards (in 0.1 M
Hydrochloric Acid) were derivatised using dansyl chloride then separated and detected (Ex 340
nm; Em 514 nm) using reverse-phase HPLC (Sections 4.37 and 4.38).
Intracellular polyamine levels in treated MDA-MB-231 and MCF-10A cells were
determined using equations from standard curves of polyamine concentration (1 – 50 µM
in 0.1 M Hydrochloric Acid) against peak area, as found in Appendix 5 (Figure A.7 – A.9).
Appendix 5 shows that the calibration was useable up to 1 µM, however, a limit of
detection was not detected as it was not necessary in this study. Intracellular polyamine
levels in treated MDA-MB-231 and MCF-10A cells are expressed as µM/1 x 106 cells.
4.3.9. Data Analysis
Unless otherwise stated, each data set expressed as mean ± SD was the average
of a minimum of three independent experiments. Each experiment comprised at least
three internal replicates. Statistical analysis was conducted using the Student’s t-test.
Data were considered significantly different when P-value < 0.05 (*P < 0.05, **P < 0.01
and ***P < 0.001).
Time
(Minutes)
Fluorescence (AU)
Fluorescence (AU)
Time
(Minutes)
Spd
Spm
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4.4. Results
4.4.1. Effect of BNIPP Derivatives on Cell Morphology
A qualitative assessment of the changes in cell morphology was assessed in
MDA-MB-231 and MCF-10A cells treated with BNIPSpd, BNIPDaoct, BNIPDaoxoct and
BNIPDaCHM, at 0.1 - 10 μM, for 24 hours using light microscopy.
4.4.1.1. Cell Morphology Changes in MDA-MB-231 Cells
Changes were observed in BNIPP derivative treated MDA-MB-231 cells after 24
hours compared to untreated cells (Figures 4.10 and 4.11). Cell shape altered in a dose
dependent manner in MDA-MB-231 cells treated with 0.1 – 10 µM BNIPDaCHM (Figure
4.10). BNIPSpd, BNIPDaoct and BNIPDaoxoct (0.1 – 10 µM) produced similar results to
BNIPDaCHM after 24 hours (data not shown). Figure 4.11 shows untreated MDA-MB-231
cells and MDA-MB-231 cells treated with 10 µM BNIPSpd, BNIPDaoct or BNIPDaoxoct for
24 hours. After 24 hours, cell shape of BNIPP derivative treated MDA-MB-231 cells had
notably changed in comparison to untreated MDA-MB-231 cells, as treated MDA-MB-231
cells appeared smaller and rounder and had become detached from the culture plate
(Figure 4.11).
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Figure 4.10.: Cell morphology of MDA-MB-231 cells treated with 0 – 10 µM BNIPDaCHM for 24
hours. Cells were visualised using a Leica DMIL inverted light microscope. Images are
representative of 3 independent experiments, each comprising of 3 replicates (n =3). Key: viable
cells, yellow arrow; rounded cells, red arrow. Magnification x 100.
Untreated 0.1 µM BNIPDaCHM
1 µM BNIPDaCHM 10 µM BNIPDaCHM
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Figure 4.11.: Cell morphology of untreated MDA-MB-231 and BNIPP derivative treated MDA-MB-
231 cells (10 µM BNIPSpd, BNIPDaoct and BNIPDaoxoct) for 24 hours. Cells were visualised
using a Leica DMIL inverted light microscope. Images are representative of 3 independent
experiments, each comprising of 3 replicates (n = 3). Key: viable cells, yellow arrow; rounded cells,
red arrow. Magnification x 100.
10 µM BNIPSpdUntreated
10 µM BNIPDaoxoct10 µM BNIPDaoct
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4.4.1.2. Cell Morphology Changes in MCF-10A Cells
Changes were also observed in BNIPP derivative treated MCF-10A cells after 24
hours compared to untreated cells (Figure 4.12). Changes in MCF-10A cells treated with
10 µM of BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM included a change to cell
shape, in comparison to untreated MCF-10A cells, in particular, after treatment with
BNIPDaoct (10 µM; 24 hours).
Untreated
10 µM BNIPDaCHM
10 µM BNIPDaoct10 µM BNIPSpd
10 µM BNIPDaoxoct
Figure 4.12.: Cell Morphology of untreated MCF-10A and BNIPP derivative treated MCF-10A cells
(10 µM BNIPDaCHM, BNIPSpd, BNIPDaoct and BNIPDaoxoct) for 24 hours. Cells were visualised
using a Leica DMIL inverted light microscope. Images are representative of 3 independent
experiments, each comprising of 3 replicates (n = 3). Key: viable cells, yellow arrow; rounded cells,
red arrow. Magnification x 200.
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4.4.2. Cytotoxicity in MDA-MB-231 and MCF-10A Cells
Cell viability of MDA-MB-231 and MCF-10A cells treated with different
concentrations (0 – 40 µM) of each BNIPP derivative for 24, 48 or 72 hours were
assessed by MTT assay.
The curves presented in Figures 4.13 and 4.14 are a representation of the
percentage of growth inhibition in MDA-MB-231 cells treated with BNIPSpd (Figure 4.12)
or BPHPDadec (Figure 4.13) (0 – 40 µM) after 24 and 48 hours obtained by measuring
reduction of MTT tetrazolium dye.
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Figure 4.13.: The growth inhibition curve of BNIPSpd in MDA-MB-231 cells after 24 and 48 hours.
Cytotoxicity was determined by MTT Assay. Data are mean ± SD of 3 independent experiments
(n = 3) each experiment consisted of 6 repeats. The curves are representative of all BNIPP
derivatives analysed within MDA-MB-231 and MCF-10A cells. **P < 0.01 and ***P < 0.001 vs.
untreated (H2O control) cells.
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Figure 4.14.: The growth inhibition curve of BPHPDadec in MDA-MB-231 cells after 24 and 48
hours. Cytotoxicity was determined by MTT Assay. Data are mean ± SD of 3 independent
experiments (n = 3) each experiment consisted of 6 repeats. The curves are representative of all
BNIPP derivatives analysed within MDA-MB-231 and MCF-10A cells.
After 24 hours, BNIPSpd significantly inhibited cell viability (P < 0.01; 47.5%
decrease) at 10 µM when compared to the control; with complete MDA-MB-231 cell death
at ≥ 20 µM (Figure 4.13). After 48 hours, BNIPSpd significantly inhibited cell viability (P <
***
**
****** ***
**
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0.01; 49.3% decrease) at 5 µM compared to the control; with complete death of MDA-MB-
231 cells observed at ≥ 10 µM (Figure 4.13). In contrast, treatment with BPHPDadec
(Figure 4.14) resulted in no growth inhibition in MDA-MB-231 cells after 24 or 48 hours
(IC50 values > 40 µM in both cell lines).
The cytotoxicities of the newly synthesised BNIPP derivatives: BNIPDaoxoct,
BNIPDaCHM, BPHPDadec and NPA (Figure 2.1) were compared with the previously
synthesised BNIPP derivatives: BNIPSpd, BNIPPut, BNIPDahex, BNIPDaoct, BNIPDadec
and BNIPDadodec (Figure 3.4) in MDA-MB-231 and MCF-10A cells. Cytotoxicity results
are shown in Tables 4.2 and 4.3.
Table 4.2.: Cytotoxicity of BNIPP derivatives in MDA-MB-231 cells
Derivativea 24 hrs 48 hrs 72 hrs
BNIPSpd 12.7 ± 0.5 4.6 ± 1.5 ND
BNIPPut 7.8 ± 3.6 5.1 ± 0.8 ND
BNIPDahex 7.2 ± 1.4 4.5 ± 0.6 ND
BNIPDaoct 5.0 ± 1.3 2.7 ± 0.3 ND
BNIPDadec 4.8 ± 0.2 3.3 ± 0.7 ND
BNIPDadodec 5.1 ± 0.5 6.9 ± 0.1 ND
BNIPDaoxoct 12.4 ± 5.8 6.1 ± 1.5 6.1 ± 0.1
BNIPDaCHM 6.8 ± 0.3 6.1 ± 0.7 4.2 ± 0.1
BPHPDadec > 40 > 40 ND
NPA > 40 > 40 ND
Etoposide > 40 17.2 ± 0.8 ND
Doxorubicin 14.3 ± 5.9 3.6 ± 0.6 ND
a Toxicity was determined by MTT Assay. The results were obtained after treating MDA-MB-231
cells with different BNIPP derivative concentrations (0 – 40 µM) for 24, 48 and 72 hours, at 37°C.
Data are mean ± SD of three independent experiments (n=3); each experiment consisted of 6
repeats.
b The IC50 value was defined as the derivative concentration that causes 50 % growth inhibition of a
cell population, compared to that of untreated cells. ND – Not Determined.
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Table 4.3.: Cytotoxicity of BNIPP derivatives in MCF-10A cells
Derivativea 24 hrs 48 hrs 72 hrs
BNIPSpd 4.2 ± 0.6 3.9 ± 0.9 ND
BNIPPut 8.1 ± 2.7 5.6 ± 2.3 ND
BNIPDahex 0.8 ± 0.1 0.8 ± 0.1 ND
BNIPDaoct 2.8 ± 0.1 0.8 ± 0.1 ND
BNIPDadec 2.8 ± 0.1 2.8 ± 0.1 ND
BNIPDadodec 4.2 ± 0.3 6.8 ± 0.8 ND
BNIPDaoxoct 6.1 ± 1.6 2.3 ± 0.0 2.4 ± 0.5
BNIPDaCHM 6.1 ± 0.1 5.7 ± 0.8 6.8 ± 0.3
BPHPDadec > 40 > 40 ND
NPA > 40 > 40 ND
Etoposide 14.2 ± 1.3 1.2 ± 0.7 ND
Doxorubicin 0.7 ± 0.0 0.2 ± 0.0 ND
a Toxicity was determined by MTT Assay. The results were obtained after treating MCF-10A cells
with different BNIPP derivative concentrations (0 – 40 µM) for 24, 48 and 72 hours, at 37°C. Data
are mean ± SD of three independent experiments (n=3); each experiment consisted of 6 repeats.
b The IC50 value was defined as the derivative concentration that causes 50 % growth inhibition of a
cell population, compared to that of untreated cells. ND – Not Determined.
In both cell lines, all BNIPP derivatives, except for BPHPDadec and NPA (IC50
values > 40 µM) exhibited cytotoxicity after 24 hours (with IC50 values in the range of 4.8 –
12.7 µM in MDA-MB-231 cells, and 0.8 – 8.0 µM in MCF-10A cells; Tables 4.2 – 4.3).
After 48 hours, the cytotoxicity of BNIPP derivatives was enhanced in MDA-MB-231 cells,
except after treatment with BNIPDadodec or BNIPDaCHM (i.e., IC50 value of
BNIPDadodec decreased from 5.1 µM to 6.9 µM after 24 and 48 hours, respectively,
whilst the IC50 value of BNIPDaCHM was similar after 24 and 48 hours at 6.8 and 6.1 µM,
respectively: Table 4.2). However, after 48 hours BNIPP treatment in MCF-10A cells,
cytotoxicity was enhanced for all BNIPP derivatives, except after treatment with
BNIPDahex or BNIPDadodec (i.e., IC50 value of BNIPDahex remained the same after 24
and 48 hours at 0.8 µM, whilst the IC50 value of BNIPDadodec decreased from 4.2 µM to
6.8 µM after 24 and 48 hours, respectively; Table 4.3).
Overall, the BNIPP derivatives were more cytotoxic than Etoposide or Doxorubicin
treated cells (IC50 values of > 40 and 14.3 µM, after 24 hours, and 17.2 and 3.6 µM, after
48 hours, respectively, in MDA-MB-231 cells) (Tables 4.2). Doxorubicin (Adriamycin) and
Etoposide (VP-16) were used as positive controls (Figures 3.1 and 3.3). These
compounds are both examples of Topoisomerase II (TOPO II) targeting antineoplastic
agents, as described in Section 1.6, and are used in the treatment of solid tumours
Cytotoxicity of BNIPP derivatives appears to be cell line dependent as the most
cytotoxic derivatives in MDA-MB-231 cells were BNIPDadec (IC50 value 4.8 µM, after 24
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hours) and BNIPDaoct (IC50 value 2.7 µM, after 48 hours). BNIPDahex (IC50 value 0.8
µM, after 24 and 48 hours) and BNIPDaoct (IC50 value 0.8 µM, after 48 hours) were the
most cytotoxic in MCF-10A cells.
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4.4.3. Cellular Uptake of BNIPP Derivatives
BNIPP derivatives display inherent fluorescent properties when taken up into cells.
These properties were exploited in this study to assess cellular uptake and distribution of
BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM in MDA-MB-231 (Figure 4.15a-c)
and MCF-10A cells (Figure 4.16a-c). The degree of fluorescence in cells treated with
BNIPP derivatives (10 µM) was assessed by fluorescence microscopy.
4.4.3.1. Cellular Uptake of BNIPP Derivatives in MDA-MB-231 Cells
MDA-MB-231 cells were treated with 10 μM of BNIPSpd, BNIPDaoct,
BNIPDaoxoct or BNIPDaCHM and visualised under the fluorescent microscope after 0.5,
1, 2, 4, 6, and 24 hours (Figure 4.15a, b and c shows only images at 0.5, 2 and 6 hours).
After 0.5 hours, only MDA-MB-231 cells treated with BNIPDaoct or BNIPDaCHM
showed fluorescence (Figure 4.15a). After 2 hours, fluorescence remained in MDA-MB-
231 cells treated with BNIPDaoct or BNIPDaCHM (Figure 4.15b). However, fluorescence
observed in BNIPDaoct treated cells after 2 hours was reduced when compared to the
fluorescence observed at 0.5 hours. After 6 hours, fluorescence was observed in MDA-
MB-231 cells treated with all BNIPP derivatives except BNIPDaoct treated cells (Figure
4.15c). Fluorescence in BNIPSpd or BNIPDaoxoct treated cells was only observed after 6
hours treatment indicating a slower uptake in MDA-MB-231 cells.
Within individual cells, fluorescence appears to be present in difference areas of
the cell: nucleus or around it. Using fluorescence microscopy alone it is difficult to clearly
locate the fluorescent BNIPP derivatives
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Figure 4.15.: Fluorescence microscopy images of MDA-MB-231 cells treated with 10 µM of
BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM for (a) 0.5, (b) 2 and (c) 6 hours. Cells were
visualised using a Leica DMIL inverted fluorescence microscope using a UV filter (ex bandpass
(blue); 340 – 380 nm; em longpass (red); 425 nm). Images are representative of 3 independent
experiments, each comprising of 3 replicates (n = 3). Magnification x 100.
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4.4.3.2. Cellular Uptake of BNIPP Derivatives in MCF-10A Cells
MCF-10A cells were treated with 10 µM of BNIPSpd, BNIPDaoct, BNIPDaoxoct or
BNIPDaCHM and visualised under the fluorescent microscope after 0.5, 1, 2, 4, 6, and 24
hours (Figure 4.16a, b and c shows only images at 0.5, 2 and 6 hours).
After 0.5 hours, only MCF-10A cells treated with BNIPDaoct and BNIPDaCHM
showed fluorescence (Figure 4.16a). After 2 hours, fluorescence was observed in MCF-
10A cells treated with BNIPDaoct, BNIPDaoxoct and BNIPDaCHM (Figure 4.16b). After 6
hours, fluorescence was observed in MCF-10A cells treated with all BNIPP derivatives
(Figure 4.16c).
Confirmation of cellular localisation in MCF-10A cells was not possible, for the
same reason as for MDA-MB-231 cells (Section 4.4.3.1).
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Figure 4.16.: Fluorescence microscopy images of MCF-10A cells treated with 10 µM of BNIPSpd,
BNIPDaoct, BNIPDaoxoct or BNIPDaCHM for (a) 0.5, (b) 2 and (c) 6 hours. Cells were visualised
using a Leica DMIL inverted fluorescence microscope using a UV filter (ex bandpass (blue); 340 –
380 nm; em longpass (red); 425 nm). Images are representative of 3 independent experiments,
each comprising of 3 replicates (n = 3). Magnification x 100.
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4.4.4. Polyamine Transporter Studies with BNIPP Derivatives
Cellular entry of BNIPP derivatives via the polyamine transporter (PAT) was
studied in CHO-MG and CHO cells treated with different concentrations (0 – 100 µM) of
BNIPP derivatives (BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM) or MGBG for 48
hours and assessed by MTT assay.
The parental CHO cells contain an active polyamine transporter (PAT-active),
whilst the mutant CHO-MG cells contain a MGBG-deficient polyamine transporter (PAT-
inactive). Comparison of the toxicities of BNIPP derivatives in both cell lines, measured
by MTT assay, provides an important indication for delivery via the PAT of the BNIPP
derivatives. Data was expressed as a CHO-MG/CHO IC50 ratio. Therefore, a derivative
that uses the PAT would be highly toxic to CHO cells, but less toxic to CHO-MG cells.
Hence, a highly selective PAT derivative would have a high (CHO-MG/CHO) IC50 ratio
(i.e., > 100).
Table 4.4.: Biological evaluation of BNIPP derivatives in CHO-MG and CHO cells
Derivativea CHO-MG Cells
IC50b (µM)
CHO Cells
IC50b (µM)
IC50 Ratioc
BNIPSpd 74.6 ± 3.1 76.5 ± 5.7 1.0
BNIPDaoct 5.1 ± 0.5 5.8 ± 0.9 0.9
BNIPDaoxoct 26.9 ± 5.9 76.1 ± 2.1 0.4
BNIPDaCHM 6.3 ± 0.4 6.2 ± 0.7 1.0
MGBGd >100 3.3 ± 0.5 >30.2
a Toxicity was determined by the MTT Assay. The results were obtained after treating CHO-MG
and CHO cells with different BNIPP derivative concentrations (0 – 100 µM) for 48 hours at 37°C.
Data are mean ± SD of three independent experiments (n=3); each experiment consisted of 6
repeats.
b The IC50 value was defined as the derivative concentration that causes 50 % growth inhibition of a
cell population, compared to that of untreated (control) cells.
c Ratio indicates the (CHO-MG/CHO) IC50 ratio; a measure of PAT selectivity.
d MGBG, a known substrate for the PAT system was used as a positive control.
BNIPSpd and BNIPDaoxoct displayed low toxicity (i.e., > 10 μM; 74.6 and 26.9
µM, respectively); whilst BNIPDaoct and BNIPDaCHM exhibited high toxicity (5.1 and 6.3
µM, respectively) in CHO-MG cells (Table 4.4). In CHO cells, a similar toxicity trend was
observed (BNIPSpd and BNIPDaoxoct showed low toxicity; 76.5 and 76.1 µM,
respectively, whilst BNIPDaoct and BNIPDaCHM showed high toxicity; 5.8 and 6.2 µM,
respectively).
BNIPSpd, BNIPDaoct nor BNIPDaCHM were not specific to either cell line and
produced similar IC50 values in both cell line, with CHO-MG/CHO IC50 ratios of 1.0, 0.9
and 1.0, respectively. In contrast, BNIPDaoxoct demonstrated a higher toxicity in CHO-
MG cells (IC50 26.9 µM compared to 76.1 μM in CHO cells), giving a CHO-MG/CHO IC50
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ratio of 0.4. This indicates that BNIPDaoxoct could enter cells by a different mechanism
to that of the other BNIPP derivatives investigated. The positive control MGBG showed a
lack of toxicity in CHO-MG cells (IC50 value of > 100 µM). This was because the CHO-MG
cells were isolated for growth resistance to MGBG and are thus defective to MGBG
uptake.
CHO-MG/CHO IC50 ratios for all BNIPP derivatives ranged from 0.4 – 1.0,
indicating that none of the BNIPP derivatives utilise the MGBG-specific PAT system to
gain access into cells. This suggests that another mode of cellular entry other than that of
the MGBG-specific PAT system is being utilised to transport BNIPP derivatives into cells.
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4.4.5. Changes in Intracellular Polyamine Levels in BNIPP
Derivative Treated MDA-MB-231 and MCF-10A Cells
Changes in intracellular polyamine levels in MDA-MB-231 and MCF-10A cells
treated with BNIPP derivatives (BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM; 0.1
– 5 µM) or DFMO (5 mM) after 24 hours were assessed by pre column derivatisation with
dansyl chloride followed by reverse-phase HPLC using fluorescent detection. Intracellular
polyamine levels are expressed as putrescine (Put), spermidine (Spd) and spermine
(Spm) levels (µM/1x106 cells) and are depicted in Figures 4.17 – 4.24. Those polyamines
were chosen as they are essential for normal mammalian cell growth and development,
for example, cell proliferation stops in polyamine-deficient cells, whilst cell proliferation is
initiated in polyamine-rich cells (Pegg 1988).
4.4.5.1. Intracellular Polyamine Levels in MDA-MB-231 Cells
MDA-MB-231 cells treated with DFMO (5 mM) mirrored that of the control cells, as
all intracellular polyamine levels were not altered (Figures 4.17 – 4.20).
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Figure 4.17: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MDA-MB-231 cells with BNIPSpd (0.1–5 µM) for 24 hours. DFMO
(5mM) was used as a positive control. Data are mean ± SEM of 3 independent experiments (n =
3). *P<0.05, **P<0.01 vs. untreated (control) cells.
After 24 hours, treatment with 0.1 µM BNIPSpd produced no change in putrescine
levels, but spermidine and spermine levels were significantly increased (P < 0.05,
increased by 2.5 µM/1x106 cells; P < 0.01, increased by 1.7 µM/1x106 cells, respectively)
compared to control (Figure 4.17). No significant change in putrescine, spermidine or
spermine levels were observed with 1 µM BNIPSpd compared to control (Figure 4.17).
However, 5 µM BNIPSpd induced a significant decrease (P < 0.05) in putrescine
(decreased by 0.43 µM/1x106 cells) and spermidine (decreased by 2.2 µM/1x106 cells)
*
* **
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levels, whilst no change in spermine levels was observed when compared to the control,
after 24 hours (Figure 4.17).
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Figure 4.18.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MDA-MB-231 cells with BNIPDaoct (0.1–5 µM) for 24 hours. DFMO
(5mM) was used as a positive control. Data are mean ± SEM of 3 independent experiments (n =
3). *P<0.05, **P<0.01 vs. untreated (control) cells.
After 24 hours, treatment with 0.1 µM BNIPDaoct produced no change in
putrescine levels, but spermidine and spermine levels were significantly (P < 0.05)
increased (increased by 3.1 and 1.3 µM/1x106 cells, respectively) compared to control
(Figure 4.18). No significant change in putrescine, spermidine or spermine levels were
observed with 1 µM BNIPDaoct compared to the control (Figure 4.18). However, at a
concentration of 5 µM, BNIPDaoct significantly reduced putrescine, spermidine and
spermine levels (P < 0.05, decreased by 0.4 µM/1x106 cells; P < 0.01, decrease by 3.2
µM/1x106 cells; P < 0.05, decrease by 1.8 µM/1x106 cells) compared to the control,
respectively (Figure 4.18).
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Figure 4.19.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MDA-MB-231 cells with BNIPDaoxoct (0.1–5 µM) for 24 hours. DFMO
(5mM) was used as a positive control. Data are mean ± SEM of 3 independent experiments (n =
3). *P<0.05 vs. untreated (control) cells.
After 24 hours, treatment with 0.1 µM BNIPDaoxoct significantly (P < 0.05)
increased (increased by 0.64 µM/1x106 cells) putrescine levels, however, no significant
changes in spermidine or spermine levels were observed when compared to the control
(Figure 4.19). Putrescine, spermidine and spermine levels were not significantly changed
following treatment with 1 and 5 µM BNIPDaoxoct compared to that of the control (Figure
4.19).
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Figure 4.20.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MDA-MB-231 cells with BNIPDaCHM (0.1–5 µM) for 24 hours. DFMO
(5mM) was used as a positive control. Data are mean ± SEM of 3 independent experiments (n =
3).
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After 24 hours, BNIPDaCHM (0.1 – 5 µM) treatment resulted in no significant
changes to putrescine, spermidine or spermine levels when compared to the control
(Figure 4.20).
4.4.5.2. Intracellular Polyamine Levels in MCF-10A Cells
Treatment with DFMO (5 mM) mirrored that of the control MCF-10A cells, as all
intracellular polyamine levels were not altered (Figures 4.21 – 4.24).
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Figure 4.21.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MCF-10A cells with BNIPSpd (0.1–5 µM) for 24 hours. DFMO (5mM)
was used as a positive control. Data are mean ± SEM of 3 independent experiments (n = 3).
After 24 hours, BNIPSpd (0.1 – 5 µM) treatment resulted in no significant changes
to putrescine, spermidine or spermine levels when compared to the control (Figure 4.21).
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Figure 4.22.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MCF-10A cells with BNIPDaoct (0.1–5 µM) for 24 hours. DFMO (5mM)
was used as a positive control. Data are mean ± SEM of 3 independent experiments (n = 3).
*P<0.05 vs. untreated (control) cells.
After 24 hours, treatment of MCF-10A cells with BNIPDaoct (0.1 – 1 µM) did not
induce any change in putrescine, spermidine or spermine levels compared to control
(Figure 4.22). However, at a concentration of 5 µM, BNIPDaoct significantly (P < 0.05)
reduced putrescine levels (decreased by 0.2 µM/1x106 cells), whilst spermidine and
spermine level were not changed compared to that of the control (Figure 4.22).
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Figure 4.23.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MCF-10A cells with BNIPDaoxoct (0.1–5 µM) for 24 hours. DFMO
(5mM) was used as a positive control. Data are mean ± SEM of 3 independent experiments (n =
3). *P<0.05 vs. untreated (control) cells.
After 24 hours, treatment with 0.1 µM BNIPDaoxoct produced no change in
putrescine levels, but spermidine and spermine levels were significantly (P < 0.05)
increased (increased by 4.2 and 2.4 µM/1x106 cells, respectively) compared to control
*
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(Figure 4.23). With 1 µM BNIPDaoxoct, putrescine and spermidine levels were not
changed, but spermine levels were significantly decreased (P < 0.05, decreased by 1.9
µM/1x106 cells) compared to the control (Figure 4.23). At 5 µM, BNIPDaoxoct did not
alter the level of putrescine, but significantly (P < 0.05) reduced spermidine and spermine
levels (decreased by 2.2 and 2.0 µM/1x106 cells, respectively) compared to the control
(Figure 4.23).
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Figure 4.24.: Intracellular polyamine levels determined by pre-column derivatisation and HPLC.
Data obtained after treating MCF-10A cells with BNIPDaCHM (0.1–5 µM) for 24 hours. DFMO
(5mM) was used as a positive control. Data are mean ± SEM of 3 independent experiments (n =
3). *P<0.05 vs. untreated (control) cells.
After 24 hours, treatment with 0.1 µM BNIPDaCHM produced no significant
changes in putrescine, spermidine or spermine levels compared to the control (Figure
4.24). With 1 µM, BNIPDaCHM significantly increased putrescine levels (P < 0.05,
increased by 0.2 µM/1x106 cells), whilst spermidine and spermine levels were not
changed when compared with the control (Figure 4.24). No significant change in
putrescine, spermidine or spermine levels were observed with 5 µM BNIPDaCHM
compared to the control (Figure 4.24).
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4.5. Discussion
4.5.1. Effect of BNIPP Derivatives on Cell Morphology
Treatment with BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM resulted in
morphological changes in both MDA-MB-231 (Figures 4.10 – 4.11) and MCF-10A cells
(Figure 4.12), as examined by light microscopy. The change in cell morphology and loss
of cell adherence, combined with cytotoxicity at µM levels (refer to Section 4.4.2) may
suggest that the mode of cell death initiated through BNIPP derivative treatment could be
that of apoptosis (Huschtscha et al. 1996, Cummings et al. 2004, Holdenrieder and
Stieber 2004, Lee et al. 2008). The mode of cell death will be further discussed in
Chapter 6.
4.5.2. Cytotoxicity in MDA-MB-231 and MCF-10A Cells
The results from the in vitro cytotoxicity study demonstrate that all BNIPP
derivatives, except BPHPDadec and NPA (IC50 values > 40 µM) were cytotoxic in MDA-
MB-231 and MCF-10A cells (Tables 4.2 and 4.3). These cytotoxicity results are
supported by the results obtained with the DNA binding studies, as discussed in Section
3.5.1. None of the BNIPP derivatives were selectively cytotoxic in either cell line studied.
BNIPDadec with an IC50 value of 4.8 µM, and BNIPDaoct with an IC50 value of 2.7 µM
were the most cytotoxic derivatives in MDA-MB-231 cells, after 24 and 48 hours,
respectively (Table 4.2), whereas in MCF-10A cells, BNIPDahex and BNIPDaoct with IC50
values of 0.8 µM were the most cytotoxic, after 24 and 48 hours (Table 4.3).
Earlier work on some BNIPP derivatives had identified the essential structural
features responsible for enhanced aqueous solubility and biological activity (Pavlov et al.
2001, Oliveira et al. 2007). These features include the bisnaphthalimidopropyl
functionality, an alkyl linker chain length ideally between 8 – 10 carbons, and the presence
of heteroatoms (2 or 3 nitrogen atoms) (Pavlov et al. 2001, Dance et al. 2005, Oliveira et
al. 2007).
The majority of research into naphthalimido and bisnaphthalimido derivatives has
been focused on the modification of the naphthalimido rings, as described in Sections
1.6.1 and 1.6.2 (Brana et al. 1995, Brana and Ramos 2001). In this study, a further
expansion of the work of Kong Thoo Lin et al. (2000) and Oliveira et al. (2007) has been
undertaken via modification to only the central linker chain. Two new BNIPP derivatives
have been synthesised (described in Section 2.4), with additional modifications to the
central linker chain achieved at a point of diversity (Figure 4.25).
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Figure 4.25.: The basic structure of a BNIPP Derivative, including the point of modification (i.e., the
point of diversity)
Modifications included the introduction of oxygen atoms (BNIPDaoxoct) and two
cyclohexane rings (BNIPDaCHM), and these modifications do not appear to affect either
aqueous solubility (results not shown) or cytotoxicity in MDA-MB-231 or MCF-10A cells
(IC50 values of 12.4 and 6.8 µM, and 6.1 and 6.1 µM, respectively, after 24 hours) (Tables
4.2 and 4.3). However, BNIPOSpm (Ralton 2006, Oliveira et al. 2007) (Figure 1.23) which
has oxygen atoms in the α-position of the naphthalimido ring was observed to be the least
active member of the BNIPP derivative series. Ralton (2006) and Oliveira et al. (2007)
studied BNIPOSpm in MCF-7, CaCO-2 and HT-29 cells and found IC50 values > 50 µM.
This observation has further verified that bisnaphthalimidopropyl functionality is an
essential structural feature required for enhanced solubility whilst maintaining a good level
of biological activity. The exact position of an oxygen atom in the linker chain is also
extremely important in maintaining a level of cytotoxicity (Kuksa et al. 2002).
Further investigations into bisnaphthalimido functionality were undertaken by
replacing the naphthalimido rings with phthalimido rings (BPHPDadec), or by removing a
naphthalimido ring entirely (NPA). The result of these modifications was the complete
loss of cytotoxicity in BPHPDadec and NPA treated MDA-MB-231 and MCF-10A cells,
with IC50 values > 40 µM (Tables 4.2 and 4.3). Again it can be stated from the results
presented, that cytotoxicity appears to be vitally dependent upon the presence of
bisnaphthalimidopropyl groups and a linker chain of < C12 in length.
Interestingly, in recent years several naphthalimide and bisnaphthalimide
derivatives have entered Phase I and II clinical trials. The naphthalimide derivative,
Amonafide was selected for Phase I and II clinical trials (Saez et al. 1989, Brana and
Ramos 2001, Brana et al. 2003). Amonafide, a mononaphthalimide had demonstrated
biological activity against metastatic breast cancer (MBC) (Alami et al. 2007) (Figure
1.16). However, amonafide was removed from clinical trials as its metabolite; N-acetyl
amonafide was responsible for severe myelosuppression (Alami et al. 2007)
Several other mononaphthalimide derivatives which are structurally similar to
amonafide have been synthesised. Among these, Azonafide (Figure 1.17) and Xanafide
(Amonafide L-malate) (Figure 4.26) were the most potent. Azonafide was highly potent
against human colon cancer cells, whereas xanafide showed comparable and significant
activity in vitro against human breast cancer (MCF-7 and MDA-MB-231), prostrate (PC-3)
and colon (COLO205) cancer cells (Mayr et al. 1998, Ajami and Barlow 2006, Alami et al.
2007, Chau et al. 2008). Xanafide has recently received FDA Orphan Drug Designation
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for the treatment of acute myeloid leukaemia (AML), and is currently undergoing Phase II
clinical trials into the treatment of secondary AML (Alami et al. 2007, Allen et al. 2009).
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Figure 4.26.: Structure of Xanafide (Amonafide L-malate)
The symmetrical bisnaphthalimide, Elinafide (Figure 1.21), is the most cytotoxic
bisnaphthalimide to date, with IC50 values of 0.02, 0.07 and 0.32 µM, after 72 hours
treatment in HT-29, cervical (HeLa) cancer and PC-3 cells, respectively (Villalona-Calero
et al. 2001, Brana et al. 2003, Denny 2004). Several years ago, elinafide was selected for
Phase I and II clinical trials, but due to its dose-limiting toxicity (DLT), being that of a
cumulative nature, its future development has been delayed (Denny 2004).
In recent years, modifications to the structure of naphthalimides and
bisnaphthalimides have resulted in the synthesis of several new analogues to improve
their therapeutic potential. These include the synthesis of naphthalimides (i) with chiral
amino acid side chains, (ii) with both natural and synthetic polyamine moieties, (iii) with
sulphur substitutions, (iv) with π-excedent furan or thiophene rings fused to the
naphthalimide moiety, or (v) with a series of 5-alkylamino substitutions (Brana et al.
2004b, Ott et al. 2008, Yang et al. 2008, Tian et al. 2009, Xie et al. 2009).
Bisnaphthalimides have also been modified with (i) natural and synthetic polyamine
moieties, or (ii) heterocyclic and other cyclic moieties (Kong Thoo Lin and Pavlov 2000,
Dance et al. 2005, Oliveira et al. 2007, Filosa et al. 2009). These structural modifications
have produced derivatives with effective cytotoxicities against various cell lines (e.g., in
HT-29, MCF-7 and CaCO-2 cancer cells). Hence, the synthesis of the BNIPP derivatives
has addressed the adverse side effects observed in previous members of this family
(Amonafide and Elinafide), due to the omission of the primary amine at the 5-position of
the naphthalimido ring (Kong Thoo Lin and Pavlov 2000, Dance et al. 2005, Oliveira et al.
2007, Xie et al. 2009).
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Figure 4.27.: Structure of BNIPSpd
128
BNIPSpd (spermidine derivative) was identified as the most active member of the
BNIPP derivative series (Pavlov et al. 2001, Dance et al. 2005, Oliveira et al. 2007, Ralton
et al. 2009) (Figure 4.27), against MCF-7, CaCO-2 and HT-29 cancer cells with IC50
values of 1.5, 0.47 and 2.4 µM, respectively, after 24 hours treatment. However, in MDA-
MB-231 and MCF-10A cells, BNIPSpd was not the most active BNIPP derivative (IC50
values of 12.7 and 4.2 µM, respectively, after 24 hours treatment). These results have
revealed that MDA-MB-231 cells, a reliable model for estrogen receptor-negative (ER-ve)
breast cancer, are more resistant to BNIPSpd treatment than MCF-7 cells (estrogen
receptor-positive (ER+ve)/p53 wild type breast cancer cells) (Dance et al. 2005). This is
possibly because MDA-MB-231 cells are estrogen receptor-independent (ER-ve), do not
express wild-type p53 (mutated), and are highly metastatic in nature, in contrast to MCF-7
and MCF-10A cells (Belkacemi et al. 2006). MDA-MB-231 cells, in comparison to MCF-7
cells are known to be highly aggressive and thus resistant to current chemotherapy
treatments. As a result, a patient diagnosed with estrogen receptor-positive breast cancer
will generally have a better prognosis than a patient diagnosed with estrogen receptor-
negative breast cancer (Koutsilieris et al. 1999, Rochefort et al. 2003, Richert et al. 2005).
It could be suggested that all the BNIPP derivatives will follow a similar trend, due to the
different levels in cytotoxicity observed after BNIPSpd treatment in MDA-MB-231 and
MCF-7 cells. The increased responsiveness of MCF-7 cells to BNIPSpd treatment could
be related to several factors, for example the role of estrogen levels, ER or p53 mutations
(Alami et al. 2007). Further comparative studies would need to be undertaken to
determine the specific and selective cytotoxicity of all the BNIPP derivatives against MDA-
MB-231 (ER-ve) and MCF-7 (ER+ve) breast cancer cell lines.
It is interesting to note that all BNIPP derivatives appeared to be more active
against MCF-10A cells rather than MDA-MB-231 cells. This may be due to the
observation that MCF-10A cells replicate at a faster rate than the MDA-MB-231 cells, as
determined by cell count measurements1 (results not shown).
BNIPP derivatives, due to their structural similarities to the natural polyamines
were initially thought to be transported into cells by the use of an active transport system,
such as the polyamine transporter (Dance et al. 2005). Several BNIPP derivatives were
selected for further investigations into their mode of action within a breast cancer cell
system. The selected derivatives were BNIPSpd, BNIPDaoct, BNIPDaoxoct and
BNIPDaCHM (Figures 4.27 and 4.28). These derivatives all possess distinct structural
variations at the point of diversity (Figure 4.25), and have exhibited varying degrees of
cytotoxicity (Section 4.4.2).
In MDA-MB-231 cells, alterations to the spermidine linker, such as removal of a
nitrogen atom (BNIPDaoct), and replacement of the spermidine linker with two
cyclohexane rings (BNIPDaCHM) resulted in an increase in cytotoxicity compared with
1 Cell count measurements were conducted following cell collection, as described in Section 4.3.1
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BNIPSpd (IC50 values decreased from 12.7 µM with BNIPSpd, to 5.0 and 6.8 µM, for
BNIPDaoct and BNIPDaCHM, Table 4.2). However, when the spermidine linker was
replaced by a dioxoctane linker (BNIPDaoxoct); a similar level of cytotoxicity was
observed with both BNIPP derivatives (IC50 values of 12.4 and 12.7 µM, respectively)
(Figure 4.28).
In MCF-10A cells, BNIPSpd had an IC50 value of 4.2 µM, after 24 hours (Table
4.3). Changes to the central linker chain as indicated above resulted in an increase in
cytotoxicity for BNIPDaoct (IC50 value of 2.8 µM), but a decrease in cytotoxicity for
BNIPDaoxoct and BNIPDaCHM (IC50 values increased from 4.2 µM with BNIPSpd, to 6.0
and 6.1 µM, for BNIPDaoxoct and BNIPaCHM) (Figure 4.28).
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Figure 4.28.: Structures of BNIPDaoct (a), BNIPDaoxoct (b) and BNIPDaCHM (c)
The modifications to the central linker chain within the selected BNIPP derivatives
have resulted in differences in their observed cytotoxicity levels against both MDA-MB-
231 and MCF-10A cells. These distinct structural differences might indicate that each
derivative may possess an entirely different mechanism for cellular uptake and entry. This
was further supported by the differing trends observed for each BNIPP derivative by
fluorescence microscopy studies (Figures 4.15a-c – 4.16a-c) (Section 4.4.3), and
polyamine transporter studies (Table 4.4) (Section 4.4.4).
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4.5.3. Cellular Uptake of BNIPP Derivatives
The inherent fluorescence properties of the BNIPP derivatives allowed the studies
of cellular uptake and distribution of BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM
(10 µM) to be monitored by fluorescence microscopy (Figures 4.15a-c – 4.16a-c).
After 0.5 hours, only MDA-MB-231 cells treated with BNIPDaoct or BNIPDaCHM
showed fluorescence (Figure 4.15a, b and c). Fluorescence was detectable over time in
MDA-MB-231 cells treated with BNIPDaCHM whereas in BNIPDaoct treated MDA-MB-
231 cells, fluorescence had disappeared after 6 hours (Figure 4.15a, b and c). This
observation is in agreement with the higher toxicity of BNIPDaoct (IC50 value 5.0 µM, after
24 hours; Table 4.2), in comparison to BNIPDaCHM (IC50 value 6.8 µM, after 24 hours;
Table 4.2) and the other BNIPP derivatives examined (BNIPSpd, IC50 value 12.7 µM;
BNIPDaoxoct, IC50 value 12.4 µM, after 24 hours; Table 4.2). The apparent loss in
fluorescence within BNIPDaoct treated MDA-MB-231 cells could be the result of
BNIPDaoct being transported into the cells faster than the other BNIPP derivatives and
metabolised very quickly. Interestingly, the fluorescence of BNIPSpd and BNIPDaoxoct in
MDA-MB-231 cells was not observed until after 6 hours incubation. This may be due to
the slower cellular uptake of BNIPSpd and BNIPDaoxoct into MDA-MB-231 cells, and
hence could explain their lower toxicities (IC50 12.7 and 12.4 µM, after 24 hours,
respectively; Table 4.2) when compared with BNIPDaoct and BNIPDaCHM (IC50 5.0 and
6.8 µM, after 24 hours, respectively; Table 4.2) (described in Section 4.5.2).
In MCF-10A cells treated with BNIPDaoct and BNIPDaCHM, fluorescence was
observed after 0.5 hours incubation (Figure 4.16a-c). In contrast to treated MDA-MB-231
cells, fluorescence in BNIPDaoct treated MCF-10A cells remained with time (Figure
4.16a-c). BNIPDaoxoct treated cells showed fluorescence after 2 hours, whereas,
BNIPSpd treated cells showed fluorescence after 6 hours. It would appear that BNIPP
derivatives in MCF-10A cells utilise a mode of cellular uptake that is independent of
cytotoxicity. This was a reasonable assumption because the uptake of BNIPSpd,
BNIPDaoct, BNIPDaoxoct and BNIPDaCHM (IC50 values: 4.2, 2.8, 6.0 and 6.1 µM, after
24 hours, respectively, Table 4.3) into the MCF-10A cells was observed in the order of
BNIPDaoct and BNIPDaCHM (0.5 hours), BNIPDaoxoct (2 hours) and BNIPSpd (6 hours).
Therefore, the order of cellular uptake and cytotoxicity levels did not correlate with one
another in MCF-10A treated cells.
Taken together, the results in this study suggest that each BNIPP derivative is
taken up into MDA-MB-231 and MCF-10A cells by different mechanisms (i.e., cytotoxicity
in MDA-MB-231 cells is related to uptake, whilst cytotoxicity in MCF-10A cells is not
related to uptake), and that BNIPP derivative uptake is cell line dependent. The
polyamine transporter studies further support this observation (Section 4.4.4).
In this study, it was difficult to confirm the cellular location of the BNIPP derivatives
in MDA-MB-231 and MCF-10A cells. Earlier work by Pavlov et al. (2001), however,
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showed that 5, 10 and 25 µM of BNIPSpd, BNIPSpm and BNIPOSpm was localised within
the cell nuclei of breast cancer (MCF-7) cells, after 8 hours incubation. Further
fluorescence microscopy studies with BNIPSpd, BNIPSpm and BNIPOSpm by Dance et
al. (2005), revealed nuclear localisation in MCF-7 and colon cancer (CaCO-2) cells, after
2, 3 and 12 hours, respectively. Although, in this study, the exact cellular location of the
BNIPP derivatives could not be determined in either cell line; it should be noted that future
studies would be undertaken using a confocal microscope to allow the greater resolution
of specific cell organelles (Cullis et al. 1999).
4.5.4. Polyamine Transporter Studies with BNIPP Derivatives
The simple, reliable and sensitive model identified for derivative and conjugate
delivery via the MGBG-specific polyamine transporter (Gardner et al. 2004, Tsen et al.
2008) has been successfully utilised in this study to investigate BNIPP derivative transport
for the first time. The PAT model which uses CHO-MG and CHO cell lines (Gardner et al.
2004, Tsen et al. 2008) was used to identify a possible mechanism of cellular entry
employed by the BNIPP derivatives: BNIPSpd, BNIPDaoct, BNIPDaoxoct and
BNIPDaCHM.
In this study, none of the BNIPP derivatives enter the cells by the MGBG-specific
PAT. This was determined by CHO-MG/CHO IC50 ratios which ranged from 0.4 – 1.0
(Table 4.4). Therefore, BNIPP derivatives must enter cells by other mechanisms that are
independent of the MGBG-specific PAT. These alternative mechanisms may include
passive diffusion and/or utilisation of another transporter or other membrane receptor
interactions (Gardner et al. 2004).
The MGBG-specific PAT has been thoroughly investigated, and the naturally
occurring polyamines (putrescine, spermidine and spermine) are all transported via this
transport system (Heaton and Flintoff 1988, Wang et al. 2003a, Wang et al. 2003b, Wang
et al. 2003c, Gardner et al. 2004, Kaur et al. 2005, Tsen et al. 2008). The structural
tolerances of the PAT system allow transport of non-native polyamine-like derivatives,
which contain linear polyamine motifs into different cellular systems (Wang et al. 2003a,
Wang et al. 2003b, Wang et al. 2003c). The affinity of a derivative to utilise the PAT has
been shown to increase with the increasing number of positive charges, therefore affinity
increases from putrescine through to spermine (Seiler et al. 1996). However, recent
studies into the anthracene-polyamine conjugates have suggested that there are several
limitations to the structural tolerances of the PAT system (Wang et al. 2001, Wang et al.
2003a, Wang et al. 2003b, Wang et al. 2003c, Kaur et al. 2008a).
While BNIPP derivatives do not use the MGBG-specific PAT, many other
polyamine-like derivatives and conjugates have been shown to successfully exploit it.
These include several anthracene-polyamine conjugates, in particular, anthracen-9-
ylmethyl-4,4-triamine trihydrochloride and anthracen-9-ylmethyl-4,4-tetraamine
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tetrahydrochloride (Figure 4.3), which are highly selective PAT substrates (CHO-MG/CHO
ratios are 148 and 3.1, respectively) (Wang et al. 2003a, Gardner et al. 2004). The
uptake of these anthracene-polyamine conjugates and their analogues has been shown to
be dependent upon the number of methylene (-CH2-) groups, in which, the naphthylmethyl
and naphthylethyl conjugates were highly selective PAT substrates (CHO-MG/CHO IC50
ratios were > 164), but the naphthylpropyl conjugate had no PAT selectivity (IC50 values
were > 500, in both cell lines) (Figure 4.29). The addition of an extra methylene group
appears to be sufficient to reduce cytotoxicity within CHO-MG and CHO cells. It was
demonstrated that increasing tether length, reduced PAT-selectivity (Gardner et al. 2004).
This trend was also apparent in the anthracenyl series of conjugates, where the most
PAT-selective conjugate was anthracen-9-ylmethyl-4, 4-tetraamine tetrahydrochloride
(CHO-MG/CHO ratio was 148) (Figure 4.3) (Wang et al. 2003a, Gardner et al. 2004).
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Figure 4.29.: Structures of anthracene-polyamine conjugates (N-(4-Aminobutyl)-N’-(2-naphthalen-
1-yl-methyl)butane-1,4-diamine trihydrochloride (a), N-(4-Aminobutyl)-N’-(2-naphthalen-1-yl-
ethyl)butane-1,4-diamine trihydrochloride (b), and N-(4-Aminobutyl)-N’-(2-naphthalen-1-yl-
propyl)butane-1,4-diamine trihydrochloride) (c)
Other anthracenyl conjugates that contain structural similarities to the BNIPP
derivatives have been investigated. These include the bis-anthracenyl conjugates, N-
Anthracen-9-ylmethyl-N1-{4-[(anthracen-9-ylmethyl)-amino]butyl}butane-1,4-diamine
tetrahydrochloride (with two bulky hydrophobic groups, secondary amines and a linker
similar to BNIPSpd); N1-Anthracen-9-ylmethyl-octane-1,8-diamine dihydrochloride (with
one bulky hydrophobic group, a primary amine and a eight methylene linker chain similar
to BNIPDaoct); 2-(2-{2-[(Anthracen-9-ylmethyl)-amino]-ethoxy}-ethoxy)-ethylamine
dihydrochloride (with one bulky hydrophobic group, a primary amine and a linker similar to
BNIPDaoxoct), and N-{4-[(Anthracen-9-ylmethyl)-amino]butyl}-cyclohexane-1,4-diamine
trihydrochloride (with one bulky hydrophobic group and a primary amine) (Figure 4.30a-d)
(Wang et al. 2003a, Gardner et al. 2004). These conjugates were shown to have no
preference for either CHO cell line, and therefore do not exploit the polyamine transporter
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(CHO-MG/CHO ratios of 1 - 7). The CHO-MG/CHO ratios were comparable to those
produced by the BNIPP derivatives (CHO-MG/CHO ratios of 0.4 – 1; Table 4.4).
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Figure 4.30.: Structure of bis-anthracenyl conjugates: N-Anthracen-9-ylmethyl-N1-{4-[(anthracen-9-
ylmethyl)-amino]butyl}butane-1,4-diamine tetrahydrochloride (a-d)
In summary, the polyamine sequence (putrescine, spermidine or spermine), size,
N1-substituents, presence of primary amine, and conjugate length (i.e., the number of
methylene groups) are all important structural features required to obtain optimum PAT-
selectivity (Seiler 2005, Kaur et al. 2008a Kaur et al. 2008b, Tsen et al. 2008). The N-
naphthylmethyl 4, 4-triamine conjugate provided the best PAT-selectivity profile (150-fold
higher cytotoxicity in CHO cells than in CHO-MG cells), and hence shorter linker groups
appear to be essential to impart PAT affinity (Kaur et al. 2008a). As a result, the BNIPP
derivatives which contain two naphthalimidopropyl groups are too large to be imported
into cells via the MGBG-specific polyamine transporter (Kaur et al. 2008b). Due to the
complexity of the polyamine transport system and its lack of characterisation at a
molecular level, it is difficult to state whether the BNIPP derivatives may utilise a currently
unknown polyamine transporter, or may due to their structure, inhibit their own cell uptake
(Cullis et al. 1999, Graminski et al. 2002, Mitchell et al. 2007, Ralton et al. 2007). Further
investigations into the mechanism of BNIPP derivative transport into cells would provide a
better understanding of the mode of action of BNIPP derivatives within cellular systems.
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4.5.5. Intracellular Polyamine Levels
In MDA-MB-231 cells, 24 hours treatment with BNIPSpd or BNIPDaoct, at 0.1 µM,
significantly increased spermidine and spermine levels (P < 0.01; BNIPSpd; Figure 4.17
and P < 0.05; BNIPDaoct; Figure 4.18), whilst BNIPDaoxoct (0.1 µM), significantly
increased putrescine levels (P < 0.05; BNIPDaoxoct; Figure 4.19) when compared to that
of the control. However, at 0.1 µM, BNIPDaCHM did not alter putrescine, spermidine or
spermine levels when compared with the control (Figure 4.19). No change to putrescine,
spermidine or spermine levels was observed after 24 hours treatment with BNIPSpd,
BNIPDaoct, BNIPDaoxoct or BNIPDaCHM, at 1 µM, when compared with the control
(Figures 4.17 – 4.19). At 5 µM, BNIPSpd significantly decreased putrescine and
spermidine levels (P < 0.05), whilst a significant decrease in putrescine (P < 0.05),
spermidine (P < 0.01) and spermine (P < 0.05) levels was observed following treatment
with BNIPDaoct (5 µM), compared to the control (Figures 4.17 – 4.18). No change in
putrescine, spermidine or spermine levels was observed after 24 hours treatment with
either BNIPDaoxoct or BNIPDaCHM (5 µM) when compared to the control (Figures 4.19 –
4.20).
In MCF-10A cells, treatment with 0.1 µM BNIPDaoxoct significantly increased
spermidine and spermine levels (P < 0.05; Figure 4.23), whilst treatment with 1 µM
BNIPDaCHM significantly increased putrescine levels (P < 0.05; Figure 4.24). Treatment
with BNIPDaoct (5 µM) or BNIPDaoxoct (1 – 5 µM) significantly decreased putrescine
(BNIPDaoct; P < 0.05; Figure 4.22), spermidine and spermine (BNIPDaoxoct; P < 0.05;
Figures 4.23) levels in MCF-10A cells. No change in polyamine levels (putrescine,
spermidine or spermine) were observed after treatment with BNIPSpd (0.1 – 5 µM) in
MCF-10A cells (Figure 4.21).
In both cell lines, it was not possible to establish trends in the levels of polyamines
after treatment with each BNIPP derivative. This conclusion was supported by
inconsistent up- and down- regulation effects reported on intracellular polyamine levels in
both MDA-MB-231 and MCF-10A cells (Figures 4.17 – 4.24). The specific effect of BNIPP
derivatives on intracellular polyamine levels appears to be related to their different
mechanisms of action which could be of a direct or an indirect nature (Holst et al. 2006).
The influence of BNIPP derivatives on intracellular polyamine levels may be related to
their cytotoxicities, and their differing trends in cellular uptake and transport (as described
in Sections 4.5.2, 4.5.3 and 4.5.4). Importantly, treatment with 0.1 µM of BNIPSpd,
BNIPDaoct or BNIPDaoxoct significantly increased intracellular polyamine levels, as cells
react and adapt to the presence of BNIPP derivatives (at a non toxic concentration),
hence an increase to cell proliferation should also be observed at this concentration.
In this study, putrescine, spermidine and spermine were all successfully detected
using the method of pre-column derivatisation with dansyl chloride followed by HPLC
separation and fluorescence detection (Marcé et al. 1995, Weeks et al. 2000, Huang et al.
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2003, Burns et al. 2009). Putrescine, the precursor of polyamine biosynthesis is rapidly
converted into the tri- and tetra-amines, spermidine and spermine, therefore low levels of
putrescine can normally be detected in eukaryotic cells (Wallace 1996, Khuhawar and
Qureshi 2001). Low levels of putrescine were detected in both MDA-MB-231 and MCF-
10A cells, in comparison to the levels of spermidine and spermine. Low or undetectable
levels of putrescine have been previously reported in several studies (Bergeron et al.
1997, Manni et al. 2002, Huang et al. 2003, Richert et al. 2005, Ralton 2006).
Polyamines are essential in cell proliferation and differentiation, and are important
in the progression of the aggressive and resistant features of metastatic breast cancer
(Pegg 1988, Glikman et al. 1989, Manni et al. 2002) (Section 1.4). Rapidly dividing cells,
(i.e., cancer cells) have higher levels of ODC activity, thus higher levels of intracellular
polyamines (Lindsay and Wallace 1999, Manni et al. 2002). These observations were in
contrast to the levels determined in the surrounding non-cancerous cells, where lower
levels of intracellular polyamines were detected (Khuhawar and Qureshi 2001). It was
observed in this study that putrescine levels were higher in untreated MDA-MB-231 cells
(0.43 µM/1x106 cells) than in untreated MCF-10A cells (0.16 µM/1x106 cells), but
spermidine and spermine levels were approximately the same in both cell lines (ranging
between 3.03 – 3.21 µM/1x106 cells and 2.56 – 2.66 µM/1x106 cells, respectively) (Figures
4.17 - 4.24). The similarity in the spermidine and spermine levels in MDA-MB-231 and
MCF-10A cells may possibly be explained by the observation that MCF-10A cells replicate
at a faster rate that the MDA-MB-231 cells (as discussed in Section 4.5.2).
Colon cancer (CaCO-2 and HT-29) cells previously investigated by Ralton (2006)
and Ralton et al. (2009) had higher concentrations of polyamines than MDA-MB-231 and
MCF-10A breast cells (Ralton 2006). The polyamine content of serum and urine in
individuals diagnosed with colon cancer have also been found to be highly elevated when
compared with breast and prostrate cancer cells, or non-cancerous cells (Levêque et al.
2000, Milovic 2001, Wallace and Caslake 2001). This was noted to be due to the readily
available uptake of exogenous polyamines from the diet, and/or from the production of
polyamines from intestinal flora (as described in Section 4.1.3) (Seiler et al. 1990, Milovic
et al. 2001, Thomas and Thomas 2001, Larqué et al. 2007).
Previous studies conducted by Ralton (2006) and Ralton et al. (2009) found that
the concentration of DFMO that significantly reduced intracellular polyamine levels after
treatment for 12 hours (HL60 cells) or 24 hours (CaCO-2 and HT-29 cells) was 5 mM,
whereas in MDA-MB-231 and MCF-10A cells, treatment with DFMO (5 mM) for 24 hours
did not significantly reduce intracellular polyamine levels. Treatment with 5 µM BNIPSpd,
BNIPDaoct, BNIPDaoxoct or BNIPDaCHM induced instead a similar or greater effect on
intracellular polyamine levels than DFMO in MDA-MB-231 and MCF-10A cells (Figures
4.17 – 4.24). It should be noted that the effect of DFMO on cancer cells is usually
cytostatic, not cytotoxic in nature. Thus, DFMO causes a decrease in cell proliferation,
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with a lack of cell death (Meyskens and Gerner 1999). The lack of an effect after DFMO
treatment observed in this study could be supported by previous studies (Glikman et al.
1989, O’Shaughnessy et al. 1999, Manni et al. 2002), which showed that DFMO may
induce cell-type specificity in metastatic breast cancer cells. Therefore, the effect of
DFMO treatment can differ depending on the breast cell line used in an investigation.
Another interesting finding was that significant suppression in MDA-MB-231 intracellular
polyamine levels was observed only after 6 days of DFMO treatment (> 0.1 mM), as
assessed by Glikman and colleagues (1989). However, in this study, DFMO treatment (5
mM) was undertaken for only 24 hours. Further investigations into the effect of DFMO
treatment in MDA-MB-231 cells after longer treatment periods would provide a true
comparison with published data.
In this study, the reduction in intracellular polyamine levels after BNIPSpd
treatment in MDA-MB-231 and MCF-10A cells was different to that observed in CaCO-2
and HT-29 cells (Ralton et al. 2009). After 24 hours, BNIPSpd induced a significant
decrease in putrescine and spermidine levels in MDA-MB-231 cells (at 5 µM) and no
change in intracellular polyamine levels in MCF-10A cells (Figures 4.17 and 4.21),
whereas BNIPSpd induced a significant reduction in spermidine and spermine levels in
CaCO-2 and HT-29 cells, from ≥ 0.01 µM (Ralton et al. 2009). This indicates the potential
for each BNIPP derivative to have a cell-specific selectivity in the reduction of intracellular
polyamine levels (Huang et al. 2003, Holst et al. 2006). Interestingly, previous reports into
BNIPSpd have proposed that the reduction of intracellular polyamine levels were a direct
effect of BNIPSpd treatment, thus contributing to its high cytotoxicity levels in CaCO-2 and
HT-29 cells (i.e., IC50 values of 0.47 and 2.4 µM, after 24 hours) (Ralton et al. 2009).
However, the lack of a significant reduction in intracellular polyamine levels in MDA-MB-
231 and MCF-10A cells, after BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM
treatment showed that the modulation of polyamine levels in these cells do not appear to
be linked directly to cytotoxicity levels. Consequently, the effect of polyamine levels on
BNIPP derivative cytotoxicity may again be cell line specific (Huang et al. 2003). It should
be noted that further investigations into the mechanistic link between the reduction of
intracellular polyamine levels and cytotoxicity would provide a better understanding into
the mode of action of BNIPP derivatives within different cellular systems.
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4.6. Conclusion
The BNIPP derivatives were shown to significantly affect cell morphology and cell
viability of MDA-MB-231 and MCF-10A cells treated for 24 hours. Cell morphology was
visually altered, with an apparent loss of cell adherence. All BNIPP derivatives, except
BPHPDadec and NPA (IC50 values of > 40 µM), exhibited cytotoxic properties in both cell
lines. With cytotoxicity results confirming the importance of (i) bisnaphthalimidopropyl
functionality; (ii) an alkyl chain length of between 8 – 10 alkyl groups; and (iii) two nitrogen
atoms in the linker by which to increase aqueous solubility, and maintain biological
activity. Cellular uptake studies have revealed that each BNIPP derivative is taken up by
a different mode of action as uptake and cytotoxicity results are in agreement in MDA-MB-
231 treated cells, but not in MCF-10A treated cells. Thus, the extent of BNIPP derivative
uptake appears to be cell line dependent. None of the selected BNIPP derivatives were
found to utilise the MGBG-specific PAT system. Due to the size of the BNIPP derivatives
(i.e., the naphthalimido groups), it appears that these derivatives are too large to exploit
the MGBG-specific PAT system, thus, they may employ another currently unknown mode
of cellular entry. Intracellular polyamine levels were up-and down- regulated with different
concentrations of BNIPP derivatives in MDA-MB-231 and MCF-10A cells, and as a result,
it was not possible to establish trends between polyamine levels and BNIPP derivative
induced cytotoxicity.
Due to variations in their central linker chain, BNIPSpd and BNIPDaCHM were
selected for further analysis. These derivatives were investigated in order to assess their
ability to (i) induce DNA damage (Chapter 5), (ii) initiate cell death (Chapter 6) and (iii)
inhibit histone deacetylase activity (Chapter 7).
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Chapter 5
DNA Damage and Repair Studies of BNIPP
Derivatives in MDA-MB-231 and MCF-10A Cells
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5.1. DNA Damage and Repair Studies of BNIPP
Derivatives in MDA-MB-231 and MCF0-10A Cells
One of the current therapeutic strategies involves the ability of anti cancer agents
to inflict DNA damage and induce cancer cell death (Liao et al. 2009). For example, many
intercalating anti cancer agents, such as diacridines (Roos et al. 1985) and anthracyclines
(Swift et al. 2006), have been shown to produce DNA strand breaks (e.g., single and
double strand breaks). Their therapeutic use relies upon their ability to target DNA by
intercalation, and their resultant cytotoxicities are related to the extent of DNA damage
induced. This mode of action is considered to be the most effective in the current
treatment of cancer (e.g., in acute leukaemias, and breast, ovarian and bladder cancers)
(Cancer Research UK, 2009a, Cancer Research UK, 2009b). DNA damaging agents are
continually being discovered and developed, supporting the need to investigate the
influence of BNIPP derivatives on intracellular DNA stability.
The aims of the experimental work reported in this chapter were to (i) study the
extent of DNA damage inflicted in MDA-MB-231 and MCF-10A cells treated with BNIPSpd
or BNIPDaCHM, and (ii) determine the ability of these derivatives to interfere with the
repair of oxidative or methylation-induced DNA strand breaks in MDA-MB-231 cells.
5.1.1. Significance of DNA Damage within a Cell System
DNA damage can occur within all eukaryotic cells, and is induced by different
endogenous or exogenous DNA damaging agents. These agents include (i) products of
normal cellular metabolism and proliferation (e.g., free radical attack, reactive oxygen
species (ROS) or spontaneous reactions, i.e., mutations), (ii) environmental agents (e.g.,
ultraviolet (UV) light or ionising (X and γ rays) radiation), or (iii) chemical agents (e.g., 
alkylating anti cancer agents) (Collins 1996, Hoeijmakers 2001) (Figure 5.1). These
agents cause structural changes to the DNA structure with alterations to nucleotides
and/or by breakage of the sugar-phosphate backbone, which can lead to a non functional
DNA structure (Vijg 2007). Structural changes are responsible for the presence of
permanent DNA damage, and if DNA damage cannot be repaired before replication
begins, disruption to DNA metabolism and cell cycle arrest can occur; causing cellular
ageing, neurodegenerative disorders, tumourigenesis or cancer in somatic cells (Figure
5.1) (Collins 1996, Hoeijmakers 2001, Kastan 2008).
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Figure 5.1.: Schematic representation of the causes and consequences of DNA damage in
somatic cells [adapted from Collins 1996, pp. 231].
DNA damage is also linked to many heritable cancers which are caused by the
inheritance of mutations to genes responsible for DNA damage responses (Kastan 2008).
For example, mutations in BRCA1/BRCA2 genes result in the predisposition of breast and
ovarian cancers or the inheritance of mutated genes involved in mismatch repair results in
the high incidence of hereditary nonpolyposis colon cancer (HNPCC) (Hoeijmakers 2001,
Kastan 2008). DNA damage responses are also relevant, as current cancer treatments
(i.e., radiotherapy or chemotherapy) target DNA, causing DNA damage and killing cancer
cells. As DNA damage can cause cancer and is used in cancer treatment; all cells,
therefore, require specific mechanisms that can detect and repair both endogenously and
exogenously induced DNA damage.
5.1.2. Mechanisms of DNA Repair within a Cell System
DNA repair mechanisms are utilised to protect cells from DNA damage in
response to DNA damaging agents. Cells have an inherent ability to repair DNA damage,
and in most cases, DNA damage is “simply reversed” (Collins 1996, pp. 237). The fate of
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a cell is dependent upon the extent of DNA damage induced. If minimal DNA damage
has been induced; repair mechanisms will cause cell cycle arrest, allowing DNA repair by
removal of damage and rejoining of strand breaks, but maximal or too much DNA damage
can lead to cells being unable to be repaired thus leading to apoptotic cell death (Figure
5.1) (Collins 1996, Damia and D’Incalci 2007). The former leads to cell survival, whilst the
latter leads to cell death (Damia and D’Incalci 2007).
The most important DNA repair mechanisms that can detect and repair DNA
damage are shown in Figure 5.2. These repair mechanisms include (i) repair of damaged
bases induced by oxidative or methylating agents, by base excision repair (BER), (ii)
repair of UV-induced DNA-distorting damage via nucleotide excision repair (NER), (iii)
repair of single- (SSBs) or DSBs induced by ionising radiation, free radical attack or
methylating anti cancer agents repaired by both homologous recombination (HR) repair or
non homologous end joining (NHEJ) repair, and (iv) repair of mispairings and
insertion/deletion of nucleotides in newly synthesised DNA by mismatch repair (MMR)
(Figure 5.2) (Collins 1996, Damia and D’Incalci 2007, Ljungman 2009). The
aforementioned DNA repair mechanisms are generally defective in cancer cells. Thus,
the manipulation of DNA repair mechanisms which induce cell death can provide potential
targets for anti cancer therapies.
Figure 5.2.: Schematic representation of the main DNA repair mechanisms. BER: Base Excision
Repair; NER: Nucleotide Excision Repair; SSBs: Single Strand Breaks; DSBs: Double Strand
Breaks; HR: Homologous Recombination; NHEJ: Non Homologous End Joining; MMR: Mismatch
Repair [Adapted from Damia and D’Incalci 2007, pp 1792].
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5.1.3. Assessment of DNA Strand Breaks
Numerous methods are available to access DNA damage within mammalian cells
(Poulsen et al. 1999, Kumari et al. 2008). Examples include (i) the detection of DNA
damage in individual cells by either the neutral or alkali comet assays (Singh et al. 1988);
(ii) the detection of oxidative DNA damage, via gas chromatography-mass spectrometry
(GC-MS) (Nyaga et al. 2007), 32P post-labelling combined with high performance liquid
chromatography (HPLC) (Munnia et al. 2007) or an immunological assay (Leuratti et al.
1998), and (iii) detection of multiple DNA modifications, by liquid chromatography tandem
MS (Nyaga et al. 2007). In this study, DNA strand breaks were assessed using the Single
Cell Gel Electrophoresis (SCGE or Comet assay). The alkaline comet assay (pH > 13)
was developed by Singh et al. in 1988, and due to its high sensitivity (50 – 15,000
breaks/cell), rapidity and reproducibility, is the most widely used technique in the
quantification of DNA damage within individual mammalian cells (Fairburn et al. 1995,
Piperakis 2009). It can not only detect SSBs and alkali-liable sites (ALS), but has also
been adapted to evaluate DNA repair in response to oxidative (Hydrogen peroxide, H2O2)
or methylation (Methyl methanesulfonate, MMS) induced DNA damage (Duthie et al.
2000, Sekihashi et al. 2003, Ralton. 2006). Figure 5.3 illustrates the general method of
the alkaline comet assay.
For the comet assay, cells were embedded in low melting point (LMP) agarose on
a frosted microscope slide (Figure 5.3) and placed in lysis solution consisting of high salts
and detergents, to remove cellular proteins (Tice et al. 2000). Prior to electrophoresis, the
slides were incubated in an alkaline (pH > 13) electrophoresis buffer to allow alkaline DNA
unwinding. Alkaline DNA unwinding produces single stranded DNA and allows the
maximum expression of ALSs as SSBs (Tice et al. 2000, Liao et al. 2009). After alkaline
unwinding, relaxed single stranded DNA was electrophoresised (alkaline conditions, pH >
13) where DNA loops are pulled towards the anode, to form ‘comets’ (Duthie et al. 2000).
After electrophoresis, the gels were neutralised and stained with a DNA-binding dye.
Comets were visualised with fluorescence microscopy analysis (Gedik et al. 1992, Tice et
al. 2000).
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Figure 5.3.: General schematic representation of the alkaline comet assay (The Eppendorf tube
image was obtained from www.freeclipartnow.com/science/flasks-tubes).
Figure 5.4 illustrates examples of the visual scoring classifications. An
undamaged nucleotid appears with an intact ‘head’ and no ‘tail’ (Score 0), whilst a
damaged nucleotid appears as a comet with a bright fluorescent ‘head’ and a ‘tail’ (Score
4) (Figure 5.4). The relative fluorescence intensity of the ‘head’ and the length of the ‘tail’
are directly proportional to the extent of DNA strand breaks (Duthie and Collins 1997).
This visualisation method has been previously validated by Duthie and Hawdon (1998),
and has been successfully used in the analysis of DNA damage exerted by BNIPSpd,
BNIPSpm and BNIPOSpm as described by Dance et al. (2005) and Ralton et al. (2009).
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Figure 5.4.: DNA damage in MDA-MB-231 cells as determined by comet assay. Cells were
visulised using a Leica DMRB fluorescence microscope with D filter (ex bandpass (violet); 355 –
425 nm; em longpass (green); 470 nm) following staining with DAPI. Images are representative for
the comet images obtained for nucleotides with scores 0 – 4 (undamaged – damaged).
Magnification x200.
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5.2 Materials
5.2.1. Materials
All reagents were purchased from Fisher Scientific, UK unless otherwise stated,
and were used without purification.
Agarose Bioline, UK
Ethylenediaminetetraacetic acid Sigma-Aldrich, UK
Hydrogen Peroxide Aldrich, UK
4’6-diamidine-2-phenylindol dihydrochloride Fluka, UK
Low Melting Point Agarose Sigma-Aldrich, UK
Methyl Methanesulfonate Aldrich, UK
Triton-X 100 Sigma-Aldrich, UK
5.2.2. Instrumentation
Aseptic cell culture techniques were undertaken as described in Section 4.2.2.
For Comet assay analysis, a Horizon 20.25 horizontal gel electrophoresis tank
(Gibco, UK) was used. The comets were visualised using a Leica DMRB fluorescence
microscope (Leica Microsystems, UK) with a D filter (excitation bandpass (violet); 355 –
425 nm, emission longpass (green); 470 nm). Microscopy images were captured using a
Leica DFC 300 FX camera (Leica Microsystems, UK), and viewed with a Leica Application
Suite (Version 2.71 RI, 2003 – 2007) (Leica Microsystems, Switzerland).
146
5.3. Methods
5.3.1. Maintenance of Cells
MDA-MB-231 and MCF-10A cells were sub cultured and counted, as described in
Sections 4.2.2 and 4.3.1 - 4.3.2. For both DNA damage and repair studies (in response to
H2O2 or MMS treatment), MDA-MB-231 and MCF-10A cells were seeded in 24 well plates
(8 x 104 cells/well) and allowed to grow for 24 hours before treatment. The cells were
incubated with BNIPSpd or BNIPDaCHM (0 – 10 µM) for up to 24 hours, at 37 °C in 24
well plates, as shown in Figure 5.5.
Figure 5.5.: An example of the set up for a 24 well plate used for the DNA damage and repair
studies
5.3.2. Preparation of BNIPP Derivatives
The BNIPP derivatives: BNIPSpd and BNIPDaCHM were synthesised as
previously described in Section 2.3. BNIPSpd and BNIPDaCHM were diluted to the
desired concentrations of 0.1, 1, 5 and 10 µM, as described in Section 4.3.3.
0 0.1 1 5 10 H2O2
MDA-MB-231 Cells (80,000 cells/well)
200 µM0 – 10 µM BNIPSpd or BNIPDaCHM
147
5.3.3. Preparation of H2O2 and Methyl Methane Sulfonate
(MMS) Solutions
The H2O2 stock solution (10 M) was diluted to the desired final concentrations of 50
– 800 µM in PBS. The MMS stock solution (45 mM) was diluted to the desired final
concentrations of 0.25 – 5 mM in serum free media. Both control solutions were prepared
immediately prior to use.
5.3.4. Slide Preparation
The slides were prepared immediately before use, following the method first
described by Singh et al. (1988), and further adapted by Dance et al. (2005). 85 µL of 1%
(w/v) agarose in PBS (at 60 °C) was quickly layered onto a fully frosted microscope slide
(Richardson Supply Co., UK) and covered with an 18 x 18 mm cover slip (No. 1 glass).
The slides were kept at 4°C until required.
5.3.5. Alkaline Single Cell Gel Electrophoresis (the Comet
Assay)
MDA-MB-231 and MCF-10A cells were treated with BNIPSpd and BNIPDaCHM
(0.1 – 10 µM) for 24 hours (refer to Figure 5.7). After 24 hours, the MDA-MB-231 and
MCF-10A cells were washed with 800 µL of medium containing either 10 % (v/v) FCS or 5
% (v/v) HS, respectively, and the cell solution collected in sterile Eppendorf tubes as
described in Section 4.3.1. The cells were centrifuged at 2000 rpm (ALC Multispeed
Refrigerated Centrifuge, Thomson Scientific, UK) for 5 minutes, at 4 °C. The supernatant
was removed and 85 µL of 1 % (w/v) LMP agarose in PBS (at 37 °C) added quickly to the
cell pellet. The cell suspension was transferred onto a pre coated microscope slide;
prepared as described in Section 5.3.4. The gel was covered with an 18 x 18 mm cover
slip (No. 1 glass) and allowed to harden for 10 minutes, at 4 °C (Figure 5.3). Slides were
placed into cooled black staining jars with 200 mL lysis solution (2.5 M NaCl, 0.1 M EDTA,
10 mM Tris, NaOH to pH 10, and 1% (v/v) Triton X-100, pH 10), and incubated for at least
1 hour, at 4 °C. Slides were arranged horizontally in an electrophoresis tank with 1500
mL of cooled electrophoresis buffer (0.3 M NaOH and 1 mM EDTA, pH >13), and
incubated for 40 minutes, at 4 °C. Electrophoresis was carried out at 25V for 30 minutes,
at 4 °C. The slides were placed into cooled black staining jars with 200 mL neutralising
buffer (0.4 M Tris-HCl, pH 7.5), and washed three times for 5 minutes each wash, at 4 °C.
Slides were left to dry at room temperature before comet scoring.
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5.3.6. Quantification of the Comet Assay
For comet scoring, 20 µL of 4’,6-diamidine-2-phenylindol dihydrochloride (DAPI) (1
µg/mL) dye was added to each gel, and covered with a 22 x 22 mm cover slip (No 1
glass). The cells were examined visually and scored using the fluorescence microscope
described in Section 5.2.2. One hundred nucleoids were scored per gel, and given a
score of 0, 1, 2, 3, or 4 (from undamaged, 0 to maximum damage, 4) (Figure 5.4). The
total score of each sample can range from 0 (all undamaged) to 400 (all maximally
damaged).
5.3.7. DNA Repair of Oxidative (H2O2)-Induced DNA Damage
MDA-MB-231 (8 x 104 cells/well) cells were treated with BNIPSpd (non toxic
concentrations, 5 and 0.05 µM) or BNIPDaCHM (non toxic concentrations, 0.1 and 1 µM)
for 4 and 24 hours, respectively. MDA-MB-231 cells were washed twice with PBS before
treatment with H2O2 (200 µM) for 5 minutes on ice, to induce oxidative DNA damage.
After 5 minutes, the H2O2 was removed, and cells washed twice with PBS (500 µL). Fresh
RPMI 1640 medium containing 10% (v/v) FCS (1 mL) was added to each well, and cells
incubated at 37 °C for up to 24 hours. Cells were collected as previously described in
Section 4.3.1 after 0, 2, 4, 8, and 24 hours, and DNA repair of oxidative damage was
detected by the Comet assay (Section 5.3.5).
5.3.8. DNA Repair of Methylative (MMS)-Induced DNA
Damage
DNA repair of MMS damage was detected in MDA-MB-231 (8 x 104 cells/well)
cells treated with BNIPDaCHM (non toxic concentration, 1 µM) for 24 hours. MDA-MB-
231 cells were washed twice with PBS, and the washes collected. The cells were
incubated with MMS (1 mM) for 30 minutes at 37 °C, to induce methylative DNA damage.
After 30 minutes, the MMS solution was removed, and collected. Cells were washed
twice with PBS (500 µL) and all washes collected. The washes and MMS solution were
centrifuged at 4000 rpm for 5 minutes, at room temperature. Fresh RPMI 1640 medium
containing 10% (v/v) FCS (1 mL) was added to each well, and cells incubated at 37 °C for
up to 24 hours. The cells were collected as previously described (Section 4.3.1) after 0, 2,
4, 8 and 24 hours and were analysed by the Comet assay (Section 5.3.5.).
5.3.9. Data Analysis
Unless otherwise stated, each data set contained a minimum of two independent
experiments, in which each experiment was comprised of at least four internal replicates,
expressed as mean ± Standard Error of the Mean (SEM). Statistical analysis was
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conducted using the unpaired Student’s t-test. Data were considered significantly
different when P-value < 0.05 (*P < 0.05, **P < 0.01 and ***P < 0.001).
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5.4. Results
5.4.1. Optimisation of H2O2-induced DNA Strand Breaks
H2O2 was used as a positive control for DNA damage and its concentration was
optimised in MDA-MB-231 and MCF-10A cells. Cells were treated with different
concentrations of H2O2 (0 – 800 µM) for 5 minutes on ice, and DNA strand breaks
assessed by Comet assay.
The diagram in Figure 5.6 presents the number of DNA strand breaks induced by
different concentrations of H2O2 (0 – 800 µM) in MDA-MB-231 cells. Data are not shown
for H2O2 treatment in MCF-10A cells, as a similar result to H2O2 treated MDA-MB-231
cells was found. H2O2 (> 50 µM) induced significant DNA strand breaks (P < 0.05), above
endogenous levels (Figure 5.6). 200 µM H2O2 was selected for the DNA damage and
repair studies (Sections 5.4.2 and 5.4.3).
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Figure 5.6.: DNA strand breaks in MDA-MB-231 cells as determined by comet assay. Data
obtained after treating MDA-MB-231 cells with H2O2 (0 – 800 µM) for 5 minutes, on ice. Data are
mean ± SEM of 2 independent experiments; with 4 replicates (n = 2). *P<0.05, **P<0.01,
***P<0.001 vs. untreated cells.
In summary, the total number of DNA strand breaks induced by H2O2 (200 µM) in
MDA-MB-231 and MCF-10A cells are shown in Table 5.1.
Table 5.1.: Total DNA strand breaks induced by 200 µM H2O2 (for 5 minutes on ice)
Cell Line Concentration of H2O2
(µM)
DNA Strand Breaks (a.u.)
MDA-MB-231 200 327
MCF-10A 200 300
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5.4.2. Effect of BNIPP Derivatives on DNA Strand Breaks
The extent of DNA strand breaks induced in BNIPSpd or BNIPDaCHM (0.1 – 10
µM) treated MDA-MB-231 (Section 5.4.2.1) and MCF-10A (Section 5.4.2.2) was
determined by Comet assay.
5.4.2.1. Effect of BNIPP Derivatives on the Levels of DNA Strand Breaks
in MDA-MB-231 Cells
Both BNIPSpd and BNIPDaCHM (0.1 – 10 µM) induced a significant increase (P <
0.05) in DNA strand breaks compared to endogenous levels, and the increase was dose
dependent, after 4 and 24 hours (Figures 5.7 – 5.8) in MDA-MB-231 cells.
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Figure 5.7.: DNA strand breaks in MDA-MB-231 cells after 4 hours treatment determined by
comet assay. Data obtained after treating MDA-MB-231 cells with BNIPSpd or BNIPDaCHM (0 –
10 µM) for 4 hours. DNA damage in H2O2 (200 µM) treated cells were used as a positive control.
Data are mean ± SEM of 8 replicates; 2 independent experiments (n = 2). *P<0.05, **P<0.01,
***P<0.001 vs. untreated (0 µM) cells.
In general, BNIPDaCHM (≥ 1 µM) induced a greater level of DNA strand breaks
than BNIPSpd in MDA-MB-231 cells, after 4 hours (Figure 5.7). No significant change in
the number of DNA strand breaks was observed with 0.1 µM BNIPSpd or BNIPDaCHM
compared to endogenous levels (Figure 5.7). At a concentration of 1 µM, BNIPSpd did
not significantly change the number of DNA strand breaks compared to endogenous
levels, however, 1 µM BNIPDaCHM significantly increased the number of DNA strand
breaks (P < 0.001, an increase of 113.7 strand breaks), compared to endogenous levels
(Figure 5.7). At a concentration of 5 µM, BNIPSpd did not significantly change the
number of DNA strand breaks compared to endogenous levels; yet, 5 µM BNIPDaCHM
significantly increased the number of DNA strand breaks (P < 0.001, an increase of 141.5
strand breaks), compared to endogenous levels (Figure 5.7). At 10 µM, both BNIPSpd
and BNIPDaCHM significantly increased the number of DNA strand breaks (P < 0.01, an
increase of 122.3 strand breaks; P < 0.001, an increase of 138.5 strand breaks,
respectively), compared to endogenous levels (Figure 5.7). At 200 µM, H2O2 significantly
****** **
*** ***
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increased the number of DNA strand breaks (P < 0.001, an increase of 241.0 strand
breaks), compared to endogenous levels (Figure 5.7).
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Figure 5.8.: DNA strand breaks in MDA-MB-231 cells after 24 hours treatment determined by
comet assay. Data obtained after treating MDA-MB-231 cells with BNIPSpd and BNIPDaCHM (0 –
10 µM) for 24 hours. DNA damage in H2O2 (200 µM) treated cells were used as a positive control.
Data are mean ± SEM of 8 replicates; 2 independent experiment (n = 2). *P<0.05, **P<0.01,
***P<0.001 vs. untreated (0 µM) cells.
However, in general after 24 hours, BNIPSpd (≥ 0.1 µM) induced a greater level of
DNA strand breaks than BNIPDaCHM in MDA-MB-231 cells (Figure 5.8). At a
concentration of 0.1 µM, BNIPSpd significantly increased the number of DNA strand
breaks (P < 0.05, an increase of 66.3 strand breaks), whilst BNIPDaCHM (0.1 µM) did not
significantly change the number of DNA strand breaks, compared to endogenous levels
(Figure 5.8). At 1 µM, BNIPSpd significantly increased the number of DNA strand breaks
(P < 0.001, an increase of 103.5 strand breaks), but 1 µM BNIPDaCHM did not change
the number of DNA strand breaks, compared to endogenous levels (Figure 5.8). At 5 µM,
both BNIPSpd and BNIPDaCHM significantly increased the number of DNA strand breaks
(P < 0.001, an increase of 127.8 strand breaks; P < 0.01, an increase of 67.4 strand
breaks, respectively), compared to endogenous levels (Figure 5.8). The number of DNA
strand breaks were also significantly increased (P < 0.001) following treatment with 10 µM
of BNIPSpd or BNIPDaCHM (an increase of 163.8 and 241.6 strand breaks, respectively),
compared to endogenous levels (Figure 5.8). At 200 µM, H2O2 significantly increased the
number of DNA strand breaks (P < 0.001, an increase of 235.2 strand breaks), compared
to endogenous levels (Figure 5.8).
5.4.2.2. Effect of BNIPP Derivatives on the Levels of DNA Strand Breaks
in MCF-10A Cells
Both BNIPSpd and BNIPDaCHM (0.1 – 10 µM) induced a dose and time
dependent significant increase (P < 0.05) in DNA strand breaks compared to endogenous
levels, after 4 and 24 hours (Figures 5.9 – 5.10), in MCF-10A cells.
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Figure 5.9.: DNA strand breaks in MCF-10A cells after 4 hours treatment determined by comet
assay. Data obtained after treating MCF-10A cells with BNIPSpd and BNIPDaCHM (0 – 10 µM) for
4 hours. DNA damage in H2O2 (200 µM) treated cells were used as a positive control. Data are
mean ± SEM of 8 replicates; 2 independent experiment (n = 2). *P<0.05, **P<0.01, ***P<0.001 vs.
untreated (0 µM) cells.
In general, BNIPSpd (≥ 0.1 µM) induced a greater level of DNA strand breaks than
BNIPDaCHM in MCF-10A cells, after 4 hours (Figure 5.9). At a concentration of 0.1 µM,
BNIPSpd significantly increased the number of DNA strand breaks (P < 0.01, an increase
of 64.2 strand breaks), whilst no change in the number of DNA strand breaks was
observed with 0.1 µM BNIPDaCHM, compared to endogenous levels (Figure 5.9). At 1
µM, BNIPSpd significantly increased the number of DNA strand breaks (P < 0.001, an
increase of 106.9 strand breaks), but BNIPDaCHM (1 µM) did not significantly change the
number of DNA strand breaks, compared to endogenous levels (Figure 5.9). However, at
a concentration of 5 µM, both BNIPSpd and BNIPDaCHM significantly increased the
number of DNA strand breaks (P < 0.001, an increase of 144.2 strand breaks; P < 0.01,
an increase of 49.9 strand breaks, respectively), compared to endogenous levels (Figure
5.9). At 10 µM, both BNIPSpd and BNIPDaCHM also significantly increased the number
of DNA strand breaks (P < 0.001, an increase of 234.1 and 104.0 strand breaks,
respectively), compared to endogenous levels (Figure 5.9). At 200 µM, H2O2 significantly
increased the number of DNA strand breaks (P < 0.001, an increase of 260.4 strand
breaks), compared to endogenous levels (Figure 5.9).
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Figure 5.10.: DNA strand breaks in MCF-10A cells after 24 hours treatment determined by comet
assay. Data obtained after treating MCF-10A cells with BNIPSpd and BNIPDaCHM (0 – 10 µM) for
24 hours. DNA damage in H2O2 (200 µM) treated cells were used as a positive control. Data are
mean ± SEM of 8 replicates; 2 independent experiment (n = 2). *P<0.05, **P<0.01, ***P<0.001 vs.
untreated (0 µM) cells.
In general, both BNIPSpd and BNIPDaCHM were able to significantly increase
DNA strand breaks in MCF-10A cells at ≥ 0.1 µM, after 24 hours (Figure 5.10). At 0.1 µM,
both BNIPSpd and BNIPDaCHM significantly increased the number of DNA strand breaks
(P < 0.001, an increase of 57.3 strand breaks; P < 0.05, an increase of 30.9 strand
breaks), compared to endogenous levels (Figure 5.10). At 1 µM, both BNIPSpd and
BNIPDaCHM significantly increased the number of DNA strand breaks (P < 0.001, an
increase of 97.3 strand breaks; P < 0.01, an increase of 55.7 strand breaks compared to
endogenous levels (Figure 5.10), with similar findings at 5 µM BNIPSpd and BNIPDaCHM
(P < 0.001, 123.7 and 77.6 strand breaks, respectively) and 10 µM BNIPSpd and
BNIPDaCHM (P < 0.001, 167.2 and 119.8 strand breaks, respectively), when compared to
endogenous levels (Figure 5.10). At 200 µM, H2O2 significantly increased the number of
DNA strand breaks (P < 0.001, an increase of 302.1 strand breaks), compared to
endogenous levels (Figure 5.10).
MCF-10A cells were observed to be more susceptible to the action of BNIPSpd or
BNIPDaCHM with respect to DNA strand breaks than MDA-MB-231 cells (Figures 5.7 –
5.10). Lower concentrations of BNIPSpd and BNIPDaCHM (≥ 0.1 µM) induced a
significant increase in the number of DNA strand breaks (P < 0.05) in MCF-10A cells, after
4 and 24 hours (Figures 5.9 – 5.10), compared to 10 µM BNIPSpd or 1 µM BNIPDaCHM,
after 4 hours (Figure 5.7), or 0.1 µM BNIPSpd or 5 µM BNIPDaCHM, after 24 hours
(Figure 5.8) in MDA-MB-231 cells.
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5.4.3. Effect of BNIPP Derivatives on DNA Repair
Mechanisms
The ability of BNIPSpd or BNIPDaCHM to interfere with DNA repair mechanisms
was determined by Comet assay in MDA-MB-231 cells damaged with H2O2 (200 μM for 5
minutes, on ice) and MMS (1 mM for 30 minutes, at 37°C).
5.4.3.1. Repair of H2O2-Induced DNA Strand Breaks in MDA-MB-231
Cells
MDA-MB-231 cells were pre incubated in the presence or absence of non toxic
concentrations of BNIPSpd (5 and 0.05 µM) or BNIPDaCHM (0.1 and 1 µM) for 4 and 24
hours, respectively. These concentrations were chosen from the DNA strand break
studies as shown in Figures 5.7 – 5.8. Repair was measured as described in Section
5.3.7.
H2O2-induced DNA strand breaks were slowly repaired in MDA-MB-231 control
(cells incubated in the absence of either BNIPP derivative) cells. This was clearly evident,
as DNA strand breaks had decreased, and had almost returned to endogenous levels,
after 24 hours (Figures 5.11 – 5.12).
After a 4 hour pre-incubation with BNIPSpd (5 µM), MDA-MB-231 cells were
unable to effectively repair H2O2-induced DNA damage. As DNA strand breaks were
significantly different (P < 0.01) between BNIPSpd treated and untreated MDA-MB-231
cells, after 8 hours (Figure 5.11A), and although, the difference between BNIPSpd treated
and untreated MDA-MB-231 cells was not significant after 24 hours; BNIPSpd treated
cells were unable to completely repair DNA strand breaks, as endogenous levels were not
reached (i.e., the number of DNA strand breaks were 36.6 strand breaks higher than
endogenous levels) (Figure 5.11A). After a 4 hour pre-incubation with BNIPDaCHM (0.1
µM), MDA-MB-231 cells were unable to effectively repair H2O2-induced DNA damage. As,
DNA strand breaks were significantly different (P < 0.05) between BNIPDaCHM treated
and untreated MDA-MB-231 cells, after 24 hours, and DNA strand breaks had not
returned to endogenous levels (i.e., the number of DNA strand breaks were 39.4 strand
breaks higher than endogenous levels, respectively) (Figure 5.11B).
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Figure 5.11.: Repair of DNA strand breaks in MDA-MB-231 cells. Cells were pre incubated in the
presence (□) and absence (●) of non toxic concentrations of either BNIPSpd (5 µM) (A) or
BNIPDaCHM (0.1 µM) (B) for 4 hours. Cells were incubated with 200 µM H2O2 for 5 minutes on
ice, and then incubated at 37 °C for up to 24 hours. At intervals during this 24 hour incubation,
DNA strand breaks were analysed immediately (0 hour) or after 2, 4, 8 and 24 hours by Comet
assay. UT represents cells which were not incubated with H2O2 (200 µM). Data are mean ± SEM
of 8 replicates; 2 independent experiments (n = 2). *P<0.05, **P<0.01, ***P<0.001 vs. absence of
BNIPP derivative at each corresponding time point.
After a 24 hour pre-incubation with BNIPSpd (0.05 µM), MDA-MB-231 cells were
unable to effectively repair H2O2-induced DNA damage. As DNA strand breaks were
significantly different (P < 0.05) between BNIPSpd treated and untreated MDA-MB-231
cells, after 2, 4 and 24 hours, and DNA strand breaks had not returned to endogenous
levels (i.e., the number of DNA strand breaks were 29.7 strand breaks higher than
endogenous levels) (Figure 5.12A). After a 24 hour pre-incubation with BNIPDaCHM (1
µM), MDA-MB-231 cell repair mechanisms were significantly delayed (P < 0.01). As
MDA-MB-231 cells were unable to repair H2O2-induced DNA damage after 4 (P < 0.01), 8
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(P < 0.001) and 24 (P < 0.001) hours, and since DNA strand breaks were not returned to
endogenous levels (i.e., the number of DNA strand breaks were 46.3 strand breaks higher
than endogenous levels) (Figure 5.12B). Therefore, BNIPDaCHM (1 µM) was more
effective than BNIPSpd (0.05 µM) in the inhibition of MDA-MB-231 cell repair mechanisms
(Figure 5.12).
Figure 5.12.: Repair of DNA strand breaks in MDA-MB-231 cells. Cells were pre incubated in the
presence (□) and absence (●) of non toxic concentrations of either BNIPSpd (0.05 µM) (A) or
BNIPDaCHM (1 µM) (B) for 24 hours. Cells were incubated with 200 µM H2O2 for 5 minutes on
ice, and then incubated at 37 °C for up to 24 hours. At intervals during this 24 hour incubation,
DNA strand breaks were analysed immediately (0 hour) or after 2, 4, 8 and 24 hours by Comet
assay. UT represents cells which were not incubated with H2O2 (200 µM). Data are mean ± SEM
of 8 replicates; 2 independent experiment.s (n = 2) *P<0.05, **P<0.01, ***P<0.001 vs. absence of
BNIPP derivative at each corresponding time point.
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5.4.3.2. Repair of BNIPDaCHM-induced DNA Strand Breaks in MDA-MB-
231 Cells
The ability of BNIPDaCHM to induce DNA strand breaks at a higher concentration
(1 µM) after 24 hours, than at 4 hours (0.1 µM) was investigated further by Comet assay
(Figure 5.13).
0
100
200
300
400
UT 0 hr 2 hrs 4 hrs 8 hrs 24 hrs
Time (hrs)
D
N
A
St
ra
nd
B
re
ak
s
(a
.u
.)
Figure 5.13.: Repair of DNA strand breaks in MDA-MB-231 cells. Cells were pre incubated in the
presence (□) and absence (●) of BNIPDaCHM (1 µM) for 24 hours.  At intervals during this 24 hour 
incubation, DNA strand breaks were analysed immediately (0 hour) or after 2, 4, 8 and 24 hours by
Comet assay. UT represents cells which were not incubated with BNIPDaCHM. Data are mean ±
SEM of 4 replicates (n = 1).
DNA strand breaks in both untreated and BNIPDaCHM treated MDA-MB-231 cells
(1 µM) were affected in a similar manner. The number of DNA strand breaks increased
up to 8 hours, but appeared to repair between 8 and 24 hours (Figure 5.13), as DNA
strand breaks were returned to endogenous levels. However, MDA-MB-231 cells were
unable to completely repair the induced DNA strand breaks, as DNA strand breaks were
not returned to endogenous levels (Figure 5.13). Thus, at the non toxic concentration of 1
µM, BNIPDaCHM induced DNA repair, following DNA damage in MDA-MB-231 cells.
5.4.3.3. Optimisation of MMS-induced DNA Strand Breaks in MDA-MB-
231 Cells
As MMS was used to induce methylative DNA damage, its concentration was
optimised in MDA-MB-231 cells. Cells were treated with different concentrations of MMS
(0 – 5 mM) for 30 minutes at 37 °C, and DNA strand breaks assessed by Comet assay.
The diagram in Figure 5.14 presents the number of DNA strand breaks induced by
different concentrations of MMS (0 – 5 mM) after 30 minutes in MDA-MB-231 cells. MMS
(≥ 0.25 mM) induced significant DNA strand breaks (P < 0.05) compared to endogenous
levels (Figure 5.14). Therefore, 1 mM MMS was selected for the DNA repair studies
(Section 5.4.3.4).
159
0
100
200
300
400
0 1 2 3 4 5
MMS Concentration (mM)
D
N
A
St
ra
nd
B
re
ak
s
(a
.u
.)
*
**
Figure 5.14.: DNA strand breaks in MDA-MB-231 cells determined by comet assay. Data
obtained after treating MDA-MB-231 cells with MMS (0 – 5 mM) for 30 minutes, at 37°C. Data are
mean ± SEM of 2 independent experiments (n = 2). *P<0.05, **P<0.01 vs. untreated cells.
5.4.3.4. Repair of MMS-Induced DNA Strand Breaks in MDA-MB-231
Cells
The ability of BNIPDaCHM (1 µM, for 24 hours) to compromise the repair of MMS-
induced DNA strand breaks in MDA-MB-231 cells was further investigated. Both
untreated and BNIPDaCHM treated MDA-MB-231 cells were unable to effectively repair
MMS-induced DNA damage, as after 24 hours, the number of DNA strand breaks were
91.5 and 77.5 strand breaks higher than endogenous levels, respectively (Figure 5.15).
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Figure 5.15.: Repair of DNA strand breaks in MDA-MB-231 cells. Cells were pre incubated in the
presence (□) and absence (●) of non toxic concentrations of BNIPDaCHM (1 µM) for 24 hours.  
Cells were incubated with 1 mM MMS for 30 minutes at 37 °C, and then incubated at 37 °C for up
to 24 hours. At intervals during this 24 hour incubation, DNA strand breaks were analysed
immediately (0 hour) or after 2, 4, 8 and 24 hours by Comet assay. UT represents cells which were
not incubated with MMS (1 mM). Data are mean ± SEM of 4 replicates only (n = 1).
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5.5. Discussion
5.5.1. Effect of BNIPP Derivatives on DNA Strand Breaks in
MDA-MB-231 and MCF-10A Cells
Treatment with BNIPSpd and BNIPDaCHM induced DNA instability in MDA-MB-
231 (Figures 5.7 – 5.8) and MCF-10A cells (Figures 5.9 – 5.10). BNIPSpd and
BNIPDaCHM significantly induced (P < 0.05) a dose dependent increase in DNA strand
breaks above endogenous levels within both cell lines.
In MDA-MB-231 cells, BNIPDaCHM induced significant strand breaks (P < 0.001)
with ≥ 1 µM after 4 hours; whereas BNIPSpd required 24 hours to induce the same level
of strand breaks (Figures 5.7 – 5.8). These results were in agreement with the cellular
uptake studies (Section 4.4.3.1 and Figure 4.16), where BNIPDaCHM was observed
within MDA-MB-231 cells after 0.5 hours whilst BNIPSpd was not observed until 6 hours.
It is important to note that these results were also consistent with the cytotoxicity studies
(Table 4.2), where after 24 hours in MDA-MB-231 cells, BNIPDaCHM was more cytotoxic
(IC50 6.8 µM) than BNIPSpd (IC50 12.7 µM).
In contrast, BNIPSpd induced significant strand breaks (P < 0.01) in MCF-10A
cells with ≥ 0.1 µM after 4 hours, and both derivatives (at ≥ 0.1 µM) were equally as
effective in the inducement of significant strand breaks (P < 0.05) after 24 hours (Figures
5.9 – 5.10). These results are in agreement with the cytotoxicity studies (Table 4.3) in
MCF-10A cells (24 hours) where BNIPSpd was shown to be more cytotoxic (IC50 4.2 µM)
than BNIPDaCHM (IC50 6.1 µM). Although the results are in contradiction to the cellular
uptake studies (Section 4.4.3.2 and Figure 4.17), where BNIPDaCHM and BNIPSpd were
observed within MCF-10A cells after 0.5 and 6 hours, respectively, these results suggest
that DNA damage may be responsible for BNIPP toxicity.
MCF-10A treated cells were more susceptible to DNA strand breaks than MDA-
MB-231 treated cells (Figures 5.7 – 5.10). This result was similar to the findings of
Starcevic et al. (2003), where sensitivity to oxidative DNA damage induced by H2O2 (1 –
100 µM for 5 minutes) decreased with progression towards tumorigenicity (i.e., the
parental nontumorigenic MCF-10A cells were more susceptible to DNA strand breaks than
the tumorgenic MCF-10AT or MCF-10ATG3B cells1).
The DNA strand breaks observed in MDA-MB-231 and MCF-10A cells may also
be attributed to the ability of BNIPP derivatives to strongly bind to DNA via bis
intercalation (Δ Tm 35.3 and 31.2 °C, respectively) (Chapter 3, in particular Table 3.1).
Results are consistent with the findings of Roos et al. (1985), who studied intracellular
DNA damage produced by a series of diacridines. Roos et al. (1985) found that a large
1 MCF-10AT cells are T24 Ha-ras-transformed MCF-10A cells, and MCF-10ATG3B cells are a third
generation MCF-10AT descendant.
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increase in DNA strand breaks was strongly related to their increased DNA binding
affinity.
The results presented in this chapter are complementary to the work carried out by
Dance et al. (2005) and Ralton et al. (2009), who investigated the extent of DNA damage
induced by BNIPSpd, BNIPSpm and BNIPOSpm within HL60, MCF-7 CaCO-2, and HT-29
cells. Both Dance et al. (2005) and Ralton et al. (2009) found that BNIPSpd was the most
effective at inducing DNA strand breaks when compared with BNIPSpm or BNIPOSpm.
After 4 hours, the extent of DNA strand breaks induced by 100 µM BNIPSpd in MCF-7,
CaCO-2 and HT29 cells (Dance et al. 2005, Ralton et al. 2009) was in the same range as
DNA strand breaks induced by 10 µM BNIPSpd in MDA-MB-231 and MCF-10A cells (i.e.,
between 250 – 300 DNA strand breaks) (Figures 5.7 and 5.9). Therefore, BNIPSpd and
BNIPDaCHM can induce greater DNA strand breaks in MDA-MB-231 and MCF-10A cells
than BNIPSpd, BNIPSpm or BNIPOSpm could in MCF-7, CaCO-2 or HT29 cells (Dance
et al. 2005, Ralton et al. 2009). This finding may suggest that within the former cell lines,
DNA damage has a greater contribution towards BNIPP toxicity.
Only two other polyamine analogues have been investigated with regards to their
effects on DNA integrity. The spermine analogue, N1, N11-diethylnorspermine (BENSpm)
(10 µM) (Figure 1.11) and the polyamine biosynthesis inhibitor, 4-amidinoindan-1-one 2’-
amidinohydrazone (CGP 48664) (20 µM) (Figure 5.16) were found to significantly induce
DNA damage in breast cancer (MCF-7, L56Br-C1 and HCC1937) cells.
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Figure 5.16.: Structure of 4-amidinoindan-1-one 2’-amidinohydrazone (CGP 48664)
Johansson et al. (2008) found that more DNA damage was detected in L56Br-C1
treated cells than in the other breast cancer cell lines investigated. BENSpm-treated
MCF-10A cells (10 µM, for 48 hours) were found to induce less DNA damage when
compared with untreated MCF-10A cells (Johansson et al. 2008). Johansson et al.
theorised that DNA damage induced by BENSpm or CGP 48664 was related to polyamine
depletion, but not apoptosis (Johansson et al. 2008). In contrast, BNIPSpd and
BNIPDaCHM do not appear to induce DNA strand breaks as a result of polyamine
depletion (Section 4.4.5 and Figures 4.16 – 4.23).
The ability of BNIPSpd and BNIPDaCHM to induce DNA damage in MDA-MB-231
and MCF-10A cells is supported by previous qualitative studies by Brana et al. (2003,
2004a, 2004b). In their studies they showed that naphthalimide derivatives did not affect
the level of DNA damage in colon HT-29 cancer cells, whereas bisnaphthalimide
derivatives induced an increase in DNA damage in colon HT-29 cancer cells, and that
their subsequent cytotoxicities were related to their ability to induce DNA damage.
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5.5.2. Effect of BNIPP Derivatives on DNA Repair
Mechanisms in MDA-MB-231 Cells
All cells have an inherent ability to effectively remove and repair DNA damage
induced by both endogenous and exogenous DNA damaging agents. BNIPP derivatives
have been shown to induce DNA damage in MDA-MB-231 and MCF-10A cells (Figure 5.7
– 5.10), and also inhibit DNA repair mechanisms. The repair of H2O2-induced DNA
damage was investigated since H2O2 can generate SSBs and DSBs as a result of
oxidative stress, and can induce carcinogenesis (Halliwell and Aruoma 1991, Lindahl
1993).
In this study, MDA-MB-231 cells treated with BNIPSpd (5 and 0.05 µM) or
BNIPDaCHM (0.1 and 1 µM) for 4 and 24 hours were unable to effectively repair
oxidative-induced DNA damage (Figures 5.11 and 5.12). After 24 hours, the ability of
MDA-MB-231 cells to repair oxidative DNA damage was significantly inhibited (P < 0.05)
by both BNIPP derivatives at non toxic concentrations (i.e., concentrations that did not
induce significant changes in DNA strand breaks after 24 hours treatment), and at
concentrations which were 6 times less toxic than the IC50 values (12.7 µM and 6.8 µM for
BNIPSpd and BNIPDaCHM, respectively). These results are in agreement to those
obtained by Ralton (2006), where DNA repair of oxidative-induced DNA damage in CaCO-
2 cells was inhibited by non toxic concentrations of BNIPSpd, BNIPSpm and BNIPOSpm
(0.1 µM).
The repair of MMS-induced DNA damage was investigated since MMS has been
shown to induce DNA methylation which causes mispairing and DSBs, and mutagenesis
(Lundin et al. 2005). DSBs occur by conversion of guanine to 7-methylguanine or adenine
to 3-methyladenine (Lundin et al. 2005). In this study, MDA-MB-231 cells treated with
BNIPDaCHM (1 µM, for 24 hours) were unable to effectively repair MMS-induced DNA
strand breaks (Figure 5.15). The type of damage induced by MMS is considerably greater
and more dramatic than that induced by H2O2 (Lundin et al. 2005, Duthie. personal
communication). The repair results in MDA-MB-231 cells are consistent with this
observation.
It is difficult to compare the BNIPP derivative results with other anti cancer agents
since their abilities to effectively repair oxidative- or alkylation-induced DNA damage
remain to be extensively investigated.
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5.6. Conclusion
BNIPSpd and BNIPDaCHM induced DNA instability in MDA-MB-231 and MCF-
10A cells. Results show that BNIPSpd and BNIPDaCHM significantly induced a dose
dependent increase in the number of DNA strand breaks compared to endogenous levels,
after 4 and 24 hours treatment. In MDA-MB-231 cells, BNIPSpd required a longer
treatment time (24 hours) to induce the same level of strand breaks as BNIPDaCHM.
However, in MCF-10A cells, BNIPSpd was able to induce more DNA strand breaks than
BNIPDaCHM suggesting that MCF-10A cells are more sensitive to the BNIPP derivatives
in relation to DNA strand breaks than MDA-MB-231 cells. Also, MDA-MB-231 cells
treated with BNIPSpd or BNIPDaCHM were unable to effectively repair oxidative-induced
DNA damage. BNIPDaCHM, however, did not inhibit the ability of MDA-MB-231 cells to
repair alkylation-induced DNA damage.
In conclusion, the results presented thus far show that the derivatives, BNIPSpd
and BNIPDaCHM, (i) bind to DNA by bis-intercalation, (ii) are cytotoxic, (iii) can induce
significant DNA strand breaks in MDA-MB-231 and MCF-10A cells, and (iv) can retard
DNA repair of oxidative- and alkylation-induced DNA damage in MDA-MB-231 cells. The
BNIPP derivatives BNIPSpd and BNIPDaCHM were further studied in order to assess
their role in inducing cell death within MDA-MB-231 cells (Chapter 6).
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Chapter 6
Cell Cycle Studies of BNIPP Derivatives in MDA-
MB-231 Cells
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6.1. Cell Cycle Studies of BNIPP Derivatives in MDA-MB-
231 Cells
Alterations to cell proliferation and suppression of cell death are important
regulatory mechanisms that are central in cancer development (Evan and Vousden 2001).
As a result, important therapeutic strategies involve the ability of anti cancer agents to
inflict cell cycle arrest and selectively trigger cancer cell death. Many cytotoxic and DNA
damaging agents, such as doxorubicin (Aroui et al. 2009) (Figure 3.1) and etoposide
(Montecucco and Biamonti 2007) (Figure 3.3) have been shown to induce cell cycle (G1
or G2/M) arrest and apoptotic cell death (Lin et al. 2010). Therefore, it is important to
investigate the potential of BNIPP derivatives to induce cell cycle arrest and apoptotic cell
death, as a consequence of their ability to intercalate with DNA (Sections 3.4.1 and 3.4.2),
and induce significant DNA strand breaks in MDA-MB-231 cells (Section 5.4.2.1).
The aims of the experimental work reported in this chapter were to study (i) the
mode of cell death, (ii) cell cycle analysis, and (iii) p53 and p21Waf1/Cip1 mRNA levels in
MDA-MB-231 cells treated with BNIPSpd or BNIPDaCHM.
6.1.1. Induction of Apoptotic Cell Death
Apoptosis is a highly controlled process that is paramount in normal cell
development and is responsible for the removal of damaged or dysfunctional cells from a
cell population, for example, during embryonic development or cell turnover (Schultz and
Harrington 2003). Apoptotic pathways are thus complex and tightly controlled by multiple
biochemical mediators, such as the B-cell lymphoma 2 (Bcl-2) family (Gross et al. 1999,
Schultz and Harrington 2003). The characteristics of apoptosis involve cell shrinkage,
cytoplasmic and plasma membrane blebbing, chromatin condensation, DNA
fragmentation and the formation of apoptotic bodies which are removed by the process of
phagocytosis (Kerr et al 1994, Jin and El-Deiry 2005, Scovassi 2006, Burz et al 2009)
(Figure 1.3).
6.1.1.1. Assessment of Apoptosis
Apoptotic cell death in vitro can be assessed using numerous methods (Tables 6.1
and 6.2). Classic morphological detection methods involve the use of light or electron
microscopic-based techniques which are, although rather non-specific, unquantifiable and
operator specific, remain in use today due to their simplicity, rapidity and/or overall low
cost (Chamond et al. 1999, Galluzzi et al. 2009) (Table 6.1). In addition, the use of vital
dyes (i.e. can distinguish between viable and dead cells) (Salami and Karami-Tehrani
2003, Baskić et al. 2006) or exclusion dyes (i.e., cannot enter healthy cells but can enter
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cells with a compromised plasma membrane) have been incorporated into light
microscopy methods to visually distinguish between viable and dead cells in a cell
population (Galluzzi et al. 2009). Besides light microscopic-based techniques, fluorescent
microscopy can provide a method with greater experimental sensitivity due to a higher
signal-to-noise ratio (Galluzzi et al. 2009) (Table 6.1). This technique can, for example,
identify viable, apoptotic and necrotic cells via acridine orange/ethidium bromide (AO/EB)
staining (Park et al. 2004, Baskić et al. 2006), or visualise nuclear condensation by
staining with Hoechst 33258/33342 or 4’,6-diamidino-2-phenylindole (DAPI) (Salami and
Karami-Tehrani 2003, Galluzzi et al. 2007).
Table 6.1.: Methods used in the morphological identification of apoptotic cell death
Method Morphological
Detection
Distinguishes
between Apoptosis
and Necrosis
Reference
Light Microscope
- Annexin V
- TUNEL
Chromatin
condensation;
plasma membrane
disruption
Yes Salami and Karami-
Tehrani 2003
Galluzzi et al. 2009
Electron Microscope
- SEM/TEM
Subtle organelle
change (i.e., at an
ultrastructural
level)
Yes Krysko et al. 2008
Wahab et al. 2009
Fluorescence
Microscope
- AO/EB staining
- Hoechst 33342
- DAPI
- TUNEL
Discrimination
between viable,
apoptotic and
necrotic cells,
nuclear
identification and
confirmation of
DNA
fragmentation
Yes Park et al. 2004,
Baskić et al. 2006,
Galluzzi et al. 2007
Abbreviations: TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling;
SEM, scanning electron microscope; TEM, transmission electron microscope; AO/EB, acridine
orange/ethidium bromide; DAPI, 4’,6-diamidino-2-phenylindole
Biochemical detection methods are also used for the determination of apoptosis by
studying cell death on a single cell basis via flow cytometry (Galluzzi et al. 2009) (Figure
6.1). Cells stained with fluorescent dyes are injected into sheath fluid and passed through
a light source (e.g., a laser). Each cell scatters light differently, with the fluorescent dye
becoming excited to a higher energy state. Energy released can be measured
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simultaneously with the use of various parameters (or detectors, e.g., forward scattered
light (FSC; equating to cell size, distinguishing between cellular debris and viable cells),
side scattered light (SSC; equating to granular content) or fluorescence detection
channels FL-1 to -4), and results indicate the physical and chemical events
(characteristics) of each cell (Rahman et al. 2006).
Laser
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Laser
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FSC
FL-1
FL-2
FL-3
FL-4
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Output
Detector
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Filters Detectors
Fluidics system
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Lasers
Figure 6.1.: Schematic diagram of a typical flow cytometer (adapted from Rahman et al. 2006)
(FSC, Forward Scattered Light; FL-1 to -4, Fluorescent detection channels; SSC, Side Scattered
Light)
In contrast to microscopy-based (light and fluorescence) methods (Table 6.1), flow
cytometric methods rapidly produce specific, quantifiable and unbiased results with high
throughput screening available (Galluzzi et al. 2009). Flow cytometry can, for example,
quantify cells with a sub-G1 DNA content via DAPI or propidium iodide (PI) staining (Shu
et al. 1997, Wang et al. 2008); detect phosphatidylserine (PS) exposure on the outer layer
of the plasma membrane (Vermes et al. 1995, Van Engeland et al. 1996, Krysko et al.
2008) and also determine caspase activation (Belloc et al. 2000, Vermes et al. 2000,
Galluzzi et al. 2009) (Table 6.2).
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Table 6.2.: Methods used in the biochemical identification of apoptotic cell death
Method Biochemical
Detection
Distinguishes
between Apoptosis
and Necrosis
Reference
Flow Cytometry
- Annexin V
- Caspase
activation
- DAPI
- PI
- TUNEL
Determination of
early apoptosis
before DNA
fragmentation or
nuclear breakdown,
identification of
active caspases,
analysis of cell cycle
distribution and
apoptosis (i.e., sub-
G1 population),
detection of free 3’
ends in DNA
Yes Vermes et al. 1995,
Van Engeland et al.
1996, Shu et al.
1997, Belloc et al.
2000, Vermes et al.
2000, Krysko et al.
2008, Wang et al.
2008, Galluzzi et al.
2009
Abbreviations: DAPI, 4’, 6-diamidino-2-phenylindole; PI, propidium iodide; TUNEL, terminal
deoxynucleotidyl transferase-mediated dUTP nick-end labelling
Additional methods to detect apoptotic cell death include DNA agarose gel
electrophoresis with ethidium bromide staining, that can determine apoptotic,
internucleosomal DNA fragmentation to produce a ‘DNA ladder’ (200 – 5000bp DNA
fragments) whilst necrotic, non-specific DNA degradation produces a ‘smear’ of randomly
fragmented DNA (Park et al. 2004, Baskić et al. 2006), nuclear magnetic resonance
(NMR) (i.e., detection of mobile lipid domains) (Mikhailenko et al. 2005), high performance
liquid chromatography (HPLC) (i.e., the detection of cytochrome c from rat liver
mitochondria) (Crouser et al. 2003) and mass spectrometry (MS) (i.e., the identification of
proteins released by mitochondria) (Patterson et al. 2000, Galluzzi et al. 2009).
In this chapter, loss of plasma membrane integrity was detected using
fluorescence microscopy and flow cytometry techniques described below (Section
6.1.1.2a and 6.1.1.2b).
6.1.1.2. Assessment of Membrane Integrity
The plasma membrane in animal cells acts as a selectively permeable barrier that
protects the cellular contents from stress or damage induced by external sources, such as
that caused by anti cancer agents (Figure 4.2). As an animal cell does not have a cell
wall for additional protection; the plasma membrane is highly vulnerable to disruption
which can ultimately lead to cell death (McNeil and Steinhardt 1997). Hence, cell
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membrane leakage has been used in the detection of apoptotic cell death (Vermes et al.
1995, Vermes et al. 2000, Krysko et al. 2008).
6.1.1.2.a. Acridine Orange/Ethidium Bromide Staining
A common, rapid and simple method for the detection of chromatin changes
relative to plasma membrane integrity is the morphological identification of viable (early
and late) apoptotic and necrotic cells by fluorescence microscopy following AO/EB
staining (Galluzzi et al. 2009). Both AO dye and EB dye intercalate with DNA; AO
fluoresces green in viable cells, whilst EB fluoresces orange in non-viable (i.e., necrotic)
cells (Park et al. 2004). AO can stain both viable and non-viable cells as it can pass
through the plasma membrane but EB can only be taken up in cells when the plasma
membrane integrity has been compromised, thus, can only be observed in late apoptotic
or necrotic cells. Therefore, dependent on the stage of membrane integrity loss (i.e.,
apoptosis or necrosis), cells can be stained in one of 4 different ways (Table 6.3).
Table 6.3.: Classification of cell viability by AO/EB staining
Cell Viability Incorporated Dye Visual Appearance of Cells after AO/EB
Staininga
Viable AO Uniformly green with intact structure
Early Apoptosis AO Green with bright green dots in nuclei showing
chromatin condensation and nuclear
fragmentation
Late Apoptosis EB Orange with bright orange dots showing
chromatin condensation and nuclear
fragmentation
Necrosis EB Uniformly orange with intact structure
a Ralton (2006) and Cao et al. (2009).
6.1.1.2.b. Annexin V-FITC/7-AAD Staining
The simple, rapid and powerful biochemical method in the detection of exposed
PS residues on the outer layer of the plasma membrane can identify between apoptotic
and necrotic cells. In normal cells, PS is located in the inner layer of the plasma
membrane, but during apoptotic cell death, PS is externalised to the outer layer of the
plasma membrane (e.g., by a ‘flip-flop’ action; an inward movement of PS refers to flip,
whilst an external movement of PS refers to flop), as its presence is required for removal
of apoptotic cells by phagocytosis (Krysko et al. 2008) (Figure 6.2).
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Figure 6.2.: Schematic representation of the annexin V-FITC assay (adapted from American Basic
Gene Associate Bioscience Inc. 2006)
As PS movement has been identified as an early marker in apoptotic cell death
(Van Engeland et al. 1996, Vermes et al. 2000, Krysko et al. 2008) detection can be
achieved through flow cytometry, following staining with an annexin V conjugate labelled
with fluorescein isothiocyanate (annexin V-FITC), in conjunction with an 7-amino-
actinomycin D (7-AAD) viability dye. Annexin V is a Ca2+-dependent phospholipid-binding
protein that can bind reversibly to PS, with high affinity (Van Engeland et al. 1996), whilst
7-AAD is fluorescent DNA-binding agent that binds specifically between the guanine and
cytosine bases (Gaforio et al. 2002). Thus, annexin V-FITC stains apoptotic cells before
morphological changes have occurred (Van Engeland et al. 1996), whereas 7-AAD labels
cells where plasma membrane integrity has been lost thus necrotic cells.
6.1.2.Cell Cycle Distribution
The regulation of the cell cycle is a highly controlled process that involves the
duplication of cell contents and is important in cell division (Deep and Agarwal 2008,
Meeran and Katiyar 2008). Alterations to, and/or arrest of cell cycle progression at any
phase can result in uncontrolled cell growth, hence, the development of cancer (Deep and
Agarwal 2008).
Cell cycle progression involves four phases: Gap phase 1 (G1); DNA synthesis
(S); Gap phase 2 (G2) collectively known as interphase, and Mitosis (M) (Figure 6.3).
During the gap (G1 and G2) phases, cells are prepared for DNA synthesis and mitosis,
respectively. DNA synthesis (i.e., replication of DNA) and mitosis (i.e., separation of the
chromosomes and division of the cell achieved via the key stages of prophase,
metaphase, anaphase and telophase) occur during the S and M phases, respectively
(Griffiths et al. 2008, Meeran and Katiyar 2008) (Figure 6.3). Also during cell division and
development, cells may exit the cell cycle and enter a non-dividing, quiescent phase (G0)
before returning to the G1 phase (Park and Lee 2003, Swanton 2004) (Figure 6.3). The
cell cycle is tightly regulated by cyclin/cyclin dependent kinase complexes (CDKs), and
multiple cell cycle “checkpoints” (Pietenpol and Stewart 2002, Meeran and Katiyar 2008).
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Figure 6.3.: Schematic representation of the cell cycle [Abbreviations: Go, quiescent phase; G1
phase, Gap phase 1; S phase, DNA synthesis; G2 phase, Gap phase 2; M phase, Mitosis]
Cell cycle checkpoints allow (i) repair of cell damage; (ii) depletion of exogenous
cell stress and/or (iii) the supply of growth factors including hormones and nutrients
(Pietenpol and Stewart 2002). If DNA repair cannot be achieved then apoptotic cell death
will be induced. Therefore, defects in cell cycle checkpoints can lead to permanent DNA
damage, thus the development of cancer (Meeran and Katiyar 2008).
Briefly, CDKs are activated when bound to regulatory proteins (cyclins), thus
forming heterodimeric complexes that control progression from one phase to the next via
cell cycle checkpoints (i.e., at G1/S phase and G2/M phase) (Swanton 2004, Deep and
Agarwal 2008, Meeran and Katiyar 2008). For example, the cyclin D family (D1, D2 and
D3; bind and activate CDK4 and CDK6), and the cyclin E family (E1 and E2; interact and
activate CDK2) are responsible for cell progression through the restriction point from G1
to S phase by phosphorylation of the retinoblastoma protein (Rb) (Swanton 2004, Deep
and Agarwal 2008). Hence, cyclin/CDK complexes play a key role in the positive
regulation and coordination of numerous cell cycle checkpoints.
Furthermore, CDK activity can be negatively regulated by CDK inhibitors (CDKIs)
which induce cell cycle arrest in response to cell cycle checkpoint signals, in particular,
the CDK-interacting protein/kinase-inhibitor protein (Cip/Kip) family: p21Waf1/Cip1, p27Kip1
and p57Kip2 (Park and Lee 2003). P21Waf1/Cip1 has a prominent role in cell growth arrest via
DNA damage and has been identified as an important downstream effector of the tumour
suppressor gene p53 (Park and Lee 2003, Ocker and Schneider-Stock 2007). Alongside
p21Waf1/Cip1, p53 gene has been implicated as an essential component in cell cycle arrest
and apoptotic cell death (Figure 6.4) but in a majority of cancers, the p53 gene is mutated,
for example, in the case of breast cancer MDA-MB-231 cells (Koutsilieris et al. 1999,
 p21Waf1/Cip1 known as a CDK inhibitor 1A (CDK-N1A), alternatively known as a CDK-interacting
protein 1 (Cip1) or wild-type p53-activated fragment 1 (Waf1) (Ocker and Schneider-Stock 2007).
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Pietenpol and Stewart 2002, Belkacemi et al. 2006). For example, DNA damage can
activate cell cycle arrest and apoptosis via p53-dependent apoptosis or p53-dependent
activation of p21Waf1/Cip1, thus protecting cells from apoptotic cell death (Gasco et al. 2002,
Park et al. 2008). Although p21Waf1/Cip1 has also been implicated in apoptotic cell death as
it possesses proapoptotic functions under certain conditions (Gartel and Tyner 2002,
Ghanem and Steinman 2005) yet these mechanisms are not fully understood. Thus
targeting p21Waf1/Cip1 may have therapeutic benefits and, as a consequence, several small
molecules have recently been identified to interact with p21Waf1/Cip1 (Park et al. 2008,
Ljungman 2009).
DNA Damage
p53
p21Apoptosis Cell Cycle
Arrest
1
2
Figure 6.4.: Simplistic scheme for p53-dependent apoptosis. DNA damage can activate two
pathways: 1, p53-dependent apoptosis and 2, p53-dependent activation of p21Waf1/Cip1 that can
protect cells from apoptosis (adapted from Gartel and Tyner 2002).
6.1.2.1. Assessment of Cell Cycle Distribution
In this study, cell cycle distribution was detected using flow cytometry following PI
staining. PI is a DNA intercalator that can bind to DNA specifically following the loss of
plasma membrane integrity (Bertho et al. 2000). The amount of PI is proportional to DNA
content and thus indicates the distribution of cells within the cell cycle (Cancer Research
UK 2008) (Figure 6.5). Cells in the G1 phase have a DNA content of 2n (i.e., diploid), the
DNA content of cells in S phase doubles from 2n to 4n and remains at 4n during the G2
phase (Figure 6.5). At M phase DNA content rapidly returns to 2n with the formation of
two daughter nuclei. In addition, cells that have DNA content of < 2n represent apoptotic
cells with a low DNA content (i.e., a sub-G1 cell population).
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Figure 6.5.: DNA distribution at each phase of the cell cycle [Abbreviations: G1, Gap phase 1; S,
DNA synthesis; G2, Gap phase 2; M, Mitosis]
6.1.2.2. Assessment of p53 and p21Waf1/Cip1 Gene Expression
P53 and p21Waf1/Cip1 messenger ribonucleic acid (mRNA) levels were detected
using reverse transcription polymerase chain reaction (RT-PCR). RT-PCR provides a
sensitive method to quantify expression of individual genes (Freeman et al. 1999, Felton
et al. 2004). Briefly, RT produces a single-stranded copy of complementary DNA (cDNA)
from the isolated RNA, via the action of the retroviral enzyme, reverse transcriptase
(Freeman et al. 1999). The cDNA is then amplified by PCR. PCR is traditionally a three
step reaction, involving denaturation (i.e., of cDNA template), annealing (i.e., binding of
primers to template) and elongation (i.e., extension from primers using Taq polymerase to
produce complementary strands) (Dale and Von Schantz 2002).
2n
4n
G1 S G2 M G1
DNA Content
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6.2. Materials
6.2.1. Materials
All reagents were purchased from Fisher Scientific, UK unless otherwise stated,
and were used without purification.
Acridine Orange Sigma-Aldrich, UK
Bovine Serum Albumin New England Biolabs Inc, UK
Citric Acid Sigma-Aldrich, UK
Chloroform Sigma-Aldrich, UK
Coulter Clenz™ Cleaning Agent Beckman Coulter, France
Ethylenediaminetetraacetic Acid Sigma-Aldrich, UK
DEPC-Treated Water Ambion Inc, UK
Deoxynucleotide Triphosphates Promega, USA
Ethidium Bromide Sigma-Aldrich, UK
Formaldehyde Sigma-Aldrich, UK
IsoFlow™ Sheath Fluid Beckman Coulter, France
Isopropanol BDH Chemicals Inc, UK
Propidium Iodide Sigma-Aldrich, UK
Random Primers Promega, USA
Ribonuclease A Sigma-Aldrich, UK
RNaseOUT Invitrogen, UK
Sodium dihydrogen orthophosphate BDH Chemicals Inc, UK
Superscript™ III Reverse Transcriptase Invitrogen, UK
Taq DNA Polymerase Sigma-Aldrich, UK
TRIzol Invitrogen, UK
100bp Ladder Promega, USA
The Annexin V-FITC/7-AAD kit (PN IM3614) was purchased from Beckman
Coulter (France). The Superscript™ III RT product (Invitrogen) contains SuperScript™ III
RT, 5x first strand buffer and dithiothreitol (DTT). The Taq DNA Polymerase product
(Sigma-Aldrich) contains Taq DNA polymerase, PCR buffer and magnesium chloride
(MgCl2) solution, whilst the 100bp ladder product (Promega) contains a 100bp ladder and
loading dye. p53, p21Waf1/Cip1 and β-actin primers (i.e., forward and reverse) were supplied
by Invitrogen, UK.
6.2.2. Instrumentation
Aseptic cell culture techniques were undertaken as described in Section 4.2.2.
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Acridine orange/ethidium bromide (AO/EB) stained MDA-MB-231 cells were
visualised using a Leica DMIL inverted fluorescence microscope (Leica Microsystems,
UK) with a UV filter (excitation bandpass (blue); 450 – 490 nm, emission longpass
(yellow); 515 nm) and Leica DC200 camera (Leica Microsystems, UK).
Flow cytometric analysis of MDA-MB-231 cells stained with reagents from the
Annexin V-FITC/7-AAD kit or propidium iodide were analysed on an Coulter Epics XL-
MCL flow cytometer (Beckman Coulter, UK) using EXPO32 ADC XL 4 color and EXPO32
ADC analysis software (Beckman Coulter, UK). For apoptosis analysis, 10,000 single
events were recorded and analysed using the FL-1 channel for annexin V-FITC detection
and the FL-4 channel for detection of 7-AAD fluorescence. The percentage of apoptotic
and necrotic cells were calculated from histograms of LOG FL-1 (525 nm) and LOG FL-4
(675 nm) plots, respectively. For cell cycle analysis, 10,000 single events were recorded.
The percentage of cells with DNA content of sub-G1 and in cell cycles phases (G1, S and
G2/M) were calculated from histograms of linear FL-2 plots (575 nm) in the ungated
region.
MDA-MB-231 cells were counted using an improved Neubauer Haemocytometer
(Assistent, Germany) and a Leica DMIL microscope (Leica Microsystems, UK) for loss of
cell number experiments.
Total RNA was quantified using a Heλios γ UV spectrophotometer (Thermo 
Spectronic, USA). Samples for RT-PCR were prepared within a Microflow Laminar Flow
Cabinet (MHD Limited, UK), and all plastics were RNase free; eppendorf tubes and tips
were Molecular BioProducts and Maxymum Recovery™ products, respectively (Thermo
Fisher Scientific, UK). RT-PCR was conducted in an iCycler Thermal Cycler (Bio-Rad
Laboratories, USA), and for gel electrophoresis analysis a Bio-Rad Wide Mini-Sub Cell gel
electrophoresis tank with PowerPac Basic power pack (Bio-Rad Laboratories, USA) was
used. Bands were visualised with a ChemiDoc EQ system (Bio-Rad Laboratories, USA)
and quantified using Quantity One (Version 4.5.0) software (Bio-Rad Laboratories, USA).
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6.3. Methods
6.3.1. Maintenance of Cells
Exponentially growing MDA-MB-231 cells were sub cultured and counted, as
described in Sections 4.2.2 and 4.3.1. The individual experimental conditions for each
method are described in subsequent sections (Sections 6.3.3 – 6.3.7).
6.3.2. Preparation of BNIPP Derivatives
The BNIPP derivatives: BNIPSpd and BNIPDaCHM were synthesised as
previously described in Section 2.3. BNIPSpd and BNIPDaCHM were diluted from stock
solutions (10 mM) to the desired concentrations of 1, 5 and 10 µM, as described in
Section 4.3.2.
6.3.3. Acridine Orange/Ethidium Bromide Staining
MDA-MB-231 cells (8 x 104 cells/mL) were treated with BNIPSpd or BNIPDaCHM
(1, 5 and 10 µM; 0.5 – 24 hours at 37°C), or etoposide (10 µM; 24 hours at 37°C) within
24 well plates. After the desired incubation time (0.5, 1, 2, 4, 6 or 24 hours), medium
containing BNIPSpd or BNIPDaCHM and non-adherent cells was removed, and adherent
cells washed twice with PBS. 40 µL of acridine orange/ethidium bromide (100 µg/mL
each in PBS) was added to 1 mL PBS and incubated with adherent cells for 2 minutes at
room temperature. The AO/EB solution was removed, cells washed twice with PBS and 1
mL PBS added. AO/EB stained cells were visualised by fluorescence microscopy, as
described in Section 6.2.2.
6.3.4. Annexin V-FITC / 7-AAD Staining
MDA-MB-231 cells (4 x 105 cells) were treated with BNIPSpd or BNIPDaCHM (1
and 5 µM) for 0.5 – 6 hours at 37°C within 6 well plates. After the desired incubation time
(0.5, 4 or 6 hours), medium containing BNIPSpd or BNIPDaCHM was removed and
discarded. Adherent cells were washed twice with ice-cold PBS. Cells were collected as
described in Section 4.3.1 and centrifuged at 2,250 rpm (ALC Multispeed Refrigerated
Centrifuge, Thomson Scientific, UK) for 5 minutes at 4°C. The supernatant was
discarded, pellet resupended in 100 µL of ice-cold Binding Buffer (1x in dH2O), 10 µL
Annexin V-FITC solution, 20 µL 7-AAD viability dye, mixed gently and incubated on ice for
15 minutes in the dark. After 15 minutes, 400 µL of ice-cold Binding Buffer (1x in dH2O)
was added and mixed gently. Annexin V-FITC and 7-AAD stained cell preparations were
analysed within 30 minutes by flow cytometry as described in Section 6.2.2.
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Formaldehyde (3%) was used as an experimental control due to its ability to
induce maximal apoptotic cell death after 30 minutes, and was used to configure the gate
settings for subsequent flow cytometry experiments. Briefly, MDA-MB-231 cells were
treated with 500 µL formaldehyde for 30 minutes on ice and centrifuged at 2250 rpm (ALC
Multispeed Refrigerated Centrifuge, Thomson Scientific, UK) for 5 minutes at 4°C. The
supernatant was removed and from this point on, cells were treated in the same manner
as samples treated with BNIPSpd and BNIPDaCHM (refer above in Section 6.3.4).
6.3.5. MDA-MB-231 Cell Number
MDA-MB-231 cells (8 x 104 cells/mL) were treated with BNIPDaCHM (1, 5 and 10
µM; 0.5 – 24 hours at 37°C) or etoposide (10 µM; 24 hours at 37°C) within 24 well plates.
After the desired incubations (0.5, 4, 6 or 24 hours), cells were collected and counted as
previously described (Section 4.3.1 and 6.2.2).
6.3.6. Cell Cycle Analysis
MDA-MB-231 cells (1 x 106 cells) were treated with BNIPSpd or BNIPDaCHM (5
µM), or etoposide (10 µM) for 24 hours at 37°C within 25 cm2 culture flasks. After 24
hours, BNIPSpd, BNIPDaCHM or etoposide solutions were removed and collected. Cells
were washed twice with PBS (2 mL) and washes collected. Cells were removed from
culture flasks as described in Section 4.3.1, combined to the collected washes, and
centrifuged at 2,500 rpm (ALC Multispeed Refrigerated Centrifuge, Thomson Scientific,
UK) for 5 minutes at 4 °C. The supernatant was discarded, pellet resuspended in 1 mL
PBS and transferred to an Eppendorf tube. Cells were centrifuged again at 2,500 rpm for
5 minutes at 4 °C, the supernatant discarded and the pellet resuspended in 100 µL PBS.
70% (v/v) ice-cold ethanol (900 µL) was added and incubated for 2 hours at -20°C. Cells
were then centrifuged 5,000 rpm for 5 minutes at 4 °C, the pellet was resuspended in 1
mL PBS followed by re-centrifugation at 5,000 rpm for 5 minutes at 4 °C. The pellet was
resuspended in 500 µL PBS and 500 µL DNA extraction buffer (0.2 M Na2HPO4, 4 mM
citric acid, pH 7.8), and incubated for 5 minutes at room temperature. The extract was
centrifuged at 5,000 rpm for 5 minutes at 4 °C, the supernatant removed, the pellet
resuspended in 500 µL of DNA staining solution (0.2 mg/mL Ribonuclease A (DNAse-free)
and 20 µg/mL propidium iodide (PI) in PBS) and incubated for 30 minutes at 4 °C in the
dark. PI stained nuclei were analysed by flow cytometry as described in Section 6.2.2.
6.3.7. RNA Extraction from MDA-MB-231 Cells
MDA-MB-231 cells (1 x 106 cells) were treated with BNIPDaCHM (5 µM; 1 – 24
hours at 37 °C) within 25 cm2 culture flasks. After the desired incubations (1, 4 or 6
hours), cells were washed twice with PBS and total RNA extracted using TRIzol reagent
178
according to manufacturer’s instructions. Briefly, 1 mL TRIzol was added to cells and
incubated for 3 minutes at room temperature. The cell lysate was transferred to an
RNase free Eppendorf tube and incubated for 5 minutes at RT. Chloroform (200 µL) was
quickly added, the tube was shaken by hand for 15 seconds, incubated for 3 minutes at
room temperature, and then centrifuged at 13,000 rpm for 5 minutes at 4°C. The
colourless aqueous layer containing RNA was removed and transferred to a fresh RNase
free Eppendorf tube. Isopropanol (500 µL) was added to the aqueous layer, mixed gently
and incubated for 10 minutes at room tempertaure. Samples were then centrifuged at
13,000 rpm for 10 minutes at 4 °C. The supernatant was removed, RNA pellet washed
with 500 µL 75% ethanol/DEPC-Treated water (DEPCH2O), mixed and centrifuged at 8,000
rpm for 5 minutes at 4 °C. The supernatant was removed and the RNA pellet air dried for
5 – 10 minutes. The RNA pellet was stored in DEPCH2O (15 – 20 µL) and incubated for 2
hours at -20 °C.
6.3.7.1. RNA Quantification
Total RNA purity and concentration were quantified by UV spectrophotometry
(Section 6.2.2). RNA samples were heated for 5 minutes at 65 °C for complete
dissolution then incubated for 5 minutes on ice prior to spectrophotometric measurements.
Samples were diluted (1:200 in DEPCH2O), mixed and the optical density (OD) read at 260
nm and 280 nm. The OD260 and OD280 readings correlate with RNA and protein
concentrations, respectively. RNA purity was calculated by a ratio of readings taken at
260 nm and 280 nm wavelengths (i.e., OD260:OD280). Total RNA concentration (RNACONC)
was determined by the following equation:
RNACONC (µg/µL) = OD260 x 40 x Dilution Factor / 1000
6.3.8. RT-PCR Analysis
6.3.8.1. Reverse Transcriptase
Reverse transcription (RT) was performed using 100 ng (1 μL) of total RNA. First
strand synthesis of complementary DNA (cDNA) was carried out with 5x first strand buffer,
DTT (100 mM), deoxynucleotide triphosphate (dNTP’s (dATP, dCTP, dGTP and dTTP);
10 mM), recombinant ribonuclease inhibitor RNaseOUT™, bovine serum albumin (BSA; 1
mg/mL), random hexadeoxynucleotides (250 ng/μL) and Superscript™ III RT in a 20 μL
RT reaction mixture. RT reaction conditions were 10 minutes at 25 °C, 52 minutes at 42
°C and 15 minutes at 72 °C.
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6.3.8.2. Polymerase Chain Reaction
A 3 μL aliquot of the RT reaction mixture was subsequently used for polymerase
chain reaction (PCR). PCR was carried out with the gene specific primers (p53 and
p21Waf1/Cip1) and β-actin as an internal control (Table 6.4). The expected amplicon size for
the DNA fragments were 205bp for p53, 130bp for p21Waf1/Cip1 and 250bp for β-actin. PCR
was carried out with 1 x PCR buffer, MgCl2 (25 mM), forward primer (10 μM), reverse
primer (10 μM) and Taq DNA polymerase in a 15 μL reaction mixture. PCR reaction
conditions were started with a ‘hot-start’ of 4 minutes at 94 °C, 25 cycles of 1 minute
denaturation at 94 °C, annealing for 2 minutes at 59 °C (2 minutes at 68 °C for β-actin), 2
minutes extension at 72 °C and 1 cycle of 8 minutes at 72 °C.
Table 6.4.: Forward and reverse primer sequences
Primer Forward Primer Sequence
(5’ – 3’)
Reverse Primer Sequence
(5’ – 3’)
p53 cca ggg cag cta cgg ttt c ctc cgt cat gtg ctg tga ctg
p21Waf1/Cip1 cct gtc act gtc ttg tac cct gcg ttt gga gtg gta gaa atc t
β-actin cat gta cgt tgc tat cca ggc ctc ctt aat gtc acg cac gat
6.3.9. Agarose Gel Electrophoresis
Amplified PCR products were separated on a 1.5% (w/v) agarose gel in 1x TRIS-
borate ethylenediaminetetraacetic acid (EDTA) buffer and stained with ethidium bromide
(10 mg/mL). PCR products (10 μL) were loaded into the gel with 2 μL 6x loading dye. A
100bp DNA ladder (7.5 μL) was added with 1.5 μL 6x loading dye as a reference
indicator. The PCR products were ran for 25 minutes at 80V, visualised, and quantified
using software as described in Section 6.2.2.
6.3.10. Optimisation of PCR Primers by Amplification Number
PCR conditions were optimised by varying the number of PCR amplification cycles
in order to be in the linear phase of the PCR reaction. Several different PCR amplification
cycles (i.e., 25, 28 and 30) were investigated (Figure 6.4.5), and RT-PCR was carried out
as described in Sections 6.3.8.1 and 6.3.8.2. 25 cycles were selected as the optimum
number of amplification cycles and used in subsequent PCR experiments (Figure 6.6).
180
Wells
Wells
500 bp
500 bp
p21 at 59°C p53 at 59°C
Β-actin at 68°C
L L
LL
x 25 x 28 x 30 H2O
H2O
x 25 x 28 x 30
x 25 x 28 x 30
500 bp
500 bp
Figure 6.6.: Optimisation of amplification cycle number. Optimisation of p21Waf1/Cip1, p53 and β-
actin expression was carried out in MDA-MB-231 cells after 24 hours [PCR conditions described in
Section 6.3.8.2]. Image is representative of one of 2 optimisation experiments. L denotes the
position of 100bp ladder.
6.3.11. Data Analysis
Unless otherwise stated, each data set contained a minimum of three independent
experiments, in which, each experiment was comprised of at least three internal replicates
expressed as mean ± Standard Error of the Mean (SEM). Statistical analysis was
conducted using an unpaired student’s t-test. Data were considered significantly different
when P-value < 0.05.
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6.4. Results
6.4.1. Membrane Integrity of BNIPP Derivative Treated MDA-
MB-231 Cells
The effect of BNIPSpd (1 - 5 µM; 0.5 – 24 hours; Figure 6.7), BNIPDaCHM (1 - 5
µM; 0.5 – 24 hours; Figure 6.8) and the positive control etoposide (10 µM; 24 hours;
Figure 6.9) on chromatin changes in MDA-MB-231 cells relative to membrane integrity
was determined by fluorescence microscopy following AO/EB staining. AO fluoresces
green in viable cells with intact membranes, whilst EB fluoresces orange in non-viable
(i.e., necrotic) cells (refer to Section 6.1.1.2.a and Table 6.3).
Figure 6.7.: Changes in cell morphology in adherent MDA-MB-231 cells treated with 1 – 5 µM
BNIPSpd for 0.5, 6 and 24 hours. Cells were visualised using a Leica DMIL inverted fluorescence
microscope using a UV filter (excitation bandpass (blue); 450 - 490 nm, emission longpass
(yellow); 515 nm. Images are representative of 3 independent experiments undertaken in triplicate
(n = 3). Key: viable cells, white arrow; early apoptotic cells, yellow arrow; late apoptotic cells, red
arrow. Magnification x 200.
After 0.5 hours treatment, MDA-MB-231 membrane integrity was compromised by
1 and 5 μM BNIPSpd with the presence of early and late apoptotic cells compared to
untreated cells (Figure 6.7). However, it was apparent that not all MDA-MB-231 cells had
been compromised after 0.5 hours as viable cells were still evident within the treated
MDA-MB-231 cell population (Figure 6.7). After 6 hours treatment, late apoptotic cells
were evident in 1 and 5 μM BNIPSpd treated MDA-MB-231 cells, in comparison to
Untreated 1 µM BNIPSpd 5 µM BNIPSpd
0.5 hours
24 hours
6 hours
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untreated cells (Figure 6.7). After 24 hours, MDA-MB-231 cells treated with 1 and 5 μM
BNIPSpd confirmed the presence of apoptotic cells, in comparison to untreated cells
(Figure 6.7). However, early and late apoptotic cells were also present in untreated cells.
Figure 6.8.: Changes in cell morphology in adherent MDA-MB-231 cells treated with 1 – 5 µM
BNIPDaCHM for 0.5, 6 and 24 hours. Cells were visualised using a Leica DMIL inverted
fluorescence microscope using a UV filter (excitation bandpass (blue); 450 - 490 nm, emission
longpass (yellow); 515 nm. Images are representative of 3 independent experiments undertaken in
triplicate (n = 3). Key: viable cells, white arrow; early apoptotic cells, yellow arrow; late apoptotic
cells, red arrow. Magnification x 200.
Membrane integrity was compromised by ≥ 1 μM BNIPDaCHM (Figure 6.8). After
0.5 hours, MDA-MB-231 cells treated with 1 and 5 μM BNIPDaCHM produced early
apoptotic cells in a dose dependent manner compared with untreated cells (Figure 6.8).
After 6 hours, late apoptotic cells were evident in 1 and 5 μM BNIPDaCHM treated MDA-
MB-231 cells, in comparison to untreated cells (Figure 6.8). However, viable and early
apoptotic cells were present in both untreated, and BNIPDaCHM treated MDA-MB-231
cells after 6 hours treatment (Figure 6.8). After 24 hours, viable, early and late apoptotic
cells were evident in untreated and treated (1 and 5 μM) MDA-MB-231 cells (Figure 6.8).
Treatment with 5 μM BNIPDaCHM (0.5 – 24 hours) was extremely toxic to MDA-MB-231
cells with the visible loss of cell number compared with untreated cells (Figure 6.8).
The results presented in Figure 6.9 demonstrate that a higher loss of membrane
integrity (i.e., late apoptotic cells) was observed in etoposide (10 μM) rather than BNIPP
derivative (5 μM) treated MDA-MB-231 cells after 24 hours (Figure 6.9). However, MDA-
Untreated 1 µM BNIPDaCHM 5 µM BNIPDaCHM
0.5 hours
24 hours
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MB-231 cells treated with BNIPSpd or BNIPDaCHM (5 µM) were found to exhibit a greater
level of cell shrinkage than etoposide (10 μM) treated MDA-MB-231 cells (Figure 6.9).
Figure 6.9.: Changes in cell morphology in adherent MDA-MB-231 cells treated with 5 µM
BNIPSpd, 5 µM BNIPDaCHM or 10 µM etoposide for 24 hours. Cells were visualised using a Leica
DMIL inverted fluorescence microscope using a UV filter (excitation bandpass (blue); 450 - 490 nm,
emission longpass (yellow); 515 nm. Images are representative of 3 independent experiments
undertaken in triplicate (n = 3). Key: viable cells, white arrow; early apoptotic cells, yellow arrow;
late apoptotic cells, red arrow. Magnification x 200.
5 µM BNIPSpdUntreated
10 µM Etoposide5 µM BNIPDaCHM
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6.4.2. Phosphatidylserine Exposure and Membrane Integrity
in MDA-MB-231 Cells Treated with BNIPP Derivatives
The effects of BNIPSpd or BNIPDaCHM (1 – 5 µM; 0.5, 4 and 6 hours) on PS
exposure and plasma membrane integrity in adherent MDA-MB-231 cells were quantified
using flow cytometry following annexin V-FITC staining and 7-AAD labelling (Figure 6.10 –
6.13). The diagram in Figure 6.10 presents the apoptotic and necrotic histograms
obtained after 0.5 hours treatment with DMSO (0.025%), BNIPDaCHM (5 µM) or
formaldehyde (3% v/v) in MDA-MB-231 cells.
A
B
1 2
3 4
1 2
3 4
Figure 6.10.: Apoptotic (A) and necrotic (B) distribution of MDA-MB-231 cells (A1-4 and B1-4).
MDA-MB-231 cells (untreated; 1) were treated for 0.5 hours with DMSO (2), 5 µM BNIPDaCHM (3)
and 3% (v/v) formaldehyde (4) and stained with annexin V-FITC/7-AAD before flow cytometric
analysis (10,000 events were recorded). Line markers indicate the gates used to detect apoptotic
(annexin V-FITC stained cells) and necrotic (7-AAD labelling) cells. Images are representative of
one of three independent experiments and were obtained using EXPO32 ADC analysis software.
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The results for PS exposure relative to increased damage of the plasma
membrane, as shown as a ratio to the control (i.e., untreated MDA-MB-231 cells), since
barely any apoptotic or necrotic cells were present in the control cells after cells were
detached by trypsinisation using Trypsin-EDTA (1x in PBS) solution (refer to Section
4.3.1). Annexin V-FITC stains apoptotic cells as it specifically binds to exposed PS
residues on the outer layer of the plasma membrane, whilst 7-AAD viability dye can only
label cells where the plasma membrane integrity has been lost. Thus, 7-AAD uptake can
occur in only necrotic cells (refer to Section 6.1.1.2.b).
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Figure 6.11.: PS exposure and membrane integrity profiles. Profiles were determined by flow
cytometry following annexin V-FITC staining and 7-AAD labelling after 0.5 hours treatment with
BNIPSpd or BNIPDaCHM (5 µM). 10,000 single events were recorded, and cells labelled with
annexin V but not 7-AAD were annexin positive. Cells labelled with 7-AAD denoted as 7-AAD
positive. Data are presented as a ratio to the untreated cells and represent mean ± SEM of 3
independent experiments conducted in duplicate (n = 3). **P<0.01, ***P<0.001 compared with
untreated MDA-MB-231 control.
After 0.5 hours, no significant difference in annexin V-FITC staining or 7-AAD
labelling was observed following DMSO (0.025%) treatment when compared to the control
(Figure 6.11). Interestingly, BNIPSpd and BNIPDaCHM (5 µM) both significantly
increased annexin V-FITC staining (P < 0.01; a 15% increase and P < 0.001; a 30%
increase, respectively) and 7-AAD labelling (P < 0.001; a 30% increase and P < 0.001; a
42% increase, respectively) when compared to the control (Figure 6.11). Plasma
membrane integrity was thus compromised following treatment with BNIPSpd or
BNIPDaCHM (5 µM; 0.5 hours) as a higher proportion of MDA-MB-231 cells were labelled
with 7-AAD rather than annexin V-FITC.
**
***
***
***0.5 hours
186
0
0.5
1
1.5
Control 0.025% DMSO 1 µM BNIPSpd 5 µM BNIPSpd 1 µM
BNIPDaCHM
5 µM
BNIPDaCHM
R
at
io
(tr
ea
te
d/
un
tr
ea
te
d
ce
lls
) Annexin positive
7-AAD positive
Figure 6.12.: PS exposure and membrane integrity profiles. Preliminary profiles were determined
by flow cytometry following annexin V-FITC staining and 7-AAD labelling after 4 hours treatment
with BNIPSpd or BNIPDaCHM (1 and 5 µM). 10,000 single events were recorded, and cells
labelled with annexin V but not 7-AAD were annexin positive. Cells labelled with 7-AAD were
denoted as 7-AAD positive. Data are presented as ratio to the untreated cells and represent mean
± SD of 2 independent experiments conducted in triplicate (n = 2).
Results from two experiments for PS exposure and membrane integrity in MDA-
MB-231 cells treated with BNIPSpd or BNIPDaCHM (1 – 5 µM) were obtained after 4
(Figure 6.12) and 6 hours (Figure 6.13). After 4 hours, DMSO (0.025%) treatment
produced no difference in annexin V-FITC staining but an increase in 7-AAD labelling was
evident when compared to the control (Figure 6.12). MDA-MB-231 cells treated with 1 – 5
μM BNIPSpd showed a similar trend with an increase in annexin V-FITC staining and a
decrease in 7-AAD staining compared to the control, thus indicating a higher proportion of
MDA-MB-231 cells without plasma membrane damage (Figure 6.12). However, treatment
with BNIPDaCHM (1 – 5 µM) resulted in an increase in both annexin V-FITC staining and
7-AAD labelling relative to the control indicating a loss of plasma membrane integrity
(Figure 6.12).
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Figure 6.13.: PS exposure and membrane integrity profiles. Preliminary profiles were determined
by flow cytometry following annexin V-FITC staining and 7-AAD labelling after 6 hours treatment
with BNIPSpd or BNIPDaCHM (1 and 5 µM). 10,000 single events were recorded, and cells
labelled with annexin V but not 7-AAD were annexin positive. Cells labelled with 7-AAD were
denoted as 7-AAD positive. Data are presented as ratio to the untreated cells and represent mean
± SD of 2 independent experiments conducted in triplicate (n = 2).
After 6 hours, DMSO (0.025%) treatment produced an increase in both annexin V-
FITC staining and 7-AAD labelling relative to the control (Figure 6.13). Following
BNIPSpd (1 µM) treatment, annexin V-FITC staining mirrored that of the control whilst 7-
AAD labelling increased relative to the control (Figure 6.13). BNIPSpd (5 µM) treatment
resulted in a decrease in both annexin V-FITC staining and 7-AAD labelling relative to the
control (Figure 6.13). A similar trend was found after treatment with 1 BNIPDaCHM and 5
µM BNIPDaCHM as annexin V-FITC staining and 7-AAD labelling were decreased and
increased, respectively indicating a loss of plasma membrane integrity (Figure 6.13).
6 hours
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6.4.3. Cell Growth in MDA-MB-231 Cells Treated with
BNIPDaCHM
The effect of BNIPDaCHM (1 - 10 µM) treatment on adherent MDA-MB-231 cell
numbers (i.e., cell proliferation) after 0.5, 4, 6 and 24 hours treatment was determined by
microscopical cell count experiments, as shown in Figure 6.14.
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Figure 6.14.: MDA-MB-231 cell number after treatment with BNIPDaCHM. MDA-MB-231 cells
were treated for 0.5, 4, 6 and 24 hours with 0 – 10 µM BNIPDaCHM. Cell number was determined
by direct microscopical cell counting of adherent cells using a Neubauer haemocytometer. Data
are mean ± SEM of 2 independent experiments conducted in quadruplicate (n = 2). aP<0.05,
bP<0.01, cP<0.001 compared with respective untreated MDA-MB-231 control.
After 0.5 hours treatment, MDA-MB-231 cell growth was significantly activated by
1 µM BNIPDaCHM (P < 0.001; a 39.5% increase) when compared to the control. MDA-
MB-231 cell growth was significantly inhibited by 5 µM (P < 0.001; a 44.2% decrease) and
10 µM (P < 0.05; a 9.3% decrease) BNIPDaCHM when compared to the control (Figure
6.14).
After 4 hours treatment, MDA-MB-231 cell growth was significantly activated by 1
µM (P < 0.001; a 15.5% increase) and 5 µM (P < 0.001; a 7.9% increase) BNIPDaCHM
when compared to the control. MDA-MB-231 cell growth was significantly inhibited by 10
µM BNIPDaCHM (P < 0.001; a 77.4% decrease) when compared to the control (Figure
6.14).
After 6 hours treatment, MDA-MB-231 cell growth was significantly activated by 1
µM (P < 0.001; a 50% increase) and 5 µM (P < 0.001; a 35.7% increase) when compared
to the control. MDA-MB-231 cell growth was significantly inhibited by 10 µM BNIPDaCHM
(P < 0.001; a 54.8% decrease) when compared to the control (Figure 6.14).
After 24 hours treatment, MDA-MB-231 cell growth was significantly activated by 1
µM (P < 0.001; a 20% increase) when compared to the control. MDA-MB-231 cell growth
was significantly inhibited by 5 µM (P < 0.001; a 96.7% decrease) and 10 µM (P < 0.001;
a 100% decrease) when compared to the control (Figure 6.14).
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In summary, BNIPDaCHM (1 µM) activated MDA-MB-231 cell growth over a 24
hour time-course. After 0.5 and 24 hours, BNIPDaCHM (5 µM) inhibited MDA-MB-231
cell growth, but after 4 and 6 hours MDA-MB-231 cell growth was activated with 5 µM
BNIPDaCHM. BNIPDaCHM (10 µM) inhibited MDA-MB-231 cell growth over a 24 hour
time-course (Figure 6.14).
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6.4.4. Cell Cycle Effects by BNIPP Derivatives in MDA-MB-
231 Cells
The effect of BNIPSpd, BNIPDaCHM (5 µM) or the positive control etoposide (10
µM) on MDA-MB-231 cell cycle was determined by flow cytometry following PI staining
after 24 hours of treatment. The diagram in Figure 6.15, presents the cell cycle
distribution histograms obtained after 24 hours treatment of DMSO (0.025%), BNIPSpd (5
µM), BNIPDaCHM (5 µM) and etoposide (10 µM) in MDA-MB-231 cells. The results of
DNA distribution are arranged as gap phase 1 (G1), DNA synthesis (S) phase and gap
phase 2/mitosis (G2/M) populations in Figure 6.16. The sub-G1 population which
represents apoptotic cells with a low DNA content are shown in Figure 6.17.
A B
C D
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Figure 6.15.: Cell cycle distribution of MDA-MB-231 cells (A-E). MDA-MB-231 cells were
untreated (A) and treated for 24 hours with DMSO (B), 5 µM BNIPSpd (C), 5 µM BNIPDaCHM (D)
and 10 µM Etoposide (E) and stained with PI before flow cytometric analysis (10,000 events were
recorded). Line markers (left – right) indicate the approximate regions of the cell cycle; sub-G1
phase; G1 phase; S phase; G2/M phase. Images are representative of one of four independent
experiments and were obtained using EXPO32 ADC analysis software.
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Figure 6.16.: Quantification of cell cycle profiles. Profiles were determined by flow cytometry
following PI staining after 24 hours treatment with BNIPSpd or BNIPDaCHM (5 µM). Etoposide (10
μM) and DMSO (0.025%) were used as positive and negative controls respectively. 10,000 single
events were recorded, and the percentage of cells with DNA content in cell cycles phases (G1, S
and G2/M) were calculated from histograms of linear FL-2 plots in the ungated region. Data are
mean ± SEM of 4 independent experiments conducted in duplicate (n = 4). *P<0.05, **P<0.01,
***P<0.001 compared with respective untreated MDA-MB-231 control.
After 24 hours, control cells had accumulated in the G1 phase (Figure 6.16).
MDA-MB-231 cells exposed to DMSO (0.025%) mirrored those of control cells (Figure
6.16). Therefore, 0.025% DMSO did not have an effect on MDA-MB-231 cells. Treatment
with BNIPSpd (5 µM) exhibited a decrease in the proportion of MDA-MB-231 cells in all
cell cycle phases relative to the control, in particular the G2/M phase (P < 0.05; a 5.5%
decrease) (Figure 6.16). Treatment with BNIPDaCHM (5 µM) also exhibited a decrease in
the proportion of MDA-MB-231 cells in all cell cycle phases relative to the control, in
particular the G1 (P < 0.01; a 21.6% decrease) and G2/M phases (P < 0.05; a 7.4%
decrease) (Figure 6.16). Treatment with etoposide (10 µM) exhibited a pronounced
decrease in the proportion of MDA-MB-231 cells in G1 phase (P < 0.001; a 32.7%
decrease) and an increase in S-phase (P < 0.001; a 7.5% increase) relative to the control.
Whereas cells present in the G2/M phase mirrored that of control cells (Figure 6.16).
Since MDA-MB-231 cell number was found to be significantly decreased with ≥ 5
µM BNIPDaCHM (Section 6.4.3 and Figure 6.13), it was important to determine the
proportion of MDA-MB-231 cells with a sub-G1 DNA content and results are presented in
Figure 6.17.
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Figure 6.17.: Quantification of sub-G1 cell cycle profile. Profiles were determined by flow
cytometry following PI staining after 24 hours treatment with BNIPSpd or BNIPDaCHM (5 µM).
Etoposide (10 μM) and DMSO (0.025%) were used as positive and negative controls, respectively.
10,000 single events were recorded, and the percentage of cells with DNA content in sub-G1 was
calculated from histograms of linear FL-2 plots in the ungated region. Data are mean ± SEM of 4
independent experiments conducted in duplicate (n = 4). ***P<0.001 compared with respective
untreated MDA-MB-231 control.
After 24 hours, treatment with DMSO (0.025%) produced cells with a sub-G1 DNA
content which mirrored that of control cells (Figure 6.17). Treatment with BNIPSpd (5 µM)
exhibited a significant increase in the proportion of cells with sub-G1 content (P < 0.001; a
30.4% increase) relative to the control (Figure 6.17). BNIPDaCHM (5 µM) treatment also
produced a significant increase in the sub-G1 population (P < 0.001; a 16.4% increase)
relative to the control, whilst 10 µM etoposide did not significantly increase the sub-G1
population to the same extent as BNIPSpd or BNIPDaCHM in relation to the control
(Figure 6.17).
***
***
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6.4.5. Effect of BNIPDaCHM on p53 and p21Waf1/Cip1 mRNA
Expression Levels in MDA-MB-231 Cells
The effect of BNIPDaCHM (5 µM) on p53 (Section 6.4.5.1) and p21Waf1/Cip1
(Section 6.4.5.2) mRNA expression levels was determined in MDA-MB-231 cells by RT-
PCR studies.
6.4.5.1. Effect on p53 mRNA Expression Levels
Treatment with BNIPDaCHM (5 µM) does not significantly alter p53 mRNA levels
after 1, 4 or 24 hours of treatment as shown in Figure 6.18.
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Figure 6.18.: Expression levels of p53 mRNA in BNIPDaCM treated MDA-MB-231 cells by RT-
PCR. MDA-MB-231 cells were treated with 5 μM BNIPDaCHM for 1 (A), 4 (B) and 24 (C) hours.
Total RNA was extracted and RT-PCR carried out using p53 specific primers and β-actin as an
internal control. Data are mean ± SEM of 3 independent experiments conducted in duplicate (n =
3).
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6.4.5.2. Effect on p21Waf1/Cip1 mRNA Expression Levels
Treatment with BNIPDaCHM (5 µM) increased p21Waf1/Cip1 mRNA levels in a time-
dependent manner with a significant increase observed after 4 hours treatment (P < 0.01;
a 24.7% increase) rather than after 1 hour treatment (Figure 6.19).
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Figure 6.19.: Expression levels of p21Waf1/Cip1 mRNA in BNIPDaCM treated MDA-MB-231 cells by
RT-PCR. MDA-MB-231 cells were treated with 5 μM BNIPDaCHM for 1 (A) and 4 (B) hours. Total
RNA was extracted and RT-PCR carried out using p21Waf1/Cip1 specific primers and β-actin as an
internal control. Data are mean ± SEM of 3 independent experiments conducted in duplicate (n =
3). **P<0.01 compared with untreated MDA-MB-231 control values.
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6.4.6. Effect of BNIPSpd on p53 and p21Waf1/Cip1 mRNA
Expression Levels in MDA-MB-231 Cells
The effect of BNIPSpd (5 µM) on p53 and p21Waf1/Cip1 mRNA levels was
determined in MDA-MB-231 cells by RT-PCR studies (Figure 6.20).
After 4 hours, treatment with BNIPSpd (5 µM) did not alter the levels of p53 or
p21Waf1/Cip1 mRNA in MDA-MB-231 cells (Figure 6.20).
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Figure 6.20.: Expression levels of p53 and p21Waf1/Cip1 mRNA in BNIPSpd treated MDA-MB-231
cells by RT-PCR. p53 (A) and p21Waf1/Cip1 (B) mRNA levels were determined after 4 hours
treatment with 5 µM BNIPSpd. Total RNA was extracted and RT-PCR carried out using p53 and
p21Waf1/Cip1 specific primers with β-actin as an internal control. Data are mean ± SEM of 3
independent experiments conducted in duplicate (n = 3).
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6.5. Discussion
6.5.1. Membrane Integrity of BNIPP Derivative Treated MDA-
MB-231 Cells
Treatment with ≥ 1 μM BNIPSpd or BNIPDaCHM resulted in changes to
membrane integrity in MDA-MB-231 cells (Figure 6.7 and 6.8), as examined by
fluorescence microscopy following AO/EB staining. The visible staining of AO/EB in
adherent MDA-MB-231 cells indicated the presence of viable, early and late apoptotic
cells identified by colour and appearance; however, it was difficult to identify necrotic cells.
This observation is supported by cell morphology changes (Section 4.4.1.1; Figure 4.11
and Section 6.4.1; Figures 6.7 and 6.8), combined with an apparent loss of cells (Section
6.4.3 and Figure 6.14) after BNIPP derivative treatment.
These results are an extension of studies carried out by Ralton et al. (2009), where
apoptotic cell death was investigated in BNIPSpd treated colon cancer CaCO-2 and HT-
29 cells. BNIPSpd (≥ 0.5 μM) was found to induce a loss of plasma membrane integrity,
chromatin condensation, nuclear and apoptotic-like cell fragmentation in CaCO-2 and HT-
29 cells after 24 hours (Ralton et al. 2009). Therefore, these results together suggest that
BNIPP derivatives can induce apoptotic cell death in breast (MDA-MB-231) and colon
(CaCO-2 and HT-29) cancer cells (Ralton et al. 2009).
6.5.2. Phosphatidylserine Exposure and Membrane Integrity
in MDA-MB-231 Cells Treated with BNIPP Derivatives
A quantitative assessment into the effect of BNIPP derivatives on the induction of
early apoptosis in adherent MDA-MB-231 cells was conducted. PS exposure and plasma
membrane integrity were measured by flow cytometry following annexin V-FITC staining
and 7-AAD labelling (Section 6.4.2 and Figures 6.11 – 6.13).
BNIPSpd and BNIPDaCHM (1 – 5 µM; 0.5, 4 and 6 hours) increased annexin V-
FITC staining, and 7-AAD labelling in MDA-MB-231 cells (Figures 6.11 – 6.13), with the
exception of BNIPSpd, where 7-AAD labelling was reduced, when compared to control,
following treatment with 1 and 5 µM BNIPSpd after 4 hours (Figure 6.12) and 5 µM
BNIPSpd after 6 hours (Figure 6.13). These results indicate that BNIPP derivatives are
able to elicit externalisation of PS residues and early plasma membrane damage in MDA-
MB-231 cells after ≥ 0.5 hours treatment (Figure 6.11). Results are supported as
treatment with DMSO (0.025%) did not induce a significant difference in annexin V-FITC
staining or 7-AAD labelling when compared to control (Figure 6.11). This result strongly
supports the conclusion that BNIPP derivatives induce early apoptosis, and that the
results are not a stress response of the cells or an experimental artefact. The
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observations of membrane integrity changes detected by AO/EB staining (Section 6.4.1
and Figures 6.7 – 6.9) also support these results.
The results presented suggest that damage to the plasma membrane could be an
important mechanism in BNIPDaCHM-induced cytotoxicity within MDA-MB-231 cells.
Given that an increase in 7-AAD labelling was observed after 0.5 hours with 5 µM, 4 hours
with 1 and 5 µM and 6 hours with 1 and 5 µM BNIPDaCHM indicating a loss in plasma
membrane integrity in a time-dependent manner. Apoptosis was also found to be
significantly induced to a greater degree in cells treated with BNIPDaCHM (P < 0.001; a
30% increase) rather than BNIPSpd (P < 0.01; a 15% increase) after 0.5 hours (Figure
6.11). This result was supported by the cellular uptake studies (Section 4.4.3.1 and
Figure 4.15), as BNIPDaCHM was observed within MDA-MB-231 cells after 0.5 hours,
whilst BNIPSpd was not observed until after 6 hours.
It is difficult to directly compare the results for early apoptotic cell death obtained in
this study with that of other apoptosis inducing anti cancer agents, as there does not
appear to be any previous information available which details apoptotic cell death after
only 0.5 hours treatment. However, one study did attempt to investigate early apoptotic
cell death following exposure to cisplatin (5 and 10 mg/L) (Figure 3.8) in human malignant
pleural mesothelioma (P31) cells after 0.5, 2 and 24 hours (Janson et al. 2008). In that
work, Janson et al. (2008) found that annexin V staining was not increased following
exposure to 5 and 10 mg/L cisplatin after 0.5 hours. This study supports the use of
annexin V-FITC staining as a reliable technique to detect early apoptotic cell death, as it
aimed to use it to detect apoptosis after 0.5 hours. Thus, the induction of early apoptosis
following 0.5 hours treatment with BNIPP derivatives is an interesting and novel
observation.
It is important to note that experiments conducted in Section 6.4.2 need to be
repeated at least one more time, particularly the annexin V-FITC / 7-AAD staining after 4
and 6 hours.
6.5.3. Cell Growth in MDA-MB-231 Cells Treated with
BNIPDaCHM
Treatment with BNIPDaCHM (0 – 10 µM) resulted in changes to cell proliferation in
MDA-MB-231 cells (Figure 6.14), as examined by microscopical cell counts. Apoptosis
can be identified by a loss of cell number or growth with the formation of floating
(apoptotic) cells (Soldatenkov et al. 1998, Holdenrieder and Stieber 2004). MDA-MB-231
cell number was found to be significantly reduced with ≥ 5 µM BNIPDaCHM (P < 0.001; a
96.7% decrease; Figure 6.14) over a 24 hour time-course. These results are in
agreement with the cell morphology studies (Section 4.4.1.1 and Figure 4.11); where
BNIPDaCHM treatment resulted in changes to the morphology of MDA-MB-231 cells and
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cytotoxicity studies (Table 4.2); where an IC50 value of 6.8 µM was determined after 24
hours treatment with BNIPDaCHM.
The decreased number of adherent MDA-MB-231 cells with ≥ 5 µM BNIPDaCHM
after 4, 6 and 24 hours treatment may imply that BNIPDaCHM could be more cytotoxic
than initially determined in Section 4.4.2. This can be proposed since only adherent, not
floating cells were investigated in the cytotoxicity study (Section 4.4.2). Therefore, for that
reason, cell cycle (Section 6.4.4) studies were undertaken using both adherent and non-
adherent MDA-MB-231 cells. The use of the whole cell population can thus provide a
more accurate assessment of the potential of BNIPP derivatives to induce cell cycle arrest
and apoptotic cell death in breast cancer cells.
6.5.4. Cell Cycle Effects by BNIPP Derivatives in MDA-MB-
231 Cells
The experimental work presented in Section 6.4.4 was the first quantitative study
of cell cycle effects to be undertaken with the BNIPP derivatives. Cell cycle analysis was
carried out using the technique of flow cytometry following PI staining reported by
Bestwick et al. (2007).
Treatment with BNIPSpd or BNIPDaCHM (5 µM) induced cell cycle instability in
MDA-MB-231 cells after 24 hours with the increased appearance of a sub-G1 population
(P < 0.001; a 30.4% and 16.4% increase, respectively) (Figure 6.17). Sub-G1 population
has been linked to cells with fragmented DNA, and is indicative of apoptotic cells (Shu et
al. 1997, Bestwick and Milne 2006, Wang et al. 2008). This result was supported by the
findings from the Annexin V-FITC/7-AAD viability assay (Section 6.4.2 and Figures 6.11 -
13) and MDA-MB-231 cell counts (Section 6.4.3 and Figure 6.14). In addition, the
significant increase in the number of DNA strand breaks induced by BNIPSpd after 24
hours (Section 5.4.2.1 and Figure 5.8) could be responsible for the high level of cells
present in the sub-G1 population (Figure 6.17).
The effect of structurally related bisnaphthalimide derivatives were studied by
Bailly et al. (2003) and Filosa et al. (2009). Bailly et al. (2003) found that MCI3335 (2 µM;
24 hours) (Figure 6.21) exhibited little effect on cell cycle progression in CEM leukaemia
cells, whilst Filosa et al. (2009) found that N, N’-bis[2-(5-nitro-1,3-dioxo-2,3-dihydro-1H-
benz[de]-iso-quinolin-2-yl)] propane-2-ethanediamine (Figure 1.25) was unable to block
cell cycle progression in HT-29 colon cancer cells. These findings are similar to those
found for BNIPSpd and BNIPDaCHM with regards to their effect on the G1, S and G2/M
phases. Bailly et al. (2003) and Filosa et al. (2009) did not document the sub-G1
populations of treated CEM or HT-29 cells; therefore it is difficult to fully compare these
bisnaphthalimide derivatives with the BNIPP derivatives used in this study.
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Figure 6.21.: Structure of MCI3335
To elucidate the mode of action utilised by BNIPP derivatives, it is important to
refer to the spermine analogues discussed in Section 5.5.1, BENSpm (Figure 1.11) and
CGP 48664 (Figure 5.16). These derivatives were investigated with regards to their
effects on cell cycle progression by Alm et al. (2000) and Johansson et al. (2008). Alm et
al. (2000) found that BENSpm (7.5 µM; 24 - 48 hours treatment) initially prolonged S
phase progression in Chinese Hamster Ovary (CHO) cells before affecting the other cell
cycle phases. In breast cancer (MCF-7 and L54Br-C1) cells, Johansson et al. (2008)
found that BENSpm (10 µM; 24, 48 and 72 hours) exhibited an increase in G1 phase and
a decrease in S phase. CGP 48664 (20 µM; 24 - 72 hours) induced an increase in G1
phase and decrease in S phase, similar to that of BENSpm, in MCF-7 and L54Br-C1 cells
after 24 hours treatment, but after 48 hours, CGP 48664 (20 µM) decreased G1 phase
and increased S phase when compared with control L54Br-C1 cells (Johansson et al.
2008). Johansson et al. (2008) also found that neither treatment induced any major
effects in G2/M phase in either cell line. It was suggested by Johansson et al. (2008) that
cell cycle arrest induced by BENSpm and CGP 48664 was cell line dependent and related
to polyamine depletion, not apoptosis. In contrast, BNIPSpd and BNIPDaCHM do not
appear to induce their effects on cell cycle progression through polyamine depletion
(Section 4.4.5 and Figures 4.16 – 4.23) but rather by apoptotic induction (Section 6.4.2
and Figure 6.11). In support, Holst et al. (2006) found that the conformationally restricted
polyamine analogue CGC-11047 (cis-iii analogue) (Figure 1.13) exhibited a significant
sub-G1 population (P < 0.05) in breast cancer L56Br-C1 cells, and it was concluded that
the effects of CGC-11047 were not related to polyamine depletion but rather another
mechanism of action, such as apoptosis (Holst et al. 2006). Confirmation that BNIPP
derivatives disrupt cell cycle progression by apoptosis induction will, however, require
further investigation.
6.5.5. Effect of BNIPP Derivatives on p53 and p21Waf1/Cip1
mRNA Expression Levels in MDA-MB-231 Cells
The experimental work presented in Sections 6.4.5 and 6.4.6 was the first
quantitative study to be carried out into the effect of BNIPP derivatives on p53 and
p21Waf1/Cip1 mRNA expression levels in MDA-MB-231 cells using RT-PCR.
The results reveal that expression levels of p53 mRNA were not altered by
BNIPDaCHM (5 µM) after 1, 4 or 24 hours treatment (Figure 6.18). Similarly expression
200
levels of p21Waf1/Cip1 mRNA was not altered by BNIPDaCHM (5 µM) after 1 hour treatment;
although after 4 hours treatment with BNIPDaCHM (5 µM), p21Waf1/Cip1 mRNA levels were
significantly increased (P < 0.01; a 24.7% increase) (Figure 6.19). BNIPSpd (5 µM) did
not alter p53 or p21Waf1/Cip1 mRNA expression levels in MDA-MB-231 cells after 4 hours
(Figure 6.20).
P53 and p21Waf1/Cip1 have both been implicated in cell cycle arrest and apoptotic
cell death (Belkacemi et al. 2006, Park et al. 2008). Functional p53 can activate
p21Waf1/Cip1 which in turn results in cell cycle arrest (refer to Figure 6.4). It is evident that
functional p53 is extremely important in the induction of p53-dependent apoptosis as a
result of DNA damage. However, in this study the breast cancer MDA-MB-231 cells used
throughout express a mutant, non functional p53. Therefore, the results suggest that DNA
damage induced following treatment with BNIPDaCHM can affect p21Waf1/Cip1 expression
and apoptotic cell death through a p53-independent pathway. Thus, the induction of
p21Waf1/Cip1 could be a possible mode of action through which BNIPDaCHM inhibits MDA-
MB-231 cell growth and provokes apoptotic cell death. However, it is difficult to compare
this result with other cytotoxic anti cancer agents as their ability to induce p21Waf1/Cip1
mRNA levels remains to be extensively investigated.
P21Waf1/Cip1 over expression after 4 hours (Figure 6.19) does not correspond with
its ability to induce cell cycle arrest since neither BNIPSpd nor BNIPDaCHM were able to
induce cell cycle arrest after 24 hours (Section 6.4.4 and Figure 6.16). These preliminary
results are inconclusive and it is, therefore, important to carry out further studies in order
to determine the mode of action utilised by the BNIPP derivatives. More extensive
investigations into the relationship between p21Waf1/Cip1 and cell cycle arrest will need to be
undertaken especially in relation to time frame and concentration.
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6.6. Conclusions
The BNIPP derivatives, BNIPSpd and BNIPDaCHM, were assessed for their effect
on the mode of cell death and cell cycle distribution within MDA-MB-231 cells. Results
presented suggest that treatment with either BNIPSpd or BNIPDaCHM can significantly
induce apoptotic cell death in MDA-MB-231 cells after only 0.5 hours treatment and that
plasma membrane integrity was lost in a time-dependent manner (1 – 5 µM; 0.5 – 24
hours). Cell cycle arrest was not evident during any phase of the cell cycle (BNIPSpd or
BNIPDaCHM; 5 µM; 24 hours), even though p21Waf1/Cip1 mRNA was over expressed after
BNIPDaCHM treatment (4 hours). Also the sub-G1 population was significantly increased
following treatment with either BNIPP derivative. This result was indicative of an apoptotic
cell population, but further investigations into the mode of cell death induced in a p53-
independent manner by the BNIPP derivatives will be required.
In conclusion, although the mode of action utilised to inhibit the proliferation of
MDA-MB-231 cells is not yet fully understood; the cytotoxic, DNA damaging and
suggested apoptotic properties of BNIPSpd and BNIPDaCHM have potential implications
on their clinical use as an anti cancer agents. To further elucidate the mode of action of
several BNIPP derivatives, histone deacetylase (HDAC) activity were studied (Chapter 7).
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Chapter 7
Histone Deacetylase Activity Studies of BNIPP
Derivatives
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7.1. Histone Deacetylase Activity Studies of BNIPP
Derivatives
One of the most recently identified therapeutic targets involves the ability of
potential anti cancer agents to inhibit histone deacetylase (HDAC) activity (Ropero and
Esteller 2007, Paris et al. 2008). Many structurally different natural and synthetic
derivatives have been shown to inhibit class I, II, III and IV HDAC activity, such as,
trichostatin A (TSA) (Yoshida et al. 1990) or splitomicin (Hirao et al. 2003) (Figure 7.1).
HDAC enzyme inhibitors are continually being discovered and developed, and in 2006 the
U.S. Food and Drug Administration (FDA) approved the first HDAC inhibitor suberoyl
hydroxamic acid (SAHA; Vorinostat; Figure 7.1), for the treatment of cutaneous T-cell
lymphoma (CTCL) (Mann et al. 2007, Richon et al. 2009). Therefore, it is important to
investigate the potential influence of BNIPP derivatives, as a consequence of their ability
to induce p21 mRNA expression levels (Section 6.4.5.2) on class I, II and III HDAC
inhibition.
The aim of the experimental work reported in this chapter was to study the effect of
BNIPP derivatives on class I, II and III HDAC activity.
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Figure 7.1.: Structures of TSA (1), SAHA (2) and splitomicin (3)
7.1.1. The HDAC Family
The control of gene expression, and thus, DNA repair, cell proliferation and
differentiation are highly regulated by the enzymes histone acetyltransferases (HATs) and
HDACs (Ropero and Esteller 2007). HATs are responsible for acetylation, whilst HDACs
control deacetylation of specific lysine residues (i.e., addition/removal of ε-amino groups,
respectively; Figure 7.2) in the N-terminal extension of core histones (i.e., H2A, H2B, H3
and H4) (Figure 1.6), and non-histone proteins (e.g., p53, forkhead box O transcription
factor (FOXO) or tubulin) (Carey and La Thangue 2006, Schemies et al. 2009, Witt et al.
2009).
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Figure 7.2.: Reversible deacetylation of specific lysine residues
Generally, histone hyperacetylation is associated with an open, unfolded
chromatin structure with transcriptional activation, whilst histone hypoacetylation
correlates with a closed, folded chromatin structure with transcriptional silencing. HDACs
are appealing therapeutic targets for the development of potential anti cancer agents
(Stimson and La Thangue 2009), since altered HDAC activity is linked to cancer
development, and its inhibition (i.e., histone hyperacetylation) can cause growth arrest,
induce cell differentiation, upregulate critical genes (e.g., p53) and induce apoptosis
(Glaser 2007, Bieliauskas and Pflum 2008).
HDACs belong to four structurally and functionally distinct classes (i.e., class I –
IV), which are subdivided according to their homology with yeast HDAC proteins, and
cellular location (Ropero and Esteller 2007). Class I (i.e., HDAC-1, -2, -3, and -8) are
homologous to the transcriptional regulatory protein Rpd3 in yeast and are located in the
nucleus; class II (i.e., class IIA; HDAC-4, -5, -7 and -9 with a single active site, or class
IIB; HDAC-6 and -10 with two active sites) are homologous to histone deacetylase Hda1
in yeast and are located in both the nucleus and cytoplasm; and class IV consists of only
one member (i.e., HDAC-11), which is homologous to the class I and II HDACs, and is
also found in the nucleus (Ropero and Esteller 2007). Very little information can be found
for the expression and function of HDAC-11; therefore it will not be discussed further in
this chapter. Class III HDAC enzymes, or sirtuins (i.e., SIRT1 – 7) are homologous to the
yeast Silent information regulator 2 (Sir2) protein family and can be found in various
cellular locations (e.g., SIRT1, SIRT2 and SIRT3 are present in the nucleus, cytoplasm
and mitochondria, respectively) (Paris et al. 2008).
Class I and II HDACs are named “classical” HDACs and are zinc (Zn2+)-dependent
proteases that are grouped together because of their sequence similarities (Paris et al.
2008), and sensitivity to TSA (1). In contrast, sirtuins are insensitive to TSA (1) and are
dependent on nicotinamide adenine dinucleotide (NAD+) (Ropero and Esteller 2007).
7.1.2. Classical HDACs
The classical HDACs consist of 10 Zn2+-dependent proteases, each with various
cellular functions. In summary, class I HDACs, HDAC-1, -2, -3 and -8, are responsible for
cell proliferation and gene regulation, including apoptosis, mitosis (Li et al. 2006),
contractile capacity (Waltregny et al. 2005, Paris et al. 2008) and cardiac morphogenesis
(Montgomery et al. 2007). Class II HDACs, HDAC-4, -5, -6, -7, -9 and -10, are
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responsible for hypoxia-inducible factor 1 (HIF-1) stability (Qian et al. 2006), cardiac
development (Chang et al. 2004), deacetylation of tubulin and microtubules (Zhang et al.
2003), and can also regulate apoptosis, while very little is known about the function of
HDAC-10 (Paris et al. 2008). Additionally, HDACs were found to be overexpressed in
several cancer cell types, for example, Jin et al (2008) found that HDAC-1, -2 and -3 were
overexpressed in 18 ovarian cancer tissues (i.e., serous, mucinous or endometrioid
ovarian cancer tissues), Saji et al. (2005) found that HDAC-6 was overexpressed in breast
cancer MCF-7 cells, and Ouaissi et al. (2008) found HDAC-7 to be increased in pancreatic
adenocarcinomas. For that reason HDACs appear to play a significant role in
carcinogenesis, and have a potential therapeutic role in cancer treatment.
Besides the treatment of cancer, HDAC inhibitors may also have a potential role in
the treatment of asthma or allergic diseases (e.g., by suppression of tumor necrosis factor
alpha (TNFα) and interleukin-1 (IL-1) (Glaser 2007, Bhavsar et al. 2008), or in the
treatment of neurodegenerative disorders (e.g., Huntington’s, Parkinson’s or Alzheimer’s
disease) (Chuang et al. 2009).
7.1.2.1. Classical HDAC Inhibitors
HDAC inhibitors fall into four structural distinct groups. These include (i)
hydroxamic acids such as, TSA (1) and SAHA (2) (Figure 7.1), PXD101 (belinostat; 4) and
scriptaid (5; has structural features similar to the BNIPP derivatives), (ii) cyclic
tetrapeptides such as, depsipeptide (FK - 228; 6), (iii) benzamides such as, pyridylmethyl-
N-{4-[2-aminophenyl)-carbamoyl]-benzyl}-carbamate (MS-275; 7) and MGCD-0103 (8)
and (iv) short chain fatty acids such as, valproic acid (9) (Figure 7.3).
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Figure 7.3.: Structures of PXD101 (4), scriptaid (5), depsipeptide (6), MS-275 (7), MGCD-0103 (8)
and valproic acid (9).
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The most extensively studied HDAC inhibitors are hydroxamic acid based
derivatives, which are highly potent (i.e., inhibition achieved at nM concentrations) with a
well-defined mechanism of action (Stimson and La Thangue 2009).
Classical HDAC inhibitors have a standard modular structure consisting of a
surface recognition cap, a linker chain and a zinc-binding group (Figure 7.4). This
structure allows extensive inhibitor recognition through several means. These include (i)
the surface recognition cap interacting with residues on the entrance of the active site, (ii)
the zinc-binding group interacting with the catalytic metal atom within the active site and
(iii) the linker chain which is generally hydrophobic allowing the cap and zinc-binding
group to position and thus interact effectively with the active site (Vannini et al. 2004,
Bieliauskas and Pflum 2009).
Figure 7.4.: General structure of class I and II HDAC inhibitors
Several HDAC inhibitors within clinical development were found to be generally
non selective towards individual HDACs, and were found to either inhibit all or several
HDAC enzymes simultaneously (Cang et al. 2009, Witt et al. 2009). Nevertheless, as an
example, hydroxamic acid based derivatives such as, TSA (1) or SAHA (2) are highly
potent non selective HDAC inhibitors (i.e., inhibition achieved at nM concentrations), and
the non-hydroxamic acid based derivatives such as, depsipeptide (6) or MS-275 (7) are
selective class I HDAC inhibitors. Details of HDAC inhibitor selectivity and clinical
development has been summarised in Table 7.1.
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Table 7.1.: Summary of classical HDAC inhibitor classification and specificity [adapted from
Stimson and La Thangue (2009) and Witt et al. 2009]
Inhibitor Inhibition Potency Clinical Status Reference
TSA (1) Unselective nM nd Yoshida et al.
1990
SAHA (2) Unselective nM Approved,
Phase I, II and
III
Mann et al.
2007
PXD101 (4) Unselective nM Phase I and II Steele et al.
2008,
Ramalingham
et al. 2009
Scriptaid (5) Unselective μM nd Su et al. 2000,
Tong et al.
2006
Depsipeptide
(6)
Class I nM Phase I and II Schrump et al.
2008
MS-275 (7) Class I μM Phase II Hauschild et al.
2008
MGCD-0103 (8) Class I µM Phase II Blum et al. 2009
Valproic acid
(9)
Class II mM Phase I and II Rocca et al.
2009
Abbreviations: nd, no data
Although not included in Table 7.1, several selective class II HDAC inhibitors exist.
These include tubacin (10) and mercaptoacetamide (11) (Figure 7.5) which exhibit
selective inhibition of HDAC-6 and thus a decrease in α-tubulin acetylation (Haggarty et al.
2003, Kozikowski et al. 2007, Schemies et al. 2009).
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Figure 7.5.: Structures of tubacin (10) and mercaptoacetamide (11)
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Extensive modifications have been made to each region of the standard modular
structure of HDAC inhibitors (Figure 7.4). These involve the addition of cyclic peptide
moieties at the cap region (e.g., depsipeptide; 6) which produced class I selectivity;
removal of the hydroxamic acid group for benzamide groups (e.g., MS-275; 7) displayed
HDAC-1 and -3 selectivity compared to HDAC-6 and -8; or the introduction of an amide
bond in the linker, in contrast to TSA (1), resulted in class I selectivity (Bieliauskas and
Pflum 2009).
The synthesis of more selective HDAC inhibitors could provide a better
understanding of the different functions of each HDAC enzyme, and may also generate
HDAC inhibitors with greater efficacy and lower toxicities (Carew et al. 2008).
7.1.3. Class III HDACs
Class III HDACs, or sirtuins are not classified as Zn2+-dependent, but rather, NAD+-
dependent that produce nicotinamide and the unique by-product O-acetyl adenosine
diphosphate (ADP) ribose (Tanner et al. 2000, Jiang 2008). Sirtuins consist of seven
protein deacetylase members and they either catalyse NAD+-dependent acetylation (i.e.,
SIRT-1 – 3, and -5) or mediate mono-ADP-ribose-ribosyltransferase (SIRT-4 and -6)
activity (Zhang et al. 2009). SIRT1 has been the most extensively investigated sirtuin, but
interest is gathering for the other sirtuin proteins. Each sirtuin has various cellular
functions which are summarised in Table 7.2.
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Table 7.2.: Summary of the biological functions of sirtuins
Sirtuin Cellular
Location
Biological Function Reference
SIRT1 nucleus target p53, FOXO,
Ku70, NF-κB, p300 by 
deacetylation
target p53-dependent
apoptosis
Vaziri et al. 2001,
Cheng et al. 2003,
Alcaίn and Villalba 
2009a
SIRT2 cytoplasm target α tubulin and
deacetylate histone
H4
North et al. 2003
SIRT3 mitochondria deacetylate acetyl co-
A synthase 2
Schlicker et al. 2008
SIRT4 mitochondria ADP-ribosylation of
glutamate
dehydrogenase
Haigis et al. 2006
SIRT5 mitochondria deacetylate
cytochrome c
Schlicker et al. 2008
SIRT6 nucleus deacetylate histone
H3 lysine 9 (H3K9),
regulate chromatin
Michishita et al. 2008
SIRT7 nucleolus nd -
Abbreviations: nd, no data
The biological function of SIRT7 is currently unknown and remains to be
elucidated, but Ashraf et al. (2006) observed that levels of SIRT7 expression were
significantly increased in breast cancer MCF-7 cells (Alcaίn and Villalba 2009a).  This 
observation has shown that sirtuins appear to play a significant role in carcinogenesis and
have, thus, the potential to aid cancer diagnosis and treatment (Ashraf et al. 2006).
Beyond cancer treatment, sirtuins have also been suggested through calorie
restriction (CR) studies, to have a role in the treatment of diseases of ageing such as,
neurodegenerative diseases (e.g., Parkinson’s or Alzheimer’s disease), type 2 diabetes
and cardiovascular diseases (Milne et al. 2007, Westphal et al. 2007, Milne and Denu
2008).
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7.1.3.1. Class III Inhibitors
Inhibitors of Class III HDACs tend to inhibit SIRT1 and SIRT2, and include suramin
(12), cambinol (13), 6-chloro-2, 3, 4, 9-tetrahydro-1H-carbazole-1-carboxamide (EX-527;
14), splitomicin (15), sirtinol (16), salermide (17) and nicotinamide (18) (Figure 7.6).
In summary, 12 and 14 have been found to be highly potent (nM) non selective
and selective (i.e., SIRT1 enzyme) inhibitors, respectively (Solomon et al. 2006, Schuetz
et al. 2007). 13, 16, 17 and 18 are potent SIRT1 and SIRT2 inhibitors at µM
concentrations (Schmidt et al. 2004, Mai et al. 2005, Heltweg et al. 2006, Lara et al.
2009), and 15 at µM levels was selective for Sir2 (Hirao et al. 2003).
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Figure 7.6.: Structures of suramin (12), cambinol (13), EX-527 (14), splitomicin (15), sirtinol (16),
salermide (17) and nicotinamide (18)
7.1.3.2. Class III Activators
Sirtuin enzymes can be activated by natural and synthetic derivatives such as
resveratrol (3,4’,5-trihydroxy-trans-stilbene, 19) (Howitz et al. 2003), and N-[2-[3-
(piperazin-1-ylmethyl)imidazo [2,1-b][1,3]thiazol-6-yl]phenyl] quinoxaline-2-carboxamide
(SRT1720, 20) (Milne et al. 2007) (Figure 7.7). SIRT activation has predominantly
focused on the SIRT1 enzyme and since sirtuins are dependent upon NAD+; activation
could result in the overconsumption or depletion of NAD+, thus provoking cell death
(Alcaίn and Villalba 2009b).  
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Figure 7.7.: Structures of resveratrol (19) and SRT1720 (20).
7.1.4. Assessment of HDAC Activity
Several methods have been utilised for the in vitro assessment of cellular HDAC
activity. Traditional detection methods involved the use of acetate-radiolabelled histones
from chicken reticulocytes (Wegener et al. 2003) or histone peptide substrates, e.g., [3H]
acetyl-histone, [3H] acetyl-histone peptides or oligopeptides (Hoffmann et al. 1999,
Engleka 2003, Heltweg and Jung 2003, Wegener et al. 2003, Heltweg et al. 2005).
Unfortunately, these labelling methods are rarely used in the detection of HDAC activity
because they (i) require radioactivity, thus the use of expensive laboratory equipment and
waste management procedures, (ii) are difficult to standardise, (iii) are time consuming,
and (iv) are not suitable for high throughput screening (Wegener et al. 2003, Heltweg et
al. 2005). Unlabelled histone peptide substrates have also been used, but detection
requires resolution by HPLC and UV detection, and thus the method has a low sample
throughput (Heltweg et al. 2005). Non isotopic substrates, e.g., fluorescence-labelled
histone peptides or acetylated lysine derivatives (e.g., N-(4-methyl-7-coumarinyl)-N-α-
(tert-butyloxycarbonyl)-N-ε-acetyllysinamide; MAL) can provide a commercially available
alternative to the radiolabelled or unlabelled histone peptide substrates (Hoffmann et al.
1999, Heltweg et al. 2005).
7.1.4.1. HDAC Colourimetric Assay
The easy to use, rapid, homogenous and non-isotope assays provided by
BIOMOL International (Plymouth Meeting, USA) can detect HDAC enzyme activity. The
BIOMOL International HDAC colourimetric assay can determine the activity of HDAC1
and 2 enzymes. The assay uses the unique Color de Lys™ (Colorimetric histone
deAcetylase Lysyl) substrate/developer system which works by a two step reaction
(Figure 7.8). In the first step, the Color de Lys™ substrate which contains an acetylated
lysine side chain was added to a sample containing HDAC activity (e.g., HeLa nuclear
extract). Deacetylation of the substrate (i.e., removal of an acetyl group from the N-acetyl
lysine side chain), results in substrate sensitisation, so that, in the second step, addition of
the Color de Lys™ developer produces a chromophore.
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Figure 7.8.: Two step reaction ([1] and [2]) of the HDAC colorimetric activity assay [adapted from
the manufacturer instructions for the HDAC Colorimetric Assay/Drug Discovery Kit – AK-501]
7.1.4.2. HDAC Fluorimetric Assay
In a similar two step reaction method, the BIOMOL International HDAC fluorimetric
assay (Figure 7.9) can detect the HDAC activity of class I HDACs (HDAC-1- 3 and HDAC-
8) and class II HDACs (HDAC-4 - 7, HDAC- 9 - 10). The assay works by the same
principle as the abovementioned assay system but in this case uses a Fluor de Lys™
(Fluorogenic histone deAcetylase Lysyl) substrate/developer system as an alternative to
the Color de Lys™ substrate/developer. The result is the formation of a fluorophore,
produced after Fluor de Lys™ substrate sensitisation.
Figure 7.9.: Two step reaction ([1] and [2]) of the HDAC fluorimetric activity assay [adapted from
the manufacturer’s instructions for the HDAC Fluorimetric Assay/Drug Discovery Kit – AK-500]
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7.1.4.3. SIRT Fluorimetric Assays
In addition, the BIOMOL International SIRT2 and SIRT1 fluorimetric assays
(Figure 7.10) can detect SIRT2 and SIRT1 enzyme activity, respectively. These assays
work by a similar principle to that of the previous HDAC fluorimetric assay (Figure 7.9), but
in this case, the cosubstrate NAD+ is required. Each assay works by a two step reaction
(Figure 7.10), so, for example, in the first step of the SIRT2 fluorimetric assay, the Fluor
de Lys™-SIRT2 substrate which contains the p53 sequence Gln-Pro-Lys-Lys(ε-acetyl) is
incubated with human recombinant SIRT2 (hSirSIRT2) and the cosubstrate NAD+.
Deacetylation of the substrate results in substrate sensitisation, so that in the second step,
addition of the Fluor de Lys™ developer II produces a fluorophore. In the SIRT1
fluorimetric assay, the same two step reaction is followed except the Fluor de Lys™-
SIRT1 substrate contains the p53 sequence Arg-His-Lys-Lys (ε-acetyl).
Figure 7.10.: Two step reaction ([1] and [2]) of the SIRT (SIRT2 and SIRT1) fluorimetric activity
assay [adapted from the manufacturer’s instructions for the SIRT2 Fluorimetric Drug Discovery Kit
(AK-556) and SIRT1 Fluorimetric Drug Discovery Kit (AK-555)]. Nicotinamide Adenine
Dinucleotide (NAD+), a cosubstrate is consumed in the reaction to produce nicotinamide (NAM)
and O-acetyl-ADP-ribose (O-ac-ADP-ribose).
7.1.4.4. Molecular Modelling
Besides the commercially available assay kits above, molecular modelling
methods were used to characterise the binding potential and inhibitory action of BNIPP
derivatives on protein models. Little is currently known about the inhibitory action of
sirtuin inhibitors as there is only the crystal structure of SIRT2 available (Finnin et al.
2001) (Figure 7.11).
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Figure 7.11.: Structure of SIRT2 (adapted from Finnin et al. 2001). The structure consists of two
binding domains that are connected by four crossovers of the polypeptide chain. The larger (NAD-
binding) domain consists of a Rossman fold (in blue), whilst the smaller domain consists of a
helical module (in red) and a Zn-binding module (in grey).
SIRT2 has a 304-amino acid catalytic core, which consists of two domains: a
larger (NAD-binding) domain and a smaller (helical and zinc (Zn)-binding) domain (Finnin
et al. 2001). The assessments of BNIPP derivative interactions were undertaken in the
NAD+ binding pocket of the larger domain. Interestingly, the NAD+ binding pocket is
divided into three distinct regions: the A site (i.e., for binding of adenine-ribose, via
residues Asn286 and Glu288), the B site (i.e., for binding of nicotinamide-ribose, via
His187 and Gln167), and the C site (i.e., completely hidden, deep within the NAD-binding
pocket) (Finnin et al. 2001, North and Verdin 2004). Finnin et al. (2001) found that
mutations in His187 and Gln167 resulted in a loss in SIRT2 enzyme activity, thus, strongly
suggesting that these residues, in the B site, have a particularly important role in human
SIRT2 catalysis (North and Verdin 2004).
N-terminus
C-terminus
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7.2. Materials
7.2.1. Materials
All reagents were purchased from Fisher Scientific, UK unless otherwise stated,
and were used without purification.
The Color de Lys™ colorimetric assay/drug discovery kit (AK-501) and Fluor de
Lys™ fluorimetric assay/drug discovery kits (AK-500, AK-555 and AK-556) were from
BIOMOL International (Plymouth Meeting, USA).
7.2.2 . Instrumentation
Colourimetric readings were obtained using a µQuant MQX200 universal
microplate spectrophotometer (Biotek International. Inc, USA), with absorbance measured
at 405 nm.
Fluorescence readings were recorded using a LS55 Luminescence
spectrophotometer with plate reader (Perkin Elmer, USA) with excitation and emission
wavelengths, 360 nm and 460 nm, respectively. Samples were analysed by FLWinLab
software operated from a DELL Optiplex GX110 computer.
All modelling and docking simulations were carried out on a Silicon Graphics Fuel
workstation with IRIX 6.5 operating system using the comparative protein structure
modelling program MODELLER, and Sybyl 6.9 molecular modelling packages (i.e., the
Biopolymer, MOLCAD and FlexX modules) (Tripos., USA).
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7.3. Methods
7.3.1. Preparation of BNIPP Derivatives
The BNIPP derivatives: BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM
were synthesised as previously described in Section 2.3. The BNIPP derivatives were
diluted from stock solutions (10 mM) to the desired concentration of 10 µM in assay buffer,
either KI-143 (HDAC assay buffer) or KI-286 (Sirtuin assay buffer), prior to use.
7.3.2. In Vitro Colourimetric Assay for Class I HDAC Activity
The assay of HDAC1 and HDAC2-inhibitory activity was performed using the Color
de Lys™ colourimetric assay/drug discovery kit (AK-501) according to manufacturer’s
instructions. Briefly, the assay was carried out in a ½ volume clear microplate (KI-101)
using 0.2 mM Color de Lys™ substrate (KI-138), nuclear extract from HeLa cells (KI-137)
and HDAC assay buffer (KI-143; 25 mM Tris/Cl, pH 8.0, 137 mM NaCl, 2.7 mM KCl and 1
mM MgCl2). The buffer, TSA (0.05 µM from BIOMOL International, GR309-9090) or
BNIPP derivative (10 µM) in assay buffer (10 µL in 50 µL total volume of reaction mixture)
and HeLa extract were equilibrated for 5 minutes, at 37 °C. The reaction was started by
addition of the Color de Lys™-substrate (25 µL). Solutions were mixed thoroughly, and
incubated for 30 minutes, at 37 °C. Subsequently, the reaction was stopped by the
addition of 50 μL of the Color de Lys™-developer (KI-139; 1x) plus 1 µM TSA, and left for
an additional 30 minutes, at 37 °C. Results were then obtained by measuring the
absorbance at 405 nm, as described in Section 7.2.2. The mean absorbance value for
HeLa extract treated with different BNIPP derivatives was expressed as a % of untreated
HeLa extract (control). The mean absorbance value for the control was equal to 100% as
no HDAC inhibition was present. The results are shown as % activity of the control versus
each BNIPP derivative (BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM, at 10 μM).
7.3.3. In Vitro Fluorimetric Assay for Class I and II HDAC
Activity
The assay for the inhibitory activity of the class I HDACs (HDAC1-3 and HDAC8)
and class II HDACs (HDAC4-7, HDAC9-10) was performed using the Fluor de Lys™
fluorimetric assay/drug discovery kit (AK-500) according to manufacturer’s instructions.
Briefly, the assay was carried out in a ½ volume white microplate (KI-110) using 116 µM
Fluor de Lys™ substrate (KI-104), nuclear extract from HeLa cells (KI-140) and HDAC
assay buffer (KI-143; see section 7.3.1 for buffer contents). The buffer, TSA (0.05 μM) or
BNIPP derivative (10 µM) in buffer (10 µL in 50 µL total volume of reaction mixture) and
HeLa extract were equilibrated for 5 minutes, at room temperature. The reaction was
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started by the addition of the Fluor de Lys™-substrate (25 µL). Solutions were mixed
thoroughly, and incubated for 10 minutes, at room temperature. Subsequently, the
reaction was stopped by the addition of 50 µL of the Fluor de Lys™-developer (KI-105; 1x)
plus 1 µM TSA, and left for an additional 10 minutes, at room temperature. Results were
then obtained by fluorescence emission and reading the samples in a luminescence
spectrophotometer, as described in Section 7.2.2. The results were expressed as %
activity of the control versus each concentration of BNIPP derivative (BNIPSpd,
BNIPDaoct, BNIPDaoxoct and BNIPDaCHM, at 10 and 50 μM), as described in Section
7.3.2.
7.3.4. In Vitro Assay for SIRT2 Enzyme Activity
The assay of SIRT2-inhibitory activity was performed using the Fluor de Lys™
fluorimetric drug discovery kit (AK-556) according to manufacturer’s instructions. Briefly,
the assay was carried out in a ½ volume white microplate (KI-110) using 186 µM Fluor de
Lys™-SIRT2 deacetylase peptide substrate (KI- 179), 547 µM NAD+ (KI-282),
recombinant hSir2SIRT2 enzyme (SIRT2; SE-251; 0.2U/µL) and sirtuin-assay buffer (KI-
286; HDAC assay buffer, KI-143, supplemented with 1 mg/mL BSA). The buffer, SIRT2-
enzyme, and suramin or BNIPP derivative in buffer (10 μM; 10 µL in 50 µL total volume of
reaction mixture) were equilibrated for 5 minutes, at 37 °C. The reaction was started by
the addition of the Fluor de Lys™-substrate with NAD+ (25 µL). Solutions were mixed
thoroughly, and incubated for 30 minutes, at 37 °C. Subsequently, the reaction was
stopped by the addition of 50 µL of the Fluor de Lys™-developer II (KI-176; 1x) plus 2 mM
Nicotinamide (KI-283), and left for an additional 45 minutes, at room temperature. After a
further 10 minutes, the results were obtained by reading the samples in a luminescence
spectrophotometer, as described in Section 7.2.2. The mean absorbance value for SIRT2
enzyme treated with different BNIPP derivatives were expressed as a % of untreated
SIRT2 enzyme (control). The mean absorbance value for the control was equal to 100%
as no SIRT2 enzyme inhibition was present. The results are shown as % activity of the
control versus each BNIPP derivative (BNIPSpd, BNIPDaoct, BNIPDanon, BNIPDaoxoct
and BNIPDaCHM, at 10 µM).
The SIRT2 enzyme (SE-251) is a 389 amino acid protein with a molecular weight
of 43 kDa; produced from human cDNA (Genbank accession no: #NM_012237)
expressed in Escherichia coli (E.coli). The SIRT2 enzyme is stored in 25 mM Tris, pH 7.5,
100 mM NaCl, 5mM dithiothreitol (DTT), and 10% glycerol, at -70 °C.
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7.3.5. In Vitro Assay for SIRT1 Enzyme Activity
The assay of SIRT1-inhibitory activity was performed using the Fluor de Lys™
fluorimetric drug discovery kit (AK-555) according to manufacturer’s instructions. Briefly,
the assay was carried out in a ½ volume white microplate (KI-110) using 64 µM Fluor de
Lys™-SIRT1 deacetylase peptide substrate (KI- 177), 558 µM NAD+ (KI-282),
recombinant hSir2SIRT1 enzyme (SE-239) and sirtuin-assay buffer (KI-286; HDAC assay
buffer, KI-143, see Section 7.3.4). The buffer, SIRT1-enzyme, and suramin, resveratrol or
BNIPP derivative in buffer (10 µM; 10 µL in 50 µL total volume of reaction mixture) were
equilibrated for 5 minutes, at 37 °C. The reaction was started by the addition of the Fluor
de Lys™-substrate with NAD+ (25 µL). Solutions were mixed thoroughly, and incubated
for 30 minutes, at 37 °C. Subsequently, the reaction was stopped by addition of 50 µL of
the Fluor de Lys™-developer II (KI-176; 1x) followed by 2 mM Nicotinamide (KI-283), and
left for an additional 45 minutes, at room temperature. After a further 10 minutes, the
results were obtained by reading the samples in a luminescence spectrophotometer as
described in Section 7.2.2. SIRT1 enzyme activity was expressed as % activity of the
control (untreated hSirSIRT1) versus each BNIPP derivative (BNIPSpd, BNIPDaoct,
BNIPDanon, BNIPDadec, BNIPDaoxaoct or BNIPDaCHM, at 10 μM), as described in
Section 7.3.4.
The SIRT1 enzyme (SE-239) is a 747 amino acid protein with a molecular weight
of 82 kDa; produced from human cDNA (Genbank accession no: #NM012238) expressed
in E.coli. The SIRT1 enzyme is stored in 25 mM Tris, pH 7.5, 100 mM NaCl, 5mM DTT,
and 10% glycerol, at -70 °C.
7.3.6. Molecular Modelling and Docking of BNIPP Derivatives
The molecular modelling and docking experiments of BNIPDanon, BNIPDaCHM,
BNIP(4,4)Dapm and BNIP(3,4)Dapm in hSIRT2 and hSIRT1 were conducted by Mr
Simranjeet Kaur and Dr. Nilanjan Roy (National Institute of Pharmaceutical Education and
Research, India) according to the method of Kadam et al. (2006) and Tavares et al.
(2010).
All molecular structures were generated and energy minimised with the
MODELLER and Sybyl molecular modelling systems (Section 7.2.2). The structure of
human SIRT2 (PDB ID 1J8F) was used as a template for both hSIRT2 and hSIRT1, and
was obtained from the Protein Data Bank, formerly the Brookhaven Protein Database
(available from www.pdb.org).
7.3.7. Data Analysis
Unless otherwise stated, each data set contained a minimum of three independent
experiments, in which each experiment was comprised of at least two internal replicates,
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expressed as mean ± Standard Error of the Mean (SEM). Statistical analysis was
conducted using a Student’s t-test. Data were considered significantly different when P-
value < 0.05.
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7.4. Results
The experimental work presented in this chapter is the first quantitative study of
HDAC activity to be undertaken with the bisnaphthalimidopropyl derivatives BNIPDaoxoct
and BNIPDaCHM.
7.4.1. Effect of BNIPP Derivatives on Class I HDAC Activity
The effect of BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM (10 µM) on
Class I HDAC activity (HDAC1 and HDAC2) was determined by the Color de Lys™ assay
system. HeLa nuclear extract, rich in HDAC activity was tested as the control, whilst TSA
(0.05 µM) was used as a positive control. The results are shown in Figure 7.12.
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Figure 7.12.: Class I HDAC activity was determined using the HDAC colorimetric assay/drug
discovery kit. HeLa nuclear extract was incubated (37 °C) with 0.2 mM Color de Lys-substrate and
TSA (0.05 µM; positive control) or BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM (10 µM).
Reactions were stopped after 30 minutes with Color de Lys-developer, and the absorbance
measured at 405 nm. Data are expressed as mean ± SEM of 3 independent experiments (n = 3).
*P<0.05, ***P<0.001 compared with control values.
TSA (0.05 μM) treatment induced a significant decrease (P < 0.001) in HDAC
activity (81% decrease) when compared to the control (i.e., untreated HeLa extract)
(Figure 7.12). However, no significant differences in HDAC activity were observed with 10
µM BNIPSpd, BNIPDaoct or BNIPDaoxoct when compared to the control (Figure 7.12).
Interestingly, BNIPDaCHM (10 μM) did induce a significant increase (P < 0.05) in HDAC
activity (64% increase) when compared to the control (Figure 7.12).
***
*
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7.4.2. Effect of BNIPP Derivatives on Class I and II HDAC
Activity
The effect of BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM (10 µM) on
class I (HDAC1-3 and HDAC8) and class II (HDAC4-7 and HDAC9-10) HDAC activity was
determined by the Fluor de Lys™ assay system. HeLa nuclear extract was tested as the
control, and TSA (0.05 µM) was used as a positive control. The results are shown in
Figure 7.13.
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Figure 7.13.: Class I and II HDAC activity was determined using the HDAC fluorimetric assay/drug
discovery kit. HeLa nuclear extract was incubated (room temperature) with 116 µM Fluor de Lys-
substrate and TSA (0.05 µM; positive control) or BNIPSpd, BNIPDaoct, BNIPDaoxoct and
BNIPDaCHM (10 μM). Reactions were stopped after 10 minutes with Fluor de Lys-developer, and
the fluorescence measured (excitation 360 nm, emission 460 nm). Data are expressed as mean ±
SEM of 3 independent experiments (n = 3). *P<0.05, ***P<0.001 compared with control values.
A significant decrease (P < 0.001) in HDAC activity (90% decrease) was induced
by 0.05 µM TSA, when compared to the control (i.e., untreated HeLa extract) (Figure
7.13). HDAC activity was not affected with BNIPSpd, BNIPDaoct or BNIPDaoxoct (10
µM) but with BNIPDaCHM (10 µM) a significant decrease (P < 0.05) in HDAC activity
(25% decrease) was observed, when compared with the control (Figure 7.13).
***
*
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7.4.3. Effect of BNIPP Derivatives on SIRT2 Enzyme Activity
The ability of BNIPSpd, BNIPDaoct, BNIPDanon, BNIPDadec, BNIPDaoxoct and
BNIPDaCHM (10 µM) to influence SIRT2 enzyme activity was determined by the Fluor de
Lys™-SIRT2 fluorescent assay system. Bisnaphthalimidopropyl diaminononane
(BNIPDanon) and Bisnaphthalimidopropyl diaminodecane (BNIPDadec) were also
investigated to determine what influence increasing the length of the central alkyl linker
chain (i.e., from 8 methylene groups to 9 - 10 methylene groups) would have on SIRT2
enzyme activity. Suramin (10 µM) was tested as a positive control. The results are
shown in Figure 7.14.
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Figure 7.14.: SIRT2 enzyme activity was determined using the SIRT2 fluorimetric drug discovery
kit. Recombinant hSir2SIRT2 enzyme was incubated (37 °C) with 186 µM Fluor de Lys™-SIRT2
substrate with 547 µM NAD+ and suramin, or BNIPP derivatives (10 µM). Reactions were stopped
after 30 minutes with Fluor de Lys™ developer II, and the fluorescence measured (excitation 360
nm, emission 460 nm). Data are expressed as mean ± SEM of 3 independent experiments (n = 3).
*P<0.05, **P<0.01, ***P<0.001 compared with control values.
Suramin (10 µM) treatment induced a significant decrease (P < 0.001) in SIRT2
enzyme activity (36% decrease) when compared to the control (Figure 7.14). Since high
concentrations of DMSO can affect SIRT2 enzyme activity; a 0.025% DMSO control (i.e.,
solvent control) was analysed, as shown in Figure 7.13. DMSO (0.025%) was found to be
a suitable solvent vehicle for the dilution of BNIPP derivatives prior to analysis in this
assay, because SIRT2 enzyme activity was not affected when compared to the control.
Two of the 6 BNIPP derivatives tested showed significant SIRT2 enzyme
activation (P < 0.01), at 10 µM (BNIPSpd, 15% increase, and BNIPDaoct, 6% increase)
when compared to the control (Figure 7.14). BNIPDanon and BNIPDaoxoct were
considered to be inactive, since SIRT2 enzyme activity was not affected by treatment at
10 µM (Figure 7.14). The remaining BNIPP derivatives, BNIPDadec (P < 0.05; 27%
decrease) and BNIPDaCHM (P < 0.001; a 41% decrease) showed significant SIRT2
enzyme inhibition, at 10 µM (Figure 7.14).
*** ***
**
**
*
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Given that BNIPDaCHM was the most active BNIPP derivative tested at 10 µM
(i.e., 41% decrease in SIRT2 enzyme activity compared to a 36% decrease with suramin)
(Figure 7.14), further analysis at various concentrations was carried out using the Fluor de
Lys™-SIRT2 fluorescent assay system. The results obtained are presented in Figure
7.15.
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Figure 7.15.: SIRT2 enzyme activity was determined using the SIRT2 fluorimetric drug discovery
kit. Recombinant hSir2SIRT2 enzyme was incubated (37 °C) with 186 µM Fluor de Lys™-SIRT2
substrate with 547 µM NAD+ and BNIPDaCHM. Reactions were stopped after 30 minutes with
Fluor de Lys™ developer, and the fluorescence measured (excitation 360 nm, emission 460 nm).
Data are expressed as mean ± SEM of 3 independent experiments (n = 3). **P<0.01, ***P<0.001
compared with control values.
From the results presented for BNIPDaCHM (Figure 7.15), all concentrations
tested (1 – 250 µM) induced a significant decrease (P < 0.01; at 1, 5, 10 and 250 µM; P <
0.001; at 50 µM) in SIRT2 enzyme activity, when compared to the control (Figure 7.15).
Interestingly, the most significant inhibition (P < 0.001) was observed at 50 µM, with a
54% decrease in activity. A saturation point appeared to have been reached at 50 µM,
since treatment with 250 µM BNIPDaCHM (50% decrease) was not able to further
decrease SIRT2 enzyme activity.
***
****
**
**
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7.4.4. Effect of BNIPP Derivatives on SIRT1 Enzyme Activity
The ability of BNIPSpd, BNIPDaoct, BNIPDanon, BNIPDadec, BNIPDaoxct and
BNIPDaCHM (10 µM) to influence SIRT1 enzyme activity was determined by the Fluor de
Lys™-SIRT1 fluorescent assay system. Suramin (10 µM) and resveratrol (10 µM) were
tested as positive controls for SIRT1 enzyme inhibition and activation, respectively.
Results are shown in Figure 7.16.
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Figure 7.16.: SIRT1 enzyme activity was determined using the SIRT1 fluorimetric drug discovery
kit. Recombinant hSir2SIRT1 enzyme was incubated (37 °C) with 64 µM Fluor de Lys™-SIRT1
substrate with 558 µM NAD+ and suramin, resveratrol or BNIPP derivatives (10 µM). Reactions
were stopped after 30 minutes with Fluor de Lys™ developer II, and the fluorescence measured
(excitation 360 nm, emission 460 nm). Data are expressed as mean ± SEM of 3 independent
experiments (n = 3). *P<0.05, ***P<0.001 compared with control values.
Suramin (10 µM) treatment induced a significant decrease (P < 0.001) in SIRT1
enzyme activity (91% decrease), whilst resveratrol (10 µM) treatment induced a significant
increase (P < 0.001) in SIRT1 enzyme activity (157% increase) when each was compared
to the control (Figure 7.16). SIRT1 enzyme activity was not affected by the solvent control
(i.e., 0.025% DMSO). Thus, DMSO (0.025%) was also a suitable solvent for the dilution
of BNIPP derivative in this fluorescent assay (refer to Section 7.4.3).
BNIPSpd, BNIPDaoct, BNIPDanon, BNIPDadec and BNIPDaCHM (10 µM) were
considered to be inactive since SIRT1 activity was not affected when compared with the
control (Figure 7.16). Therefore, only one among the 6 BNIPP derivatives tested showed
a significant effect (P < 0.01; 34% increase) on SIRT1 enzyme activity; BNIPDaoxoct (10
µM), when compared to the control (Figure 7.16).
***
***
*
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7.4.5. Examination of hSIRT2 and hSIRT1 Inhibitor Binding
Sites
BNIPDaCHM, the BNIPP derivative with the greatest observed inhibitory action
towards SIRT2 enzyme activity (refer to Section 7.4.3) was selected for docking studies to
determine its binding potential and validate its inhibitory action on hSIRT2 and hSIRT1
protein models. The results for BNIPDaCHM binding on hSIRT2 and hSIRT1 can be
found in Figures 7.17a and b, and 7.18a and b, respectively.
Figures 7.17a and 7.18a represent the results of docking BNIPDaCHM into the
NAD+ binding pocket (A, B and C pockets) of hSIRT2 or hSIRT1, respectively, with the
competitive binding of BNIPDaCHM with NAD+ on hSIRT2 and hSIRT1, respectively
shown in Figures 7.17b and 7.18b. BNIPDaCHM was found to bind within the NAD+
binding pocket, hence showing competition with NAD+, as shown in Figures 7.17 - 7.18a
and b. The docking scores for BNIPDaCHM binding on hSIRT2 and hSIRT1 were -13.648
and -21.240 kcal/mol-1, respectively (i.e., the more negative the docking score, the
stronger the interaction), and the numbers of hydrogen bonds formed were five and four
bonds, respectively (Tables 7.3 and 7.4). In hSIRT2, BNIPDaCHM interacts with the
residues Ser263 and Thr262 in the A pocket, and with His187 and Gln167 in the B pocket;
it is directed away from the C pocket, as shown in Figure 7.17. BNIPDaCHM shows an
interaction with the A and C pockets in hSIRT1, but not with the B pocket (Figure 7.17).
The residues involved in hydrogen bonding with BNIPDaCHM in hSIRT1 include Ser201
and Asn224 present in the A pocket, with Asn105 and Arg33 in the C pocket. Thus,
based on these docking studies, subtle differences in the docking mode of BNIPDaCHM
on hSIRT2 and hSIRT1 can be observed.
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Figure 7.17.: Docking studies of BNIPDaCHM (a) and competitive binding of BNIPDaCHM and
NAD+ (b) in the NAD+ binding pocket of hSIRT2. BNIPDaCHM is depicted as a ball and stick
model (carbon atoms are coloured white, nitrogen atoms in blue, oxygen atoms in red and
hydrogen atoms in turquoise), and the NAD+ molecule is shown in yellow. The A, B and C pockets
of the NAD+ binding site are indicated (a) (black letters).
a
b
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Figure 7.18.: Docking studies of BNIPDaCHM (a) and competitive binding of BNIPDaCHM and
NAD+ (b) in the NAD+ binding pocket of hSIRT1. BNIPDaCHM is depicted as a ball and stick
model (carbon atoms are coloured white, nitrogen atoms in blue, oxygen atoms in red and
hydrogen atoms in turquoise), and the NAD+ molecule is shown in yellow. The A, B and C pockets
of the NAD+ binding site are indicated (a) (black letters).
Based on the results obtained for BNIPDaCHM, additional docking studies on
hSIRT2 and hSIRT1 were carried out for the structurally similar BNIPP derivatives
BNIPDanon, BNIP(4,4)Dapm and BNIP(3,4)Dapm (Figure 7.19). The results obtained on
each protein model are shown in Tables 7.3 and 7.4.
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Figure 7.19.: Structures of bisnaphthalimidopropyl diaminononane (BNIPDanon), BNIPDaCHM,
bisnaphthalimidopropyl-4,4-diaminophenylmethane (BNIP(4,4)Dapm) and bisnaphthalimidopropyl-
3,4-diaminophenylmethane (BNIP(3,4)Dapm)
Table 7.3.: Docking studies for BNIPP derivatives in hSIRT2
BNIPP Derivative Docking Score
(kcal/mol-1)
H Bond Residues Total No. of H
Bonds
BNIPDanon -14.639 His187a, Gln267,
Ala85, Gly261,
Ser263
6
BNIPDaCHM -13.648 His187a, Gln167a,
Ser263, Thr262
5
BNIP(4,4)Dapm -21.626 Gln267, Gln167a 3
BNIP(3,4)Dapm -21.023 Phe234, Gln167a,
Ala85
3
a Residues in bold, i.e., His187 (His122 in hSIRT1) and Gln167 (Gln104 in hSIRT1) are reported
to have a role in SIRT2 enzyme catalysis (Finnin et al. 2001).
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Table 7.4.: Docking studies of BNIPP derivatives in hSIRT1
BNIPP Derivative Docking Score
(kcal/mol-1)
H Bond Residues Total No. of H
Bonds
BNIPDanon -14.770 Gln104a, Ser201,
Arg33, Asn224
5
BNIPDaCHM -21.240 Asn105, Ser01,
Arg33, Asn24
4
BNIP(4,4)Dapm -25.208 Arg33, Asp31,
Asn224
5
BNIP(3,4)Dapm -26.704 Gln104a, His122a,
Phe172
3
a Refer to footnote of Table 7.1.
The results presented in Tables 7.3 and 7.4 show that alterations to the central
alkyl linker chain increased interactions in the NAD+ binding pocket, since more negative
docking scores were observed with BNIP(4,4)Dapm and BNIP(3,4)Dapm, when compared
to BNIPDaCHM (Figures 7.17 and 7.18). The order of docking, as represented by
docking score (kcal/mol-1) in hSIRT2 was BNIP(4,4)Dapm > BNIP(3,4)Dapm >
BNIPDanon > BNIPDaCHM, whilst in hSIRT1, the order was BNIP(3,4)Dapm >
BNIP(4,4)Dapm > BNIPDaCHM > BNIPDanon. All BNIPP derivatives were found to bond
to hSIRT2 and hSIRT1 with at least one of the essential residues (i.e., His187 and Gln167
in hSIRT2, or His122 and Gln104 in hSIRT1), which are available to make hydrogen
bonds. Therefore, BNIP(4,4)Dapm and BNIP(3,4)Dapm could be the most potent SIRT2
and -1 inhibitors of the BNIPP derivative series, respectively.
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7.5. Discussion
Previous studies into the BNIPP derivatives has been focused on their effects on
(i) cell cytotoxicity, (ii) intracellular polyamine levels, (iii) cellular localisation and DNA
damage, (iv) their interaction with DNA, and (v) their mode of cell death (Pavlov et al.
2001, Dance et al. 2005, Ralton et al. 2009). The effect of BNIPP derivatives on the
regulation of HDAC activity, had not, thus far, been assessed.
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Figure 7.20.: Structures of the polyaminohydroxamic acids SV-63-41 (i) and SV-65-38C (ii), and
polyaminobenzamides SV-65-50C (iii) and SV-68-3 (iv).
Polyamine-based analogue induced HDAC inhibition has not been widely reported,
with research predominantly focused on Class I and II HDAC inhibition. A small number
of polyamine-based analogues, for example, polyaminohydroxamic acids (PAHAs; e.g.,
SV-63-41 and SV-65-38C) and polyaminobenzamides (PABAs; e.g., SV-65-50C and SV-
68-3) (Figure 7.20) have been found to inhibit HDAC activity by Boncher et al. (2007) and
Varghese et al. (2008) (Casero and Woster 2009). PAHA’s and PABA’s inhibition of
Class I and II HDACs was detected by the Fluor de Lys™ assay system (Boncher et al.
2007, Varghese et al. 2008). Varghese et al. (2008) found that the PAHA analogues SV-
63-41 and SV-65-38C produced 46.3 and 51.5 % inhibition of HDAC activity at 1 µM,
respectively, whilst the PABA analogues SV-65-50C and SV-68-3 produced 37.4 and
51.2% inhibition of HDAC activity, at 5 µM, respectively. It was also highlighted by
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Varghese et al. (2008) that HDAC inhibition with PAHAs and PABAs was increased as the
length of the linker chain was increased.
7.5.1. Effect of BNIPP Derivatives on Class I Activity
Class I (HDAC1 and -2) activity levels were measured by the Color de Lys™ assay
system (Huang et al. 2002) (Figure 7.8). Data showed that 10 µM of BNIPSpd,
BNIPDaoct or BNIPDaoxoct did not affect HDAC1 and -2 activity; however HDAC activity
was significantly increased (P < 0.05; a 64% increase) when the HeLa nuclear extract was
treated with 10 µM BNIPDaCHM (Figure 7.12). These results were similar to the findings
of Do et al. (2009), who studied HDAC activity in murine S91 and B16 melanoma cells
treated with sulforaphane microspheres2 (Figure 7.21) using the same colorimetric Color
de Lys™ assay system. HDAC activity was increased when compared to that of the
positive control (HeLa nuclear extract), when S91 and B16 cells were treated with 20 and
30 µM sulforaphane microspheres (Do et al. 2009). However, a decrease in HDAC
activity was observed in S91 and B16 cells treated with 50 µM of sulforaphane
microspheres when compared with control (Do et al. 2009). These findings may suggest
that a higher concentration of each BNIPP derivative (i.e., > 10 µM) may be required to
significantly decrease HDAC1 and -2 activities, in particular, decrease HDAC activation
observed after treatment with 10 µM of BNIPDaCHM.
S
N C S
O
H3C
Figure 7.21.: Structure of sulforaphane.
In contrast, Ohtsuki et al. (2009), who also studied HDAC activity using the same
colorimetric Color de Lys™ assay system found that for the first time, the N-methylpyrrole
(P) and N-methyllimidazole (I) polyamide (PI polyamide) SAHA conjugates, i and ii
(Figure 7.22) were able to significantly decrease (P < 0.05) HDAC activity at 1 µM.
2 Sulforaphane is an effective anticancer agent which acts by HDAC inhibition (Clarke et al. 2008,
Do et al. 2009). However, sulforaphane has a short half-life (i.e., < 2 hours) and is very unstable in
normal conditions due to its rapid metabolism and excretion. Therefore, to overcome these
problems, sulforaphane was encapsulated in albumin microspheres (Do et al. 2009).
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Figure 7.22.: Structures of the PI polyamine-SAHA conjugates, i and ii.
PI polyamide-SAHA conjugates, i and ii (Figure 7.22) contain, as their names
indicate, SAHA: the most potent hydroxamic acid-based inhibitor of class I, II and IV
HDACs (Ohtsuki et al. 2009, Smith and Workman 2009). The structure of SAHA is very
important to its overall HDAC inhibitory activity, in particular, the presence of a hydroxamic
acid group (i.e., a zinc binding functional group). The BNIPP derivatives were found to be
inactive as class I HDAC inhibitors (Section 7.4.1; Figure 7.12), and this could be due to
the absence of a hydroxamic acid group, rather than the naphthalimide groups. Scriptaid
(Figure 7.3), a HDAC inhibitor which possesses a naphthalimide group, a five methylene
linker chain and a hydroxamic acid group was observed to be an effective HDAC inhibitor
(i.e., > 100-fold increase in histone acetylation in cultured human pancreatic carcinoma
(PANC-1) cells) with low toxicity as reported by Su et al. (2000). Scriptaid does contain a
hydroxamic acid group, and therefore, supports the importance of hydroxamic acid-based
derivatives as potent (nM) class I HDAC inhibitors (Marks et al. 2000, Stimson et al.
2009).
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7.5.2. Effect of BNIPP Derivatives on Class I and Class II
HDAC Activity
A further assessment into the effect of BNIPP derivatives on HDAC activity levels
was conducted, where class I and II HDAC activity was measured by the Fluor de Lys™
assay system (Figure 7.9). HDAC enzyme activity was not altered by treatment with
BNIPSpd, BNIPDaoct or BNIPDaoxoct at 10 µM, but was significantly decreased (P <
0.05; a 25% decrease) when HeLa nuclear extract was treated with 10 µM BNIPDaCHM
(Figure 7.13). This finding suggests that BNIPDaCHM may inhibit class I and II HDAC
enzymes.
Caution should be employed when comparing the % inhibition results of the BNIPP
derivatives directly with other potential HDAC inhibitors investigated using the Fluor de
Lys™ assay system, since other groups, such as Son et al. (2007), Oyelere et al. (2009)
and Patil et al. (2010) tend to note HDAC enzyme activity as only an IC50 value (i.e., the
concentration that inhibits 50% of HDAC activity), which was not determined for the
BNIPP derivatives in this study.
Chen et al. (2008), who studied HDAC inhibition by a series of SAHA-like
hydroxamates incorporating a 1, 2, 3-triazole ring as a surface recognition cap discovered
that derivatives with cap groups consisting of naphthalenes and quinolines were potent
HDAC inhibitors (IC50 values ranged between 1.8 – 15.3 nM for naphthalenes; 2.1 – 151.5
nM for quinolines). However, Andrianov et al. (2009) reported that if a derivative
consisted of two aromatic groups linked together to form a tricyclic system; HDAC
inhibitory activity was lost (IC50 value 338 nM). Therefore, the lack of potent class I and II
HDAC inhibition observed after treatment with BNIPP derivatives could be due to the lack
of a hydroxamic acid group as discussed in Section 7.5.1, together with the presence of
two large aromatic caps (i.e., the naphthalimidopropyl groups). However, the replacement
of the naphthalimido groups with phthalimido groups could provide a suitable alternative.
Remiszewski et al. (2002) found two phthalimide derivatives with 5 and 6 carbon linker
chains were potent HDAC enzyme inhibitors with IC50 values of 0.515 and 0.357 μM,
respectively. Furthermore, Shinji et al. (2005) found that additional phthalimide-based
derivatives (Figure 7.23) could inhibit HDAC enzyme activity at nM levels (i.e., IC50 values
of 572, 358 and 709 nM on HDAC1, -4 and -6, respectively). Thus, the
bisphthalimidopropyl derivative BPHPDadec should be investigated to determine its
potential effects on class I and II HDAC inhibition.
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Figure 7.23.: Structures of (i) the phthalimido-based derivatives from Remiszewski et al. (2002),
and (ii) the most potent phthalimido-based derivative from Shinji et al. (2005).
In addition to the importance of cap size, it is also important to consider the length
of the linker chain. Chen et al. (2008) found that an increase in HDAC inhibition was
related to the presence of more methylene groups in the linker chain3. The observation
that linker chain length was an important structural feature required in achieving optimum
HDAC inhibition was also highlighted by Varghese et al. (2008) and Andrianov et al.
(2009). For that reason, the activity of SIRT1 and SIRT2 enzymes were monitored with
the inclusion of BNIPDanon and BNIPDadec to give an indication as to whether increasing
the length of the linker chain in BNIPP derivatives could increase their potential to inhibit
HDAC enzymes.
To date, no other symmetrical derivatives have been found to inhibit Class I and II
HDAC enzyme activity. Therefore, the BNIPP derivatives may provide a novel structural
backbone, unlike SAHA-based derivatives for potential Class I and II HDAC inhibition.
7.5.3. Effect of BNIPP Derivatives on SIRT2 Enzyme Activity
The effect of BNIPSpd, BNIPDaoct, BNIPDanon, BNIPDadec, BNIPDaoxoct and
BNIPDaCHM (10 µM) on SIRT2 enzyme activity was also determined by the Fluor de
Lys™ fluorescent assay system (Figure 7.10). As mentioned above, BNIPDanon and
BNIPDadec were investigated to determine their effect on SIRT2 enzyme activity with the
length of the central alkyl linker chain of the BNIPP derivatives being increased (> 8
methylene groups). Data showed that 10 µM of BNIPDanon or BNIPDaoxoct did not
affect SIRT2 enzyme activity and were considered to be inactive (Figure 7.14). However,
10 µM of BNIPSpd or BNIPDaoct significantly activated SIRT2 enzyme activity (P < 0.01;
a 15 and 6% increase, respectively), whereas, 10 µM of BNIPDadec and BNIPDaCHM
significantly inhibited SIRT2 enzyme activity (P < 0.05; a 27% decrease, and P < 0.001; a
41% decrease, respectively) (Figure 7.14). These results show that alkyl linker chain
length appears to contribute in some way in the activity of BNIPP derivatives against the
SIRT2 enzyme. For example, SIRT2 enzyme inhibition increases from BNIPDanon to
BNIPDadec; as the length of the alkyl linker chain increases from nine to ten methylene
3 IC50 values for derivatives with 5 – 6 methylene groups in the linker chain were 14.2 and 9.6 µM,
respectively whereas, derivatives with 3 – 4 methylene groups in the linker chain were not
determinable and 110.0 µM, respectively as determined by the Fluor de Lys™ assay system (Chen
et al. 2008).
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groups. The most effective and selective SIRT2 enzyme inhibitor in this series has two
cyclohexane rings in its linker chain (i.e., nine carbons), and was more potent than
suramin (10 μM; P < 0.001; a 36% decrease) (Figure 7.14). Inhibitory activity of suramin
(10 µM) towards SIRT2 was in agreement with the previously published results presented
in the BIOMOL International manufacturer’s instructions and Zhang et al. (2009) (i.e., an
IC50 value of 20.5 µM). Additional BNIPP derivatives will need to be examined to provide
a full assessment of the optimum alkyl linker chain length required for SIRT2 enzyme
inhibition.
It is important to note that a series of symmetrical SIRT2 enzyme inhibitors have
been synthesised by Kiviranta et al. (2006). In this series of derivatives, the backbone
contains a central aromatic group which is either a 1, 4-disubstituted benzene or
naphthalene group connected by a nitrogen atom with an amine or imine function
(Kiviranta et al. 2006) (Figure 7.23). These derivatives (Figure 7.24) contain similar
structural features to that of the BNIPP derivatives, especially BNIPDaCHM. Both sets of
derivatives contain a central aromatic group, which is disubstituted, and connected by a
nitrogen atom with amine functionality. This is very interesting since BNIPDaCHM was
found to be the most active and selective member of the BNIPP derivative series.
R3
R1R2
N N
R1 R2
R3
R = H, OH OR OCH3
Figure 7.24.: General structures of N, N’-Bisbenzylidenebenzene-1,4-diamines and N, N’-
Bisbenzylidenenaphthalene-1,4-diamines [Dashed bonds show the various structures for these
derivatives].
Surprisingly, the BNIPP derivatives bearing either a spermidine linker or eight
methylene groups within their linker chain (BNIPSpd and BNIPDaoct, respectively), did
not inhibit SIRT2 enzyme activity, but rather behaved as modest selective SIRT2 enzyme
activators at 10 µM (Figure 7.14). This is the first time that BNIPP derivatives have been
reported as SIRT2 enzyme activators, and is also a very important finding given that
SIRT2 enzyme activation has not been widely reported, with most research focused on
SIRT1 enzyme activation (Borra et al. 2005, Mai et al. 2009). Results are in agreement
with the findings of Mai et al. (2009), who studied activation and inhibition of SIRT1,
SIRT2 and SIRT3 enzyme activities with a series of 1, 4-Dihydropyridine (DHP)
derivatives at 50 µM by using the same Fluor de Lys™ assay system. Mai et al. (2009)
found that the insertion of a benzyl group in the N1 position of the DHP ring led to a dose-
dependent activation of all SIRT enzymes (i.e., by derivatives i (MC2562), ii (MC2563)
and iii (MC2566); Figure 7.25). However, if a cyclopropyl, phenyl or phenethyl group was
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inserted at the same N1 position; SIRT1 and -2 enzyme inhibition, not activation, was
evident (Mai et al. 2009).
COC2H5
C2H5OC
i
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ii
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H2N
iii
Figure 7.25.: Structures of the 1,4-Dihydropyridine derivatives, i (MC2562), ii (MC2563) and iii
(MC2566).
It is unclear at this stage the mode of action utilised by BNIPSpd and BNIPDaoct
for SIRT2 enzyme activation, but it appears that enzyme activation with these BNIPP
derivatives is specific for the SIRT2 enzyme, as shown by comparison with the results
obtained in the SIRT1 enzyme activity studies (Section 7.4.4; Figure 7.16).
7.5.4. Effect of BNIPP Derivatives on SIRT1 Enzyme Activity
The effect of BNIPSpd, BNIPDaoct, BNIPDanon, BNIPDadec, BNIPDaoxoct and
BNIPDaCHM (10 µM) on SIRT1 enzyme activity was determined by the Fluor de Lys™
fluorescent assay system (Figure 7.10). BNIPDanon and BNIPDadec were again
investigated to determine the effect of increasing the length of the alkyl linker chain (> 8
methylene.groups). The results show that 10 µM of BNIPDaoxoct significantly activated
SIRT1 enzyme activity (P < 0.01; a 34% increase); whilst the remaining BNIPP derivatives
did not affect SIRT1 enzyme activity, and were thus considered to be inactive (Figure
7.16). The significant inhibitory activity (P < 0.001; a 91% decrease) of suramin (10 µM)
towards SIRT1 was in agreement with results presented in the BIOMOL International
manufacturer’s instructions. However, it was found that in this Fluor de Lys™ assay,
suramin exerted a greater level of SIRT1 inhibition than has been previously reported by
Schuetz et al. (2007), Zhang et al. (2009) and Tavares et al. (2010).
The results towards the SIRT1 enzyme were in contrast to the SIRT2 enzyme
activity results (Figure 7.14), since alkyl chain length does not appear to contribute to an
increase in activity of the BNIPP derivatives. For example, the activity of the SIRT1
enzyme was not altered as the length of the alkyl linker chain was increased from eight to
ten methylene groups (i.e., from BNIPDaoct to BNIPDadec). This result was not
surprising as Tavares et al. (2010) had found that a greater level of SIRT1 inhibition was
observed by BNIPP derivatives with ≤ 6 methylene groups (e.g., BNIPDabut; IC50 73.1 µM
or BNIPDahex; IC50 93.5 µM).
The lack of SIRT1 enzyme inhibitory activity observed after treatment with the
BNIPP derivatives at 10 µM could be explained by the findings of Tavares et al. (2010).
Tavares et al. (2010) studied 12 BNIPP derivatives with regard to their activity against the
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human SIRT1 enzyme using a commercially available Cyclex SIRT1/Sir2 deacetylase
fluorimetric kit (Cyclex Co. Ltd, Japan), and found that all BNIPP derivatives were less
potent against SIRT1 than the Leishmania infantum SIR2-related protein 1 (LiSIR2RP1).
Four out of the 12 BNIPP derivatives tested by Tavares et al. (2010) (i.e., BNIPSpd,
BNIPDaoct, BNIPDanon and BNIPDadec) were also tested against the SIRT1 enzyme in
Section 7.4.4. These derivatives exhibited IC50 values of 94.8, 116.5, 97.4 and 113.8 µM,
respectively. Therefore, these findings suggest that a higher concentration of each BNIPP
derivative (i.e., > 10 µM) may be required to significantly inhibit the activity of the SIRT1
enzyme.
The selective activation of SIRT1 enzyme activity by BNIPDaoxoct was an
interesting and novel discovery. This result has identified a synthetic SIRT1 activator, with
a structural backbone that is unrelated to resveratrol or other recognized small-molecule
SIRT1 activators including SRT1720 (Figure 7.7).
The natural and synthetic SIRT1 activators resveratrol and SRT1720, respectively,
are structurally unrelated to one another (Figure 7.7); however they are both potent and
selective SIRT1 activators (Milne et al. 2007, Alcaín and Villalba 2009b, Baur 2009).
SRT1720 can bind to the same site on the SIRT1-acetylated peptide complex and can
mimic the same anti-ageing effects of calorie restriction, but is 1000 times more effective
than resveratrol (Milne et al. 2007, Alcaín and Villalba 2009b). Milne et al. (2007) found
that the potency of SRT1720 (i.e., the concentration of derivative required to increase
enzyme activity by 50%; EC1.5) was 0.16 µM with a maximum activation of 781%
(compared with an EC1.5 of 46.2 µM and maximum activation of 201% for resveratrol).
BNIPDaoxoct was not able to induce SIRT1 activation to the same extent as
resveratrol, as was evident in Figure 7.16. However, the results presented in Section
7.4.4 are in partial agreement with results revealed by Howitz et al. (2003) as to the level
of resveratrol activation achieved. Howitz et al. (2003) found that resveratrol could induce
a 2-fold increase at 11 µM, but in this study, it was found that resveratrol had induced a
2.5-fold increase in SIRT1 activation at 10 µM (P < 0.001; 157.2% increase). The results
also show that BNIPDaoxoct (P < 0.01; a 33.9% increase) was almost two times less
effective than resveratrol (P < 0.001; 157.2% increase) (Figure 7.16).
Borra et al. (2005) and Pacholec et al. (2010) have observed that the activation of
SIRT1 by resveratrol and SRT1720 is dependent upon an acetyl-peptide substrate
covalently attached to a non-physiological fluorophore, like that of the substrate available
in the Fluor de Lys™ assay system. No SIRT1 enzyme activation by either activator was
observed when the same acetylated peptide, lacking a fluorophore, was used (Denu
2005, Alcaín and Villalba 2009b). Given this information, the use of resveratrol or
SRT1720 to activate the SIRT1 enzyme has to be carefully interpreted (Denu 2005).
Therefore, further experiments will need to be conducted to confirm the direct or indirect
activation of the SIRT1 enzyme with BNIPDaoxoct.
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7.5.5. Examination of hSIRT2 and hSIRT1 Inhibitor Binding
Sites
The binding potential and inhibitory action of BNIPDaCHM were determined by
docking on to the crystal structures of hSIRT2 and hSIRT1 (Finnin et al. 2001).
BNIPDaCHM was found to be best suited as a SIRT2 inhibitor rather than a SIRT1
inhibitor, owing to its (i) low docking score (i.e., -13.648 kcal/mol-1), (ii) high number of
hydrogen bonds (i.e., five hydrogen bonds), (iii) greater interaction with the SIRT2 target
(i.e., hydrogen bonding with the residues His187, Gln167, Ser263 and Thr262), and (iv)
snug fit into the NAD+ binding pocket (Figure 7.17). These results can be related to the in
vitro SIRT2 activity studies (Section 7.4.4 and Figure 7.14), which show BNIPDaCHM to
be a potent SIRT2 inhibitor (P < 0.001; a 41.4% decrease).
In addition to BNIPDaCHM, three other BNIPP derivatives BNIPDanon,
BNIPDa(4,4)Dapm and BNIPDa(3,4)Dapm were investigated for their binding potentials
and inhibitory action on hSIRT2 and hSIRT1 (Tables 7.3 and 7.4). Data revealed that
alterations to the central alkyl linker chain such as, replacement of the two cyclohexane
rings (BNIPDaCHM) with (i) 9 methylene groups (BNIPDanon), (ii) para substituted
diphenylmethane groups (BNIP(4,4)Dapm), or (iii) meta substituted diphenylmethane
groups (BNIP(3,4)Dapm) resulted in an increase in docking score compared with
BNIPDaCHM (e.g., docking scores obtained with hSIRT2 were decreased from -13.648
kcal/mol-1 with BNIPDaCHM, to – 14.639, -21.023 and -21.626 kcal/mol-1 for BNIPDanon,
BNIP(3,4)Dapm and BNIP(4,4)Dapm, respectively; Table 7.3). In contrast to hSIRT2
results, the docking scores obtained with hSIRT1 revealed that BNIP(3,4)Dapm was the
most potent SIRT1 inhibitor (Table 7.4). It is important to note that docking scores can be
misleading, and are not absolute. Therefore, the docking score, position docked in the
NAD+ binding pocket, number of hydrogen bonds, and number of hydrogen bonds made
with important residues (i.e., His167 and Gln167 in hSIRT2, and Gln104 and His122 in
hSIRT1) of each BNIPP derivative needs to be considered before the most active BNIPP
derivative can be identified. As a result of these considerations, BNIPDaCHM and
BNIP(3,4)Dapm were identified as the most potent SIRT2 and SIRT1 inhibitors,
respectively.
The results presented for BNIPDanon on hSIRT1 were in agreement with those of
Tavares et al. (2010), who studied BNIPDanon in a similar hSIRT1 protein model.
BNIPDanon was found to be a good SIRT1 inhibitor with a low docking score (i.e., -15.8
kcal/mol-1), high interaction with the SIRT1 target (i.e., five hydrogen bonds), and was
shown to competitively bind to the NAD+ binding pocket.
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7.6. Conclusion
The BNIPP derivatives, BNIPSpd, BNIPDaoct, BNIPDaoxoct and BNIPDaCHM,
including BNIPDanon and BNIPDadec were tested in vitro for their effect on HDAC
activity. The most effective HDAC inhibitor was BNIPDaCHM with a 24.8 and 41.4%
decrease in Class I – II and SIRT2 enzyme activities at 10 µM, respectively, while the
most effective SIRT2 and SIRT1 enzyme activators were BNIPSpd (a 14.5% increase in
SIRT2 enzyme activity, at 10 μM) and BNIPDaoxoct (a 33.9% increase in SIRT1 enzyme
activity, at 10 µM), respectively. Furthermore, BNIPDaCHM exhibited potent and selective
SIRT2 enzyme inhibitor properties, with the ability to bind strongly to the NAD+ binding
pocket by the formation of hydrogen bonds with the residues His187 and Gln167.
In conclusion, symmetrical BNIPP derivatives with a novel structural backbone
have, for the first time, been identified as potential effective and selective HDAC inhibitors,
and activators.
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Chapter 8
Final Summary, Conclusion and Future Work
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8.1. Final Summary and Conclusion
The aim of this study was to synthesise new bisnaphthalimidopropyl polyamine
(BNIPP) derivatives and evaluate their effect and mode of action in a breast cancer cell
system. The work presented in this study is complementary to the work previously
undertaken by Kong Thoo Lin and Pavlov (2000), Pavlov et al. (2001), Kong Thoo Lin et
al. (2003), Dance et al. (2005), Oliveira et al. (2007) and Ralton et al. (2009).
It was essential to determine the influence of BNIPP derivatives on their DNA
binding ability, as DNA is an important and valuable target in anti cancer drug design.
The strong DNA binding affinities observed in this study may account for the subsequent
changes to cell morphology, cytotoxicity and DNA instability (i.e., through DNA strand
breaks and repair mechanisms) detected after BNIPP derivative treatment in MDA-MB-
231 and MCF-10A cells. Apoptotic cell death was determined in breast cancer MDA-MB-
231 cells to identify the mode of cell death attained by BNIPP derivatives. Interestingly,
apoptosis had been previously observed in HL-60 promyelocytic leukaemia cells (Kong
Thoo Lin et al. 2003) and colon cancer (CaCO-2 and HT-29) cells (Ralton et al. 2009). In
addition, effects of BNIPP derivative treatment on cell cycle distribution and p53 and
p21Waf1/Cip1 mRNA expression levels were determined to further evaluate the mode of cell
death. Finally, it was important to investigate the potential role of the BNIPP derivatives
on HDAC inhibition, since HDAC inhibitors have shown promise as anti cancer agents.
Four new BNIPP derivatives (BNIPDaoxoct, BNIPDaCHM, BPHPDadec and NPA)
were successfully synthesised by modification of the N-alkylation reaction previously used
to synthesise the parent BNIPP derivatives (Kong Thoo Lin and Pavlov 2000, Oliveira et
al. 2007). The simple and reproducible three step procedure (Scheme A and B; Chapter
2) utilised in this study was highly convenient, adaptable and could easily be used for the
synthesis of future BNIPP and related derivatives (as it has been employed by Filosa et al.
2009).
The BNIPP derivatives interact with DNA by bis-intercalation (i.e., via the
naphthalimido groups) and groove binding (i.e., via the aminoalkyl linker chain). The
results presented in this study are in agreement with those previously obtained by Pavlov
et al. (2001) and Dance et al. (2005). BNIPDahex was the most active BNIPP derivative
(Δ Tm 35.7 °C) closely followed by BNIPSpd (Δ Tm 35.3 °C); both of which had a greater
DNA affinity than the extensively studied intercalator, doxorubicin (Δ Tm 30.2 °C) (Table
3.1). It was observed that modifications to the central linker chain resulted in changes to
DNA binding affinity. BNIPP derivatives whose central linker chain resembled that of the
natural polyamines (i.e., spermidine or spermine) (Pavlov et al. 2001, Dance et al. 2005)
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exhibited a higher degree of DNA binding affinity than their linear alkyl linker counterparts
(Tables 3.1 and 3.3). BNIPPut, BNIPDahex and BNIPDaoct with 4, 6 and 8 methylene
groups respectively exhibited high DNA binding affinities (Δ Tm values ranging between
32.5 - 35.7 °C) whereas DNA binding affinity was reduced with BNIPDadec and
BNIPDadodec with 10 and 12 methylene groups respectively (Δ Tm values of 28.2 and
25.0 °C). The new BNIPP derivatives, BNIPDaoxoct and BNIPDaCHM exhibited a
marginal decrease in DNA binding affinity compared with the more active BNIPP
derivatives (i.e., BNIPPut, BNIPDahex or BNIPDaoct), with Δ Tm values of 31.7 and 31.2
°C, respectively; but were more effective than BNIPP derivatives with a linker chain of > 8
methylene groups (Tables 3.1 and 3.3). It was found that BPHPDadec and NPA were not
effective DNA intercalators (Δ Tm values of 15.8 and 10.1 °C, respectively and C50 values
of > 10 µM; Tables 3.1 and 3.3). This emphasises the importance of
bisnaphthalimidopropyl functionality and an optimum alkyl linker chain length of between 4
– 8 methylene groups.
BNIPP derivatives (except BPHPDadec and NPA; IC50 values > 40 µM) were
cytotoxic in both cell lines (MDA-MB-231 (Table 4.2) and MCF-10A (Table 4.3) cells).
Cytotoxicity was also affected by modifications to the central linker chain, for example, in
MDA-MB-231 cells, alterations to the spermidine linker chain (BNIPSpd) with removal of a
nitrogen atom (BNIPDaoct) or replacement with two cyclohexane rings resulted in an
increase in cytotoxicity (IC50 values decreased from 12.7 µM with BNIPSpd to 5.0 and 6.8
μM for BNIPDaoct and BNIPDaCHM, respectively (Table 4.2).
In MDA-MB-231 and MCF-10A cells, the BNIPP derivatives BNIPSpd, BNIPDaoct,
BNIPDaoxoct and BNIPDaCHM resulted in alterations to cell morphology (Figures 4.9 –
4.11). Furthermore, MDA-MB-231 cells treated with BNIPDaoct and BNIPDaCHM
exhibited fluorescence after 0.5 hours. BNIPSpd and BNIPDaoxoct, however, required a
longer incubation time to enter the cell, as fluorescence was not observed until after 6
hours (Figure 4.15), suggesting that uptake time might be related to cytotoxicity in MDA-
MB-231 cells as BNIPDaoct and BNIPDaCHM were observed to have a higher toxicity
(IC50 values 5.0 and 6.8 µM after 24 hours, respectively; Table 4.2) and faster uptake (0.5
hours) than BNIPSpd and BNIPDaoxoct (IC50 values 12.7 and 12.4 µM after 24 hours,
respectively; Table 4.2; observed after 6 hours). A different mechanism of cellular uptake
and entry unrelated to cytotoxicity was observed in MCF-10A cells treated with BNIPSpd,
BNIPDaoct, BNIPDaoxoct or BNIPDaCHM. Fluorescence was observed after 0.5 hours in
MCF-10A cells treated with BNIPDaoct and BNIPDaCHM; BNIPDaoxoct treated MCF-10A
cells showed fluorescence after 2 hours, whereas MCF-10A cells treated with BNIPSpd
showed fluorescence after 6 hours (Figure 4.16). The results suggest that BNIPP
derivative uptake is cell line dependent.
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Four BNIPP derivatives (i.e., BNIPSpd, BNIPDaoct, BNIPDaoxoct and
BNIPDaCHM with different modifications to the central linker chain) were chosen to
determine whether these BNIPP derivatives entered cells via the MGBG-specific PAT and
reduced intracellular polyamine levels. None of the BNIPP derivatives chosen entered
cells by use of the MGBG-specific PAT, as CHO-MG/CHO IC50 ratios ranged from 0.4 –
1.0 (Table 4.4). The BNIPP derivatives must, therefore, utilise alternative entry
mechanisms that are independent of the MGBG-specific PAT, such as, passive diffusion
or through another transporter, as suggested by Gardner et al. (2004) for N1-
arylalkylpolyamines. It is possible that BNIPP derivatives are too large to be imported into
cells via the MGBG-specific PAT system, as suggested by Kaur et al. (2008b) for large N1-
cargoes (e.g., N-[4-(4-amino-butylamino)-butyl]-N’-(4,6-dihydro-pyren-1-ylmethyl)-butane-
1,4-diamine). The BNIPP derivatives were able to induce different responses in
intracellular polyamine levels in MDA-MB-231 and MCF-10A cells. Responses included:
(i) no change (i.e., BNIPDaCHM and BNIPSpd (0.1 – 5 μM) in MDA-MB-231 and
MCF-10A cells, respectively; Figures 4.19 and 4.20)
(ii) an increase (i.e., BNIPSpd, BNIPDaoct and BNIPDaoxoct (0.1 μM) in MDA-
MB-231 cells (Figures 4.16 – 4.18), and BNIPDaoxoct and BNIPDaCHM (0.1
μM) in MCF-10A cells (Figures 4.22 and 4.23)
(iii) a decrease (i.e., BNIPSpd and BNIPDaoct (5 µM) significantly reduced
intracellular polyamine levels in MDA-MB-231 cells (P < 0.05 and P < 0.01,
respectively; Figures 4.16 and 4.17), whilst BNIPDaoct (5 μM) and
BNIPDaoxoct (≥ 1 μM) significantly reduced intracellular polyamine levels in
MCF-10A cells (P < 0.05; Figures 4.21 and 4.22) in intracellular polyamine
levels.
The reduction of intracellular polyamine levels could be responsible for the toxicity
of BNIPSpd or BNIPDaoct, but not in the case of BNIPDaCHM within MDA-MB-231 cells.
Intracellular DNA stability was assessed to support BNIPP derivative induced
cytotoxicity and, in the case of BNIPSpd treated cells, to support the significant reduction
(P < 0.05) of intracellular polyamine levels. BNIPSpd and BNIPDaCHM significantly
induced (P < 0.05) DNA strand breaks above endogenous levels in a dose dependent
manner in both cell lines (MDA-MB-231 and MCF-10A cells). However, BNIPSpd
required a longer treatment time to induce the same level of DNA strand breaks as
BNIPDaCHM in MDA-MB-231 cells (Figures 5.7 and 5.8). These results suggest that
DNA strand breaks may be related to:
(i) cellular uptake studies, as BNIPDaCHM was observed after 0.5 hours, whilst
BNIPSpd was not observed until after 6 hours (Figure 4.15)
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(i) cytotoxicity, as BNIPDaCHM was more cytotoxic (IC50 6.8 μM) than BNIPSpd
(IC50 12.7 μM) after 24 hours (Table 4.2)
(ii) DNA binding affinity via bis-intercalation (Δ Tm 35.3 and 31.2 °C, for BNIPSpd
and BNIPDaCHM, respectively).
However, MCF-10A cells were more sensitive to the effect of BNIPSpd than
BNIPDaCHM (Figures 5.19 and 5.10). These results indicate that DNA damage is a
principal mode of action for BNIPSpd and BNIPDaCHM in MDA-MB-231 and MCF-10A
cells
It was important to determine the effect of BNIPP derivatives on DNA repair
mechanisms, as cells have an inherent ability to effectively remove and repair DNA
damage. BNIPSpd and BNIPDaCHM were found to significantly inhibit the ability of MDA-
MB-231 cells to repair oxidative-induced DNA damage at non toxic concentrations (i.e.,
concentrations that did not induce significant changes to DNA strand breaks nor induced
cytotoxicity in MDA-MB-231 cells), even after 24 hours. However, following MMS-induced
DNA damage, BNIPDaCHM did not inhibit the ability of MDA-MB-231 cells to repair DNA
damage. Thus, BNIPDaCHM induces contrasting effects on the repair of DNA strand
breaks. The results, however, confirm that DNA damage induced by MMS was greater
and more dramatic than oxidative-induced DNA damage (Lundin et al. 2005, Duthie.
personal communication). Therefore, the inability to repair DNA damage following
treatment with either BNIPSpd or BNIPDaCHM could be exploited to increase DNA strand
breaks, and induce apoptotic cell death.
Apoptotic cell death was preliminarily investigated in this study in BNIPSpd or
BNIPDaCHM treated MDA-MB-231 cells. BNIPSpd and BNIPDaCHM induced apoptosis
(i.e., by loss of plasma membrane integrity, PS externalisation and increase in the
proportion in sub-G1 population) and, BNIPDaCHM resulted in a decrease of cell number,
in a time dependent manner (0.5 – 24 hours). Interestingly, apoptotic cell death was
observed after only 0.5 hours treatment; a remarkable and novel discovery for derivatives
belonging to the BNIPP family. 7-AAD labelling was also prominent after 0.5 hours, thus
indicating the strong presence of necrotic cells (P < 0.001; a 0.30 increase with BNIPSpd,
and P < 0.001; a 0.42 increase with BNIPDaCHM; Figure 6.10). Cell cycle arrest was not
evident after 24 hours, although p21Waf1/Cip1 mRNA expression was significantly over
expressed (P < 0.01; a 24.7% increase; Figure 6.20) in a p53-independent manner after 4
hours treatment with BNIPDaCHM (5 µM). BNIPSpd did not alter p53 or p21Waf1/Cip1
mRNA expression levels after 4 hours in MDA-MB-231 cells. It can be hypothesised that
BNIPSpd and BNIPDaCHM initiate cell death by different mechanisms (Figures 8.1 and
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8.2), and modifications to the central linker chain have resulted in dramatic changes to the
individual response produced.
As HDACs are responsible for the control of gene expression including the
activation of DNA damage and induction of p21Waf1/Cip1 mRNA expression levels; it was
important to determine the effect of BNIPP derivatives with modifications to their central
linker chain on HDAC inhibition. BNIPDaCHM (10 µM) was the most effective HDAC
inhibitor as demonstrated by a 24.8% (P < 0.05) decrease in Class I-II activity (Figure
7.12) and a 41.4% (P < 0.001) decrease in SIRT2 enzyme activity (Figure 7.13). In
addition, BNIPDaCHM was also found to be a potent and selective SIRT2 enzyme
inhibitor as demonstrated by strong binding to the NAD+ binding pocket (i.e., formation of
hydrogen bonds with His187 and Gln167 residues). BNIPSpd (10 µM), however, was an
effective SIRT2 activator (a 14.5% (P < 0.01) increase). Once more modifications to the
central linker chain appeared to contribute to the activity of BNIPP derivatives against
HDAC inhibition, in particular, SIRT2 enzyme activity (e.g., alterations to the central linker
chain with an increase in alkyl length from nine to ten methylene groups (BNIPDanon to
BNIPDadec) or replacement with two cyclohexane rings (BNIPDaCHM) resulted in an
increase in HDAC inhibition; Figure 7.13).
The results discussed in this study indicate that BNIPSpd and BNIPDaCHM have
different modes of action in treated MDA-MB-231 cells. The proposed modes of actions
are presented in Figures 8.1 and 8.2.
Finally, the BNIPP derivative that would be offered to a manufacturer for further
development would be BNIPDaCHM. This is due to its ability to induce a cytotoxic effect
(at a µM level), fast cellular uptake (0.5 hours), induction of significant DNA strand breaks
(> 1 µM), and early apoptotic cell death (0.5 hours) and, the potent and selective inhibition
of the SIRT2 enzyme. Thus, providing a potential anti cancer agent.
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Figure 8.1.: Schematic representation of the mode of action of BNIPSpd in MDA-MB-231 cells
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Figure 8.2.: Schematic representation of the mode of action of BNIPDaCHM in MDA-MB-231 cells
[Key: - - - denotes possible mode of action]
247
8.2. Future Work
8.2.1. DNA Binding Affinity
All BNIPP derivatives were found to interact with DNA through bis-intercalation
and it was proposed that the mechanism of groove binding may be utilised. Therefore, to
further determine the DNA binding affinity of these derivatives; it is important to verify their
groove binding potential and sequence specificity, allowing a complete study and
comparison with structurally related derivatives, via NMR spectroscopy (Strekowski and
Wilson 2007). Furthermore, repeating the molecular modelling with a more suitable DNA
duplex model (with various spacers between the DNA intercalation sites) could provide a
better computational model for high throughput screening of future BNIPP and related
derivatives.
8.2.2. Cellular Uptake and Localisation
Although experiments into the exact cellular location of BNIPP derivatives could
not be conducted in this study; it would be of benefit to explore this area further as an
indication of BNIPP derivative action. Analysis of specific cell organelles after BNIPP
treatment would further elucidate their mode of action in a breast cancer cell system, for
example, use of nuclear specific Picogreen quenching by flow cytometry to analyse
mitochondrial DNA, as carried out by Ashley and Poulton (2009), or real time fluorescence
microscopy to analyse cell distribution undertaken by Peixoto et al. (2009).
8.2.3. DNA Damage and Repair
Both BNIPP derivatives were able to induce DNA strand breaks and hinder DNA
repair suggesting a principal mode of action for BNIPSpd and BNIPDaCHM in MDA-MB-
231 cells. To further elucidate their mode of action, with regards to DNA repair
mechanisms; it is important to investigate the main DNA repair pathways (Section 5.1.2;
Figure 5.2) by, for example, microarray analysis of gene expression (Collins 1996, Damia
and D’Incalci 2007, Ljungman 2009). This would offer a valuable insight into the potential
these derivatives have as anti cancer agents. In addition, analysis into the regulation of
specific DNA repair enzymes, for example, O6-alkylguanine-DNA-alkyltransferase (AGT)
or poly (ADP-ribose) polymerase (PARP) could provide opportunities by which to identify
novel targets for, or increase the known DNA damaging abilities of BNIPSpd or
BNIPDaCHM (Damia and D’Incalci 2007).
As the accumulation of DNA damage and defects in DNA repair mechanisms have
been linked to HDAC inhibition (Gaymes et al. 2006); it would be encouraging to analyse
248
and confirm that DNA damage was caused by HDAC inhibition after BNIPP derivative
treatment.
8.2.4. Mode of Cell Death
Apoptosis induced in MDA-MB-231 cells by BNIPSpd and BNIPDaCHM was
investigated in this study using morphological (i.e., AO/EB staining observed via
fluorescence microscopy) and biochemical detection methods (i.e., PS externalisation by
annexin V-FITC staining and 7-AAD labelling, and detection of a sub-G1 population
through PI staining). The observation that apoptotic cell death was induced by BNIPSpd
and BNIPDaCHM should be confirmed by further investigations including, caspase
activation (i.e., caspase-3, 7 and 8), DNA fragmentation, and also a detailed analysis into
the principal biochemical mediators of apoptosis, in particular, the pro- (Bax, Bak, etc.)
and antiapoptotic families (Bcl-2, Bcl-XL, etc.) (Carew et al. 2008).
Apoptotic cell death was observed in BNIPSpd and BNIPDaCHM (5 µM) treated
cells after only 0.5 hours; however, necrotic cells were also evident (Figure 6.10). This
implies that BNIPSpd and BNIPDaCHM could activate other forms of cell death, rather
than apoptosis, for example, mitotic catastrophe, necrosis, autophagy or senescence
(Cohen-Jonathan et al. 1999, Mansilla et al. 2006, Portugal et al. 2009). These forms of
cell death (in particular, mitotic catastrophe explained by abnormal mitosis caused by a
p53 mutation) (Bertheau et al. 2008) can be determined, for example, by characterising
the main DNA repair pathways (refer to Section 8.2.3) and investigating protein levels
during mitosis (Cahuzac et al. 2010).
8.2.5. Cell Cycle Regulation
Cell cycle arrest in MDA-MB-231 cells treated with BNIPSpd and BNIPDaCHM
was not evident after 24 hours following PI staining, even though p21Waf1/Cip1 mRNA
expression was induced in a p53-independent manner: a classical mechanism in HDAC
inhibitor-induced cell cycle arrest (Carew et al. 2008). Further research into the CDK-
Cip/Kip family, including p27Kip1 (Park and Lee 2003) would be required (Rao et al. 1998).
Supplementary studies into the cyclin D and E families should also be investigated to
determine the role that BNIPP derivatives have on cell cycle regulation (Rao et al. 1998).
8.2.6. HDAC Inhibition
The preliminary investigation into HDAC inhibition by BNIPP derivatives found that
BNIPDaCHM was a more potent and selective SIRT2 enzyme inhibitor than suramin (a
known SIRT2 inhibitor) (Zhang et al. 2009). Thus, determining the further potential of
BNIPDaCHM as a selective SIRT2 inhibitor would establish a novel mode of action for
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BNIPP derivatives. For that reason, all BNIPP derivatives will need to be examined, thus,
providing a full assessment into what effect modifications to the central linker chain have
on HDAC inhibition.
As SIRT2 inhibitors have been shown to target α tubulin, and deacetylate histone
H4 (North et al. 2003, Schemies et al. 2009); it would be important to determine the ability
of BNIPDaCHM to elicit an effect on each of these SIRT2 targets in vitro.
As ERs play an important role in cell proliferation, and since they are positively or
negatively regulated by HATs or HDACs, respectively (Im et al. 2008); further
investigations could provide an important link between BNIPP derivatives, ERs and HDAC
activity. Additionally, to determine cell-specific mechanisms; it would be beneficial to
evaluate cell cycle arrest and induction of apoptotic cell death within ER positive breast
cancer cells (previously investigated by Dance et al. 2005).
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New naphthalimidopropyl, bisphthalimidopropyl and bisnaphthalimidopropyl (BNIP) derivatives were
synthesised and characterised. Their interactions with Calf Thymus DNA were studied by UV spectro-
photometric analysis and a competitive Ethidium bromide displacement assay. Cytotoxicity was deter-
mined by MTT assay in a breast cell system (MDA-MB-231 and MCF-10A cells). All BNIPs exhibited strong
DNA-binding properties and cytotoxic activity with IC50 values in the range of 0.83–12.68 mM (24 and
48 h treatment). In addition, the uptake of BNIP derivatives within cancer cells was not via utilisation of
the MGBG polyamine transporter. Put together the results conﬁrm that the presence of the bisnaph-
thalimidopropyl and alkyl linker functionality are crucial for exerting DNA-binding and cytotoxic
properties, hence demonstrating promise in their further development as potential anti cancer agents.
 2009 Elsevier Masson SAS. All rights reserved.1. Introduction
DNA-binding compounds, such as, the cytotoxic DNA-inter-
calating compounds, naphthalimides and bisnaphthalimides have
been shown to exert potential anti cancer activity [1–3]. However
these compounds tend to be insoluble in aqueous solutions, thus
making their testing difﬁcult [4]. For a number of years, we have
been designing and synthesising bisnaphthalimidopropyl deriva-
tives (BNIPs) linked to natural polyamines [5] and to a selection of
diamino and triamino alkyl chains, which resulted in enhanced
aqueous solubility, without compromising their biological activity
against a panel of cancer cell lines [6–8]. Furthermore, Bisnaph-
thalimidopropyl spermidine (BNIPSpd) (Fig. 1), the most active
member of the BNIP series was shown to cause cell death byputrescine; BNIPDahex, Bis-
Bisnaphthalimidopropyl dia-
aminodecane; BNIPDadodec,
oct, Bisnaphthalimidopropyl
ropyl diaminodicyclohexyl-
thylsulfoxide; MTT, 3-(4,5-
de; Tm, midpoint of thermal
: þ44 1224 262828.
in).
son SAS. All rights reserved.apoptosis, deplete polyamine pools in drug treated cells, and also
induce oxidative DNA damage at a non toxic concentration [8,9]. In
addition to our current research, Filosa et al. [10] have recently
reported the synthesis and biological activity of a number of bis-
naphthalimido derivatives containing heterocycles and other cyclic
moieties, such as, piperazine, cis-dimethylpiperazine, diazabicyclo
[3.2.1] octane and cyclopropane. These compounds exhibited in
vitro cytotoxicity with IC50 values ranging from 0.04 to 6.1 mM after
72 h treatment in human colon carcinoma HT-29 cells [10].
Here, we report the synthesis of a selection of new derivatives:
bisnaphthalimidopropyl diamino alkylamines (BNIPDahex, BNIP-
Dadodec, BNIPDaoxoct, BNIPDaCHM), bisphthalimidopropyl
diaminodecane (BPHPDadec) and mononaphthalimidopropyl-
amine (NPA) (Fig. 2). The rationale for synthesising these analogues
(Fig. 2) was to demonstrate that the bisnaphthalimido moiety is
essential for biological activity. For example, in BPHPdadec, the
naphthalimido rings had been replaced by phthalimido rings, and
in NPA, only one naphthalimido ring was present. Furthermore
oxygen atoms or cyclohexane rings were also introduced into the
linker chain to determine whether the biological activity of these
derivatives would be affected, bearing in mind that earlier work
demonstrated that the length of the linker chain was important for
enhanced solubility and effective biological activity [7]. The DNA-
binding afﬁnity was studied using UV and ﬂuorescence spectros-
copy, and cytotoxicity against human breast MDA-MB-231 and
NO
O
N
H
N
H
H
N N
O
O.3HBr
Fig. 1. Structure of bisnaphthalimidopropyl spermidine (BNIPSpd).
G.A. Barron et al. / European Journal of Medicinal Chemistry 45 (2010) 1430–1437 1431MCF-10A cells was evaluated with the MTT assay. The results were
compared with previously synthesised analogues: BNIPSpd, BNIP-
Put, BNIPDaoct and BNIPDadec [5,7,9]. By using ﬂuorescence
microscopy and exploiting the inherent ﬂuorescent properties of
these derivatives, BNIPSpm and BNIPSpd were found to be located
within human breast carcinoma MCF-7 cells after 6 h drug expo-
sure [9]. In this paper, we have extended these studies to assess the
relationship between uptake times and cytotoxicity of BNIPSpd,
BNIPDaoct, BNIPDaoxoct and BNIPDaCHM (10 mM) in MDA-MB-231
cells. Furthermore, we have also for the ﬁrst time determined
whether these BNIP derivatives enter cells via the polyamine
transport system (PAT) [11]. Chinese hamster ovary (CHO) cells and
a PAT deﬁcient mutant cell line (CHO-MG) were used to assess the
selective transport of these BNIP derivatives via the PAT system
[12–16].
2. Results and discussion
2.1. Chemistry
The synthetic strategy (Scheme 1A) adopted to synthesise the
bisnapthalimidopropyl diamino analogues; BNIPDahex, BNIPDa-
dodec, BNIPDaoxoct and BNIPDaCHM was based on methods
previously developed [5,7,9]. The common starting material in the
synthesis of BNIPDahex, BNIPDadodec, BNIPDaoxoct and BNIP-
DaCHMwas toluenesulfonyloxypropylnaphthalimide, 2, which wasH
N
N
H
N
H
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Fig. 2. Structures of the new bisnaphthalimidopropylalkyl-diamine, bisphthalimprepared from N-(3-hydroxypropyl) naphthalimide, 1. Protection
and activation of the alkyldiamines was carried out with mesity-
lenesulfonyl chloride in pyridine at room temperature to give
compounds 3–6 in high yield. For the synthesis of the fully pro-
tected BNIP derivatives, N-alkylation with toluenesulfonylox-
ypropylnaphthalimide, 2, in the presence of caesium carbonate in
anhydrous DMF yielded fully protected BNIP derivatives which
upon deprotection with hydrobromic acid/glacial acetic acid in
CH2Cl2 gave BNIPDahex, BNIPDadodec, BNIPDaoxoct and BNIP-
DaCHM, as their corresponding dihydrobromide salts. To synthesise
naphthalimidopropylamine (NPA) (Scheme 1A), nucleophilic
substitution of the O-tosyl group from 2 was achieved with
potassium phthalimide. Treatment with hydrazine hydrate gave
the corresponding amine that was converted to its hydrochloric
salt, NPA. BPHPDadec was synthesised by treating dimesitylene-
diaminodecane, 7, with N-(3-bromopropyl) phthalimide in DMF in
the presence of caesium carbonate (Scheme 1B). Subsequent
deprotection with hydrobromic acid/glacial gave BPHPDadec. All
derivatives studied exhibited good solubility (50% DMSO/water) at
10 mM concentration and were stored at 0–5 C.
2.2. Biological activities
2.2.1. DNA-binding properties
The midpoint of thermal denaturation (Tm) of Calf Thymus DNA
duplexes in the presence of the synthesised BNIP derivatives wasO
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Scheme 1. A: Synthetic strategy for the synthesis of bisnaphthalimidopropylalkyl-diamine derivatives. Reagents and Conditions: (i) tosyl-Cl, Pyridine, 0–5 C, 12 h (ii) 2, Mts,
Cs2CO3, DMF, 85 C, 12 h for 3 and 4, 50 C, 96 h for 5 and 6. (iii) HBr/glacial CH3CO2H, CH2Cl2, RT, 24 h (iv) tosyl-Cl, C8H4KNO2, DMF, 50 C, 12 h (v) 8, C2H5OH, hydrazine hydrate,
85 C, 12 h; Ethanol/conc. HCl. B: (vi) 7, N-(3-(bromopropyl) phthalimide, Cs2CO3, DMF, 85 C, 12 h.
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DNA intercalators [17–19] were used as positive controls and the
results are presented in Table 1.
All BNIP derivatives (10 mM) showed an increase in Tm ranging
between D 25.0–35.7 C when compared to the melting point of
a Calf ThymusDNAduplex. The increase inTm from these derivatives
is in the same range as the positive controls (doxorubicin (D
30.2 C) and mitoxantrone (D 34.8 C)). Among all the BNIP
derivatives, the BNIP derivative with the longest linker chain
(BNIPDadodec) resulted in the smallest increase in Tm (D 25.0).
However, the introduction of oxygen atoms (BNIPDaoxoct) and
cyclohexane rings (BNIPDaCHM) in the linker chain did not affect
the enhanced stability of the DNA duplex (D 31.7 C and D 31.2 C,
respectively). Bisphthalimidopropyl diaminodecane (BPHPDadec)
and mononaphthalimidopropylamine (NPA) induced a relatively
small increase in the Tm of D 15.8 C and D 10.1 C, respectively
compared to the BNIP derivatives. These results conﬁrm that the
presence of the bisnaphthalimido functionality is essential to ach-
ieve high DNA–BNIP interactions.
Ethidium bromide (EtBr) binds to DNA by intercalation and its
ﬂuorescence is enhanced when bound to DNA [6,20]. Compoundswhich exert a higher DNA-binding afﬁnity than EtBr displace the
EtBr, causing ﬂuorescence quenching [9]. The concentration (mM) of
BNIP derivative that causes a 50% decrease in the ﬂuorescence of
DNA bound EtBr is deﬁned as C50 value. A competitive displace-
ment ﬂuorimetric assay of DNA bound EtBr was performed to
evaluate the DNA-binding afﬁnity of all of the following BNIP
derivatives: BNIPSpd, BNIPPut, BNIPDahex, BNIPDaoct, BNIPDaoct,
BNIPDadec, BNIPDadodec, BNIPDaCHM, BNIPDaoxoct, BPHPDadec
and NPA (Table 1). All BNIP derivatives, except BPHPDadec and NPA
displaced ethidium bromide from DNAwith C50 values in the range
of 1.4–3.8 mM (Table 1). The order of binding strength to
DNA is BNIPSpd> BNIPPut¼ BNIPDahex> BNIPDaoct> BNIPDadec
> BNIPD aoxoct > BNIPDadodec > BNIPDaCHM > BPHPDadec
¼ NPA (C50 > 10 mM) (Table 1). These results conﬁrmed that
bisnapthalimido functionality is paramount in achieving strong
DNA–BNIP interactions.
2.2.2. Cytotoxic studies
In our previous work, the natural polyamines, spermidine
(BNIPSpd) and spermine (BNIPSpm) were linked to bisnaph-
thalimidopropyl moieties to enhance solubility, whilst retaining
Table 2
Cytotoxicity of BNIP derivatives against MDA-MB-231 and MCF-10A cells.
Compounda MDA-MB-231 Cells MCF-10A Cells
IC50 (mM)
b IC50 (mM)
b
24 h 48 h 24 h 48 h
BNIPSpd 12.68  0.47 4.59  1.35 4.19  0.55 3.97  0.97
BNIPPut 7.86  3.59 5.12  0.83 8.1  2.68 5.67  2.31
BNIPDahex 7.22  1.43 4.54  0.57 0.84  0.09 0.83  0.11
BNIPDaoct 4.99  1.34 2.68  0.29 2.77  0.09 0.87  0.12
BNIPDadec 4.85  0.22 3.32  0.69 2.77  0.11 2.82  0.05
BNIPDadodec 5.11  0.51 6.88  0.06 4.17  0.25 6.83  0.82
BNIPDaCHM 6.84  0.26 6.06  0.68 6.06  0.13 5.71  0.83
BNIPDaoxoct 12.39  5.78 6.15  1.49 6.1  1.56 2.27  0.01
BPHPDadec >40 >40 >40 >40
NPA >40 >40 >40 >40
Doxorubicinc 14.35  5.92 3.61  0.61 0.75  0.01 0.18  0.01
a Cytotoxicity was determined by MTT Assay. The results were obtained after
treating MDA-MB-231 and MCF-10A cells with different BNIP derivative concen-
trations (0–40 mM) for 24 and 48 h at 37 C. Data are mean  SD of 3 independent
experiments (n ¼ 3).
b IC50 is deﬁned as the drug concentration required to reduce the absorbance to
50% of the control values [9].
c Doxorubicin, an important DNA intercalator was used as a control.
Table 3
Cytotoxicity of BNIP derivatives against CHO and CHO-MG cells.
Compounda CHO CHO-MG IC50 Ratio
c
IC50
b (mM) IC50
b (mM)
BNIPSpd 76.5  5.7 74.6  3.1 1.0
BNIPDaoct 5.8  0.9 5.1  0.5 0.9
BNIPDaoxoct 76.1  2.1 26.9  5.9 0.4
BNIPDaCHM 6.2  0.7 6.3  0.4 1.0
MGBGd 3.3  0.5 >100 >30.2
a Toxicity was determined by MTT Assay. The results were obtained after treating
CHO-MG and CHO cells with different BNIP derivative concentrations (0–100 mM)
for 48 h at 37 C. Data are mean  SD of 3 independent experiments.
b IC50 is deﬁned as the drug concentration required to reduce the absorbance to
50% of the control values [9].
c The ratio indicates the (CHO-MG/CHO) IC50 ratio, a measure of PAT selectivity.
Highly selective polyamine transporter ligands will have high (CHO-MG/CHO) IC50
ratios [15].
d MGBG, a known substrate for the PAT system was used as a control.
Table 1
Effect of derivative treatment on the thermal denaturation (Tm) of Calf thymus DNA
and ethidium bromide displacement bound to Calf thymus DNA (C50).
Compounda Tm (C)
b C50 (mM)
c
10 mM
Calf Thymus DNA alone 56.2  0.4 ND
BNIPSpd 91.5  0.6 1.4  0.1
BNIPPut 89.2  2.5 1.5  0.3
BNIPDahex 91.9  0.6 1.5  0.1
BNIPDaoct 88.7  0.3 1.7  0.2
BNIPDadec 84.4  0.2 1.8  0.1
BNIPDadodec 81.2  0.7 3.4  0.3
BNIPDaCHM 87.4  1.2 3.8  0.1
BNIPDaoxoct 87.9  0.6 1.9  0.4
BPHPDadec 72.0  2.4 > 10
NPA 66.3  0.9 > 10
Doxorubicin 86.4  1.2 ND
Mitoxantrone 91.0  1.5 ND
Hoesht 33258 78.8  0.9 ND
a Calf Thymus DNA was incubated in the presence or absence of the BNIP deriv-
atives overnight.
b Tm is the temperature (C) when 50% of the DNA is denatured. Data are the
means  SD of three independent experiments.
c C50 is the drug concentration (mM) required to generate a 50% decrease in the
ﬂuorescence of bound Ethidium Bromide. Data are the mean  SD of three inde-
pendent experiments.
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with IC50 values in the region of 1.38–2.91 mM after 48 h treatment
[6]. Our second generation of BNIP derivatives showed that
modulating the length of the alkyl linker chain had an effect on
both solubility and in vitro cytotoxicity against human colon cancer
Caco-2 cells [7]. In the latter work [7], we showed that longer alkyl
chains (C7–C10) provided a moderate increase in solubility,
although cytotoxicity was not affected, with IC50 values in the range
of 0.47–6.2 mM after 24 h treatment. In vitro cytotoxicity of the
novel BNIP derivatives with linker chains containing the longest
alkyl chain to date (C12), oxygen (BNIPDaoxoct) and cyclohexane
rings (BNIPDaCHM) together with BPHPDadec and NPA were
assessed against the human breast adenocarcinoma cell line (MDA-
MB-231) and the non-tumorigenic epithelial cell line (MCF-10A).
Both cell lines (1  104cells/100 mL) were incubated in growth
media (FCS free media) containing each BNIP derivative at various
concentrations (0–40 mM, for 24 or 48 h) (Tables 2 and 3) and their
cytotoxicities determined by MTT assay [21].
In both cell lines, all the BNIP derivatives tested, except for
BPHPDadec and NPA (IC50 values > 40 mM) exhibited good cyto-
toxicity with IC50 values in the range of 4.85–12.68 mM inMDA-MB-
231 cells, and 0.84–8.1 mM in MCF-10A cells after 24 h treatment.
Treatment after 48 h resulted in an approximately two fold increase
in cytotoxicity for most of the BNIP derivatives tested. The presence
of oxygen atoms and cyclohexane rings within the linker chain do
not appear to affect cytotoxicity. It is interesting to note that all the
derivatives appeared to bemore active againstMCF-10A cells rather
than MDA-MB-231 cells. This may be due to the observation that
MCF-10A cells replicate at a faster rate than the MDA-MB-231 cells,
determined by cell count measurements (results not shown). From
the above results, it can clearly be shown that the presence of the
bisnaphthalimidopropyl moieties is vital for maximum in vitro
cytotoxicity.
2.2.3. Drug uptake
In order to relate cytotoxicity of BNIP derivatives to the speed of
uptake into cells, the property of BNIP derivatives to ﬂuorescence
once taken up into cells was exploited [22]. MDA-MB-231 cells
(8  104 cells/well) were treated with 10 mM of BNIPSpd, BNIP-
Daoct, BNIPDaoxoct or BNIPDaCHM and they were visualised using
a ﬂuorescence microscope after 0.5, 1, 2, 4, 6 and 24 h.After 0.5 h incubation, only cells incubated with BNIPDaoct and
BNIPDaCHM showed ﬂuorescence. The ﬂuorescence remained with
time, except for BNIPDaoct, which after 2 h the ﬂuorescence had
almost completely disappeared. This observation may explain the
higher toxicity of BNIPDaoct (IC50 4.99 mM), whereby it is being
taken up andmetabolised resulting in the quick lost of ﬂuorescence
by the cells compared with the other derivatives examined. Inter-
estingly, ﬂuorescence in cells incubated with BNIPSpd and BNIP-
Daoxoct was noted after only 6 h incubation, indicating slower
uptake into the cells. This may reﬂect the lower toxicity of these
BNIP derivatives (IC50 12.68 and 12.39 mM, respectively) when
compared with BNIPDaoct and BNIPDaCHM (IC50 4.99 and 6.84 mM,
respectively).
2.2.4. Polyamine transporter
The drug uptake experiments discussed above, demonstrate
that each BNIP derivative has a different rate of uptake inMDA-MB-
231 cells. Many polyamine analogues and derivatives have been
shown to use a polyamine transporter (PAT) system to enter cells. It
has been reported that methylglyoxalbis(guanylhydrazone)
(MGBG) uses a distinct polyamine transporter, which is also used by
several anthracene-polyamine conjugates [12–15,23–26]. We
assessed whether the BNIP derivatives reported in this paper
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Two Chinese Hamster Ovary (CHO) cell lines were used: the
parental CHO cells with an active polyamine transporter and the
polyamine-transport deﬁcient mutant cell line, CHO-MG. The latter
represents cells with no polyamine transporter activity. This
provides a delivery system model which is independent of the
polyamine transporter [12,23,27]. CHO-MG cells were isolated for
growth resistance to MGBG, which is a known substrate for PAT
[12,15,23,28]. The comparison between the toxicity of the BNIP
derivatives in both cell lines provided an important indication of
BNIP delivery via the polyamine transporter system. A derivative
which uses the polyamine transporter would be highly toxic to CHO
cells, yet less toxic to CHO-MG cells [12–14,29]. Therefore, highly
selective polyamine transporter ligands will have high (CHO-MG/
CHO) IC50 ratios [15].
The toxicity of the BNIP derivatives, BNIPSpd, BNIPDaoct,
BNIPDaoxoct and BNIPDaCHM was determined in CHO and CHO-
MG cells using the MTT assay [21].
BNIPSpd and BNIPDaoxoct exhibited weak activity in CHO
cells with IC50 values of 76.5 and 76.1 mM, respectively (Table 3).
This may be due to the slow uptake of these compounds as
demonstrated in MDA-MB-231 cells. However, BNIPDaoct, BNIP-
DaCHM and MGBG showed high activity with IC50 ranging from
3.3 to 6.2 mM. All BNIP derivatives except for MGBG produced
similar results in CHO-MG cells. The lack of activity from MGBG
was due to its inability to enter the cells. Based on the IC50 ratio
values of CHO-MG/CHO, it would appear that none of the BNIP
derivatives (CHO-MG/CHO ratios ranging from 0.4 to 1.0) utilised
the PAT system, in contrast to MGBG (ratio > 30.2) to gain access
to CHO-MG and CHO cells. Therefore, the uptake of BNIPs into
cells may involve different mechanisms of entry, such as passive
diffusion, utilisation of another transporter, interactions on the
outer surface of the plasma membrane and other membrane
receptor interactions [15].3. Conclusions
All BNIP derivatives, except BPHPDadec and NPA exhibited good
cytotoxic activity in both MDA-MB-231 and MCF-10A cells.
Furthermore all BNIP derivatives intercalate effectively to Calf
Thymus DNA, as demonstrated by the increased Tm values and
effective competitive displacement of EtBr from EtBr bound to DNA.
The BNIP derivative with the longest alkyl chain (BNIPDadodec)
resulted in a decrease in DNA-binding, while the introduction of
oxygen atoms (BNIPDaoxoct) and cyclohexane rings (BNIPDaCHM)
in the linker chain did not signiﬁcantly affect DNA-binding.
BPHPDadec and NPA demonstrated much lower DNA-binding
afﬁnities than the other BNIP derivatives, resulting in a loss of
toxicity. These results conﬁrm that the presence of bisnaph-
thalimidopropyl functionality and a linker chain of <C12 are
essential in achieving high DNA-binding interactions and cytotoxic
properties. Fluorescence microscopy analysis showed BNIPDaoct
and BNIPDaCHM are being taken up by cells much quicker than
BNIPSpd and BNIPDaoxoct. None of the BNIP derivatives studied
used the MGBG speciﬁc PAT system suggesting that another mode
of cellular entry other than this PAT is being utilised by the BNIP
derivatives.
In conclusion modiﬁcations to the linker chain in the BNIP
derivatives, by the introduction of oxygen atoms and cyclohexane
rings enhanced cellular uptake and biological activity in breast
cancer cells. It is suggested that DNA may be a potential target for
the cytotoxic activity of these BNIP derivatives. The biological
properties of these BNIP derivatives indicate their potential as
future cancer therapeutic agents.4. Experimental
4.1. Materials
Human breast cancer MDA-MB-231 (ECACC, 92020424) and
human breast epithelial MCF-10A cells (ATCC, CRL-10317) were
purchased from the European Collection of Cell Cultures and the
American Tissue Culture Collection respectively. Chinese Hamster
Ovary (CHO) cells and polyamine-transport deﬁcient mutant (CHO-
MG) cells were kindly provided by Dr. Wayne Flintoff, from the
University of Western Ontario, Canada. All reagents were
purchased from Acros Organics, Fisher Scientiﬁc, Lancaster and
Sigma–Aldrich, unless otherwise stated and were used without
puriﬁcation. Thin Layer Chromatography (TLC) was performed on
silica gel 60 F254 aluminium plates (Merck) in chloroform/methanol
(99:1 or 97:3). 1H NMR was recorded on a Bruker 400 Ultrashield
spectrometer operating at 400.1 MHz for 1H and 100.6 MHz for 13C.
Accurate mass spectra were obtained by ESI on a ZQ4000 (low
resolution) or MAT95XP (accurate mass) analytical instrument
(EPSRC National Mass Spectrometry Service Centre at Swansea
University, Swansea). BNIPSpd, BNIPPut, BNIPDaoct and BNIPDadec
were synthesised and characterised according to our methods
previously described [5,7].
4.2. Chemical synthesis
The synthetic strategy (Scheme 1A) adopted to synthesise the
bisnapthalimidopropylalkyl-diamine analogues; BNIPDahex, BNIP-
Dadodec, BNIPDaoxoct and BNIPDaCHM was based on methods
previously developed in our laboratory [5,7,9].
4.2.1. General method for the synthesis of dimesityalkyl diamines
(3–7) (Schemes 1A–B)
Corresponding diamines were dissolved in anhydrous pyridine
followed by the addition of mesitylenesulphonyl chloride (2.1 M
excess). The resulting solution was stirred at room temperature for
4 h. Removal of the pyridine followed by the addition of icy water
(200 mL), resulted in the formation of a precipitate. The latter was
ﬁltered off, washed thoroughly with water and dried under vacuo.
All the dimesitylalkyldiamines synthesised, showed only one spot
on TLC and they were used in the next step without further
puriﬁcation.
4.2.1.1. N1,N8-Dimesitylhexane 3. (58%), 1H NMR (CDCl3): d 7.0 (s,
aromatic protons), 4.8 (t, NH), 2.8 (q, –CH2–N), 2.6 (s, CH3.Mts), 2.3
(s, CH3.Mts), 1.4 (t, –CH2–), 1.1 (s, –CH2–).
13C NMR (CDCl3): d 140–
127 (aromatic carbons), 42.3 (2  CH2–NH), 29.3 (2  CH2), 25.9
(2  CH2), 22. (CH3.Mts), 20.9 (CH3.Mts).
4.2.1.2. N1,N12-Dimesityldodecane 4. (74%) 1H NMR (CDCl3): d 7.0 (s,
aromatic protons), 4.4 (t, NH), 2.9 (q, –CH2–N), 2.6 (s, CH3.Mts), 2.3
(s, CH3.Mts), 1.5 (t, –CH2–), 1.2 (s, –CH2–).
13C NMR (CDCl3): d 140–
127 (aromatic carbons), 41.6 (2  CH2–NH), 28.5 (2  CH2), 26.9
(2  CH2), 25.8 (2  CH2), 22.7 (2  CH2), 22.5 (2  CH2), 21.5
(CH3.Mts), 13.6 (CH3.Mts).
4.2.1.3. N1,N8-Dimesityl-3,6-dioxaoctane 5. (66%), 1H NMR (CDCl3):
d 6.9 (s, aromatic protons), 5.5 (t, –CH2–O), 3.4 (t, –CH2–O), 3.0 (q,
–CH2–N), 2.5 (s, CH3.Mts), 2.2 (s, CH3.Mts).
13C NMR (CDCl3): d 140–
127 (aromatic carbons), 70.7 (4  CH2–O), 40.7 (2  CH2–NH), 21.5
(CH3.Mts), 13.6 (CH3.Mts).
4.2.1.4. N4,N4-Dimesityldicyclohexylmethane 6. (61%), 1H NMR
(CDCl3): d 8.6 (s, NH), 7.7–7.0 (m, aromatic protons), 4.6 (t, –CH2–N),
2.6 (q, CH3.Mts), 2.3 (q, CH3.Mts), 1.8–0.8 (m, –CH2– and
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carbons), 43 (2 CH–N), 39 (CH2), 30.1–27.0 (cyclohexane carbons),
21.5 (CH3.Mts), 13.6 (CH3.Mts).
4.2.1.5. N1,N10-Dimesityldecane 7. (75%), 1H NMR (CDCl3): d 6.9 (s,
aromatic protons), 4.6 (t, NH), 2.9 (q, –CH2–N), 2.7 (s, CH3.Mts), 2.3
(s, CH3.Mts), 1.5 (t, –CH2–), 1.2 (s, –CH2–).
13C NMR (CDCl3): d 140.0–
127.0 (aromatic carbons), 40.7 (2  CH2–NH), 30.0–26.0 (8  CH2),
21.5 (CH3.Mts), 13.6 (CH3.Mts) (Scheme 1B).
4.2.2. Synthesis of toluenesulfonyloxypropylnaphthalimide (2)
(Scheme 1A)
Naphthalic anhydride (6.46 g, 32.58 mmol) was dissolved in
DMF (70 mL), followed by the addition of aminopropanol (2.45 g,
32.58 mmol) and DBU (7.45 mL). The solution was stirred at 85 C
for 4 h. The resulting residue was poured into icy water (200 mL) to
form a precipitate. The latter was ﬁltered off and washed with
water. This compound, N-(3-hydroxypropyl) naphthalimide 1
(82.9%), was pure enough to be taken to the next step without
further puriﬁcation. 1H NMR (CDCl3): d 8.5–7.5 (m, aromatic
protons), 4.3 (t, CH2–O), 3.6 (t, N–CH2), 3.2 (broad, s, OH), 2.1 (m,
CH2).
13C NMR (CDCl3): d 161 (C]O), 136–122 (aromatic carbons),
58, 38, 31 (3  CH2).
1 (5.10 g, 20 mmol) was dissolved in anhydrous pyridine
(80 mL). The solution was stirred for 15 min at 0 C. Tosyl chloride
(5.72 g, 30 mmol) was added, slowly, over 30 min. The solutionwas
left overnight at 4 C. The solution was poured into icy water
(200 mL) to form a precipitate. The latter was ﬁltered off and
washed thoroughly with water. The crude product was recrystal-
lised with ethanol to form Toluenesulfonyloxypropylnaphthalimide
2 (75%). 1H NMR (CDCl3): d 8.6–7.6 (m, aromatic protons), 7.2 (m, O-
Tos aromatic protons), 4.2 (m, CH2–O, CH2), 2.3 (s, CH3), 2.0 (m,
CH2).
13C NMR (CDCl3): d 161 (C]O), 138–125 (aromatic carbons),
129–144 (O-Tos aromatic carbons), 70, 38, 29 (3  CH2), 20 (CH3).
4.2.3. General N-alkylation reaction (Scheme 1A)
Dimesitylated polyamines (3–6) (0.5 g) were dissolved in DMF
(7 mL) followed by the addition of 2 (2.1 M excess) and caesium
carbonate (6 M excess). The solution was left stirring overnight at
85 C (3-4). For5 and6, the solutionwas left for 96hat50 C. Reaction
completion was monitored by thin layer chromatography. The solu-
tion was poured into icy water (200 mL) to form a precipitate. HCl
(20mL, 2M)was added to neutralise the solution, the precipitatewas
collected by ﬁltration and washed thoroughly with water.
4.2.4. General deprotection reaction (Scheme 1A–B)
The fully protected polyamine derivatives were dissolved in
anhydrous dichloromethane followed by the addition of hydro-
bromic acid/glacial acetic acid. The solutionwas left stirring for 24 h
at room temperature. The precipitate formed was ﬁltered off and
washed with dichloromethane (20 mL) and, ether (5 mL) (BNIP-
Dahex, BNIPDadodec and BNIPDaCHM). For BNIPDaoxoct, the
dichloromethane/hydrobromic acid/glacial acetic acid was
removed under vacuo and the residue was washed with dichloro-
methane (5 mL). The crude product recrystallised with absolute
ethanol.
4.2.4.1. BNIPDahex. (91%) 13C NMR (DMSO-d6): 24.5 (CH2), 25.2
(CH2), 25.4 (CH2), 36.7 (CH2), 44.8 (N–CH2), 46.5 (N–CH2), 122.0,
127.1, 130.6, 131.2, 134.3 (Aromatic Carbons), 163.6 (C]O). HRMS
(FAB): Calcd. for C36H40N4O4 Br2, 671.2227 [M  Br]þ, found:
671.2221 [M  Br]þ.
4.2.4.2. BNIPDadodec. (80%) 13C NMR (DMSO-d6): d 163.6 (C]O),
134.3, 131.2, 130.6, 127.1, 122.0 (aromatic carbons), 46.6 (N–CH2),44.7 (N–CH2), 36.7–24.5 (–CH2–). HRMS (FAB): Calcd. for
C42H52N4O4 Br2, 755.3166 [M  Br]þ, found: 755.3168 [M  Br]þ.
4.2.4.3. BNIPDaoxoct. (69%) 13C NMR (DMSO-d6): d 161 (C]O),
138–125 (aromatic carbons), 72 (O–CH2), 70 (O–CH2), 50–30
(–CH2–). HRMS (FAB): Calcd. for C36H40N4O6Br2, 702.6134
[M  2H  Br]þ, found: 702.2589 [M  2H  Br]þ.
4.2.4.4. BNIPDaCHM. (75%) 13C NMR (DMSO-d6): d 161.0 (C]O),
136.0–122.0 (aromatic carbons), 51.0–27.0 (–CH2– and cyclohexane
carbons). HRMS (FAB): Calcd. for C43H50N4O4Br2, 685.3753
[M  H  2Br]þ, found: 685.3748 [M  H  2Br]þ.
4.2.5. Synthesis of naphthalimidopropylamine, NPA (Scheme 1A)
4.2.5.1. Step 1 (Scheme 1A). 2 (0.5 g, 1.22 mmol) was dissolved in
DMF (7 mL) followed by the addition of Potassium phthalimide
(1.95 M excess) (0.44 g, 2.37 mmol). The solution was left stirring
for 12 h at 50 C. Reaction completion was monitored by thin layer
chromatography. The solution was poured into icy water (200 mL)
to form a precipitate. The precipitate was collected by ﬁltration,
washed thoroughly with water and recrystallised with absolute
ethanol. 8 (65%) 1H NMR (CDCl3): d 8.2–7.5 (m, aromatic protons),
4.3 (t, CH2–N), 3.8 (t, N–CH2, naphthalimido), 2.1 (m, –CH2).
13C
NMR (CDCl3): d 161.0 (C]O), 140.0–123.0 (aromatic carbons), 39.0
(CH2–N), 38.0 (N–CH2), 27.0 (–CH2–).
4.2.5.2. Step 2 (Scheme 1A). 8 (0.5 g, 1.3 mmol) was dissolved in
Ethanol (25 mL) followed by the addition of Hydrazine hydrate
(10 M excess) (650 mL, 13 mmol). The solution was left stirring for
12 h at 85 C. Reaction completion was monitored by thin layer
chromatography. The ethanol was evaporated followed by the
addition of dichloromethane (10 mL) giving rise to a precipitate.
The latter was ﬁltered off and the ﬁltrate was evaporated to dryness
to give a thick oil as naphthalimidopropylamine in quantitative
yield. The latter was immediately converted to its corresponding
hydrochloride salt by dissolving the amine in ethanol (2 mL), fol-
lowed by the addition of conc. HCl (3 mL) and ether (10 mL). The
white precipitate formed was ﬁltered off, recrystallised (95%
ethanol) and dried under vacuo to give NPA (26%) as the hydro-
chloride salt. 13C (DMSO-d6): d 165 (C]O), 140–125 (aromatic
carbons), 39 (CH2–NH2), 38 (N–CH2), 30 (–CH2–). HRMS (FAB):
Calcd. For C15H14N2O2 255.1131 [M þ H]þ, found: 255.1128
[M þ H]þ.
4.2.6. Synthesis of bisphthalimidopropyldiaminodecane
(BPHPDadec)
4.2.6.1. N1,N10-Dimesityldecane 7. (0.5 g, 0.931 mmol) was dis-
solved in DMF (7 mL) followed by the addition of N-(3-bromo-
propyl) phthalimide (2.1 M excess) (0.52 g, 19.56 mmol) and
caesium carbonate (6 M excess) (1.81 g, 5.586 mmol). The solution
was left stirring overnight at 85 C. Reaction completion was
monitored by thin layer chromatography. The solution was poured
into icy water (200 mL) to form a precipitate followed by the
addition of HCl (20 mL, 2 M) The precipitate was collected by
ﬁltration, washed thoroughly with water and dried under vacuo.
The fully protected polyamine derivative (0.2 g, 2.19 mmol) was
dissolved in anhydrous dichloromethane (5 mL) followed by the
addition of hydrobromic acid/glacial acetic acid (0.8 mL).
The solution was left stirring for 24 h at room temperature. The
precipitate formed was ﬁltered off and washed with dichloro-
methane (20 mL), ether (5 mL) and dried under vacuo (BPHPDadec)
as its dihydrobromide salt.
4.2.6.2. BPHPDadec. (96%) 13C NMR (DMSO-d6): d 168 (C]O), 142–
122 (aromatic carbons), 46 (NH–CH2), 39 (N–CH2), 32–27 (–CH2–).
G.A. Barron et al. / European Journal of Medicinal Chemistry 45 (2010) 1430–14371436HRMS (FAB): Calcd. for C32H44N4O4Br2, 547.3279 [M  2HBr þ H]þ,
found: 547.3281 [M  2HBr þ H]þ
4.3. Biological activities
4.3.1. Thermal denaturation studies
Thermal denaturation (melting) experiments were performed
in a stoppered quartz cuvettes (1 cm path length) using a Shimadzu
UV-1650 PC UV–vis spectrophotometer ﬁtted with a temperature
controller (Shimadzu, Japan) and water supply. The temperature
was increased at a rate of 1 C/min over a range of 40–100 C. Calf
Thymus DNA working solutions were prepared by dissolving DNA
(2.5 mg) in 0.01 M Saline Sodium Citrate (SSC) Buffer (100 mL). The
DNA–BNIP solutions were prepared from BNIP stock solutions
(10 mM in 50% DMSO), which were further diluted from a working
solution (100 mM) to give the ﬁnal concentration of 10 mM. The
thermal melting point, Tm (C) was measured by determining the
change in midpoint of the thermal denaturation curves of DNA.
4.3.2. Fluorescence-binding studies
Fluorescent-binding experiments were carried out by the
competitive displacement ﬂuorometric assay of DNA bound
Ethidium Bromide (EtBr)-BNIP solutions. Calf Thymus DNA solution
was prepared by dissolving DNA (2.5 mg) in 0.01 M SSC Buffer
(100 mL). EtBr solution (200 mM) was prepared by dissolving EtBr
(7.886 mg) in distilled water (100 mL). The BNIP solutions were
prepared from BNIP stock solutions (10 mM in 50% DMSO) and
were further diluted from a working solution (100 mM), to give the
ﬁnal concentrations of 1, 2, 4, 6, 8 and 10 mM in 0.01 M SSC buffer.
DNA–BNIP test solutions were prepared by adding varying volumes
of BNIP solutions in 0.01 M SSC Buffer, dependent upon drug
concentration (mM) to a ﬁxed volume of Calf Thymus DNA (200 mL)
and EtBr (20 mL) in 1 mL Eppendorfs. All measurements were
determined in disposable cuvettes (1 cm path length) using an LS55
Luminescence spectrophotometer (Perkin Elmer, USA), at room
temperature (excitation 481 nm and emission 596 nm). The C50
values are deﬁned as the drug concentration (mM) required to
generate a 50% decrease in the ﬂuorescence of bound EtBr.
4.3.3. Cell culture and drug treatment
MDA-MB-231 cells were maintained in RPMI 1640 medium
(containing GlutaMAX-1 with 25 mM HEPES) (Gibco, UK) sup-
plemented with 10% (v/v) foetal calf serum (FCS) (Biosera, UK) and
1% penicillin (100 U/mL)/streptomycin (100 mg/mL) (Gibco, UK).
MCF-10A cells were maintained in DMEM/F12 medium (Lonza,
Belgium) supplemented with 5% (v/v) horse serum, human insulin
(10 mg/mL), hydrocortisone (0.5 mg/mL), epidermal growth factor
(20 ng/mL) (Invitrogen, UK), chloratoxin (100 ng/mL), penicillin
(100 U/mL)/streptomycin (100 mg/mL) (Invitrogen, UK). CHO and
CHO-MG cells were maintained in RPMI 1640 medium (containing
L-Glutamine, no Phenol Red) (Gibco, UK) supplemented with 10%
(v/v) FCS (Biosera, UK) and 0.5% (v/v) penicillin (100 U/mL)/strep-
tomycin (100 mg/mL) (Invitrogen, UK). All cells were incubated at
37 C in a humidiﬁed 5% CO2 atmosphere. Exponentially growing
cells were plated at 8  104/mL into 24 well plates or 1  104cells/
100 mL into 96-well plates and incubated for 24 h, before incubation
with BNIP derivatives. Stock solutions (10 mM) of the BNIP deriv-
atives in 50% (v/v) dimethylsulfoxide (DMSO) were stored at 4 C
and were further diluted in fresh FCS free medium immediately
prior to use.
4.3.4. Cytotoxic studies
The growth inhibitory effect of the BNIP derivatives were
determined using the standard colourimetric 3-(4,5-dimethylth-
iazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. MDA-MB-231 and MCF-10A (1  104cells/100 mL) cells were incubated
with BNIPSpd, BNIPPut, BNIPDahex, BNIPDaoct, BNIPDadec, BNIP-
Dadodec, BNIPDaoxoct, BNIPDaCHM, BPHPDadec and NPA (0–
40 mM; 24 and 48 h) in 96-well plates (Nunc, UK). After the desired
incubation timewith BNIP derivatives, at 37 C, the culturemedium
was removed and 100 mL of MTT solution (1 mg/mL) in FCS free
mediumwas added to eachwell. The plates were incubated at 37 C
for 4 h. At the end of incubation period, the MTT solution was
removed and pure DMSO (200 mL) added to each well. The plates
were shaken for 20min. ThemetabolisedMTT product, dissolved in
DMSO was quantiﬁed by reading the absorbance at 560 nm from
a plate reader (MRX II, Dynex Technologies, USA). IC50 values are
deﬁned as the drug concentrations required to reduce the absor-
bance to 50% of the control values.
4.3.5. Drug uptake
BNIP derivative localisationwithin exponentially growingMDA-
MB-231 cells plated at a density of 8  104/mL into 24 well plates
(Nunc, UK) was observed using ﬂuorescencemicroscopy. After 24 h,
10 mM BNIPSpd (data not shown), BNIPDaoct, BNIPDaoxoct or
BNIPDaCHM were added to the cells. After the desired incubation
time, the cell culture medium was removed, and the cells washed
twice with Phosphate Buffer Saline (PBS) (Oxoid Ltd, UK). 1 mL PBS
was added to each well, and the cells observed under an inverted
ﬂuorescence microscope (Leica DMIL) with a high pressure
mercury burner (Leica Microsystems, UK), using a UV ﬁlter (exci-
tation bandpass (blue); 340–380 nm, emission longpass (red);
425 nm). Images were captured using a Leica DC 200 camera (Leica
Microsystems, UK) and viewed using Irfanview 3.91 software (Leica
Microsystems, UK).
4.3.6. Polyamine transporter
CHO and CHO-MG cells were used to assess the selective
transport of BNIP derivatives via the polyamine transporter (PAT).
CHO and CHO-MG (1  104cells/100 mL) cells were incubated with
BNIPSpd, BNIPDaoct, BNIPDaoxoct or BNIPDaCHM (0–100 mM; for
48 h) in 96-well plates (Nunc, UK). After 48 h incubation, at 37 C,
cell viability was determined using the MTT assay, as described
above.4.4. Statistics
A minimum of three independent experiments were conducted
for each set of analyses, where all experiments comprised of at least
three internal replicates. Data is presented as mean  SD.Acknowledgements
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The in vitro studies of novel polyamine derivatives; Bisnaphthalimidopropyl Spermidine
(BNIPSpd), Decane (BNIPDadec) and Diaminononane (BNIPDanon), were investigated to
establish their therapeutic anti-cancer potential against human colon cancer cells (CaCo-2). These
novel compounds demonstrated good in vitro cytotoxicity with CaCo-2 cells exhibiting IC50 values
ranging between 0.5 μM – 19.9 μM and 1.3 μM – 11.2 μM after 24 and 48 hours drugs exposure
respectively. Strong evidence of apoptotic cell death from these novel compounds was determined
through Acridine Orange/Ethidium Bromide uptake and cell morphology experiments. The effect of
BNIPSpd, BNIPDadec and BNIPDanon (1 μM – 10 μM drug concentrations) on the level of
polyamines on CaCo-2 cells were studied. The results showed significant changes in polyamine
levels after 24 hour drug exposure. Furthermore, the modulation of HO-1 (Heme-Oxygenase) and
Bcl-xL (Anti-apoptotic) genes was also studied after drug treatment and these results will be
presented and discussed. In conclusion, the results obtained from this work demonstrate that the
novel Bis-naphthalimidopropyl polyamine derivatives exhibit very good potency against CaCo-2
cells while initiating cell death by apoptosis and hence have the potential in the future to become
therapeutic anti-cancer agents.
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Cytotoxicity Studies Using MTT Assay
HO-1 and Bcl-xL Gene Expression
Acridine Orange/Ethidium Bromide Staining in Drug
Treated Cells (24 h)
To determine the cytotoxicity of the recently synthesised
novel bis-naphthalimidopropyl polyamine compounds,
BNIPSpd, BNIPDadec and BNIPDanon against CaCO-2 cells.
All three compounds demonstrate significant in vitro
cytotoxicty with IC50 values of 0.5µM – 19.9µM (24h)
and 1.3µM – 11.2µM (48h).
Bis-naphthalimidopropyl polyamine derivatives may have the
potential in the future to become therapeutic cancer agents.
Further work is ongoing to elucidate the mode of action of
these drugs.
Polyamine Levels in Drug Treated Cells
No change in the expression of HO-1 (Heme-Oxygenase
- stress gene) and Bcl-xL (Anti-apoptotic gene) genes
was observed following exposure to BNIPSpd (19.9μM),
BNIPDadec (4.0μM) and BNIPDanon (0.5μM) for 24 h.
1.30.5BNIPDanon
1.54.0BNIPDadec
11.219.9BNIPSpd
48 h Exposure IC50
(µM)
24 h Exposure IC50
(µM)
Drug
IC50 Values of BNIPSpd, BNIPDanon, and BNIPDadec measured on CaCO-2 Cells
after 24 and 48 h Drug Treatment. Data are mean ± SD for 6 replicates. 5-
Fluorouracil was used as a positive control and gave IC50 values of 184.1µM and
115.3µM for 24 h and 48 h respectively.
Control Cells (x200) Cells Treated With BNIPSpd (19.9µM)
(x200)
Cells Treated With BNIPDadec (4.0µM)
(x200)
Cells Treated With BNIPDanon (0.5µM)
(x200)
A B
All of the novel polyamine derivatives inhibit the growth of
CaCO-2 cells. The order of cytotoxicity was BNIPDanon >
BNIPDadec > BNIPSpd.
All compounds tested induced morphological changes and
initiated early apoptosis. Late apoptosis was observed in
BNIPSpd and BNIPDadec treated cells.
In 2000, novel Bisnaphthalimidopropyl polyamine
compounds were synthesised in our laboratories. These
compounds consist of two naphthalimido rings linked by
natural polyamines, such as spermidine and spermine.
They exhibit cytotoxic activity in a variety of cancer cell
lines cultured in vitro.
Viable Cells
Early Apoptotic
Cells
Late Apoptotic
Cells
Dose-response curve obtained after treating CaCO-2 cells with varying
drug concentrations (0.01 – 100µM) for 48 h.
Polyamine levels were decreased after 24, 48 and 72 h
treatment with either BNIPSpd or BNIPDadec (1µM & 10µM).
The discovery of new therapeutic targets and hence the
design and synthesis of novel compounds are active
cancer research areas.
To determine whether these bis-naphthalimidopropyl
compounds cause cell death by apoptosis.
To investigate the effect of these compounds on
polyamine levels in drug treated CaCO-2 cells.
*Corresponding Author. Tel: +44-1224-262831 Email Address: prs.barron@rgu.ac.uk
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(A) Light Microscope (B) Acridine Orange/Ethidium Bromide Staining
Polyamine levels were extracted after 24 h and determined by pre-column derivatisation with
dansyl chloride followed by HPLC analysis.
Polyamine levels exhibited a significant decrease after 24
h treatment with BNIPSpd and BNIPDadec at 1µM
(presented result) and 10µM. Similar observations were
obtained after 48 and 72 h drug exposure.
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DNA binding compounds exhibit the potential to exert anti cancer activities, such as, the
cytotoxic DNA-intercalating compounds; naphthalimides and bisnaphthalimides1,2. These
compounds, however, tend to be very insoluble in aqueous solutions, which subsequently makes
their testing difficult. In our laboratory, we have designed and synthesised bisnaphthalimidopropyl
fragments linked to the natural polyamines; putrescine, spermidine and spermine3, resulting in
enhanced aqueous solubility, without compromisation of biological activity4. More recent work has
shown that these derivatives are observed within the cell nuclei (after 6 and 12 hours treatment),
produce significant DNA damage, DNA fragmentation, elevated caspase-3 activity and form
‘condensed bodies’ strongly suggesting that the mechanism of cell death is apoptosis5,6.
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Figure 1.: BNIPP derivatives, BPHPDadec and Naphthalimidopropylamine
Here we report the synthesis of a number of derivatives including the
Bisnaphthalimidopropyl diaminoalkanes, Bisnaphthalimidopropyl diaminodecane (BPHPDadec)
and Naphthalimidopropylamine (Figure 1). We also study the structure activity relationship of these
newly synthesised derivatives compared with the derivatives previously reported by our group6,
determined by MTT assay7, in a breast cancer cell system (MDA-MB-231 and MCF-10A cells).
The DNA binding properties were studied using UV spectrophotometric analysis and competitive
ethidium bromide displacement experiments. All the BNIPPs exerted cytotoxic activity with IC50
values in the range of 0.83 – 12.68 μM (24 and 48 hour treatment) and, an increase of Tm by Δ 
26.85 – 37.2°C with C50 values between 1.46 – 3.8. μM. The C50 values are defined as the drug
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concentration required to reduce the fluorescence of initially DNA-bound ethidium bromide by 50%.
These results signifiy the importance of Bisnaphthalimidopropyl functionality in exerting significant
cytotoxic and DNA binding properties, consequently demonstrating promise in their further
development as potential anti cancer agents. Their mode of action is currently under investigation.
Keywords: Bisnaphthalimidopropyl; Synthesis; Cytotoxicity; DNA Binding
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DNA binding compounds exhibit the potential to exert anti cancer
activities, such as, the cytotoxic DNA-intercalating compounds;
naphthtalimides and bisnaphthalimides.
However, these compounds tend to be very insoluble in aqueous
solutions, thus making their testing difficult.
In 2000, our laboratory designed and synthesised
bisnaphthalimidopropyl fragments linked to the natural polyamines,
putrescine, spermidine and spermine, resulting in enhanced
aqueous solubility, without compromising biological activity.
Cytotoxicity
To design, synthesise and characterise new BNIPPs with a number of
alkyl diamines and, to establish structure activity relationships (SARs) in
a breast cell system (MDA-MB-231 and MCF-10A Cells), determined
using the MTT Assay
DNA Binding
To determine the effects of the BNIPPs on DNA binding capacity,
determined by midpoint of thermal denaturation (Tm) and ethidium
bromide displacement experiments.
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Fig 1. Reagents and Conditions: (i) naphthalic anhydride in DMF, DBU, 85°C, 4 h; (ii) tosyl-Cl in
pyridine, 0-5°C, overnight; (iii) mesitylated polyamines, DMF, 85°C, overnight; (iv) HBr/glacial
CH3CO2H in CH2Cl2, RT , 24 h.
Fig 2. Reagents and Conditions: (i) mesitylated polyamines, DMF, Mts, Cs2CO3, 85°C, overnight;
(ii) HBr/glacial CH3CO2H in CH2Cl2, RT , 24 h; (iii) tosyl-Cl, DMF, C8H4KNO2, 50°C, overnight; (iv)
C2H5OH, hydrazine hydrate, 85°C, overnight.
The results confirm the importance of naphthalimido functionality, in exerting
significant cytotoxic and DNA binding properties, consequently demonstrating
promise in their further development as potential anti cancer agents.
The mode of action of selected compounds is currently under investigation
Fig 3. Structures of BNIPP Derivatives
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Fig 4. The Reduction Reaction of MTT Solution
Compound (a) 24 hrs (µM) 48 hrs (µM)
BNIPSpd 12.7 ± 0.5 4.6 ± 1.4
BNIPDaoct 5.0 ± 1.3 2.7 ± 0.3
BNIPDadec 4.9 ± 0.2 3.3 ± 0.7
BNIPDadodec 5.1 ± 0.5 6.9 ± 0.1
BNIPDaoxoct 12.4 ± 5.8 6.2 ± 1.5
BNIPDaCHM 6.8 ± 0.3 6.1 ± 0.7
BPHPDadec > 40 > 40
Naphthalimidopr
opylamine > 40 > 40
Etoposide > 40 17.2 ± 0.7
Fig 5. IC50 values of BNIPP derivatives against
MDA-MB-231 Cells
Fig 6. IC50 values of BNIPP derivatives against
MCF-10A Cells
(a) Cytotoxicity was determined by MTT Assay. The results were obtained after treating MDA-MB-231 and MCF-10A cells with
different derivative concentrations (0-40 µM) after 24 and 48 hours incubation at 37°C. Data are mean ± SD of 6 replicates of three
independent experiments
(IC50 is defined as the concentration of the BNIPPs requires to inhibit cell growth by 50%, compared to the control values)
Naphthalimido
propylamine
78.3 ± 0.0 79.8 ± 1.5
Tm (°C) (b)
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Fig 7. An example of the 1st Derivative curve of
temperature vs absorbance for Calf Thymus DNA
and BNIPDaoxoct (10µM)
Fig 8. Effect of BNIPP treatment on the Thermal
Denaturation (Tm) of Calf Thymus DNA
(a) Calf Thymus DNA was incubated in the presence or absence of the BNIPP derivatives for 5 minutes. The temperature was
increased at the rate of 2°C/minute over a range of 40°C to 100°C. Data are means ± SD of three independent experiments. Tm
was determined from the maxima peak of the first derivative, when 50% of the DNA is denatured.
Thermal Denaturation
Fluorescence – Binding Studies
Naphthalimido
propylamine
> 10
Fig. 9. An example of the fluorescence
reduction for BNIPDaCHM
Fig. 10. Effect pf BNIPP treatment on Ethidium
Bromide displacement
(a) Calf Thymus DNA was incubated in the presence
and absence of BNIPP derivatives for 5 minutes.
Concentration range 0-10µM. Data are means ± SD of
three independent experiments. C50 was determined as
the concentration required to reduce the fluorescence of
initially DNA-bound Ethidium Bromide by 50%.
The SAR results reveal that two naphthalimido rings are required, the alkyl
chain improves biological activity, although is not dependent upon length and,
a decrease in activity was observed with the presence of heteroatoms within
the chain (BNIPSpd and BNIPDaoxoct).
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Calf Thymus DNA Alone
BNIPDaoxoct and DNA
Compound (a) C50 (µM)
BNIPSpd 1.5 ± 0.1
BNIPDaoct 1.7 ± 0.2
BNIPDadec 1.8 ± 0.1
BNIPDadodec 3.4 ± 0.3
BNIPDaoxoct 1.9 ± 0.4
BNIPDaCHM 3.8 ± 0.1
BPHPDadec > 10
Compound (a) 5 µM 10 µM
Calf Thymus
DNA alone
57.7 ± 0.9
BNIPSpd 93.2± 0.2 93.5 ± 0.7
BNIPDaoct 92.2 ± 0.2 91.7 ± 0.5
BNIPDadec 88.0 ± 0.0 88.6 ± 0.5
BNIPDadodec 85.5 ± 0.2 84.5 ± 0.7
BNIPDaoxoct 89.5 ± 0.3 92.1 ± 0.7
BNIPDaCHM 88.4 ± 0.5 89.6 ± 0.0
BPHPDadec 69.5 ± 3.0 70.2 ± 2.4
Compound (a) 24 hrs (µM) 48 hrs (µM)
BNIPSpd 4.2 ± 0.5 3.9 ± 0.9
BNIPDaoct 2.7 ± 0.1 0.8 ± 0.1
BNIPDadec 2.7 ± 0.1 2.8 ± 0.1
BNIPDadodec 4.2 ± 0.3 6.8 ± 0.8
BNIPDaoxoct 6.1 ± 0.5 2.3 ± 0.0
BNIPDaCHM 6.1 ± 0.1 5.7 ± 0.8
BPHPDadec > 40 > 40
Naphthalimidopr
opylamine > 40 > 40
Etoposide 14.2 ± 1.3 1.2 ± 0.7
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Naphthalimides and bisnaphthalimides are cytotoxic DNA-intercalating compounds which
exert potential as anti-cancer agents 1, 2 . However, these compounds generally tend to be
insoluble in aqueous solutions, thus making biological testing difficult. For several years, our group
have been synthesising and characterising bisnaphthalimidopropyl derivatives linked by natural
polyamines 3, diamino and, triamino alkyl linker chains, which resulted in enhanced aqueous
solubility, without significantly affecting their biological activity 4, 5, 6. Recent work has shown that
bisnaphthalimidopropyl spermidine (BNIPSpd) induces oxidative DNA damage, depletes polyamine
levels and causes cell death, by apoptosis, within HT-29 and CaCO-2 cells 7. Here we report upon
a number of new phthalimide and naphthalimidopropyl polyamine derivatives, including the
bisnaphthalimidopropyl diaminoalkanes (BNIPPs), bisphthalimidopropyl diaminodecane
(BPHPDadec) and mononaphthalimidopropylamine (NPA). Their cytotoxic properties were
determined by MTT assay, in breast cancer MDA-MB-231 cells and compared with derivatives
previously reported by our group 6. All the BNIPPs exhibited significant cytotoxic activity, after 24
and 48 hours, with IC50 values in the range of 2.68 – 12.68 µM. The fluorescent properties of
BNIPSpd, bisnaphthalimidopropyl diaminooctane (BNIPDaoct), bisnaphthalimidopropyl
diaminooxaoctane (BNIPDaoxoct) and bisnaphthalimidopropyl diaminodicyclohexylmethane
(BNIPDaCHM), in relation to cellular localisation, were determined by fluorescence microscopic
analysis. It was revealed that a 10 µM derivative concentration and after a 6-h drug incubation,
showed BNIPDaoct, BNIPDaoxoct and BNIPDaCHM were all located within the cell, while the
presence of BNIPSpd was not observed until after 24-h drug incubation. Using the single cell gel
electrophoresis (COMET) assay, it was found that BNIPSpd and BNIPDaoxoct, showed significant
DNA damage to MDA-MB-231 treated cells, in a dose dependent manner, after 4 and 24-h drug
incubations. The mode of cell death, in relation to apoptosis, shall also be discussed. Therefore, it
is concluded that these derivatives exert cytotoxic effects, DNA damage and apoptosis, which have
been shown to be related to the rate of derivative uptake into the cells, consequently demonstrating
promise in their further development as potential anti cancer agents. The study of BNIPPs as
potential Histone Deacetylases (HDAC) inhibitors will also be discussed.
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Appendix 1
Figure A.1.: 1H, 13C and DEPT spectra of N-(3-hydroxypropyl) naphthalimide, 1 (1H, top, 13C,
middle and DEPT, bottom).
Figure A.2.: 13C and DEPT spectra of toluensulfonyloxypropylnaphthalimide, 2 (13C, top and DEPT,
bottom).
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Appendix 2
Figure A.3.: 1H spectra of the dimesitylalkyldiamines, 3 and 5. (5, top and 3, bottom).
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Appendix 3
Figure A.4.: 13C and DEPT spectra of BNIPDaoxaoct. (13C, top and DEPT, bottom).
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Appendix 4
Figure A.5.: MS for BNIPDaCHM
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Figure A.6.: MS for BPHPDadec
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Appendix 5
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Figure A 7.: Standard curve for putrescine
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Figure A 8.: Standard curve for spermidine
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Figure A 9.: Standard Curve for Spermine
